

*The  
Complete Patents  
of  
Ananda M. Chakrabarty*

*By*

*Abhay B. Solunke*

*Head Department of Microbiology,  
Shri Govindrao Munghate  
Arts & Science College,  
Kurkheda. 441209.*

[www.abhaysolunke.info/www.sgmunghatecollege.in](http://www.abhaysolunke.info/www.sgmunghatecollege.in)



Ananda M. Chakrabarty was born in India on 4 April 1938. He attended Sainthia High School, Belur Bidyamandir and St. Xavier's College, Calcutta. Prof. Chakrabarty received his Ph.D. from the University of Calcutta in Kolkata, West Bengal in 1965.

Ananda M. Chakrabarty -Ph.D. is a microbiologist, scientist, and researcher, known for his most notable work in directed evolution and in developing a genetically engineered organism using plasmid transfer while working at GE.

Chakrabarty genetically engineered a new species of *Pseudomonas* bacteria ("the oil-eating bacteria") in 1971 while working for the Research & Development Centre at General Electric Company in Schenectady, New York. Till this time, four known species of oil-metabolizing bacteria were known to exist.

Chakrabarty discovered a method for genetic cross-linking that fixed all four plasmid genes in place and produced a new, stable, bacteria species (now called *Pseudomonas putida*) capable of consuming oil one or two orders of magnitude faster than the previous four strains of oil-eating microbes. The new microbe, which Chakrabarty called "**multi-plasmid hydrocarbon-degrading *Pseudomonas*,**" could digest about two-thirds of the hydrocarbons that would be found in a typical oil spill.

The bacteria drew international attention when he applied for a patent—the first-ever patent for living organism. He was initially denied the patent by the Patent Office because it was thought that the patent code precluded patents on living organisms.

Chakrabarty's landmark research has since paved the way for many patents on genetically modified micro-organisms and other life forms and catapulted him into the international spotlight.

He has isolated a bacterial protein, azurin, with potential antineoplastic properties.

In 2001, Prof. Chakrabarty founded a company, CDG Therapeutics, (incorporated in Delaware) which holds proprietary information related to five patents generated by his work at the University of Illinois at Chicago.

In 2008, Prof. Chakrabarty co-founded a second bio-pharmaceutical discovery company, Amrita Therapeutics Ltd., registered in Ahmedabad, Gujarat, to develop therapies, vaccines and diagnostics effective against cancers and/or other major public health threats derived from bacterial products found in the human body.

Chakrabarty is a Distinguished University Professor in the Department of Microbiology and Immunology in the University of Illinois at Chicago College of Medicine. Apart from being an eminent scientist, Ananda Chakrabarty has been an advisor to judges, governments, and the UN. As one of the founding members of a UNIDO Committee that proposed the establishment of the International Centre for Genetic Engineering & Biotechnology (ICGEB), he has been a member of its Council of Scientific Advisors ever since. He has also served the Stockholm Environment Institute of Sweden. He has been on the Scientific Advisory Board of many academic institutions such as the Michigan Biotechnology Institute, the Montana State University Centre for Biofilm Engineering, the Centre for Microbial Ecology at the Michigan State University, and the Canadian Bacterial Diseases Network based in Calgary, Canada. Chakrabarty has also served as a member of NIAG, the NATO Industrial Advisory Group based in Brussels, Belgium. He is a member of the Board of Directors of Einstein Institute for Science, Health and the Courts, where he participates in judicial education. More recently, he has been involved in international judicial work, serving as a Scientific Advisor for meetings in Hawaii and Ottawa, Canada,



organized by the Supreme Court of Canada. For his work in genetic engineering technology, he was awarded the **Padmashri** by the Government of India in 2007.



- **Cytotoxic factors for modulating cell death**

**Patent number:** 10421801

**Abstract:** Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death or uncontrolled growth. The present inventors have found that different microorganisms produce different cytotoxic factor(s) having anticancer activity. The substantially pure cytotoxic factors can be used in a method of treating an infectious disease or a cancer.

**Type:** Grant

**Filed:** November 8, 2013

**Date of Patent:** September 24, 2019

**Inventors:** Ananda M Chakrabarty, Tapas K Das Gupta, Vasu Punj, Olga Zaborina, Yoshinori Hiraoka, Tohru Yamada

- **Cytotoxic factors for modulating cell death**

**Patent number:** 10266573

**Abstract:** Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death. The present inventors have found that different pathogens produce different cytotoxic factor(s) having anticancer activity. The substantially pure cytotoxic factors can be used in a method of treating an infectious disease or a cancer.

**Type:** Grant

**Filed:** May 19, 2008

**Date of Patent:** April 23, 2019

**Assignee:** THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

**Inventors:** Ananda M. Chakrabarty, Tapas K. Das Gupta, Vasu Punji, Olga Zaborina

- **Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof**

**Patent number:** 10072049

**Abstract:** The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer.

**Type:** Grant

**Filed:** April 11, 2016

**Date of Patent:** September 11, 2018

**Assignee:** THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

**Inventors:** Chang Soo Hong, Tohru Yamada, Arsenio M. Fialho, Tapas K. Das Gupta, Ananda M. Chakrabarty

- **TRANSPORT AGENTS FOR CROSSING THE BLOOD-BRAIN BARRIER AND INTO BRAIN CANCER CELLS, AND METHODS OF USE THEREOF**

**Publication number:** 20160289276



**Abstract:** The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer.

**Type:** Application

**Filed:** April 11, 2016

**Publication date:** October 6, 2016

**Inventors:** Chang Soo Hong, Tohru Yamada, Arsenio M. Fialho, Tapas K. Das Gupta, Ananda M. Chakrabarty

- **Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof**

**Patent number:** 9309292

**Abstract:** The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer.

**Type:** Grant

**Filed:** September 30, 2013

**Date of Patent:** April 12, 2016

**Assignee:** The Board of Trustees of the University of Illinois

**Inventors:** Chang Soo Hong, Tohru Yamada, Arsenio M. Fialho, Tapas K. Das Gupta, Ananda M. Chakrabarty

- **Compositions and methods to control angiogenesis with cupredoxins**

**Patent number:** 9107881

**Abstract:** The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.

**Type:** Grant

**Filed:** February 11, 2013

**Date of Patent:** August 18, 2015

**Assignee:** The Board of Trustees of the University of Illinois

**Inventors:** Rajeshwari R Mehta, Brad N Taylor, Tohru Yamada, Craig W Beattie, Tapas K Das Gupta, Ananda M Chakrabarty

- **Cytotoxic Factors For Modulating Cell Death**



**Publication number:** 20140179617

**Abstract:** Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death or uncontrolled growth. The present inventors have found that different microorganisms produce different cytotoxic factor(s) having anticancer activity. The substantially pure cytotoxic factors can be used in a method of treating an infectious disease or a cancer.

**Type:** Application

**Filed:** November 8, 2013

**Publication date:** June 26, 2014

**Applicant:** THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

**Inventors:** ANANDA M. CHAKRABARTY, TAPAS K. DAS GUPTA, VASU PUNJ, OLGA ZABORINA, YOSHINORI HIRAOKA, TOHRU YAMADA

- **Transport agents for crossing the blood-brain barrier and into brain cancer cells and methods of use thereof**

**Patent number:** 8545812

**Abstract:** The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer.

**Type:** Grant

**Filed:** May 25, 2012

**Date of Patent:** October 1, 2013

**Assignee:** The Board of Trustees of the University of Illinois

**Inventors:** Chang Soo Hong, Tohru Yamada, Arsenio M. Fialho, Tapas K. Das Gupta, Ananda M. Chakrabarty

- **Compositions and methods to control angiogenesis with cupredoxins**

**Patent number:** 8372962

**Abstract:** The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.

**Type:** Grant

**Filed:** February 27, 2012

**Date of Patent:** February 12, 2013

**Assignee:** The Board of Trustees of the University of Illinois

**Inventors:** Rajeshwari R. Mehta, Brad N. Taylor, Tohru Yamada, Craig W. Beattie, Tapas K. Das Gupta, Ananda M. Chakrabarty



- **TRANSPORT AGENTS FOR CROSSING THE BLOOD-BRAIN BARRIER AND INTO BRAIN CANCER CELLS AND METHODS OF USE THEREOF**

**Publication number:** 20130004431

**Abstract:** The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer.

**Type:** Application

**Filed:** May 25, 2012

**Publication date:** January 3, 2013

**Applicant:** The Board of Trustees of the University of Illinois

**Inventors:** Chang Soo Hong, Tohru Yamada, Arsenio M. Fialho, Tapas K. Das Gupta, Ananda M. Chakrabarty

- **COMPOSITIONS AND METHODS TO CONTROL ANGIOGENESIS WITH CUPREDOXINS**

**Publication number:** 20120196805

**Abstract:** The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.

**Type:** Application

**Filed:** February 27, 2012

**Publication date:** August 2, 2012

**Inventors:** Rajeshwari R. Mehta, Brad N. Taylor, Tohru Yamada, Craig W. Beattie, Tapas K. Das Gupta, Ananda M. Chakrabarty

- **Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof**

**Patent number:** 8188251

**Abstract:** The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP (SEQ ID NO: 25). The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particularly brain cancer.

**Type:** Grant

**Filed:** October 4, 2010

**Date of Patent:** May 29, 2012

**Assignee:** The Board of Trustees of the University of Illinois





**Inventors:** Chang Soo Hong, Tohru Yamada, Arsenio M. Fialho, Tapas K. Das Gupta, Ananda M. Chakrabarty

- **Compositions and methods to control angiogenesis with cupredoxins**

**Patent number:** 8124055

**Abstract:** The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.

**Type:** Grant

**Filed:** June 3, 2009

**Date of Patent:** February 28, 2012

**Assignee:** The Board of Trustees of the University of Illinois

**Inventors:** Rajeshwari R. Mehta, Brad N. Taylor, Tohru Yamada, Craig W. Beattie, Tapas K. Das Gupta, Ananda M. Chakrabarty

- **TRANSPORT AGENTS FOR CROSSING THE BLOOD-BRAIN BARRIER AND INTO BRAIN CANCER CELLS, AND METHODS OF USE THEREOF**

**Publication number:** 20110077387

**Abstract:** The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP (SEQ ID NO: 25). The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particularly brain cancer.

**Type:** Application

**Filed:** October 4, 2010

**Publication date:** March 31, 2011

**Inventors:** Chang Soo Hong, Tobru Yamada, Arsenio M. Fialho, Tapas K. Das Gupta, Ananda M. Chakrabarty

- **Cytotoxic factors for modulating cell death**

**Patent number:** 7888468

**Abstract:** Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death or uncontrolled growth. The present inventors have found that different microorganisms produce different cytotoxic factor(s) having anticancer activity. The substantially pure cytotoxic factors can be used in a method of treating an infectious disease or a cancer.

**Type:** Grant

**Filed:** August 23, 2006

**Date of Patent:** February 15, 2011

**Assignee:** The Board of Trustees of the University of Illinois





**Inventors:** Ananda M. Chakrabarty, Tapas K. Das Gupta, Vasu Punj, Olga Zaborina, Yoshinori Hiraoka, Tohru Yamada

- **Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof**

**Patent number:** 7807183

**Abstract:** The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP (SEQ ID NO: 25). The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particularly brain cancer.

**Type:** Grant

**Filed:** July 19, 2006

**Date of Patent:** October 5, 2010

**Assignee:** The Board of Trustees of the University of Illinois

**Inventors:** Chang Soo Hong, Tohru Yamada, Arsenio M. Fialho, Tapas K. Das Gupta, Ananda M. Chakrabarty

- **COMPOSITIONS AND METHODS TO CONTROL ANGIOGENESIS WITH CUPREDOXINS**

**Publication number:** 20100008919

**Abstract:** The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.

**Type:** Application

**Filed:** June 3, 2009

**Publication date:** January 14, 2010

**Inventors:** Rajeshwari R. Mehta, Brad N. Taylor, Tohru Yamada, Craig W. Beattie, Tapas K. Das Gupta, Ananda M. Chakrabarty

- **Compositions and methods to control angiogenesis with cupredoxins**

**Patent number:** 7556810

**Abstract:** The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.

**Type:** Grant



**Filed:** July 19, 2006

**Date of Patent:** July 7, 2009

**Assignee:** The Board of Trustees of the University of Illinois

**Inventors:** Rajeshwari R. Mehta, Brad N. Taylor, Tohru Yamada, Craig W. Beattie, Tapas K. Das Gupta, Ananda M. Chakrabarty

- **CYTOTOXIC FACTORS FOR MODULATING CELL DEATH**

**Publication number:** 20090137468

**Abstract:** Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death. The present inventors have found that different pathogens produce different cytotoxic factor(s) having anticancer activity. The substantially pure cytotoxic factors can be used in a method of treating an infectious disease or a cancer.

**Type:** Application

**Filed:** May 19, 2008

**Publication date:** May 28, 2009

**Inventors:** Ananda M. Chakrabarty, Tapas K. Das Gupta, Vas Punj, Olga Zaborina

- **Cytotoxic factors for modulating cell death**

**Patent number:** 7491394

**Abstract:** Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death or uncontrolled growth. The present inventors have found that different microorganisms produce different cytotoxic factor(s) having anticancer activity. The substantially pure cytotoxic factors can be used in a method of treating an infectious disease or a cancer.

**Type:** Grant

**Filed:** November 24, 2003



**Date of Patent:** February 17, 2009

**Assignee:** The Board of Trustees of the University of Illinois

**Inventors:** Ananda M. Chakrabarty, Tapas K. Das Gupta, Vasu Punj, Olga Zaborina, Yoshinori Hiraoka, Tohru Yamada









Report: The Department of Commerce 17 miles from NYC  
 dated 10/11/54, has been 10/11/54.

014748Y II- .H. 18-5-20\*

[illegible][illegible]**RECEIVED DIRECTOR OF THE FBI**

The main purpose of the information will be used as a management device and for control by internal management of the following small business relating to the information system.

The company's network of retail units, made up of 1,000 stores in the home-pair and 1,100 in the UK, and 100 of its own stores in the UK, is planned to be the source of its income.

FIG. 1. Distribution of mean (standard error) for each of 10 observations on the 100th percentile of white males aged 18 years, 1960-1970, by age group. The distribution is shown for the period 1960-1964 and 1965-1970.

THE REPUBLIC OF THE PHILIPPINES  
DEPARTMENT OF JUSTICE  
OFFICE OF THE ATTORNEY GENERAL  
DIVISION OF COUNSEL

4. The company has a 100% ownership interest in  
its subsidiaries and is not controlled by a foreign  
person or persons. The company is not a subsidiary  
of a foreign company.

1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 26

For more information, call 1-800-368-7233, ext. 100 or write to: Personnel Manager, 10000 1st Avenue, Suite 100, Houston, TX 77036.

A former member of the National Student Reliance Corporation, Inc., has been charged with conspiracy to defraud the company. The charge was filed by the U.S. Attorney General's Office.

Unemployment compensation is more available in the U.S. than in other countries, and the U.S. has a higher unemployment rate than most other countries. The U.S. has a higher unemployment rate than most other countries.

$\rho = 0$  (Figure 1) The initial stage, i.e., of polymerization. The maximum yield of the above-mentioned super crystals is obtained at about 70% conversion.

[illegible][illegible][illegible][illegible]

(f) The value of  $\alpha$  will be the difference of the power  
of the test - the value of  $\alpha = 0.05$ . It is not  
zero.

11. I am a member of the following organizations:

[illegible]

1. The first step is to identify the problem or question that needs to be answered.

1. Legal - company has the right to use the trademark used

Afternoon tea, the program, an outdoor concert, and a full afternoon and evening with the September 1995 parade and activities, including a parade of floats and a band (see <http://www.milwaukee.gov>).

<sup>10</sup> In the last reported instance of violence against a woman, the woman, Susan G. (name changed), was shot in the chest, the lower left chest, near the heart, on May 19, 1997, near the same address, 1112 E. 12th Ave., during a party. In the case of the 1997 shooting,

Each participant was randomly assigned to either the positive or negative feedback condition. In the positive condition, the participant was given a positive feedback message (e.g., "good job") after each correct response. In the negative condition, the participant was given a negative feedback message (e.g., "bad job") after each incorrect response.

It is noted that, although the 1990-1991 season was not a record for the province of planted trees, it was the highest for the last 10 years, with 1990-1991 the highest at 1,000,000 trees, with 1990-1991 the highest at 1,000,000 trees.

The development of any new product requires

depression is more common in people with chronic  
pain, and we found a correlation between the two.  
We also found that people with chronic pain are more  
likely to be depressed than people without chronic pain.









[illegible]

As part of the study, the EAGLE OCTOPUS-1000 was used to compare the fallow regime with the fallow of the 1970s, and to make plots, single fallow and two fallows, the same size as the old plots. The comparison with the 1970s was made by the use of the same plots. The fallow of the 1970s was made by the use of the same plots. The fallow of the 1970s was made by the use of the same plots.

4774

Topic	Category	Reference		Reference
		Index	Symbol	
1. Introduction to the subject	General	1-10	1-10	1-10
2. The subject of the study	General	11-20	11-20	11-20
3. The subject of the study	General	21-30	21-30	21-30
4. The subject of the study	General	31-40	31-40	31-40
5. The subject of the study	General	41-50	41-50	41-50
6. The subject of the study	General	51-60	51-60	51-60
7. The subject of the study	General	61-70	61-70	61-70
8. The subject of the study	General	71-80	71-80	71-80
9. The subject of the study	General	81-90	81-90	81-90
10. The subject of the study	General	91-100	91-100	91-100

[illegible][illegible]

It is important to note that the proposed model may partially degrade or perturb the true unknown parameters provided the number of iterations is finite. As an alternative, Carmona et al. [15] present and justify an algorithm of choice for EM, EM-EM, EM-EM, and EM-EM-EM. The authors also provide a comparison of the EM algorithm with the EM-EM algorithm. The authors also provide a comparison of the EM algorithm with the EM-EM algorithm. The authors also provide a comparison of the EM algorithm with the EM-EM algorithm.

Further work is being done on the design of the aircraft engine and the use of a new type of engine in the engine. The use of a new type of engine in the engine is being done.

implies that the total welfare depends on the number of small and large firms in the economy. This makes the theory of firm size distribution of great interest for all economists. In this paper we consider a simple model of the firm size distribution in a two sector economy, and show that the theory of firm size distribution is closely related to the theory of the distribution of income.

1. The  $\text{Ca}^{2+}$ -ATPase and  $\text{Na}^{+}$ /K<sup>+</sup> ATPase pumps are located on the basolateral membrane and maintain a low  $\text{Ca}^{2+}$  level.

- 24 -

Date	Amount	Balance	
		Debit	Credit
Feb. 1	100.00		100.00
Feb. 15	50.00	50.00	
Feb. 28	25.00		25.00
Mar. 1	75.00		75.00
Mar. 15	30.00	30.00	
Mar. 31	10.00		10.00
Apr. 1	10.00		10.00
Apr. 15	20.00	20.00	
Apr. 30	10.00		10.00
May 1	10.00		10.00
May 15	20.00	20.00	
May 31	10.00		10.00
Jun. 1	10.00		10.00
Jun. 15	20.00	20.00	
Jun. 30	10.00		10.00
Jul. 1	10.00		10.00
Jul. 15	20.00	20.00	
Jul. 31	10.00		10.00
Aug. 1	10.00		10.00
Aug. 15	20.00	20.00	
Aug. 31	10.00		10.00
Sep. 1	10.00		10.00
Sep. 15	20.00	20.00	
Sep. 30	10.00		10.00
Oct. 1	10.00		10.00
Oct. 15	20.00	20.00	
Oct. 31	10.00		10.00
Nov. 1	10.00		10.00
Nov. 15	20.00	20.00	
Nov. 30	10.00		10.00
Dec. 1	10.00		10.00
Dec. 15	20.00	20.00	
Dec. 31	10.00		10.00
Total	1000.00	1000.00	1000.00

we were in a real "what if" situation of possibly becoming  
an "early" or "late" mover, but we did not want to be  
one of the "early" movers. We were not sure if we were

Thus, the ability of such experiments to determine maximum molecular weights of polymers is greatly dependent upon the initial period of study of the polymerization. In this respect, the use of a low-boiling solvent such as benzene and polymeric hydrocarbons such as polyethylene or polypropylene is preferred over the use of high-boiling solvents such as benzene and nitrobenzene.

THE UNIVERSITY OF CHICAGO PRESS

1 The report is made pursuant to the direction of the U.S. House of Representatives, H. Res. 100, passed July 11, 1956, which authorized the House Committee on Education and the Labor Committee to conduct a study of the Federal Bureau of Investigation's activities in the field of racial discrimination. The report is made pursuant to the direction of the U.S. House of Representatives, H. Res. 100, passed July 11, 1956, which authorized the House Committee on Education and the Labor Committee to conduct a study of the Federal Bureau of Investigation's activities in the field of racial discrimination. The report is made pursuant to the direction of the U.S. House of Representatives, H. Res. 100, passed July 11, 1956, which authorized the House Committee on Education and the Labor Committee to conduct a study of the Federal Bureau of Investigation's activities in the field of racial discrimination.



[illegible][illegible]

The average of all possible predictions by the model is equivalent to the best prediction by the process at observation time. However, the internal model is substituted in place of the true model, and consequently, the prediction error is generally non-zero. The prediction error is a function of the model and the process, and is denoted by  $\epsilon_t$ .

Still more growth is needed to allow NTJOL to continue to expand its activities. The number of members is small and the budget is very low. NTJOL needs more funds for the direct costs of higher prices and more indirect costs of travel, as well as funds for administration.

Highly variable growth rates among some *Acetivibrio* strains and *Acetivibrio* "strains" of 1, 10, 100, and 1,000 h<sup>-1</sup> have been reported (Krause, 1980). The authors note a significant correlation between the growth rate and the amount of acetate produced, but do not discuss the mechanism of this correlation. The authors also note that the growth rate of *Acetivibrio* is not related to the amount of acetate produced, but do not discuss the mechanism of this correlation. The authors also note that the growth rate of *Acetivibrio* is not related to the amount of acetate produced, but do not discuss the mechanism of this correlation.

[illegible]

The authors gratefully acknowledge the assistance of Dr. J. A. B. Smith, who provided the initial sample of the polymer used in this study.

[illegible][illegible]

© 1996 by the author. Published by Blackwell Science Ltd, 108 Cowley Road, Oxford OX4 1JF, UK and 350 Main Street, Malden, MA 02148, USA.

**Address:** 1000 University Ave., Suite 1000  
New York, NY 10017-2498

1. A **character** is a person, place, or thing that is used to represent an idea or a quality. For example, a character in a story might be a brave knight or a cunning thief.

2. The 2004 survey, conducted in June 2004, will be by a multi-lingual multi-cultural staff of 2004 and the group consisting of about 1000 people. The survey will be conducted in the following manner:

ALL INFORMATION CONTAINED HEREIN IS UNCLASSIFIED  
DATE 01/14/2009 BY 60322 UCBAW

© 1997 by the American Psychological Association, 0893-3200/97/\$12.00  
DOI: 10.1037/0893-3200.11.4.511

117 - Item 6 was not with me at the time I did the work  
on the box and the contents of the box.

[illegible]

7. A. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 84

[illegible]

4. The lack of knowledge of the law among the layman has led to the development of the law firm. The law firm has become a monopoly of the legal profession, and the layman has been excluded from the legal profession.

✓ The second variable is the number of hours worked per week. The third variable is the number of children under the age of 18 in the household. The fourth variable is the number of children under the age of 18 in the household who are under the age of 5.

(i) The interval on the real line between the points representing the two roots  $r_1$  and  $r_2$  is given by  $\sqrt{b^2 - 4ac}$ .

[illegible]

across the surface of the sample. The sample is then placed in a desiccator and allowed to dry. The sample is then placed in a desiccator and allowed to dry. The sample is then placed in a desiccator and allowed to dry.

12. The sample is then placed in a desiccator and allowed to dry. The sample is then placed in a desiccator and allowed to dry.

13. The sample is then placed in a desiccator and allowed to dry. The sample is then placed in a desiccator and allowed to dry.

14. The sample is then placed in a desiccator and allowed to dry. The sample is then placed in a desiccator and allowed to dry.

with the sample. The sample is then placed in a desiccator and allowed to dry. The sample is then placed in a desiccator and allowed to dry.

15. The sample is then placed in a desiccator and allowed to dry. The sample is then placed in a desiccator and allowed to dry.

16. The sample is then placed in a desiccator and allowed to dry. The sample is then placed in a desiccator and allowed to dry.

17. The sample is then placed in a desiccator and allowed to dry. The sample is then placed in a desiccator and allowed to dry.

18. The sample is then placed in a desiccator and allowed to dry. The sample is then placed in a desiccator and allowed to dry.

19

20

21

22

23

24

25

26

27

28

29

- |     |   |
|-----|---|
| 126 | 44-38861-104 (44-38861-103) (1975-1976)<br>COP. FURNITURE ROOMS (12/1/75)   |
| 127 | 44-38861-105 (44-38861-104) (1976-1977)<br>Domestic Products, Inc. (1976-1977)<br>Domestic Products, Inc. (1976-1977) |
| 128 | 44-38861-106 (44-38861-105) (1977-1978)<br>Domestic Products, Inc. (1977-1978)  |
| 129 | 44-38861-107 (44-38861-106) (1978-1979)<br>Domestic Products, Inc. (1978-1979)  |
| 130 | 44-38861-108 (44-38861-107) (1979-1980)<br>Domestic Products, Inc. (1979-1980)  |
| 131 | 44-38861-109 (44-38861-108) (1980-1981)<br>Domestic Products, Inc. (1980-1981)  |
| 132 | 44-38861-110 (44-38861-109) (1981-1982)<br>Domestic Products, Inc. (1981-1982)  |
| 133 | 44-38861-111 (44-38861-110) (1982-1983)<br>Domestic Products, Inc. (1982-1983)  |
| 134 | 44-38861-112 (44-38861-111) (1983-1984)<br>Domestic Products, Inc. (1983-1984)  |
| 135 | 44-38861-113 (44-38861-112) (1984-1985)<br>Domestic Products, Inc. (1984-1985)  |
| 136 | 44-38861-114 (44-38861-113) (1985-1986)<br>Domestic Products, Inc. (1985-1986)  |
| 137 | 44-38861-115 (44-38861-114) (1986-1987)<br>Domestic Products, Inc. (1986-1987)  |
| 138 | 44-38861-116 (44-38861-115) (1987-1988)<br>Domestic Products, Inc. (1987-1988)  |
| 139 | 44-38861-117 (44-38861-116) (1988-1989)<br>Domestic Products, Inc. (1988-1989)  |
| 140 | 44-38861-118 (44-38861-117) (1989-1990)<br>Domestic Products, Inc. (1989-1990)  |
| 141 | 44-38861-119 (44-38861-118) (1990-1991)<br>Domestic Products, Inc. (1990-1991)  |
| 142 | 44-38861-120 (44-38861-119) (1991-1992)<br>Domestic Products, Inc. (1991-1992)  |
| 143 | 44-38861-121 (44-38861-120) (1992-1993)<br>Domestic Products, Inc. (1992-1993)  |
| 144 | 44-38861-122 (44-38861-121) (1993-1994)<br>Domestic Products, Inc. (1993-1994)  |
| 145 | 44-38861-123 (44-38861-122) (1994-1995)<br>Domestic Products, Inc. (1994-1995)  |
| 146 | 44-38861-124 (44-38861-123) (1995-1996)<br>Domestic Products, Inc. (1995-1996)  |
| 147 | 44-38861-125 (44-38861-124) (1996-1997)<br>Domestic Products, Inc. (1996-1997)  |
| 148 | 44-38861-126 (44-38861-125) (1997-1998)<br>Domestic Products, Inc. (1997-1998)  |
| 149 | 44-38861-127 (44-38861-126) (1998-1999)<br>Domestic Products, Inc. (1998-1999)  |
| 150 | 44-38861-128 (44-38861-127) (1999-2000)<br>Domestic Products, Inc. (1999-2000)  |
| 151 | 44-38861-129 (44-38861-128) (2000-2001)<br>Domestic Products, Inc. (2000-2001)  |
| 152 | 44-38861-130 (44-38861-129) (2001-2002)<br>Domestic Products, Inc. (2001-2002)  |
| 153 | 44-38861-131 (44-38861-130) (2002-2003)<br>Domestic Products, Inc. (2002-2003)  |
| 154 | 44-38861-132 (44-38861-131) (2003-2004)<br>Domestic Products, Inc. (2003-2004)  |
| 155 | 44-38861-133 (44-38861-132) (2004-2005)<br>Domestic Products, Inc. (2004-2005)  |
| 156 | 44-38861-134 (44-38861-133) (2005-2006)<br>Domestic Products, Inc. (2005-2006)  |
| 157 | 44-38861-135 (44-38861-134) (2006-2007)<br>Domestic Products, Inc. (2006-2007)  |
| 158 | 44-38861-136 (44-38861-135) (2007-2008)<br>Domestic Products, Inc. (2007-2008)  |
| 159 | 44-38861-137 (44-38861-136) (2008-2009)<br>Domestic Products, Inc. (2008-2009)  |
| 160 | 44-38861-138 (44-38861-137) (2009-2010)<br>Domestic Products, Inc. (2009-2010)  |
| 161 | 44-38861-139 (44-38861-138) (2010-2011)<br>Domestic Products, Inc. (2010-2011)  |
| 162 | 44-38861-140 (44-38861-139) (2011-2012)<br>Domestic Products, Inc. (2011-2012)  |
| 163 | 44-38861-141 (44-38861-140) (2012-2013)<br>Domestic Products, Inc. (2012-2013)  |
| 164 | 44-38861-142 (44-38861-141) (2013-2014)<br>Domestic Products, Inc. (2013-2014)  |
| 165 | 44-38861-143 (44-38861-142) (2014-2015)<br>Domestic Products, Inc. (2014-2015)  |
| 166 | 44-38861-144 (44-38861-143) (2015-2016)<br>Domestic Products, Inc. (2015-2016)  |
| 167 | 44-38861-145 (44-38861-144) (2016-2017)<br>Domestic Products, Inc. (2016-2017)  |
| 168 | 44-38861-146 (44-38861-145) (2017-2018)<br>Domestic Products, Inc. (2017-2018)  |
| 169 | 44-38861-147 (44-38861-146) (2018-2019)<br>Domestic Products, Inc. (2018-2019)  |
| 170 | 44-38861-148 (44-38861-147) (2019-2020)<br>Domestic Products, Inc. (2019-2020)  |
| 171 | 44-38861-149 (44-38861-148) (2020-2021)<br>Domestic Products, Inc. (2020-2021)  |
| 172 | 44-38861-150 (44-38861-149) (2021-2022)<br>Domestic Products, Inc. (2021-2022)  |
| 173 | 44-38861-151 (44-38861-150) (2022-2023)<br>Domestic Products, Inc. (2022-2023)  |
| 174 | 44-38861-152 (44-38861-151) (2023-2024)<br>Domestic Products, Inc. (2023-2024)  |
| 175 | 44-38861-153 (44-38861-152) (2024-2025)<br>Domestic Products, Inc. (2024-2025)  |
| 176 | 44-38861-154 (44-38861-153) (2025-2026)<br>Domestic Products, Inc. (2025-2026)  |
| 177 | 44-38861-155 (44-38861-154) (2026-2027)<br>Domestic Products, Inc. (2026-2027)  |
| 178 | 44-38861-156 (44-38861-155) (2027-2028)<br>Domestic Products, Inc. (2027-2  |

**OT HER FLEET-ATI 305**

Address: University of Iowa, 1000  
 Johnson Drive, Iowa City, IA 52242  
 e-mail: jerry.kirchhoff@uiowa.edu  
 Tel.: 319/335-3111

171 1571

As previously discussed, the use of a single, linear model of a single gene with a single, linear chromosome, is a very simple model. However, it is not a very good model of the real world. The real world is a very complex system of many genes, many chromosomes, and many interactions between them. The real world is a very complex system of many genes, many chromosomes, and many interactions between them. The real world is a very complex system of many genes, many chromosomes, and many interactions between them.

**13.00 : 4 hours.**



1. NAME OF THE PARTY  
 2. ADDRESS  
 3. DATE

14 SEP 1944 11 06 04216H

Pharmacy and medical schools are not subject to the same standards as other health care professions. There are no national standards for example. There are no national accreditation standards. The only national accreditation standards are for the pharmacy and medical schools, which are not subject to the same standards as other health care professions.

[illegible]

4. The applicant must be at least 18 years of age and have a minimum of 12 months of experience in the field of the proposed research.

The Bureau of the Census has announced that it will release the results of its survey of the economic conditions of the nation's poor in the next few months.

[illegible]

It is noted in the case that the defendant's conduct was not a crime under the law of the state where it occurred.

NY - continued

**Conclusions** — The present study did not demonstrate a statistically significant association between the use of a mobile phone and the risk of a road traffic accident. However, the use of a mobile phone while driving was associated with a significant increase in the risk of a road traffic accident.

© 1999 The Pennsylvania State University, Harrisburg, PA 17122-3200  
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without permission in writing from The Pennsylvania State University.

1. The first step is to identify the problem. In this case, the problem is that the system is not working properly.

Transportation patterns — if you are driving, make sure you follow the 55 mph speed limit. If you are walking, the pedestrian movement is the same as if you were walking on a normal road with no overhead wires.

Of course, the lack of an overall ranking of the 300 ranked products would be interesting, as a statistical distribution of the products would be

1. The first step is to identify the problem or question that needs to be answered. This involves understanding the context and the specific requirements of the task.

1. **Introduction**

10/10/1964. 1st annual Fall for Children concert was  
collected above.

Highly sensitive and accurate, the microarrayed DNA probes: The probe sequences were synthesized manually, the ability to form a specific complex with a target sequence and the high degree of selectivity and sensitivity for the detection of target sequences were confirmed.

Phone Jan my number 310-241-1111. I am a female and  
I like to meet you. All my love and affection. I love you

1. The defendant is a person who is a member of the same family as the plaintiff.

—P9'U'P#U— E6H4WHI 05

1. *Journal of the American Medical Association*, 2000; 284: 2689-2695.

10. The results of the analysis are discussed in a paper being prepared for publication in the near future. I have ONCE AGAIN BEEN INFORMED THAT THE RESULTS OF THE ANALYSIS OF THE DATA FROM THE 1980-1981 season are being prepared for publication.

11 In a recent meeting the High Level Group produced a  
conclusion that it would be necessary to provide the  
mainstreaming an appropriate period of time for the  
work to be done. It is also noted that the  
city of London is a special case, and it is  
acknowledged that the city of London is a special case,  
and it is noted that the city of London is a special case.

11. The following programs have been identified as having received a high level of support from the community, with funding and other resources, and should be maintained. A 2011-12 period of review, however, was not completed because the program boundaries were previously defined. EPA's August 2010 report reflects the findings of a community assessment of the program boundaries, which was not completed. The community program was completed and the results of the assessment were published.

15. The way conditions of labor improve can be improved and will soon be, especially, as the social conditions of life for the people as a whole improve. This is the only way to achieve the best results. The only way to achieve the best results is to improve the social conditions of life for the people as a whole.

11. *U.S. Department of Health, Education and Welfare, Public Health Service, Office of Statistics, Office for Research and Statistics, "The Health of the Nation: A Report on the Health of the Nation, 1975,"* (Washington, D.C.: U.S. Government Printing Office, 1976), p. 113.

<sup>12</sup> *Id.* at 1000 n.10 (citing *United States v. Gurnea*, 465 F.2d 1061, 1063 (1st Cir. 1972)).

[illegible]

development stimulated by the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) on the use of the Internet for clinical research. The FDA has issued guidance on the use of the Internet for clinical research, and the NIH has issued guidance on the use of the Internet for clinical research.

[illegible]

UNCLASSIFIED//FOR OFFICIAL USE ONLY

Tel.: +86-909-8222222 Fax: +86-909-8222222

<sup>20</sup> *Id.* at 1100-1101; see also *Id.* at 1102 (noting that the Commission's decision to use the Commission's position that it is a public utility in the first instance of the inquiry is not binding on the Commission in the second instance of the inquiry).

<sup>40</sup> See, e.g., *Planned Parenthood v. Casey*, 505 U.S. 823, 846 (1992) (citing *Roe v. Wade*, 410 U.S. 113, 137 (1966), and *Stenberg v. Carhart*, 530 U.S. 913, 922 (2000)).



Stressor - Item	Cronbach's Alpha	Constructs			
		Self-Confidence	Self-Respect	Self-Reliance	Self-Trust
Each	1	-	-	-	-
Each 15	0.91	0.91	0.91	0.91	0.91
Each 30	0.91	0.91	0.91	0.91	0.91
Each 45	0.91	0.91	0.91	0.91	0.91
Each 60	0.91	0.91	0.91	0.91	0.91
Each 75	0.91	0.91	0.91	0.91	0.91
Each 90	0.91	0.91	0.91	0.91	0.91

The authors are grateful to the Department of Education, Higher Education, for the award of a research grant for the FET/PhD programme and for the award of a research grant for the FET/PhD programme and for the award of a research grant for the FET/PhD programme.

[illegible]

### Table 1—Contd.

Group	Age	Gender	Mean Age
Group 1	18-24	Male	20.5
Group 2	25-34	Female	29.5
Group 3	35-44	Male	39.5
Group 4	45-54	Female	49.5
Group 5	55-64	Male	59.5
Group 6	65-74	Female	69.5
Group 7	75-84	Male	79.5
Group 8	85-94	Female	89.5
Group 9	95-104	Male	99.5
Group 10	105-114	Female	109.5

[illegible]

1. The authors of the study of Krasovskii (1992) and the  
2. authors of the study of Krasovskii (1992) and the  
3. authors of the study of Krasovskii (1992) and the  
4. authors of the study of Krasovskii (1992) and the  
5. authors of the study of Krasovskii (1992) and the  
6. authors of the study of Krasovskii (1992) and the  
7. authors of the study of Krasovskii (1992) and the  
8. authors of the study of Krasovskii (1992) and the  
9. authors of the study of Krasovskii (1992) and the  
10. authors of the study of Krasovskii (1992) and the

- 44 -

NAME	ADDRESS	TELEPHONE	TELETYPE	TELEFAX
ALFA	1001	200	1001	1001
BETA	2002	300	2002	2002
CHARLIE	3003	400	3003	3003
DELTA	4004	500	4004	4004
ECHO	5005	600	5005	5005
FOXTROT	6006	700	6006	6006
GOLF	7007	800	7007	7007
HOTEL	8008	900	8008	8008
INDIA	9009	000	9009	9009
JULIETT	0000	100	0000	0000
KILO	1001	200	1001	1001
LIMA	2002	300	2002	2002
MIKE	3003	400	3003	3003
NOVEMBER	4004	500	4004	4004
OSCAR	5005	600	5005	5005
PAPA	6006	700	6006	6006
QUEBEC	7007	800	7007	7007
RADIO	8008	900	8008	8008
ROMEO	9009	000	9009	9009
SIGMA	0000	100	0000	0000
TANGO	1001	200	1001	1001
UNIFORM	2002	300	2002	2002
VICTOR	3003	400	3003	3003
WHISKEY	4004	500	4004	4004
XRAY	5005	600	5005	5005
YANKEE	6006	700	6006	6006
ZULU	7007	800	7007	7007

TABLE 1

Country	Year	Population (millions)	Population Growth Rate (%)
USA	1990	248	0.7
USA	2000	268	0.8
USA	2010	288	0.9

The majority of the respondents from the 1995 survey of 411 "PRACTICE" in 1995, 1996 and 1997, were from the 1995 survey. The majority of the respondents from the 1995 survey were from the 1995 survey. The majority of the respondents from the 1995 survey were from the 1995 survey.







**References cited**

CHINESE PATENT APPLICATION NO. 95 10 101, filed February 1995, page 27, abstract, claims, drawings, and U.S. PATENT NO. 5,411,711.  
 The contents of the Chinese patent application and the U.S. patent are hereby incorporated by reference.

CHINESE PATENT APPLICATION NO. 95 10 101, filed February 1995, page 27, abstract, claims, drawings, and U.S. PATENT NO. 5,411,711.  
 The contents of the Chinese patent application and the U.S. patent are hereby incorporated by reference.

CHINESE PATENT APPLICATION NO. 95 10 101, filed February 1995, page 27, abstract, claims, drawings, and U.S. PATENT NO. 5,411,711.  
 The contents of the Chinese patent application and the U.S. patent are hereby incorporated by reference.

CHINESE PATENT APPLICATION NO. 95 10 101, filed February 1995, page 27, abstract, claims, drawings, and U.S. PATENT NO. 5,411,711.  
 The contents of the Chinese patent application and the U.S. patent are hereby incorporated by reference.

CHINESE PATENT APPLICATION NO. 95 10 101, filed February 1995, page 27, abstract, claims, drawings, and U.S. PATENT NO. 5,411,711.  
 The contents of the Chinese patent application and the U.S. patent are hereby incorporated by reference.

The contents of the Chinese patent application and the U.S. patent are hereby incorporated by reference.





**For Further Study:**

**MEMORANDUM FOR THE RECORD**

in accordance with the law under which it was created. On March 1, 1997, it was dissolved from a business and its affairs and accounts of the organization have been reported without incident to the FBI, the Department of Justice, Washington, D.C. and to the State of New York. The organization is now defunct and no longer active.

[illegible]

Figure 1 shows the phase diagram of  $\text{SiO}_2$  in terms of a mixture consisting of different hydrocarbons and carbon dioxide. The solid is controlled by the gas phase with 20% and 40%  $\text{CO}_2$  and the mixture becomes completely solid at temperatures very high and at low pressures. At 1000°C, 100 atm, solid cells are added to 100% of  $\text{CO}_2$  to make another phase (10% of volume), indicating 10% increase of molecules in phase, with the following structure in case of solid and different properties from the liquid phase (10% of volume).

It is not clear whether the low levels of  $^{14}\text{C}$  in the aqueous phase indicate that the polymer is not growing, such as glucosyl, galactosyl, sucrose, and glutamyl synthetase (Figure 2) but does not grow on glucose, mannose, or maltose.<sup>10</sup> Some  $^{14}\text{C}$  is taken up into the cells but after a pathway through to the  $\text{CO}_2$  compartment in the aqueous phase, a 25% increase in polymerization was observed. A similar result was obtained previously by the authors applying to radiolabeled monomers using  $^{14}\text{C}$  and  $^3\text{H}$  as tracers in growth.

[illegible]

The reported capacity of operating at up to 100 g/min under maximum flow rate has not been previously achieved with this burner by means of use of a mixture of 50% acetylene and 50% oxygen, and it is the first time that this burner has been used in the Type Culture Collection Working Unit, as indicated above.

[illegible]

The vote by players for Simpson was based on his role in the 1980 Olympic team, which at the end of the 1980-1991 season he was named MVP of the NHL. The team was coached by Al MacGregor, who was named coach of the year in 1990. Simpson was named MVP of the NHL in 1990. The team was named the 1990 Stanley Cup champion.

[illegible]

**Redacted: b6; b7C**

[illegible]

Approximately 100,000 pounds of polyethylene terephthalate (PET) were produced in 1968. These products were used in a wide range of applications, including packaging for soft drinks, food, and other consumer products. The production of PET was primarily for the domestic market, with a small portion exported to other countries.

[illegible]

Page 4 of 11

[illegible]

All of these items make for a high degree of reliability in the use of the instrument. The instrument is composed of 100 items, each with a rating scale of 1 to 5. The instrument is composed of 100 items, each with a rating scale of 1 to 5. The instrument is composed of 100 items, each with a rating scale of 1 to 5.

[illegible]

The hyperconjugative nature of the amine function has been developed in a series of papers of a chemist and his co-workers (1956, 1957, 1958, 1959, 1960, 1961, 1962, 1963, 1964, 1965, 1966, 1967, 1968, 1969, 1970, 1971, 1972, 1973, 1974, 1975, 1976, 1977, 1978, 1979, 1980, 1981, 1982, 1983, 1984, 1985, 1986, 1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633,

The series of measures available for the treatment of patients including the various techniques of shock therapy, the use of insulin and ECT, the 1950s and 1960s saw a rapid development of the use of psychotropic drugs, particularly the antidepressants, and the use of psychotherapy, including the practice of psychoanalysis. The positive influence will combined with the use of the drugs, the treatment of mental illness has become to be a rapid and effective and it is not only the treatment of mental illness, but also the treatment of the patient's social and psychological problems.

Series 50— and 70— differ in that all cells produced were differentially fluorescent, as opposed to the previous, all-negative experiment. In the 50— and 70— series, a majority of cells in each passage were fluorescent. In the 50— series, the majority of 50— cells were fluorescent, while in the 70— series, a majority of 70— cells were fluorescent. In the 50— series, greater fluorescence was observed than in the 70—, thus permitting a more detailed study of the fluorescence of the cells produced in each series.

in 1984, when the Japanese Government announced that it would provide \$100 million in grants to help the Government of the Philippines develop its health care system. The Japanese Government also provided \$100 million in grants to help the Government of the Philippines develop its health care system. The Japanese Government also provided \$100 million in grants to help the Government of the Philippines develop its health care system.

most of the animals had. There were some very ill specimens, but generally the specimens collected during the trip had been exposed to 50 or more days of 12 to 14 hrs. light and 0.5 to 1.0 m. water column water temperatures. As in the area before, the majority of the fish had been collected during the summer months. The majority of the specimens were 12 to 14 cm long, and 100 mm or more in total length. The majority of the specimens were 12 to 14 cm long, and 100 mm or more in total length. The majority of the specimens were 12 to 14 cm long, and 100 mm or more in total length.

Fig. 10.8 shows that the dose of 100 mg/kg—50% for the production of anti-hepatitis virus—was more effective than 50 mg/kg against the virus production in the liver. The results of the study of the effect of the dose of 100 mg/kg on the production of anti-hepatitis virus in the liver of mice are shown in Table 10.1. The results of the study of the effect of the dose of 100 mg/kg on the production of anti-hepatitis virus in the liver of mice are shown in Table 10.1. The results of the study of the effect of the dose of 100 mg/kg on the production of anti-hepatitis virus in the liver of mice are shown in Table 10.1.

**מס' תיק:** 67-000981  
**תאריך הדפסה:** 22.09.2016

14. A sample with initial temperature  $T_0 = 20^\circ\text{C}$  and  $SE = 0.01^\circ\text{C}$  is heated in a sample furnace of capacity  $Q = 1000\text{ cal/}^\circ\text{C}$  at a rate of  $10^\circ\text{C/min}$ . The sample has a mass  $m = 10\text{ g}$  and a specific heat  $c_p = 0.1\text{ cal/g}^\circ\text{C}$ .

After the trade in the town of Lumberton, North Carolina, the two men, a white man and a black man, were taken to a local court. The white man was charged with the murder of the black man. The black man was charged with the murder of the white man. The court found the white man guilty and sentenced him to death. The black man was found not guilty and was released.

It is difficult to make a fair appraisal of the results of the above analysis and with a given amount of data, it is not possible to determine the effect of changing the trade area and the effect of the trade area on the results. The results of the analysis are not statistically significant and the results of the analysis are not statistically significant. The results of the analysis are not statistically significant and the results of the analysis are not statistically significant.

The results are shown in Table 1. The overall results indicate that the 100% and 50% reduction in the number of cigarettes smoked per day significantly reduced the risk of developing lung cancer. The results also indicate that the 100% and 50% reduction in the number of cigarettes smoked per day significantly reduced the risk of developing lung cancer.



# GP 0 151 581 EN

There are several different methods for determining the relative humidity of a gas. The most common method is by using a psychrometer, which consists of a dry-bulb thermometer and a wet-bulb thermometer. The wet-bulb thermometer is covered with a wet cloth, and the difference in temperature between the two thermometers is used to determine the relative humidity. Another method is by using a hygrometer, which is a device that measures the amount of moisture in the air. A third method is by using a dew point meter, which measures the temperature at which the air becomes saturated with moisture.

The most common method for determining the relative humidity of a gas is by using a psychrometer. This method involves measuring the temperature of a dry bulb and a wet bulb. The wet bulb is covered with a wet cloth, and the difference in temperature between the two bulbs is used to determine the relative humidity. The relative humidity is then calculated using a psychrometric chart. Another method is by using a hygrometer, which is a device that measures the amount of moisture in the air. A third method is by using a dew point meter, which measures the temperature at which the air becomes saturated with moisture.

1

2

3

4

5

6

7

8

9

10

11

TABLE 2

Reduction of Viscosity Coefficient of Water by Brink'Flow Produced by Growth of SD 1 and SD-10 on Different Substrates

Serial	Substr. Source	Amount of Brink'Flow (ml)	Initial Viscosity of Water (0.05%SD)
—	—	—	—
SD-1	Casein	20	24
SD-1	Glucose	10	25
SD-10	Glucose	1	26
SD-10	Casein	1	27
SD-10	Glucose + Glycerol	1	28
SD-10	Casein	1	29
SD-10	Glucose	1	30
SD-10	Glucose + Glycerol	1	31
SD-10	Casein	1	32
SD-10	Glucose	1	33
SD-10	Glucose + Glycerol	1	34
SD-10	Casein	1	35
SD-10	Glucose	1	36
SD-10	Glucose + Glycerol	1	37
SD-10	Casein	1	38
SD-10	Glucose	1	39
SD-10	Glucose + Glycerol	1	40
SD-10	Casein	1	41
SD-10	Glucose	1	42
SD-10	Glucose + Glycerol	1	43
SD-10	Casein	1	44
SD-10	Glucose	1	45
SD-10	Glucose + Glycerol	1	46
SD-10	Casein	1	47
SD-10	Glucose	1	48
SD-10	Glucose + Glycerol	1	49
SD-10	Casein	1	50
SD-10	Glucose	1	51
SD-10	Glucose + Glycerol	1	52
SD-10	Casein	1	53
SD-10	Glucose	1	54
SD-10	Glucose + Glycerol	1	55
SD-10	Casein	1	56
SD-10	Glucose	1	57
SD-10	Glucose + Glycerol	1	58
SD-10	Casein	1	59
SD-10	Glucose	1	60
SD-10	Glucose + Glycerol	1	61
SD-10	Casein	1	62
SD-10	Glucose	1	63
SD-10	Glucose + Glycerol	1	64
SD-10	Casein	1	65
SD-10	Glucose	1	66
SD-10	Glucose + Glycerol	1	67
SD-10	Casein	1	68
SD-10	Glucose	1	69
SD-10	Glucose + Glycerol	1	70
SD-10	Casein	1	71
SD-10	Glucose	1	72
SD-10	Glucose + Glycerol	1	73
SD-10	Casein	1	74
SD-10	Glucose	1	75
SD-10	Glucose + Glycerol	1	76
SD-10	Casein	1	77
SD-10	Glucose	1	78
SD-10	Glucose + Glycerol	1	79
SD-10	Casein	1	80
SD-10	Glucose	1	81
SD-10	Glucose + Glycerol	1	82
SD-10	Casein	1	83
SD-10	Glucose	1	84
SD-10	Glucose + Glycerol	1	85
SD-10	Casein	1	86
SD-10	Glucose	1	87
SD-10	Glucose + Glycerol	1	88
SD-10	Casein	1	89
SD-10	Glucose	1	90
SD-10	Glucose + Glycerol	1	91
SD-10	Casein	1	92
SD-10	Glucose	1	93
SD-10	Glucose + Glycerol	1	94
SD-10	Casein	1	95
SD-10	Glucose	1	96
SD-10	Glucose + Glycerol	1	97
SD-10	Casein	1	98
SD-10	Glucose	1	99
SD-10	Glucose + Glycerol	1	100










FIG. 3

36












FIG. 10





6 6  
EE 10







(51) International Patent Classification:  
**A61K 35/74 (2006.01)**

(21) International Application Number:  
PCT/IN20 13/0005 17

(22) International Filing Date:  
27 August 2013 (27.08.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
578/MUM/2012 5 September 2012 (05.09.2012) IN

(71) Applicant: **AMRITA THERAPEUTICS LIMITED**  
[IN/IN]; C/O Ayurnet Health Care LTD, located, 304 Regency Plaza, Near Rahul Tower Cross Roads, Satellite, 380015 Ahmedabad (IN).

(72) Inventors; and

(71) Applicants : **SALUNKHE , Prabhakar** [IN/IN]; A/P-Bhilali, Tal-Parola, 425 113 Jalgaon (IN). **CHAKRA-BARTY, Ananda** [US/US]; 206 Julia Drive, Villa Park, IL 60181 (US).

(74) Agents: **SHARMA, Rajashree** et al; Corporate Law Group, 1101-1104, 11th Floor, Kailash Building, 26, Kasturba Gandhi Marg, 110001 New Delhi (IN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.1 7(H))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.1 7(in))*

**Published:**

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) Title: A NOVEL BIOMEDICAL DEVICE FOR CANCER THERAPY

(57) Abstract: The present invention provides a device comprising stent or catheter containing biofilms or suspension, of microorganisms selected from *Pseudomonas aeruginosa*, *Streptococcus*, *Staphylococcus*, *Salmonella*, *Clostridia*, *Mycobacterium bovis* BCG useful in cancer therapy. The microorganisms may be attenuated in their virulence factors and with cloned genes encoding specific proteins with anticancer activity. The microorganism-containing devices may be encased in membranes that allow diffusion of proteins with molecular masses of 25, 50, 75 or 100 kDa but not live organisms *per se*.

## BIOMEDICAL DEVICE FOR CANCER THERAPY.

### FIELD OF THE INVENTION:

- The present invention is in the field of medical devices. Particularly, the invention relates to in-dwelling therapeutic device. The therapeutic device is basically a drug eluting device and may be a stent or a catheter. The invention further relates to a therapeutic device having microorganisms harboured therein, useful in cancer therapy. The microorganisms may be attenuated in their virulence factors and with cloned genes encoding specific proteins with anticancer activity. The microorganisms in **suspension** or biofilm form in the devices may be encased in membranes that allow only diffusion of proteins with molecular masses of 25, 50, 75 or 100 kDa but not live biofilm organisms *per se*. The device of the present invention is intended to deliver drugs of microbial origin directly to the tumor site without reaching the blood stream.



### BACKGROUND OF THE INVENTION:

- Live bacteria that have been used for treating cancers, primarily in animal models, are strictly anaerobic such as *Clostridia* and *Bifidobacteria* or facultative anaerobic such as *Listeria monocytogenes* or *Salmonella typhimurium* (1, 2). Al-R strain of *S. typhimurium* had significant tumor regressing effect, such as that of orthotopic human pancreatic tumors, in nude mice. In addition, Al-R strain was also shown to significantly reduce the metastasis of lung and high grade osteosarcoma in nude mice as well as spinal cord gliomas (3, 4). Genetically improved avirulent mutants had also been shown to retain the tumor targeting properties (4) and will be excellent candidates for further testing in humans. However, so far, earlier phase I human clinical trials have not shown significant effects in colonization or cancer regression in metastatic melanoma, due to certain toxicity associated with injections of live bacteria in humans (5). Such injections trigger both innate and adaptive immune responses for clearance of the foreign bacteria, thereby enhancing side effects in already debilitated patients.

The reasons bacteria such as *Salmonella*, *Listeria*, *Clostridia* and others allow cancer regression are believed to be due to the activation of the immune system elicited by the bacteria as well as active growth of the bacteria in the hypoxic regions of the core of the tumors. Usually, virulence deletion mutants are rapidly cleared from the host compared to the wild type. So lack of toxicity in the blood stream has a negative effect on the retention and proliferation of live bacteria in the host tumors. For example, mutants attenuated in *actA* and *plcB* genes in *Listeria monocytogenes* have been shown to have a reasonable safety profile in adult volunteers (5), although no tumor regression effects were studied.

Phase I human clinical trials of a live, attenuated *L. monocytogenes* strain in 15 patients with recurrent metastatic squamous cell carcinoma of the cervix at doses of  $1 \times 10^9$ ,  $3.3 \times 10^9$  or  $1 \times 10^{10}$  cfu showed toxicity with flu-like syndrome such as fever, chills, nausea and/or vomiting/headache (6). Such symptoms are typical of administration of IL-2, indicating the involvement of innate immune response to the i.v. infusions of live bacteria.

The use of *Clostridia* in cancer therapy has shown efficacy in tumor regression, but with considerable toxicity. Consequently, *Clostridial* strains have been used more as diagnostic agents for detection of tumors because of their high specificity for targeting tumor cells (7).

A very promising *Clostridial* strain, *C. novyi-NT* (8) was used as spores in phase I human clinical trials in 2006 (NCT 00358397, [www.clinicaltrials.gov](http://www.clinicaltrials.gov)), but the study was suspended for safety issues, again demonstrating the problem of using live bacteria through the i.v. or i.m. route.

From the above discussion, it is interesting to note that most of the efforts, lasting for more than 60 years, for cancer therapy basically involve anaerobic bacteria. Yet, the most successful practical use of bacteria in cancer therapy involves the use of an aerobe, *Mycobacterium bovis* BCG, the vaccine strain for tuberculosis,

to treat superficial urothelial carcinoma of the bladder. Live BCG cells are administered through a urethral catheter directly into an emptied bladder. The catheter is then removed, leaving the live bacteria in the bladder, which then induce an immune reaction in the bladder, leading to tumoricidal activity (9, 10).

- However, BCG therapy for bladder cancer is associated with a variety of complications, ranging from minor cystitis to life-threatening BCG sepsis, occurring in up to 90% of patients (11, 12).

- As of today, there are no live bacteria, other than *M. bovis* BCG which has a very limited application only in superficial bladder cancer therapy, that have gone past phase III human clinical trials successfully and none is on the horizon, given the toxicity associated with intravenous injections of live bacteria in the blood stream evoking strong immune reaction. Attenuated bacteria, with or without cloned genes, get cleared by the immune system quickly, thereby reducing their effectiveness and staying power in the tumor vicinity.

- A major problem in the application of live bacteria in cancer therapy (1, 2) is a lack of understanding of how bacteria actually cause tumor regression. Spectacular antineoplastic effect, when *C. parvum*-NT was used along with mitomycin C and dolastatin-10, instead of just mitomycin C and dolastatin-10, certainly points out to the active involvement of bacteria in tumor regression and lysis (13). Similarly, the exquisite targeting of tumor and growth in the core of the tumors is known to be a hallmark of *Salmonella*'s ability to cause tumor shrinkage (2, 4, 14). However, such therapies are often known as immunotherapy because the tumor regression is believed to be due to bacteria's preferential growth in the hypoxic core of the tumor, thereby depriving the tumor cells of nutrients, and eliciting immune action that causes tumor regression.

- Do certain bacteria actually fight tumors by elaborating anticancer agents, rather than simply targeting tumors or invoking a strong immune response? indeed, an enzyme arginine deiminase (ADI) produced by *Mycoplasma arginini* has been

shown as early as in 1990 to have anti-tumor activity (15). Since then, many studies including phase III human clinical studies, have been performed with ADI and a polyethylene glycol (PEG)-conjugated ADI, termed ADI-PEG20, in patients with hepatocellular carcinoma and malignant melanoma (16). In general, such results have shown modest anticancer effect of ADI-PEG20 in such patients with tolerable side effects and the clinical trials are continuing with additional patient recruitment (16). ADI action is believed to be due to depletion of arginine in such cancer cells as hepatocellular carcinoma, melanoma or renal cell carcinoma which do not express arginino-succinate synthetase in vivo,

The successful use of a bacterial protein, ADI, rather than live bacteria in human clinical trials raises an interesting question: do other bacteria produce similar proteins or small molecule compounds to fight cancer? Arginine deiminase is not unique to *Mycoplasma*, including *M. arginini*. The ADI from *Pseudomonas aeruginosa*, an aerobic opportunistic pathogen, has also been shown to have anticancer activity against a range of cancers such as fibrosarcoma, breast and ovarian cancers (17). Most interestingly, a 17 kDa truncated N-terminal part of ADI, called Pa-CARD because it harbors a caspase recruitment domain (CARD), has even higher anticancer activity than ADI in such cancers and in liquid-borne cancers such as chronic myeloid leukemia (CML) or acute myeloid leukemia (AML) cell lines (17; 18).

*Pseudomonas aeruginosa*, not previously known or tried in any live cell anticancer drug development, not only produces ADI, but another protein with significant anticancer activity called azurin (19). Azurin has not only anticancer activity against a range of cancers, but also strong growth suppressing activity against viruses such as the HIV/AIDS virus HTV-1 or parasites such as the malarial parasite *Plasmodium falciparum* or the toxoplasmosis parasite *Toxoplasma gondii* (19). Most interestingly, azurin, which is an intracellular periplasmic protein, is secreted by *P. aeruginosa* when *P. aeruginosa* cells are exposed to cancer cells, suggesting that azurin is a weapon that *P. aeruginosa* uses

to keep cancer cells in check. *Pseudomonas aeruginosa* is a biofilm-forming extracellular pathogen that prefers to establish long term residence in human tissues without causing much harm to the host normal cells but becomes very protective of the host as its habitat and has developed promiscuous protein weapons to target other invaders of the human body such as cancers, viruses and parasites (19). A similar azurin-like protein, termed Laz, is produced by *gonococci/meningococci* which also retains such activity against cancers, HIV-1, *P.falciparum* and *T. gondii* (19). A 28 amino acid peptide derived from azurin, azurin 50-77 termed p28, has no toxicity or immunogenicity in animals, including non-human primates (20). In phase I human clinical trials in Chicago, p28 (NSC 745104, www.clinicaltrials.gov) has shown no side effects in 10 advanced cancer patients where no drug is working and who have an average life expectancy of 8 weeks. p28 has shown significant beneficial effect in such patients in a dose dependent manner without demonstrating any side effects.

The therapeutic efficacy of azurin in mouse xenograft models, and the lack of side effects of the p28 peptide with anticancer activity in both animal and phase I human clinical trials raises an important question: can live cells of *P. aeruginosa* fight cancer similar to the anaerobic or facultative anaerobic bacteria such as *Clostridia*, *Salmonella*, etc, as mentioned earlier? As a known pathogen, *P. aeruginosa*, even attenuated strains lacking its major virulence factors such as Exotoxin A, elastase, and other toxins such as ExoS, ExoT and ExoU, that are injected in host cells by a type III secretion mechanism, will evoke strong immune response resulting in considerable toxicity when given intravenously. A unique feature of many pathogenic bacteria such as *P. aeruginosa*, *Streptococcus* and many others is their ability to form biofilms which allows surface adhesion of such bacteria on biotic or abiotic surfaces and acquisition of enough nutrients to allow a slow mode of growth. Indeed, biofilm formation of *P. aeruginosa* in both the lungs of cystic fibrosis patients and in-dwelling medical devices is well known for its pathogenesis, allowing the biofilm bacteria to resist both immune attack and antibiotic treatment. It is also conceivable that *P. aeruginosa* biofilms in an

in-dwelling medical device such as a catheter or stent inserted near a tumor can keep the tumor growth in check through elaboration of weapons such as azurin. This approach can contribute to effective cancer therapy, alone or in combination with common anticancer drugs.

Since azurin is a small 14 kDa protein secreted in presence of cancer cells, other pathogenic bacteria with long term residence in human bodies that can secrete small (less than 25 to 30 kDa) protein with anticancer activity may prove to be a potential component for cancer treatment. Having access to such bacterial protein weapons, with inhibitory activity against a range of cancers, viruses, parasites and pathogenic bacteria, perhaps even multiply drug resistant ones, will not only provide us with promiscuous, multi-disease-targeting drugs, but will provide a general principle of method development for isolation of such potential drugs. Indeed, we have recently described the isolation of a 17 kDa protein, MPT63, produced and secreted by *Mycobacterium tuberculosis* and *M. bovis* BCG, and a 30 amino acid peptide derived from MPT63, termed MB30, that, similar to azurin-p28, have strong anticancer activity against a range of cancers such as bladder, colon, etc.. Similar to azurin, MPT63 demonstrates promiscuity by strongly inhibiting the growth of the HIV/AIDS virus HIV-1. The production of such a protein weapon by *M. bovis* BCG, widely used in the treatment of superficial bladder cancer as mentioned earlier (9, 10), clearly suggests that bacterial regression of cancer is not just due to growth inside tumors or induction of an immune response, as is widely believed (24), but is due to active participation by the microorganisms in secreting or exposing on the surface various protein or other weapons to suppress invasion and growth of a variety of invaders of the human body including cancers, viruses, parasites and pathogenic bacteria/fungi. It is thus quite possible that anaerobic/facultative anaerobic bacteria such as *Clostridia*, *Salmonella*, etc, mentioned earlier, may produce and secrete similar weapons to fight cancers and other invaders. This kind of an approach will allow them to be used as biofilms on catheters/stents or other in-dwelling devices and inserted in the vicinity of the tumor, singly or in combination with other in-

dwelling medical devices harboring other types of bacteria as biofilms. The protein weapons can also be isolated and used as diagnostic agents and/or therapeutic compounds. The in-dwelling devices containing the biofilms of *P. aeruginosa*, *M. tuberculosis/M. bovis*, *Clostridia*, *Salmonella*, etc, either wild type or attenuated by mutations/deletions in various genes contributing to their virulence, can be used as is, or preferably encased by membrane filters with pore sizes that allow diffusion of only molecules with a mass of 25 kDa or 40 kDa. For example, a catheter with attenuated *P. aeruginosa* harboring deletions in exotoxin A, elastase (lasA/lasB) and type III secretion systems (but with or without hyperexpression of the azurin gene), and encased by a membrane filter with a cut-off molecular mass of 25 kDa will allow secretion and diffusion of azurin to reach the tumor but not any residual toxins with molecular mass higher than 25 kDa. In none of the cases, the biofilm bacteria can escape from the catheter to reach the blood stream but remains very close to the tumor to sense its presence. Such an approach greatly reduces any toxicity associated with an immune response, as is normally observed with live bacteria given orally, intravenously or by other means. Multiple catheters with multiple different bacterial biofilms will produce a synergistic effect without concomitant side effects, in absence or in presence of treatments with other drugs.

#### OBJECTIVES OF THE INVENTION:

The main objective of the present invention is to provide a biomedical device for cancer therapy.

Specifically the objective of the invention is to provide an in-dwelling or inserted / catheterized therapeutic device with regulated delivery of drug of microbial origin. Further, neither the microbes nor the drug enter the blood stream. Thus, the invention provides a device with novel drug delivery system.



The other objective is to provide a therapeutic device that may be a stent or a catheter.

Yet another objective is to provide a therapeutic device with microorganisms harboured therein in the form of suspension or biofilms useful in cancer therapy.

The device may be made of any physiologically acceptable material comprising plastic, ceramic, wood, metal, polymer (natural or synthetic) or hydrogel.

Still another objective is to provide a therapeutic device containing live *Pseudomonas aeruginosa* biofilms. *Pseudomonas aeruginosa* may be wild type, or virulence compromised or mutated to reduce toxin and/or cloned with the azurin gene under a strong promoter to hyper express the desired protein or derivative thereof..

The mutations may be in genes encoding type III secretion and Exotoxin A and the elastase genes las A/las B that are important virulence factors for *P. aeruginosa*. For other biofilms comprising of other bacteria such as *Salmonella*, *Clostridia*, *M. bovis* BCG, etc, in the in-dwelling device, appropriate attenuated strains may be used.

Yet

another objective is to insert a therapeutic device at the tumor site wherein the biofilm microorganisms be encased in a membrane surrounding the device. The membrane may be provided with pore sizes capable of preventing diffusion of macromolecules with masses greater than 25 KDa to 40 kDa. Such membranes with defined pore sizes will prevent the release of any bacteria from the biofilm to the blood stream. It is to be noted that while biofilm bacteria are resistant to antibiotics or immune attack, in the absence of membrane encasing, any released bacteria from the device will be susceptible to antibiotics or immune attack, facilitating their clearance.

11

SUMMARY OF THE INVENTION:

Accordingly the present invention provides a biomedical device for cancer therapy comprises indwelling medical device encased in a filter with cut off molecular mass of 25 kDa, the said device harbor live microorganisms selected from *Pseudomonas aeruginosa*, *Streptococcus*, *Staphylococcus*, *Salmonella*, *Clostridia Mycobacterium bovis* BCG.

In one of the embodiment, the device may be a stent or catheter or any other similar means that can be implanted at tumor site.

- 12 In other embodiment, the device could be made of any physiologically acceptable biocompatible material that will not hamper the growth of the microorganism and selected from plastic, wood, polymer (natural or synthetic) or hydrogel.

- 13 In yet other embodiment, the therapeutic device may harbor suspension or biofilms of microorganism either wild type or attenuated or modified, wherein the organisms preferably be *Pseudomonas aeruginosa*. *Pseudomonas aeruginosa* may be virulence compromised or mutated to eliminate toxin production, and cloned with azuringene under a strong promoter to hyperproduce azurin protein.

- 14 The mutations may be in genes encoding type III secretion and Exotoxin A and the elastase genes las A/las B.

- 15 The biofilms may be composed of different sets of bacteria such as *Salmonella*, *Clostridia*, *M. bovis* BCG, etc. Such medical devices can be used in conjunction with other traditional anticancer drug treatment.

#### DETAILED DESCRIPTION:

- 16 There are emerging reports on the use of live and virulence attenuated bacteria for the treatment of cancers. Few bacterial species such as *Salmonella*, *Clostridia*, *Mycobacterium bovis*, when injected intravenously, intramuscularly or other

means, have the ability to enter into the human tumors and allow tumor regression. *Mycobacterium bovis* BCG is used in the treatment of superficial bladder cancer and is thought to induce cancer regression through activation of the immune system.

.

However, there is no report on the use of live wild type or attenuated *Pseudomonas aeruginosa* for the treatment of cancers.

In prior art, the organisms being administered parenterally via injections or orally pose problem in reaching and targeting the poorly vascularized tumors, which have no or low level oxygen. Additionally, eradication of the disseminated/migrated organisms to other parts of the body is another problem. Further, these pathogenic organisms, even when attenuated, evoke strong immune response, leading to toxicity problems.

The biomedical device of the present invention having confinement of microorganisms encased in the membrane of the device eliminates the problem of dissemination in other parts of the body or blood stream and toxicity development. Further the right choice of microorganism, attenuated *Pseudomonas aeruginosa* with mutations/deletions in various toxin genes helps in solving certain problems of accumulation of toxins.

The novel device of the present invention is a novel drug delivery system (NDDS) that provides the benefits of protein / peptide therapy via a combination medical device. The device is a drug eluting oncology stent a first-ever combination medical device designed to deliver in situ microbial therapy directly to the tumor site without reaching the blood stream. This revolutionary approach to cancer therapy will provide an important alternative or adjunct treatment to surgery, radiation or chemotherapy, particularly for inoperable or hard to reach cancer tumors.

The device preferably encases a biofilm in a membrane filter, enabling secretion and diffusion of bacterial proteins/peptides to reach the tumor and blocking release of any residual toxins with molecular mass higher than 25 kDa. The

concentration of anticancer molecule released from bacteria to the tumor site allow tumor regression effectively, while the device will prevent the bacterium as well as the toxic molecules having size more than 25 kDa to be released thereby minimizing risk of potential side effects of using live bacterium in cancer therapy. A range of cancers may be treatable by this method, either as an alternative or adjunct to surgery, radiation or chemotherapy.

The device was tried in preclinical trials wherein the experiments were conducted on nude mice. The two experimental nude mice (Figures 1 A, B) were subcutaneously injected with one million cells of human breast tumor (cancer cell line MCF-7) to instate infection. After 5 days, when both the mice showed small visible tumors, a device of the present invention (drug eluting stent) harboured with *Pseudomonas aeruginosa* was inserted in the experimental mouse, while the other (control) mouse was devoid of such stent. The sizes of tumors in both mice were measured twice a week by an electronic caliper over a period of five weeks. Such measurements demonstrated that the size of the tumor in the experimental mouse (with catheter) was about half the size of the tumor in the control mouse up to about three and a half weeks. Most surprisingly, the tumor in the experimental mouse went necrotic and burst after about three and a half weeks (Figure 1B, experimental mouse) while the tumor in the control (without any catheter) mouse kept growing (Figure 1A, control mouse). At about 5 weeks, while the tumor in the control mouse kept growing and the mouse was extremely lethargic and sick, the necrotic tumor and the wound surrounding it of the experimental mouse gradually healed (Figure 1C, experimental mouse). This mouse exhibited good mobility and activity like any mouse without tumor.

The device was also tested on human subjects with high grade prostate cancer. Insertion of a catheter containing pseudomonas proved to be promising in regression of tumor

The applicant had recently described the production of anti-cancer proteins, or peptides derived from microorganisms,, such as **azurin**, arginine deiminase (ADI), Pa-CARD and azurin-p28 that allow tumor regression both *in vitro* and *in vivo* in mice (1, 17, 18, 19). Although, as described earlier, live bacteria such as

- *Clostridia*, *Salmonella*, etc., have been shown to allow tumor regression, there is no report on the use of live or attenuated *Pseudomonas aeruginosa* for the treatment of cancers. *Pseudomonas aeruginosa* is known to form biofilms on the abiotic or biotic surfaces and can grow under microaerophilic conditions. The use of a stent, catheter or other similar therapeutic device that contains biofilm
- bacteria of the wild type or virulence compromised *P. aeruginosa* strains may provide potential and viable treatment of cancers in humans. The stent, catheter, hydrogel or other similar therapeutic device containing *P. aeruginosa* is administered in the human body at the site of the tumors or near to the tumors where the anticancer proteins or small molecules secreted by the bacterium allow
- regression of solid tumors. The use of wild type or virulence compromised *P. aeruginosa* is an excellent way to treat a variety of human cancers. For example, a patient with prostate cancer may have a catheter containing *P. aeruginosa* biofilms in the urovesicular region near the tumor. While the *P. aeruginosa* persists in the catheter, the patient's condition will be relatively stable with the
- tumor either stabilized or undergoing shrinkage. Additional therapy with anticancer drugs will help in the complete elimination of the tumor.

Further, it is clear that such a stent, catheter, or similar therapeutic device with *P. aeruginosa* also may be encased in membranes with pore sizes that allow diffusion of only 25 Kda to 40 kDa macromolecules. Because the *P. aeruginosa* toxins such as Exotoxin A or ExoS/T are larger than 40 Kda, the live cells of *P. aeruginosa* or their released toxins cannot come out of the catheter to enter the tumors or surrounding tissues, leaving the release of low molecular weight anticancer proteins such as azurin to fight cancer.

- Here, we focus on the use of plastic, ceramic, wooden or metal stent, catheter, or similar therapeutic device containing a biofilm of the live bacterium *Pseudomonas*

*aeruginosa* that is either wild type or genetically modified to eliminate its pathogenicity and to be inserted at the site of the tumors to allow tumor regression in cancer patients.

- 5 The strain of the *P. aeruginosa* in the biofilm could be laboratory or clinical isolates of wild-type bacteria or laboratory-derived mutants of such bacteria defective in the production of toxins such as Exotoxin A, Elastase or toxins elaborated through the type III secretion system (ExoS, ExoT, ExoU, etc). *P. aeruginosa* may have cloned azurin gene under a strong promoter to
- 10 hyperexpress azurin gene with its signal sequence to allow secretion of the azurin.

Other biofilm-forming bacteria such as *Streptococcus*, *Staphylococcus*, *Mycobacterium bovis* BCG, etc, also may be used in place of *P. aeruginosa*.

- 15 The cancers to be treated by the live cells of *P. aeruginosa* or other biofilm-forming bacteria as part of catheters or stent surfaces are prostate, melanoma, sarcoma, breast, lung, ovarian, kidney, cervical, liver, bladder, colon, pancreas or other tumor types. The use of catheter/stent or similar therapeutic device containing *P. aeruginosa* or other bacterial biofilms inserted at the site of the
- 20 tumor(s) is a treatment modality that can be given singly or in conjunction with other treatments such as radiation, chemotherapy or the emerging treatments with bacterial proteins or peptides given via intravenous/intra muscular routes.

#### References

- 25 1. Fialhp, A.M. & Chakrabarty, A.M. Editors. 2010. Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools. John Wiley & Sons, Hoboken, New Jersey.
- 2. Forbes, N.S. 2010. Engineering the perfect (bacterial) cancer therapy. Nature Rev./Cancer **10**: 785-794.
- 3. Hayashi, K., Zhao, M., Yamaguchi, K., Yamamoto, N., Tsuchiya, H., Tomita, K., Kishimoto, H., Bouvet, M. & Hoffman, R.M. 2009. Systemic
- 30 targeting of primary bone tumor and lung metastasis of high-grade

osteosarcoma in nude mice with a tumor-selective strain of *Salmonella typhimurium*. *Cell Cycle* **8**: 870-875.

- 1 Hoffman, R.M. 2010. *Salmonella typhimurium* mutants selected to grow only in tumors to eradicate them in nude mouse models. In *Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools*. Fialho, A.M. & Chakrabarty, A.M., Eds. Pages 3-12. John Wiley & Sons, Hoboken, New Jersey.
- 2 Angelakopoulos, H., Loock, K., Sisul, D.M., Jensen, E.R., Miller, J.F. & Hohman, E.L. 2002. Safety and shedding of an attenuated strain of *Listeria monocytogenes* with a deletion of *actA/plcB* in adult volunteers: a dose escalation study of oral inoculation. *Infect. Immun.* **70**: 3592-3601.
- 3 Maciag, P.C, Radulovic, S. & Rothman, J. 2009. The first clinical use of a live, attenuated *Listeria monocytogenes* vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. *Vaccine* **27**: 3975-3983.
- 4 Schmidt, W., Fabricius, E.M. & Schneeweiss, U. 2006. The tumour-*Clostridium* phenomenon: 50 years of developmental research. *Int. J. Oncol.* **29**: 1479-1492.
- 5 Bettegowda, C, Huang, X., Lin, J., Cheon, I., Kohli, M., Szabo, S.A., Zhang, X., Diaz, L.A.Jr., Velculesen, V.E., Permigiani, G., Kinzler, K.W., Vogelstein, B. & Zhou, S. 2006. The genome and transcriptomes of the anti-tumor agent *Clostridium novyi-HY*. *Nature Biotechnol.* **24**: 1573-1580.
- 6 Herr, H.W. & Morales, A. 2008. History of *bacillus* Calmette-Guerin and bladder cancer: an immunotherapy success story. *J. Urol.* **179**: 53-56.
- 7 Morales, A., Phadke, K. & Steinhoff, G. 2009. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. *J. Urol.* **181**: 1040-1045.
- 8 Bohle, A., Jocham, D. & Bock, P.R. 2003. Intravesical *bacillus* Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-

analysis of comparative studies on recurrence and toxicity. J. Urol. **169**: 90-95.

12. Rawls, W.H., Lamm, D.L., Lowe, B.A., Crawford, E.D., Sarosdy, M.F., Montie, J.E., Grossman, H.B. & Scardino, P.T. 1990. Fetal sepsis following intravesical *bacillus* Calmette-Guerin administration for bladder cancer. J. Urol. **144**: 1328-1330.

13. Dang, L.H., Bettegowda, C, Huso, D.L., Kinzler, K.W. & Vogelstein, B. 2001. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl. Acad. Sci. USA **98**: 15155-15160.

14. Sznol, M., Lin, S.L., Bermudes, D., Zheng, L.M. & King, I. 2000. Use of preferentially replicating bacteria for the treatment of cancer. J. Clin. Invest. **105**: 1027-1030.

15. Miyazaki, K., Takaku, H., Umeda, M., Fujita, T., Huang, W.D., Kimura, T., Yamashita, J. & Horio, T. 1990. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a *Mycoplasma-mfected* cell line. Cancer Res. **50**: 4522-4527.

16. Feun, L., Kuo, M.T., You, M., Wu, C.J., Wangpaichitr, M. & Savaraj, N. 2010. Arginine deiminase and cancer therapy. In Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools. Fialho, A.M. & Chakrabarty, A.M., Eds. Pages 199-217, John Wiley & Sons, Hoboken, New Jersey.

17. Kundu, M., Thomas, J., Fialho, A.M., Kwan, J.M., Moreira, L.M., Mahfouz, M., Das Gupta, T.K. & Chakrabarty, A.M. 2009. The anticancer activity of the N-terminal CARD-like domain of arginine deiminase (ADI) from *Pseudomonas aeruginosa*. Lett. Drug Design Discov. **6**: 403-412.

18. Kwan, J.M., Fialho, A.M., Kundu, M., Thomas, J., Hong, C.S., Das Gupta, T.K. & Chakrabarty, A.M. 2009. Bacterial proteins as potential drugs in the treatment of leukemia. Leuk. Res. **33**: 1392-1399.

19. Chakrabarty, A.M. 2010. Bioengineered bugs, drugs and contentious issues in patenting. Bioeng. Bugs **1**: 2-8.



1. Jia, L., Gorman, G.S., Coward, L.U., Noker, P.E., McCormick, D., Horn, T.L., Harder, J.B., Muzzio, M., Prabhakar, B., Ganesh, B., Das Gupta, T.K. & Beattie, C.W. 2010. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC 745104), a peptide inhibitor of p53 ubiquitination. *Cancer Chemother.Pharmacol.*, Nov. 18 issue, Pubmed/21085965.
2. Kresowik, T.P. & Griffith, T.S. 2010. *Bacillus Calmette-Guerin (BCG) for urothelial carcinoma of the bladder. In Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools.* Fialho, A.M. & Chakrabarty, A.M., Eds. Pages 49-70. John Wiley & Sons, Hoboken, New Jersey.

WE CLAIM:

1. A biomedical device for cancer therapy comprises indwelling medical device encased in a filter with cut off molecular mass of 25 kDa, the said device harbor live microorganisms selected from *Pseudomonas aeruginosa*, *Streptococcus*, *Staphylococcus*, *Salmonella*, *Clostridia*, *Mycobacterium bovis* BCG.
2. The device as claimed in claim 1 wherein the microorganisms are either in the form of biofilm or suspension.
3. The device as claimed in claim 1 wherein the indwelling medical device is a stent or a catheter or any other similar means that can be implanted at tumor site.
4. The device as claimed in claim 3 wherein the indwelling medical device is made of any physiologically acceptable biocompatible material selected from plastic, ceramic, wood, metal, polymer (natural or synthetic) or hydrogel.
5. The device as claimed in claim 1 wherein the live microorganisms harbored are either wild type or attenuated or modified
6. The device as claimed in preceding claims wherein the organism is *Pseudomonas aeruginosa*.
7. The device as claimed in claim 6 wherein *Pseudomonas aeruginosa* is virulence compromised, mutated to eliminate toxin production, or cloned with azurin gene under a strong promoter to hyperproduce azurin protein.
8. The device as claimed in claim 7 wherein the mutations are in genes encoding type III secretion and Exotoxin A and the elastase genes las A/las B.

- 10 The device as claimed in claim 1 for use to treating cancers of prostate, melanoma, sarcoma, breast, lung, ovarian, kidney, cervical, liver, bladder, colon, pancreas or other tumor types and HIV/AIDS without entering in blood stream.

11

- 12 The device as claimed in claim 9 for use in conjunction with other traditional anticancer drug to treating cancers of prostate, melanoma, sarcoma, breast, lung, ovarian, kidney, cervical; liver, bladder, colon, pancreas or other tumor types and HTV/AIDS.

13

14

15

16

17

.

1.2




Fig. 1.2. The photograph of the mineral specimen, which is a natural specimen of the mineral.





Fig. 1.2. The photograph of the mineral specimen, which is a natural specimen of the mineral.



(19) World Intellectual Property Organization  
International Bureau

(43) International Publication Date  
5 April 2012 (05.04.2012)



(10) International Publication Number  
**WO 2012/042540 A2**

(51) International Patent Classification:  
**A61K 38/16** (2006.01) **A61K 39/04** (2006.01)

(21) International Application Number:  
PCT/IN20 11/000680

(22) International Filing Date:  
30 September 2011 (30.09.2011)

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
2754/MUM/2010 1 October 2010 (01.10.2010)

(71) Applicant (for all designated States except US): **AMRI-TA THERAPEUTICS LIMITED** [—/IN]; c/o Ayurnet Health Care Ltd., 304 Regency Plaza, Near Rahul Tower, Cross Roads, Satellite, 380015 Ahmedabad (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SURI, Anil** [IN/IN]; A-2, National Institute of Immunology, Aruna Asaf Ali Marg, 110 067 New Delhi (IN). **KANOJIA, Deepika** [IN/IN]; B-12, National Institute of Immunology, Aruna Asaf Ali Marg, 110 067 New Delhi (IN). **SALUNKHE, Prabhakar** [IN/IN]; A/P-Bhilali, Tal-Parola, Dist- Jalgaon, 425 113 (IN). **MAHALI, Sidharth** [IN/IN]; 12 Nupatna, Manglabag, Cuttack, 753 001 Cuttack, ORISSA (IN). **MANNA, Sunil Kumar** [IN/IN]; Village - Jagatpur, Post Office -, Patanda, Police Station - Panskura, 721 139 District - Midnapur East (WB) (IN). **SUROLIA, Avadhe-sha** [IN/IN]; Director Residence, National Institute of Immunology, Aruna Asaf Ali Marg, 110 067 New Delhi (IN). **CHAKRABARTY, Ananda** [US/US]; 206 Julia Drive, Villa Park IL 60181 (US).

(74) Agents: **SHARMA, Rajashree** et al; Corporate Law Group, 1101-1104, 11th Floor, Kailash Building, 26, Kasturba Gandhi Marg, 110 001 New Delhi (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(Hi))

**Published:**

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: ANTICANCER AGENT

(57) Abstract: The present invention thus provides microbial products as anticancer agents and pharmaceutical compositions comprising isolated and purified proteins or synthetic peptides, and methods of using them for the treatment of cancer. It is very important to develop new anticancer bioactive peptides having high activity and low toxicity; given that most currently available anticancer therapies either have significant toxicity, and/or are prone to development of resistance.

## ANTICANCER AGENT

### FIELD OF THE INVENTION:

The present invention particularly relates to a broad spectrum anticancer agent that is of microbial origin. More particularly, the invention relates to proteins either secreted by or surface associated in microorganisms including but not limiting to bacteria both pathogenic and nonpathogenic, viruses, and/or parasites. The anticancer agents of the present invention are purified proteins isolated from bacteria and parasites. Specifically, the agent of the present invention comprising at least proteins isolated from *Mycobacterium bovis* BCG, and *Toxoplasma gondii*. It also encompasses peptides derived from such proteins, synthetically prepared peptides, and proteins or peptides modified by PEGylation, acetylation, phosphorylation, etc. The proteins or various truncated derivatives thereof possess enhanced efficacy and reduced toxicity. The modifications made to the active purified proteins and peptides extend half life of the active ingredient or reduce immunogenicity in the patient blood stream.

The present invention also discloses the compositions, pharmaceutical compositions and the manner of its applications as therapeutic agent to treat mammalian cancer. The pharmaceutical composition comprises an active ingredient i.e. proteins, peptides, including PEGylated, acetylated, phosphorylated form thereof in isolation or in combination and physiologically and pharmaceutically accepted adjuvants or excipients.

### BACKGROUND OF THE INVENTION:

Bladder cancer is one of the deadliest forms of cancer, considered the sixth most common cause of cancer-related death in the United States (Jemal et al., 2008). One of the major weapons in the arsenal of cancer fighting drugs is the use of the bacterium *Mycobacterium bovis* (Bacillus Calmette-Guerin, BCG) since 1976 to fight superficial urothelial carcinoma of the bladder (Herr and Morales, 2008; Kresowik and Griffith, 2010). For its use as an anticancer therapy, **live BCG cells** are taken from lyophilized powders and introduced into emptied bladders through a urethral catheter. After a residence varying from a few minutes to a few hours,

the BCG cells are eliminated by the patients through emptying of the bladder. The patients are subsequently monitored by cystoscopy, conventional cytology and FISH analysis. The BCG effect is believed to be mediated through induction of an immune reaction in the bladder such as release of cytokines IL 8 and TRAIL that leads to tumoricidal activity (Herr and Morales, 2008; Kresowik and Griffith, 2010). This immune response is greatly amplified with repeated instillations of BCG, demonstrating the importance of elevated cytokine levels including IL2, IL6, IL8, TNF, and IFNs (Shintani et al., 2007; Bisiaux et al., 2009) and the subsequent infiltrations of neutrophils, lymphocytes, and monocytes/macrophages. Indeed, BCG-stimulated neutrophils have been shown to kill bladder cancer cells in vitro in a TRAIL-dependent manner (Ludwig et al., 2004).

Unfortunately, therapeutic use of live BCG cells for bladder cancer treatment is associated with many debilitating and/or serious side effects, ranging from cystitis and gross hematuria to life-threatening BCG sepsis. Such major side effects during intravesical BCG therapy can affect treatments in 30% of patients while mild cystitis, malaise, low grade fever and other side effects are common in about 90% of patients (Bohle et al., 2003; Sylvester et al., 2003). Further, some recent observations endorse that certain single nucleotide polymorphisms (SNPs) in humans can promote disease progression in spite of BCG therapy (Basturk et al., 2006; Decobert et al., 2006), making use of the immune response-invoking live BCG bacteria less effective in such patients. Thus toxicity and efficacy issues have been a major deterrent in the use of live BCG cells in bladder cancer immunotherapy.

The ability of *M. bovis* BCG to attack cancer cells and suppress their growth is not unique to this organism. Indeed, many other bacteria such as *Salmonella*, *Clostridia*, *Listeria*, etc, are known to allow cancer regression both by inducing an immune response as well as actively growing in the core of the tumor (Mahfouz et al., 2007; Fialho and Chakrabarty, 2010a). Even many viruses have been designed for cancer therapy (Fialho and Chakrabarty, 2010a).



Recently pathogenic bacteria such as *Pseudomonas aeruginosa* or *gonococci/meningococci* such as *Neisseria meningitides* reported to produce proteins such as azurin or Laz that demonstrate strong anticancer activity both in vivo and in vitro (Chakrabarty, 2010; Fialho and Chakrabarty 2010 a,b). Not only the full-length proteins, but peptides derived from them such as the 28 amino acid peptide P28 or the 26 amino acid peptide P26, derived from different parts of azurin, show entry specificity in cancer cells (Taylor et al., 2009) and high cytotoxicity in cancers such as breast, melanoma, prostate, brain, etc (Taylor et al., 2009, Chaudhari et al., 2007). Proteins such as azurin, considered a bacterial weapon against cancer (Chakrabarty, 2010; Fialho and Chakrabarty, 2010b), are secreted in response to the presence of cancer cells (Mahfouz et al., 2007), while the *Neisserial* protein weapon Laz is surface-exposed (Hong et al., 2006). The phase I human clinical trials of p28 were performed as per US-FDA guidelines. The p28 peptide has shown lack of toxicity and partial tumor regression in 2 patients and complete regression in 2 other patients out of 15 advanced stage (stage IV) cancer patients where no drugs were working and where the patients had less than 6 months life span. When given in 5 escalating doses 3 times a week for 4 weeks, followed by a break of 2 weeks, several patients showed stunted tumor growth but 2 patients showed partial regression and 2 patients showed complete regression of their tumors (where no drugs were working any longer). The 2 patients where the tumors completely regressed (making them disease free) as well as another patient (altogether 3) are alive today (middle of August 2011) beyond one and a half year (Richards et al., 2011), showing that such bacterial peptides as p28, derived from azurin, have unique modes of action so that they work against drug-resistant cancers. We hope that the newly identified peptide MB30 will behave similarly.

To the best of the knowledge of the applicant and/or inventors, no efforts have been made to look for protein/peptide weapons produced by such bacteria. However, considering the ability of microbial products being used as potential anticancer agent, the applicant/inventors carried out pains taking research to arrive at other protein weapons, either secreted or surface-associated in microorganisms including pathogens, or that could be designed as synthetic peptides, that would

demonstrate anticancer activity for use as anticancer therapies instead of the live bacteria.

#### OBJECT OF THE INVENTION:

- ❖ The main object is to provide an anticancer agent pharmaceutical compositions and application thereof eliminating the limitations of prior art.

- ❖ The other object is to provide an anticancer agent, particularly broad spectrum anticancer agent of microbial origin, more particularly, proteins either secreted by or surface associated in microorganisms including but not limiting to bacteria both pathogenic and nonpathogenic, viruses, and/or parasites.

- ❖ Yet another object is to provide purified proteins isolated from bacteria and parasites specifically, proteins isolated from *M. bovis* BCG, and *Toxoplasma gondii* useful as an anticancer agent.

- ❖ Still other object is to provide peptides derived from such proteins, synthetically prepared peptides, and proteins or peptides modified by PEGylation, acetylation, phosphorylation, etc. useful as an anticancer agent.

- ❖ Still another object is to also provide anticancer agent comprising the proteins or various truncated derivatives thereof that possess enhanced efficacy and reduced toxicity.

- ❖ Yet other object is to provide purified proteins and peptides, as an anticancer agent, with extended half life and reduced immunogenicity in the patient blood stream.

- ❖ The other object of the present invention also discloses the compositions, pharmaceutical compositions and the manner of its applications as therapeutic agent to treat mammalian cancer.

The pharmaceutical composition comprises an active ingredient i.e. proteins, peptides, including PEGylated, acetylated, phosphorylated form thereof in isolation or in combination and physiologically and pharmaceutically accepted adjuvants or excipients.

2

## DESCRIPTION OF THE DRAWINGS:

**Figure 1:** depicts the cytotoxicity effect of varying concentrations of peptides on HTB-9 bladder cancer cell line, which was comparable with the controls cisplatin and azurin.  $1 \times 10^4$  cancer cells were seeded and after 24h, media were changed with varying concentrations of anticancer peptides (TG20, TG23, and MB30), azurin and cisplatin as positive controls. The viability of the cells was estimated by using MTT assay on the basis of formazan formed, which was detected spectrophotometrically by optical density at 570 nm at 24h, 48h and 72h [Bar-mean  $\pm$  S.E.]

**Figure 2:** Depicts the cytotoxicity effect of varying concentrations of peptides on UM-UC-3 bladder cancer cell line, which was comparable with the controls cisplatin and azurin.  $1 \times 10^4$  cancer cells were seeded and after 24h, media were changed with varying concentrations of anticancer peptides (TG20, TG23, and MB30), azurin and cisplatin as positive controls. The viability of the cells was estimated by using MTT assay on the basis of formazan formed, which was detected spectrophotometrically by optical density at 570 nm at 24h, 48h and 72h [Bar- mean+ S.E.].

3

**Figure 3:** Depicts the cytotoxicity effect of varying concentrations of peptides on COLO 205 colorectal cancer cell line, which was comparable with the controls cisplatin and azurin.  $1 \times 10^4$  cancer cells were seeded and after 24h, media were changed with varying concentrations of anticancer peptides (TG20, TG23 and MB30), azurin and cisplatin as positive controls. The viability of the cells was estimated by using MTT assay on the basis of formazan formed, which was

detected spectrophotometrically by optical density at 570 nm at 24h, 48h and 72h [Bar- mean+ S.E.]

**Figure 4:** Depicts the cytotoxicity effect of varying concentrations of peptides on HCT 116 colorectal cancer cell line, which was comparable with the controls cisplatin and azurin.  $1 \times 10^4$  cancer cells were seeded and after 24h, media were changed with varying concentrations of anticancer peptides (TG20, TG23 and MB30), azurin and cisplatin as positive controls. The viability of the cells was estimated by using MTT assay on the basis of formazan formed, which was detected spectrophotometrically by optical density at 570 nm at 24h, 48h and 72h [Bar- mean + S.E.].

**Figure 5:** Depicts the cytotoxicity effect of varying concentrations of peptides on SiHa cervix cancer cell line which was comparable with the controls cisplatin and azurin.  $1 \times 10^4$  cancer cells were seeded and after 24h, media were changed with varying concentrations of anticancer peptides (TG20, TG23 and MB30), azurin and cisplatin as positive controls. The viability of the cells was estimated by using MTT assay on the basis of formazan formed, which was detected spectrophotometrically by optical density at 570 nm at 24h, 48h and 72h [Bar-mean  $\pm$  S.E.].

**Figure 6:** Depicts the cytotoxicity effect of varying concentrations of peptides on CaSki cervix cancer cell line which was comparable with the controls cisplatin and azurin.  $1 \times 10^4$  cancer cells were seeded and after 24h, media were changed with varying concentrations of anticancer peptides (TG20, TG23 and MB30), azurin and cisplatin as positive controls. The viability of the cells was estimated by using MTT assay on the basis of formazan formed, which was detected spectrophotometrically by optical density at 570 nm at 24h, 48h and 72h [Bar-mean  $\pm$  S.E.].

**Figure 7:** Depicts the cytotoxicity effect of MB30 peptide and MPT-63 protein on U87 human glioblastoma, HepG2 liver cancer and MDA-MB-231 breast cancer

cell lines.  $1 \times 10^4$  cancer cells were seeded and after 24 hours it was treated separately with varying concentrations of either MB30 peptide or MPT63 protein or cisplatin as a positive control. The viability of the cells were estimated by using MTT assay on the basis of formazan formed, which was detected spectrophotometrically by measuring optical density at 570 nm at 24h and % cell cytotoxicity was determined.

#### SUMMARY OF THE INVENTION:

The present invention relates to an anticancer agent with enhanced activity and reduced toxicity, which is a protein of microbial origin having SEQ ID NO. 1 and/or SEQ ID NO. 2 and variants thereof.

The anticancer agent of SEQ ID NO. 1 may be a secreted protein of *Mycobacterium tuberculosis*, and/or *Mycobacterium bovis* BCG and termed as MPT 63.

The anticancer agent of SEQ ID NO. 2 may be a surface protein from the parasite *Toxoplasma gondii*, and termed as SAG1.

The variants of SEQ ID NO. 1 are peptides such as MB30 of SEQ ID NO. 3 and other peptides from other regions having 10 to 50% variation in the amino acid sequence without affecting the anticancer activity.

The variants of SEQ ID NO. 2 are peptides such as TG20 of SEQ ID NO. 4 and TG23 of SEQ ID NO. 5 and other peptides from other regions having 10 to 50% variation in the amino acid sequence without affecting the anticancer activity.

The anticancer agent of the present invention exhibits anticancer activity against the group consisting of melanoma, leukemia, breast, ovarian, cervical, lung, pancreatic, colon, bladder, prostate, liver, renal and brain cancers.

The invention also relates to a pharmaceutical composition comprising an anticancer agent as herein before described.

The pharmaceutical composition may further comprises adjuvant(s).

The anticancer agent may be modified by PEGylation, acetylation, phosphorylation or prepared synthetically. The modification thus made extends the half life of the active ingredient and/or reduce immunogenicity in the blood stream of the subject.

- ❖ The pharmaceutical composition may be useful for intravenous (iv), intramuscular, oral, subcutaneous or topical application, in presence or absence of adjuvants or excipients for the therapeutic and /or prophylactic treatment of melanoma, leukemia, breast, ovarian, cervical, lung, pancreatic, colon, bladder, prostate, liver, renal and brain cancers.

•

The applicant has found out that the secreted protein MPT63 and of a peptide, termed MB30, derived from it possess anticancer activity and can be used for treating cancers in mammals. Similarly, they also found out the anticancer activity of a surface protein from the parasite *Toxoplasma gondii*, termed SAG1, and two

- peptides TG20 and TG23 derived from it. Such proteins and peptides proved to be an excellent candidate drugs to treat a variety of human cancers. The present invention thus provides microbial products as anticancer agents and pharmaceutical compositions comprising isolated and purified proteins or synthetic peptides, and methods of using them for the treatment of cancer. It is

▪ . very important to develop new anticancer bioactive peptides having high activity and low toxicity; given that most currently available anticancer therapies either have significant toxicity, and/or are prone to development of resistance.

The inventors carrying out research over long period could demonstrate that the

- ▪ *Mycobacterium-specific* secreted protein, MPT63, of hitherto unknown function produced by both the human pathogen *M. tuberculosis* and the bovine strain *M. bovis* and a peptide derived from it termed MB30, exhibit its use in bladder and other cancer therapy.

- ❖ MPT63 is a small (16 kDa) protein which is secreted after 2-3 weeks of culturing and decreases with longer cultivation. This protein has been shown to have

immunogenic property and has been implicated in virulence. It is specific to *mycobacteria* as homologues of MPT63 have only been found in *mycobacterial* species like *M. smegmatis*, *M. bovis* and *M. avium*. A pseudogene of MPT63 has been found within the *M. lapre* genome, but is thought not to be translated into protein. The analysis of DNA sequence encoding MPT63 revealed an ORF encoding a protein of 159 amino acids (aa). It consists of a 130 aa mature protein preceded by 29 aa signal peptide. The X-ray crystal structure of MPT63 was determined to 1.5-Angstrom resolution with the hope of yielding functional information about MPT63. The structure of MPT63 is a  $\beta$ -sandwich consisting of two antiparallel  $\beta$ -sheets similar to an immunoglobulin like fold, with an additional small, antiparallel  $\beta$ -sheet. Apart from immunoglobulin structure, MPT63 has some structural homology to cell surface binding proteins such as Homo sapiens  $\beta$ -adaptin, bovine arrestin and *Yersinia pseudotuberculosis* invasin. It has also structural similarity to eukaryotic fibronectin-binding proteins, major histocompatibility domains and T-cell receptors. The function of MPT63 has hitherto been unknown and could not be predicted by its structural features as it has an extremely common immunoglobulin like fold that occurs in about 24% of the structures in the Protein Data Bank. The  $\beta$ -sandwich fold that MPT63 resembles is at the core of many proteins with diverse functions.

Interestingly, the inventor also found out that not only pathogenic bacteria and viruses have been shown to allow cancer regression, but a few parasites have also been implicated in this process. For example, concurrent infection by enteric helminth, a parasite, and *Helicobacter felis* in mice can attenuate gastric atrophy, a pre-malignant lesion in mice. The helminth pre-infection was shown to reduce helicobacter gastritis but not *H. felis* colonization, presumably due to a shift in the balance of Th1 to Th2 response. However, the production of anticancer agent(s) by the helminths, just as secretion of azurin by *P. aeruginosa* or MPT63 by *M. bovis*, cannot be ruled out.

An interesting case of tumor regression by a parasite is the regression of B16 melanoma cells in mice by *Toxoplasma gondii*, an obligate intracellular parasite

- that is the causative agent of toxoplasmosis. In absence of *T. gondii* infection, challenge with B16 melanoma cells in mice led to tumor formation. In *T. gondii*-infected mice, however, B16 cells failed to form subcutaneous tumors. To determine if the immune system activation in *T. gondii*-infected mice was responsible for the failure of the B16 melanoma cells to form tumors, a variety of mutant mice lacking major immune functions such as iNOS or perforin where cytolytic functions of lymphocytes were severely reduced, were used. These investigators also used scid-beige mice in which cytotoxic T lymphocytes are absent and NK cells are not cytotoxic. Even in scid-beige and perforin knock-out mice where cytolytic functions of lymphocytes are severely impaired and immune functions are greatly reduced, the anticancer activity of *T. gondii* was clearly evident, suggesting the presence of active anticancer agents produced by *T. gondii*. Further experimentations with blood vessel formation demonstrated that hemoglobin levels in Matrigels from *T. gondii*-infected mice were 50 to 100 fold lower than the control mice without *T. gondii* infection with very little histopathologically-observed vascular channels. This suggested that *T. gondii* infection led to systemic suppression of angiogenesis, although the nature or the origin of the anti-angiogenic agent(s) could not be determined. There was some evidence that the circulating anti-angiogenic factors were soluble and not cell-associated but whether such factors were produced by the mice cells or *T. gondii* could not be determined.

- The applicant also demonstrated that the anticancer activity of *T. gondii* can be attributed, at least in part, to the presence of the surface antigen called SAG1. SAG1 is one of the more prominent surface proteins in *T. gondii* involved in host cell attachment and is considered a key virulence factor for *T. gondii*. SAG1 is a 30 kDa immunodominant surface antigenic glycoprotein, also known as P30, highly conserved in *T. gondii* strains, particularly in tachyzoites. The monomelic SAG1 has two domains, a N-terminal 130 amino acid domain D1 and a C-terminal 120 amino acid domain D2. Remarkably, SAG1 shows structural similarity to azurin and interacts with azurin, but it interacts much more strongly with the azurin-like protein Laz. Because SAG1 is surface-associated similar to



- Laz, and shows structural similarity with the anticancer agents azurin and Laz, it was of great interest to the applicant to determine if similar to Laz, SAGI might possess anticancer activity against some of the human cancers. To eliminate the likely toxicity of the protein itself in human patients, two peptides TG20 and TG23, were designed taking advantage of the structural similarities between azurin (and the azurin-like protein Laz) and SAGI. These two peptides were thought to harbor the potential anticancer activity of SAGI, somewhat similar to azurin peptides P28 and P26 with known anticancer activity.

Further, TG20 and TG23, derived from different parts of SAGI, did demonstrate anticancer activity against bladder and colon cancers. For comparison purposes, the applicant has also included azurin and cisplatin in assays.

#### MATERIALS AND METHODS:

The complete amino acid sequence of MPT63 protein (SEQ ID NO. 1) from *Mycobacterium bovis* is given below. The first 29 amino acids (underlined) in the following MPT63 sequence form secretion signal peptide (leader) sequence and the MB30 peptide (amino acids 44-73 of mature protein) sequence is highlighted in bold.

MKLTTMIKTAVAVVAMAAIATFAEPVALAAYPITGKLGSELTMTDTVGO  
 WLGWKVSDDLKSSTAVIPGYPVAGQVWEATATVNAIIRGSVTPAVSQFN  
 ARTADGINYRVLWQAAGPDTISGATIPQGEQSTGKIYFDVTGPSPTrVAMN  
 NGMQDLLIWEP

The peptide sequence of 30 amino acids derived from MPT63 protein, called MB30, peptide is given below.

MB30 peptide sequence (SEQ ID NO.3):

**GQVWEATATVNAIIRGSVTPAVSQFNARTAD**

The complete amino acid sequence of SAGI protein (SEQ ID NO. 2) from *Toxoplasma gondii* is given below.

MFPKAVRRAVTAGVFAAPTLMSFLRCGVMASDPPLVANQWTCDDKST  
 AAVILTPTENHFTLKCPKTALTEPPTLAYSPNRQICSAGTTSSCTSKAVTLS  
 SLIPEAEDSWWTGDSASLDTAGIKLTVPIEKFPVTTQTFWGCIGDDAQS  
 CMVTVTVQARASSVNNVARCSYGANSTLGPVKLSAEGPTTMTLVCGK  
 5 DGVKVPQDNNQYCSGTTLTGCNEKSFKDILPKLTENPWQGNASSDKGAT  
 LTIKKEAFPAESKSVIIGCTGGSPEKHHCTVKLEFAGAAGPAKSAAGTASH  
 VSIFAMVIGLIGSFAACVA

The peptide sequence of 20 amino acids derived from SAG1 protein of *T. gondii*,  
 1 termed TG20, is given below.

**TG20 peptide sequence** (SEQ ID NO. 4): **NHFTLKCPKTALTEPPTLAY**

The peptide sequence of 23 amino acids derived from SAG1 protein *T. gondii*,  
 5 termed TG23, is given below.

**TG23 peptide sequence** (SEQ ID NO. 5):  
**TAGIKLTVPIEKFPVTTQTFWG**

6 For illustrating the invention, experiments detailing the anticancer activity of the  
 bioactive peptides are described below. It should be noted that the following  
 examples are intended to describe such activities and not to limit the invention.  
 The isolation and purification of the proteins have previously been described in  
 the literature while all the peptides were chemically synthesized by commercial  
 15 concerns. We have cloned and expressed the MPT-63 protein and its anticancer  
 activity was evaluated in various cancer cell lines.

#### **Cloning and expression of MPT63 protein:**

The MPT63 gene was amplified by PCR using the following primers with *NdeI*  
 20 restriction site on the forward primer and *HindIII* restriction site on the reverse  
 primer:

Forward primer: 5'-TCGATCCATATGGCCTATCCC ATCACCGGA-3', and

Reverse primer: 5'- TCGATCAAGCTTCTACGGCTCCC AAATCAG-3'.

The *Ndel* and *HindIII* PCR product is ligated in the pUC18 cloning vector. The MPT63 gene is excised from pUC18 and ligated into prerestricted pET28a expression vector and transformed into *E. coli* BL21de3. For MPT63 purification, a single colony of BL21de3 was inoculated into LB broth and inoculated at 37°C until the OD reached to 0.5. The culture was induced with 1mM IPTG for overnight at 37°C.

After overnight incubation period, the culture was centrifuged and the cell pellets were incubated on ice for 15 minutes. Cells were re-suspended in 10ml native lysis buffer with benzonase and lysozyme, incubated on ice for 30 minutes, and intermittently mixed so as to ensure homogenous suspension. Cell lysate was centrifuged at 14000g/4°C for 30 minutes to pellet the cellular debris. The cell lysate supernatant was loaded on the Ni-NTA column supplied by Qiagen, and the flow-through fraction was collected. The column was washed twice with wash buffer. The bound 6xHis-tagged protein was eluted with two 1 ml aliquots of native elution buffer. Both the elution fractions were collected in separate tubes. At each step of the process, samples were analyzed by SDS PAGE. This purified protein was used in the further experiments at concentration of 1 µM, 5 µM and 10 µM to determine its cytotoxic effect on the various cell lines.

### Cell culture:

Bladder cancer cell lines HTB-9 [Grade II Bladder carcinoma], CRL-1749 (UM-UC-3) [High grade bladder carcinoma], and colorectal carcinoma cell lines CCL-222 (COLO 205) [Dukes Type D colorectal adenocarcinoma], CCL-247 (HCT-116), SiHa, CaSki, MDA-MB-231, U87 and HepG2 were procured from American Type Culture Collection (ATCC). All cell lines were grown under standard conditions in humidified 37°C incubator in 5% CO<sub>2</sub> as described earlier (Garg et al., 2009; Kanojia et al., 2010).

- ATCC: **HTB-9:** Human cell line with epithelial-like characteristics established from a urinary bladder carcinoma (grade II) of a 68 year old male patient. This cell line is tumorigenic in nature. These cells lack a functional retinoblastoma protein, Rb. HTB-9 cells proliferate in response to a variety of growth factors, including IL2, IL3, G-CSF, GM-CSF, and M-CSF. Goselink et al (1996) have shown that the serum-free conditioned medium of HTB-9 cells can replace serum to support the growth of hematopoietic progenitor cells (HPC) in semi-solid cultures.
- ATCC: **UM-UC-3:** Human cell line with epithelial-like characteristics established from a high grade invasive urinary bladder carcinoma of a male patient. This is a hypertriploid human cell line and IFN non responsive. This cell line is tumorigenic in nature.
- ATCC **COLO 205:** Human cell line derived from colorectal adenocarcinoma Dukes' type D of 70 year old male patient. The cells are CSAP negative. The cells are positive for keratin by immunoperoxidase staining. COLO 205 cells express a 36000 Dalton cell surface glycoprotein related to GA733-2 tumor associated antigen.
- ATCC **HCT 116:** Human cell line with epithelial-like characteristics established from colorectal carcinoma from an adult male patient. The cells are positive for keratin by immunoperoxidase staining. HCT 116 cells are positive for transforming growth factor beta 1 (TGF beta 1) and beta 2 (TGF beta 2) expression. This line has a mutation in codon 13 of the ras protooncogene, and can be used as a positive control for PCR assays of mutation in this codon.
- ATCC: **SiHa:** Human cell line established from fragments of a primary tissue sample obtained after surgery from a Japanese patient. Electron microscopic observations revealed presence of typical desmosomes at the cell junctions and an abundance of tonofilaments in the cytoplasm. The line is reported to contain an

integrated human papillomavirus type 16 genome (HPV-16, 1 to 2 copies per cell).

ATCC: **CaSki:** Human cell line derived from 40 year-old Caucasian female patient. The line was established from cells from a metastasis in the small bowel mesentery. The cells are reported to contain an integrated human papillomavirus type 16 genome (HPV-16, about 600 copies per cell) as well as sequences related to HPV-18.

ATCC: **MDA-MB-231:** It is a human cell line with epithelial like characteristics established from mammary gland (breast) adenocarcinoma from a 51 year old Caucasian female patient. The cells express the WNT7B oncogene.

ATCC: **U87:** It is a human glioblastoma cell line formally known as U-87 MG. It has epithelial morphology, and was obtained from 44 year old Caucasian female patient.

ATCC: **HepG2:** Human cell line derived from the liver tissue of a 15 year old Caucasian American male with a well differentiated hepatocellular carcinoma. These cells are epithelial in morphology and are not tumorigenic in nude mice. The cells secrete a variety of major plasma proteins; e.g., albumin, transferrin and the acute phase proteins fibrinogen, alpha 2-macroglobulin, alpha 1-antitrypsin, transferrin and plasminogen.

### Cytotoxicity Assay:

The cytotoxicity assays performed in this investigation were designed to evaluate the cytotoxic potential of bioactive peptides from Table 1 in cancer cell lines at the given concentrations. MTT [3-(4, 5- dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] assay was carried out for measurement of the cytotoxicity of different anticancer peptides. The water soluble tetrazolium salt, MTT [3-(4, 5- dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] is metabolized to the water insoluble formazan by intact mitochondrial dehydrogenases. The formazan

is then solubilized by adding 2-propanol + 40 mM HCl for 4h incubation.  $1 \times 10^4$  cells were seeded and after 24h, media were changed with varying concentrations of anticancer peptides (TG20, TG23 and MB30), azurin (known to have anticancer activity, Chakrabarty, 2010) and cisplatin, also a known anticancer compound (Sedletska et al., 2005), as positive controls [Table 1]. The viability of the cells was estimated on the basis of formazan formed, which was detected spectrophotometrically by optical density at 570 nm at 24h, 48h and 72h. At every time point such as 24h, 48h and 72h,  $1 \times 10^4$  cells were seeded without the peptide in triplicate in each plate for a given treatment of peptide. This was used as control cytotoxicity levels to calculate the percent cell cytotoxicity of every peptide treatment. The cytotoxicity of full length protein MPT-63 was also determined using this assay, where protein was used instead of peptides. All the experiments were carried out in triplicates and repeated three times.

**Table 1:**

Peptide TG20	1 $\mu$ M	10 $\mu$ M
Peptide TG23	1 $\mu$ M	10 $\mu$ M
Peptide MB30	1 $\mu$ M	10 $\mu$ M
Azurin		10 $\mu$ M
Cisplatin		10 $\mu$ M

## RESULTS;

Treatment with various peptides in this investigation revealed anticancer properties of the peptides. *In vitro* analysis of cytotoxicity results distinctly revealed reduction in cellular proliferation. All the experiments were carried out in triplicates and repeated three times.

MTT assays demonstrated the cytotoxic activity in HTB-9 bladder cancer cells of all the 3 peptides (TG20, TG23, and MB30, Table 1) when used at concentrations of 1.0 and 10.0 micromolar, along with the other positive controls azurin and cisplatin. All the three peptides demonstrated cytotoxicity upto 40% and 60% at 48 and 72 h respectively, comparable to azurin and cisplatin (Fig. 1). Such results demonstrated that peptide concentrations as low as 1.0 micromolar were enough

and higher concentrations did not add substantially to the cytotoxicity. Also, while low at 24 h, the cytotoxicity levels increased with increasing times of incubation up to 72 h (Fig. 1).

In order to assess the cytotoxicity of all these peptides in different bladder cancer cell lines, UM-UC-3 bladder carcinoma cell line was incubated with the peptides at 1.0 and 10  $\mu$ M concentrations and cytotoxicity was monitored at 24, 48 and 72 hours. At 24 h, TG23 and MB30 peptides demonstrated higher cytotoxicity levels than the other peptide, comparable to azurin but less than cisplatin. With prolonged exposure up to 72h, all the three peptides demonstrated about 45% cytotoxicity in the UM-UC-3 bladder cancer cell line (Fig. 2).

Although the ability of live cells of *M. bovis* BCG to allow regression of cancers such as melanoma, prostate or leukemia has been reported in the past, such effects were not consistent. The consistent efficacy in human patients was only against bladder cancer. To evaluate if the MB30 peptide or the other peptides would demonstrate cytotoxicity against other cancers, the cytotoxicity of all the three peptides was also assessed in a colon cancer cell line, called COLO 205, at various concentrations up to 72 hour. All the three peptides demonstrated varying cytotoxicity, about 10-20%, during 48h incubation (Fig. 3).

The anticancer activity of all the three peptides was also checked in the colon cancer cell line HCT 116 and in cervical cancer cell lines (SiHa and CaSki). The peptide MB30 killed about 40% of the colon and cervical cancer cells at both the concentrations when incubated up to 24 h, higher than azurin but somewhat less than cisplatin. The other peptides TG20 and TG23 showed less cytotoxicity (Fig. 4, 5 and 6). Such data clearly indicate that peptides like MB30, as well as TG20 and TG23, demonstrate significant cytotoxicity in bladder and other cancer cells. The full length MPT-63 protein was purified and its cytotoxicity was compared with MB30 peptide in U87, HepG2 and MDA-MB-231 cell lines. The MPT-63 protein has also shown cytotoxicity in all the three cell lines (brain, liver and breast cancers) tested (Fig. 7). However, the MB30 peptide has demonstrated better cytotoxicity in comparison to the full length protein MPT-63 in all the

three cell lines (brain, liver and breast cancers) at 24 h (Fig. 7). This indicates that the full length protein as well as MB30 peptide shows anticancer activities in a variety of cancer cell lines.



SEQUENCE LISTING

<110> AMRITA THERAPEUTICS LTD

<120> ANTICANCER AGENT

<130> ATIN/0001/2011

<150> 2754/MUM/2010

<151> 2010-10-01

<160> 5

<170> Patentln version 3.3

<210> 1

<211> 159

<212> PRT

<213> Mycobacterium bovis

<400> 1

Met Lys Leu Thr Thr Met lie Lys Thr Ala Val Ala Val Val Ala Met  
1 5 10 15

Ala Ala Ile Ala Thr Phe Ala Glu Pro Val Ala Leu Ala Ala Tyr Pro  
20 25 30

He Thr Gly Lys Leu Gly Ser Glu Leu Thr Met Thr Asp Thr Val Gly  
35 40 45

Gin Val Val Leu Gly Trp Lys Val Ser Asp Leu Lys Ser Ser Thr Ala  
50 55 60

Val Ile Pro Gly Tyr Pro Val Ala Gly Gin Val Trp Glu Ala Thr Ala  
65 70 75 80

Thr Val Asn Ala lie Arg Gly Ser Val Thr Pro Ala Val Ser Gin Phe  
85 90 95

Asn Ala Arg Thr Ala Asp Gly Ile Asn Tyr Arg Val Leu Trp Gin Ala  
100 105 110

Ala Gly Pro Asp Thr Ile Ser Gly Ala Thr He Pro Gin Gly Glu Gin  
115 120 125

Ser Thr Gly Lys He Tyr Phe Asp Val Thr Gly Pro Ser Pro Thr He  
130 135 140

Val Ala Met Asn Asn Gly Met Gin Asp Leu Leu lie Trp Glu Pro  
145 150 155

<211> 319  
 <212> PRT  
 <213> Toxoplasma gondii  
 <400> 2  
 Met Phe Pro Lys Ala Val Arg Arg Ala Val Thr Ala Gly Val Phe Ala  
 1 5 10 15  
 Ala Pro Thr Leu Met Ser Phe Leu Arg Cys Gly Val Met Ala Ser Asp  
 20 25 30  
 Pro Pro Leu Val Ala Asn Gin Val Val Thr Cys Pro Asp Lys Lys Ser  
 35 40 45  
 Thr Ala Ala Val He Leu Thr Pro Thr Glu Asn His Phe Thr Leu Lys  
 50 55 60  
 Cys Pro Lys Thr Ala Leu Thr Glu Pro Pro Thr Leu Ala Tyr Ser Pro  
 65 70 75 80  
 Asn Arg Gin He Cys Ser Ala Gly Thr Thr Ser Ser Cys Thr Ser Lys  
 85 90 95  
 Ala Val Thr Leu Ser Ser Leu He Pro Glu Ala Glu Asp Ser Trp Trp  
 100 105 110  
 Thr Gly Asp Ser Ala Ser Leu Asp Thr Ala Gly He Lys Leu Thr Val  
 115 120 125  
 Pro He Glu Lys Phe Pro Val Thr Thr Gin Thr Phe Val Val Gly Cys  
 130 135 140  
 He Lys Gly Asp Asp Ala Gin Ser Cys Met Val Thr Val Thr Val Gin  
 145 150 155 160  
 Ala Arg Ala Ser Ser Val Val Asn Asn Val Ala Arg Cys Ser Tyr Gly  
 165 170 175  
 Ala Asn Ser Thr Leu Gly Pro Val Lys Leu Ser Ala Glu Gly Pro Thr  
 180 185 190  
 Thr Met Thr Leu Val Cys Gly Lys Asp Gly Val Lys Val Pro Gin Asp  
 195 200 205  
 Asn Asn Gin Tyr Cys Ser Gly Thr Thr Leu Thr Gly Cys Asn Glu Lys  
 210 215 220

Ser Phe Lys Asp Ile Leu Pro Lys Leu Thr Glu Asn Pro Trp Gin Gly  
 225                    230                    235                    240

Asn Ala Ser Ser Asp Lys Gly Ala Thr Leu Thr Ile Lys Lys Glu Ala  
 245                    250                    255

Phe Pro Ala Glu Ser Lys Ser Val He He Gly Cys Thr Gly Gly Ser  
 260                    265                    270

Pro Glu Lys His His Cys Thr Val Lys Leu Glu Phe Ala Gly Ala Ala  
 275                    280                    285

Gly Pro Ala Lys Ser Ala Ala Gly Thr Ala Ser His Val Ser He Phe  
 290                    295                    300

Ala Met Val He Gly Leu He Gly Ser Phe Ala Ala Cys Val Ala  
 305                    310                    315

<210> 3  
 <211> 30  
 <212> PRT  
 <213> Mycobacterium bovis

<400> 3

Gly Gin Val Trp Glu Ala Thr Ala Thr Val Asn Ala He Arg Gly Ser  
 1                    5                    10                    15

Val Thr Pro Ala Val Ser Gin Phe Asn Ala Arg Thr Ala Asp  
 20                    25                    30

<210> 4  
 <211> 20  
 <212> PRT  
 <213> Toxoplasma gondii

<400> 4

Asn His Phe Thr Leu Lys Cys Pro Lys Thr Ala Leu Thr Glu Pro Pro  
 1                    5                    10                    15

Thr Leu Ala Tyr  
 20

<210> 5  
 <211> 23  
 <212> PRT  
 <213> Toxoplasma gondii

<400> 5

Thr Ala Gly He Lys Leu Thr Val Pro Ile Glu Lys Phe Pro Val Thr  
 1 5 10 15

Thr Gin Thr Phe Val Val Gly  
 20

## REFERENCES:

1. Basturk, B., Yavascaoglu, I., Oral, B., Goral, G. and Oktay, B. 2006. Cytokine gene polymorphisms can alter the effect of Bacillus Calmette-Guerin (BCG) immunotherapy. *Cytokine* 35:1-5.
2. Bisiaux, A., Thiounn, N., Timsit, M.O., Eladaui, A., Chang, H.H. et al. 2009. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus Calmette-Guerin therapy in patients with superficial bladder cancer. *J. Urol.* 181:1571-1580.
3. Bohle, A., Jocham, D. and Bock, P.R. 2003. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. *J. Urol.* 169:90-95.
4. Chakrabarty, A.M. 2010. Bioengineered bugs, drugs and contentious issues in patenting. *Bioengineered Bugs* 1:2-8.
5. Chaudhari, A., Mahfouz, M., Fialho, A.M., Yamada, T., Granja, A.T., Zhu, Y., Hashimoto, W., Schlarb-Ridley, B., Cho, W., Das Gupta, T.K. and Chakrabarty, A.M. 2007. Cupredoxin-cancer interrelationship: Azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth. *Biochemistry* 46:1799-1810.
6. Decobert, M., Larue, H., Bergeron, A., Harel, F., Pfister, C, Rousseau, F., Lacombe, L. and Fradet, Y. 2006. Polymorphisms of the human NRAMPI gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. *J. Urol.* 175:1506-1511.
7. Fialho, A.M. and Chakrabarty, A.M. 2010a. *Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools*. John Wiley & Sons, Inc., New York.
8. Fialho, A.M. and Chakrabarty, A.M. 2010b. Promiscuous anticancer drugs from pathogenic bacteria: Rational versus intelligent drug design. In *Emerging Cancer Therapy: Microbial Approaches and Biotechnological*

Tools, A.M. Fialho and A.M. Chakrabarty, Eds., pages 181-198, John Wiley & Sons Inc., New York.

9. Garg, M., Kanojia, D., Seth, A., Kumar, R., Gupta, A., Surolia, A., and Suri, A. 2009. Heat-Shock Protein 70-2 (HSP70-2) Expression in Bladder Urothelial Carcinoma is Associated with Tumor Progression and Promotes Migration and Invasion. *Eur J Cancer*. 46:207-215.
10. Goselink, H.M., van Damme, J., Hiemstra, P.S., Wuyts, A., Stolk, J., Fibbe, W.E., Willemze, R., Falkenburg, J.H. 1996. Colony growth of human hematopoietic progenitor cells in the absence of serum is supported by a proteinase inhibitor identified as antileukoproteinase. *J Exp Med*. 184:1305-1312.
11. Herr, H.W. and Morales, A. 2008. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. *J. Urol*. 179:53-56.
12. Hong, C.S., Yamada, T., Hashimoto, W., Fialho, A.M., Das Gupta, T.K. and Chakrabarty, A.M. 2006. Disrupting the entry barrier and attacking brain tumors: The role of the Neisseria H.8 epitope and the Laz protein. *Cell Cycle* 5:1633-1641.
13. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., Thun, M.J. and Ward E. 2008. Cancer statistics. *CA Cancer J. Clin*. 58:71-96.
14. Kanojia, D., Garg, M., Gupta, S., Gupta, A., and Suri, A. 2010. Sperm-Associated Antigen 9 Is a Novel Biomarker for Colorectal Cancer and Is Involved in Tumor Growth and Tumorigenicity. *Am J Pathol*. 178:1009-1020.
15. Kresowik, T.P. and Griffith, T.S. 2010. Bacillus Calmette-Guerin (BCG) for urothelial carcinoma of the bladder. In *Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools*, A.M. Fialho and A.M. Chakrabarty, Eds., pages 49-70, John Wiley & Sons Inc., New York.
16. Ludwig, A.T., Moore, J.M., Luo, Y., Chen, X., Saltsgaver, N.A., O'Donnell, M.A. and Griffith, T.S. 2004. Tumor-necrosis factor-related apoptosis-

inducing ligand: A novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. *Cancer Res.* 64:3386-3390.

17. Mahfouz, M., Hashimoto, W., Das Gupta, T.K. and Chakrabarty, A.M. 2007. Bacterial proteins and CpG-rich extrachromosomal DNA in potential cancer therapy. *Plasmid* 57:4-17.
18. Richards, JM., Warso, MA., Mehta, D., Christov, K., Schaeffer, CM., Yamada, T., Beattie, CW., Bressler, LR and Das Gupta, TK. 2011. A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors. *J. Clin. Oncol.* 29:2511.
19. Sedletska, Y., Giraud-Panis, M.J. and Malinge, J.M. 2005. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: Importance of apoptotic pathways. *Curr. Med. Chem. Anticancer Agents* 5: 251-265.
20. Shintani, Y., Sawada, Y., Inagaki, T., Kohjimoto, Y., Uekado, Y. and Shinka, T. 2007. Intravesical instillation therapy with bacillus Calmette-Guerin for superficial bladder cancer: Study of the mechanism of bacillus Calmette-Guerin immunotherapy. *Intl. J. Urol.* 14:140-146.
21. Sylvester, R.J., van der Meijden, A.P., Oosterlinck, W., Hoeltl, W. and Bono, A.V. 2003. The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III trial. *Eur. Urol.* 44:423-428.
22. Taylor, B.N., Mehta, R.R., Yamada, T., Lekmine, F., Christov, K., Chakrabarty, A.M., Green, A., Bratescu, L., Shilkaitis, A., Beattie, C.W. and Das Gupta, T.K. 2009. Noncationic peptides obtained from azurin preferentially enter cancer cells. *Cancer Res.* 69:537-546.


# WHAT IS CLAIMED IS:

- 1. An anticancer agent with enhanced activity and reduced toxicity is a protein of microbial origin having SEQ ID NO. 1 and/or SEQ ID NO. 2 and variants thereof.
- 2. The anticancer agent as claimed in claim 1, wherein the protein of SEQ ID NO. 1 is a secreted protein of *Mycobacterium tuberculosis*, and/or *Mycobacterium bovis* BCG and termed as MPT 63.
- 3. The anticancer agent as claimed in claim 1, wherein the protein of SEQ ID NO. 2 is a surface protein from the parasite *Toxoplasma gondii*, and termed as SAG1.
- 4. The anticancer agent as claimed in claim 1 wherein the variants of SEQ ID NO. 1 are peptides such as MB30 of SEQ ID NO. 3 and other peptides from other regions having 10 to 50% variation in the amino acid sequence without affecting the anticancer activity.
- 5. The anticancer agent as claimed in claim 1, wherein the variants of SEQ ID NO. 2 are peptides such as TG20 of SEQ ID NO. 4 and TG23 of SEQ ID NO. 5 and other peptides from other regions having 10 to 50% variation in the amino acid sequence without affecting the anticancer activity.
- 6. The anticancer agent as claimed in claims 1 exhibits anticancer activity against the group consisting of melanoma, leukemia, breast, ovarian, cervical, lung, pancreatic, colon, bladder, prostate, liver, renal or brain cancers.
- 7. A pharmaceutical composition comprising an anticancer agent as claimed in claims 1 and 2.
- 8. The pharmaceutical composition as claimed in claim 7 further comprises adjuvant(s).



- 1
1
The anticancer agent as claimed in claims 1 and 2 is modified by PEGylation, acetylation, phosphorylation or prepared synthetically.
- 2
1
The pharmaceutical composition as claimed in claims 7 and 8 is useful for intravenous (iv), intramuscular, oral, subcutaneous or topical application, in presence or absence of adjuvants or excipients for the therapeutic and /or prophylactic treatment of melanoma, leukemia, breast, ovarian, cervical, lung, pancreatic, colon, bladder, prostate, liver, renal or brain cancers.
- 3
1
An anticancer agent is a protein of microbial origin having SEQ ID NO. 1 and/or SEQ ID NO. 2 variants thereof substantially such as herein described with reference to figures.

17



R31

22

37





Figure 2

Figure 1



17




图 4

27





FIG. 1

42



43

37




Fig. 7



(1) NAME OF APPLICANT OR INVENTOR  
OR ASSIGNOR (PRINT FULL NAME)  
CHEMICAL ABSTRACTS

(2) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(3) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(4) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(5) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(6) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(7) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(8) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(9) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(10) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(11) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(12) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(13) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(14) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(15) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(16) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(17) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(18) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(19) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(20) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(21) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(22) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(23) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(24) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(25) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(26) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(27) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(28) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(29) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(30) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(31) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(32) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(33) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

(34) ADDRESS (Print full name and address)  
1000 17th St. N.W.  
Washington, D.C. 20036

Patent Service Form 100

[illegible]

<sup>a</sup> \*P < .05 compared with control.

The official name of the company is **Systemic**, and the official logo is a stylized 'S' made of dots. The company is a subsidiary of the **Systemic Group**, which is a part of the **Systemic Group**.

1. Abstract is a short summary of the paper. It should be written in a clear, concise, and factual manner. It should state the purpose of the study, the methods used, the results obtained, and the conclusions drawn. It should be written in a way that is easy to read and understand. It should be written in a way that is easy to read and understand.

[illegible][illegible]

1. The first step in the process of photosynthesis is the light reaction.

2. The light reaction takes place in the thylakoid membranes of the chloroplasts. It is the process by which light energy is converted into chemical energy in the form of ATP and NADPH. This process involves the absorption of light by chlorophyll and other pigments, the transfer of electrons from water to various electron acceptors, and the pumping of protons across the thylakoid membrane to create a proton gradient. The overall equation for the light reaction is:  $2H_2O + 2NADP^+ + 2ADP + 2P_i \rightarrow 2H_2 + 2NADPH + 2ATP$ .

3. The Calvin cycle, also known as the dark reaction, is the process by which carbon dioxide is fixed into organic molecules. It takes place in the stroma of the chloroplasts. The cycle begins with the fixation of  $CO_2$  by the enzyme RuBisCO, which combines it with a five-carbon sugar (RuBP) to form a six-carbon intermediate. This intermediate then splits into two three-carbon molecules. One of these molecules is used to form glucose, while the other is used to regenerate RuBP, completing the cycle. The overall equation for the Calvin cycle is:  $6CO_2 + 12H_2O + 18ATP + 12NADPH \rightarrow C_6H_{12}O_6 + 6H_2O + 18ADP + 12NADP^+$ .

4. The light reaction and the Calvin cycle are coupled by the transfer of ATP and NADPH from the light reaction to the Calvin cycle.

5. The light reaction is a series of redox reactions that convert light energy into chemical energy. It involves the absorption of light by chlorophyll and other pigments, the transfer of electrons from water to various electron acceptors, and the pumping of protons across the thylakoid membrane to create a proton gradient. The overall equation for the light reaction is:  $2H_2O + 2NADP^+ + 2ADP + 2P_i \rightarrow 2H_2 + 2NADPH + 2ATP$ .

6. The Calvin cycle is a series of reactions that fix carbon dioxide into organic molecules. It takes place in the stroma of the chloroplasts. The cycle begins with the fixation of  $CO_2$  by the enzyme RuBisCO, which combines it with a five-carbon sugar (RuBP) to form a six-carbon intermediate. This intermediate then splits into two three-carbon molecules. One of these molecules is used to form glucose, while the other is used to regenerate RuBP, completing the cycle. The overall equation for the Calvin cycle is:  $6CO_2 + 12H_2O + 18ATP + 12NADPH \rightarrow C_6H_{12}O_6 + 6H_2O + 18ADP + 12NADP^+$ .

1. The light reaction of photosynthesis is the process by which light energy is converted into chemical energy in the form of ATP and NADPH.

$$2H_2O + 2NADP^+ + 2ADP + 2P_i \rightarrow 2H_2 + 2NADPH + 2ATP$$

2. The light reaction takes place in the thylakoid membranes of the chloroplasts. It is the process by which light energy is converted into chemical energy in the form of ATP and NADPH.

3. The light reaction involves the absorption of light by chlorophyll and other pigments, the transfer of electrons from water to various electron acceptors, and the pumping of protons across the thylakoid membrane to create a proton gradient. The overall equation for the light reaction is:  $2H_2O + 2NADP^+ + 2ADP + 2P_i \rightarrow 2H_2 + 2NADPH + 2ATP$ .

$$2H_2O + 2NADP^+ + 2ADP + 2P_i \rightarrow 2H_2 + 2NADPH + 2ATP$$

4. The light reaction and the Calvin cycle are coupled by the transfer of ATP and NADPH from the light reaction to the Calvin cycle.

$$2H_2O + 2NADP^+ + 2ADP + 2P_i \rightarrow 2H_2 + 2NADPH + 2ATP$$

5. The light reaction is a series of redox reactions that convert light energy into chemical energy.

- 1. Absorption of light
- 2. Transfer of electrons
- 3. Pumping of protons
- 4. Formation of ATP
- 5. Formation of NADPH

6. The light reaction is coupled to the Calvin cycle by the transfer of ATP and NADPH from the light reaction to the Calvin cycle.

7. The light reaction is a series of reactions that convert light energy into chemical energy in the form of ATP and NADPH.

$$2H_2O + 2NADP^+ + 2ADP + 2P_i \rightarrow 2H_2 + 2NADPH + 2ATP$$

8. The light reaction is a series of reactions that convert light energy into chemical energy in the form of ATP and NADPH. It involves the absorption of light by chlorophyll and other pigments, the transfer of electrons from water to various electron acceptors, and the pumping of protons across the thylakoid membrane to create a proton gradient. The overall equation for the light reaction is:  $2H_2O + 2NADP^+ + 2ADP + 2P_i \rightarrow 2H_2 + 2NADPH + 2ATP$ .

9. The light reaction is coupled to the Calvin cycle by the transfer of ATP and NADPH from the light reaction to the Calvin cycle.

$$2H_2O + 2NADP^+ + 2ADP + 2P_i \rightarrow 2H_2 + 2NADPH + 2ATP$$

10.

$$2H_2O + 2NADP^+ + 2ADP + 2P_i \rightarrow 2H_2 + 2NADPH + 2ATP$$

11. The light reaction is a series of reactions that convert light energy into chemical energy in the form of ATP and NADPH.



and the following information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve: (1) The 100 percent point of the curve is at 100 percent of the maximum value of the curve; (2) The 90 percent point of the curve is at 90 percent of the maximum value of the curve; (3) The 80 percent point of the curve is at 80 percent of the maximum value of the curve; (4) The 70 percent point of the curve is at 70 percent of the maximum value of the curve; (5) The 60 percent point of the curve is at 60 percent of the maximum value of the curve; (6) The 50 percent point of the curve is at 50 percent of the maximum value of the curve; (7) The 40 percent point of the curve is at 40 percent of the maximum value of the curve; (8) The 30 percent point of the curve is at 30 percent of the maximum value of the curve; (9) The 20 percent point of the curve is at 20 percent of the maximum value of the curve; (10) The 10 percent point of the curve is at 10 percent of the maximum value of the curve.

The above information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve. The following detailed description of the curve is given:

#### DETAILED DESCRIPTION

The above information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve. The following detailed description of the curve is given:

The above information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve. The following detailed description of the curve is given:

The above information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve. The following detailed description of the curve is given:

The above information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve. The following detailed description of the curve is given:

#### T-100

The above information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve. The following detailed description of the curve is given:

The above information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve. The following detailed description of the curve is given:

The above information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve. The following detailed description of the curve is given:

The above information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve. The following detailed description of the curve is given:

#### T-100

The above information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve. The following detailed description of the curve is given:

The above information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve. The following detailed description of the curve is given:

The above information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve. The following detailed description of the curve is given:

The above information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve. The following detailed description of the curve is given:

The above information was obtained from the 7, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent points of the curve. The following detailed description of the curve is given:









UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

NUMBER 4,525,641

DATE August 13, 1982

INVENTOR: ARTHUR K. GERSHBERG and ROBERT L. KILGUS

Attorney: The undersigned is a duly qualified and duly sworn attorney-at-law, duly admitted to practice in the State of New York.

Column 2, line 51, change "interference" to  
"interference, and/or,"

Column 3, line 36, change "interference" to  
"interference, and/or,"

Column 3, line 27, change "to be" to "and/or,"

Column 13, line 11, change "concentration" to  
"concentration, and/or,"

Column 14, line 29, change "to be" to "and/or,"

Signed and Sealed this

Sixteenth Day of December, 1982

\_\_\_\_\_  
Notary Public

\_\_\_\_\_  
Attorney at Law

\_\_\_\_\_  
Inventor

\_\_\_\_\_  
Inventor

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. 2,711,761

FILED

DATED August 17, 1955

INVENTOR(S): ARTHUR H. GRAMBERG and JOHN T. COLLINS

PRODUCED PURSUANT TO A REQUEST FOR CORRECTION MADE BY THE APPLICANT(S) IN  
ORIGINAL APPLICATION

THE FOLLOWING IS THE CORRECTION:

Column 1, line 1, replace "said" with "the" and delete "the" after "said".

in column 4, line 15, replace "5402" and substitute --5307  
Dependent with the American Type Casting Corporation, 1917

East Ave. New York 10, New York 10, N.Y. 10001, and the

of the same, the word "5402" and read the

5307-- corrected.

in column 5, line 3, replace "5402" and read the  
--5307-- corrected.

in column 6, line 11, replace "5402" and read the

5307-- corrected.

in column 11, line 1, replace "5402" and substitute

5307-- corrected.

in column 12, line 11, replace "5402" and read the

--5307-- corrected.

in column 13, line 2, replace "5402" and substitute

5307-- corrected.

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF COLLECTION

PATENT NO. : 5,555,000.

Page 1 of 1

DATE : August 12, 1902

INVENTOR(S) : George W. Bickley and George T. Kellogg

In consideration of the application for a patent for the above invention, the following certificate is hereby made:

As shown in the first sheet of the application, the following is the first sheet of the application:

As shown in the second sheet of the application, the following is the second sheet of the application:

As shown in the third sheet of the application, the following is the third sheet of the application:

Signed and Sealed this  
Fifth Day of February, 1902

WITNESSES

ATTESTED

COMMISSIONER OF PATENTS

## UNITED STATES PATENT AND TRADEMARK OFFICE

**PLTFLTH1** : 1.51:04

## Discussion

DATE : 24/05/12 4:00

INVENTOR: Andrew P. HARRINGTON & Son, Inc.      02-1995

It is possible that the above approach is flawed and that the observed association between the use of a mobile phone and the use of a mobile phone is a result of the use of a mobile phone.

100-111484 100-111484

At 13th St, 1900-1901 1st and 2nd Sts, 1902-1903 1st and 2nd Sts, 1904-1905 1st and 2nd Sts, 1906-1907 1st and 2nd Sts, 1908-1909 1st and 2nd Sts, 1910-1911 1st and 2nd Sts, 1912-1913 1st and 2nd Sts, 1914-1915 1st and 2nd Sts, 1916-1917 1st and 2nd Sts, 1918-1919 1st and 2nd Sts, 1920-1921 1st and 2nd Sts, 1922-1923 1st and 2nd Sts, 1924-1925 1st and 2nd Sts, 1926-1927 1st and 2nd Sts, 1928-1929 1st and 2nd Sts, 1930-1931 1st and 2nd Sts, 1932-1933 1st and 2nd Sts, 1934-1935 1st and 2nd Sts, 1936-1937 1st and 2nd Sts, 1938-1939 1st and 2nd Sts, 1940-1941 1st and 2nd Sts, 1942-1943 1st and 2nd Sts, 1944-1945 1st and 2nd Sts, 1946-1947 1st and 2nd Sts, 1948-1949 1st and 2nd Sts, 1950-1951 1st and 2nd Sts, 1952-1953 1st and 2nd Sts, 1954-1955 1st and 2nd Sts, 1956-1957 1st and 2nd Sts, 1958-1959 1st and 2nd Sts, 1960-1961 1st and 2nd Sts, 1962-1963 1st and 2nd Sts, 1964-1965 1st and 2nd Sts, 1966-1967 1st and 2nd Sts, 1968-1969 1st and 2nd Sts, 1970-1971 1st and 2nd Sts, 1972-1973 1st and 2nd Sts, 1974-1975 1st and 2nd Sts, 1976-1977 1st and 2nd Sts, 1978-1979 1st and 2nd Sts, 1980-1981 1st and 2nd Sts, 1982-1983 1st and 2nd Sts, 1984-1985 1st and 2nd Sts, 1986-1987 1st and 2nd Sts, 1988-1989 1st and 2nd Sts, 1990-1991 1st and 2nd Sts, 1992-1993 1st and 2nd Sts, 1994-1995 1st and 2nd Sts, 1996-1997 1st and 2nd Sts, 1998-1999 1st and 2nd Sts, 2000-2001 1st and 2nd Sts, 2002-2003 1st and 2nd Sts, 2004-2005 1st and 2nd Sts, 2006-2007 1st and 2nd Sts, 2008-2009 1st and 2nd Sts, 2010-2011 1st and 2nd Sts, 2012-2013 1st and 2nd Sts, 2014-2015 1st and 2nd Sts, 2016-2017 1st and 2nd Sts, 2018-2019 1st and 2nd Sts, 2020-2021 1st and 2nd Sts, 2022-2023 1st and 2nd Sts, 2024-2025 1st and 2nd Sts, 2026-2027 1st and 2nd Sts, 2028-2029 1st and 2nd Sts, 2030-2031 1st and 2nd Sts, 2032-2033 1st and 2nd Sts, 2034-2035 1st and 2nd Sts, 2036-2037 1st and 2nd Sts, 2038-2039 1st and 2nd Sts, 2040-2041 1st and 2nd Sts, 2042-2043 1st and 2nd Sts, 2044-2045 1st and 2nd Sts, 2046-2047 1st and 2nd Sts, 2048-2049 1st and 2nd Sts, 2050-2051 1st and 2nd Sts, 2052-2053 1st and 2nd Sts, 2054-2055 1st and 2nd Sts, 2056-2057 1st and 2nd Sts, 2058-2059 1st and 2nd Sts, 2060-2061 1st and 2nd Sts, 2062-2063 1st and 2nd Sts, 2064-2065 1st and 2nd Sts, 2066-2067 1st and 2nd Sts, 2068-2069 1st and 2nd Sts, 2070-2071 1st and 2nd Sts, 2072-2073 1st and 2nd Sts, 2074-2075 1st and 2nd Sts, 2076-2077 1st and 2nd Sts, 2078-2079 1st and 2nd Sts, 2080-2081 1st and 2nd Sts, 2082-2083 1st and 2nd Sts, 2084-2085 1st and 2nd Sts, 2086-2087 1st and 2nd Sts, 2088-2089 1st and 2nd Sts, 2090-2091 1st and 2nd Sts, 2092-2093 1st and 2nd Sts, 2094-2095 1st and 2nd Sts, 2096-2097 1st and 2nd Sts, 2098-2099 1st and 2nd Sts, 2100-2101 1st and 2nd Sts, 2102-2103 1st and 2nd Sts, 2104-2105 1st and 2nd Sts, 2106-2107 1st and 2nd Sts, 2108-2109 1st and 2nd Sts, 2110-2111 1st and 2nd Sts, 2112-2113 1st and 2nd Sts, 2114-2115 1st and 2nd Sts, 2116-2117 1st and 2nd Sts, 2118-2119 1st and 2nd Sts, 2120-2121 1st and 2nd Sts, 2122-2123 1st and 2nd Sts, 2124-2125 1st and 2nd Sts, 2126-2127 1st and 2nd Sts, 2128-2129 1st and 2nd Sts, 2130-2131 1st and 2nd Sts, 2132-2133 1st and 2nd Sts, 2134-2135 1st and 2nd Sts, 2136-2137 1st and 2nd Sts, 2138-2139 1st and 2nd Sts, 2140-2141 1st and 2nd Sts, 2142-2143 1st and 2nd Sts, 2144-2145 1st and 2nd Sts, 2146-2147 1st and 2nd Sts, 2148-2149 1st and 2nd Sts, 2150-2151 1st and 2nd Sts, 2152-2153 1st and 2nd Sts, 2154-2155 1st and 2nd Sts, 2156-2157 1st and 2nd Sts, 2158-2159 1st and 2nd Sts, 2160-2161 1st and 2nd Sts, 2162-2163 1st and 2nd Sts, 2164-2165 1st and 2nd Sts, 2166-2167 1st and 2nd Sts, 2168-2169 1st and 2nd Sts, 2170-2171 1st and 2nd Sts, 2172-2173 1st and 2nd Sts, 2174-2175 1st and 2nd Sts, 2176-2177 1st and 2nd Sts, 2178-2179 1st and 2nd Sts, 2180-2181 1st and 2nd Sts, 2182-2183 1st and 2nd Sts, 2184-2185 1st and 2nd Sts, 2186-2187 1st and 2nd Sts, 2188-2189 1st and 2nd Sts, 2190-2191 1st and 2nd Sts, 2192-2193 1st and 2nd Sts, 2194-2195 1st and 2nd Sts, 2196-2197 1st and 2nd Sts, 2198-2199 1st and 2nd Sts, 2200-2201 1st and 2nd Sts, 2202-2203 1st and 2nd Sts, 2204-2205 1st and 2nd Sts, 2206-2207 1st and 2nd Sts, 2208-2209 1st and 2nd Sts, 2210-2211 1st and 2nd Sts, 2212-2213 1st and 2nd Sts, 2214-2215 1st and 2nd Sts, 2216-2217 1st and 2nd Sts, 2218-2219 1st and 2nd Sts, 2220-2221 1st and 2nd Sts, 2222-2223 1st and 2nd Sts, 2224-2225 1st and 2nd Sts, 2226-2227 1st and 2nd Sts, 2228-2229 1st and 2nd Sts, 2230-2231 1st and 2nd Sts, 2232-2233 1st and 2nd Sts, 2234-2235 1st and 2nd Sts, 2236-2237 1st and 2nd Sts, 2238-2239 1st and 2nd Sts, 2240-2241 1st and 2nd Sts, 2242-2243 1st and 2nd Sts, 2244-2245 1st and 2nd Sts, 2246-2247 1st and 2nd Sts, 2248-2249 1st and 2nd Sts, 2250-2251 1st and 2nd Sts, 2252-2253 1st and 2nd Sts, 2254-2255 1st and 2nd Sts, 2256-2257 1st and 2nd Sts, 2258-2259 1st and 2nd Sts, 2260-2261 1st and 2nd Sts, 2262-2263 1st and 2nd Sts, 2264-2265 1st and 2nd Sts, 2266-2267 1st and 2nd Sts, 2268-2269 1st and 2nd Sts, 2270-2271 1st and 2nd Sts, 2272-2273 1st and 2nd Sts, 2274-2275 1st and 2nd Sts, 2276-2277 1st and 2nd Sts, 2278-2279 1st and 2nd Sts, 2280-2281 1st and 2nd Sts, 2282-2283 1st and 2nd Sts, 2284-2285 1st and 2nd Sts, 2286-2287 1st and 2nd Sts, 2288-2289 1st and 2nd Sts, 2290-2291 1st and 2nd Sts, 2292-2293 1st and 2nd Sts, 2294-2295 1st and 2nd Sts, 2296-2297 1st and 2nd Sts, 2298-2299 1st and 2nd Sts, 2300-2301 1st and 2nd Sts, 2302-2303 1st and 2nd Sts, 2304-2305 1st and 2nd Sts, 2306-2307 1st and 2nd Sts, 2308-230

Re: COPIES OF THE FBI REPORT DATED 10/17/68 AND LETTER DATED 10/29/68  
IDENTIFIED WITH THE ABOVE SUBJECTS AND RECALLED BY 10/10/68 & 10/11/68  
IN THE BUREAU, WASHINGTON ON JANUARY 20, 1969 - MEMPHIS.

RECEIVED, THE 27 JANUARY 1971, BY AIRMAIL - 100  
/00000

As shown in Table 1, the data indicate that the majority of the respondents are male, with a mean age of 34.5 years. The majority of the respondents are married, with a mean number of children of 2.5. The majority of the respondents are employed, with a mean number of years of employment of 10.5 years.

Ar column 2, 1000. Volume 1000. The substance is a solid.

As shown in Table 1, the  $\Delta$  values for the  $\alpha$ -substituents are

As volume II, the 25. January 1946 and subsequent - 1946

[illegible]

STANDARD-1. 31 volume 12, issue 70, p. 100, 35233. and new eleven -- 35235 --

STANDARD FORM NO. 64 (Rev. 1-60) GSA GEN. REG. NO. 27

UNITED STATES PATENT AND TRADEMARK OFFICE  
 CERTIFICATE OF CORRECTION

PLT Avg (Lb) : ■ 273.55

1 2 3 4 5

DATE : APRIL 23, 1975

INVENTOR: [Signature] - 11-11-11 - 11-11-11 - 11-11-11

© International Patent Commission, 1991. All rights reserved. Printed in the United Kingdom. Printed by the Stationery Office, London. Printed on acid-free paper.

NO RECORD IN FILE 58, DATED 1967 -- REFERENCE --BIB(1)--  
 LARGEST

ALL INFORMATION CONTAINED HEREIN IS UNCLASSIFIED  
DATE 08-11-2010 BY 60322 UCBAW

© 1997 by American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.

**Agenda: September**

Signature: h. Peter of Alexandria 2/2/84

94

Don't know

**Abstract**

**Abstract**

١٠٠٠



US 2018/0132413 A1

United States

Patent Application Publication  
Publication No.

Pub No. US 2018/0132413 A1  
Pub Date Dec. 18, 2018

1.01. CONTINUED FROM US PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION

1.02. CONTINUED FROM US PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION

NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION

1.03. CONTINUED FROM US PATENT APPLICATION

1.04. CONTINUED FROM US PATENT APPLICATION

Continued from U.S. Patent Application No.

1.05. CONTINUED FROM US PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION

NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION

1.06. CONTINUED FROM US PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION


Continued from U.S. Patent Application No.

1.07. CONTINUED FROM US PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION

1.08. CONTINUED FROM US PATENT APPLICATION

1.09. CONTINUED FROM US PATENT APPLICATION

1.10. CONTINUED FROM US PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION  
NO. 2016/0100000, DATED MAR. 2, 2016,  
WHICH IS A CONTINUATION OF U.S. PATENT APPLICATION






FIG. 1

Header	G E H T T C V S . . . . . X L F E U E L A P P T X
5th loop of frame sphere 5-7	V L T T I C F S A I C P C D M Q L K R S P C C L . . . . .
mainframe	V T A P T A B . . . . . T Q T E N C M C O
6th loop of frame sphere 8-9	V A C A C S P A P . . . . . T M I E I J E C L C Y T T T
mainframe	S O T A . . . . . S T S S S A I S T L K L C M
7th loop of frame sphere 10-11	M K T L A L T A C L S P C L M Q K H C O E E C C L I L S L
mainframe	P T V P B Y L S I . . . . . P Q V E C Y Y C E
8th loop of frame sphere 12-13	M P C L I V P S P . . . . . A M I E C L P Y T E I I S S T
Carriage proceeds with loop of frame sphere 14-15	A L O G L A . . . . . L A M Q M T C I C M
Carriage proceeds	M K T L A L T A C L S P C L M Q K H C O E E C C L I L S L
Carriage proceeds	I L Y L K K A S . . . . . S M A T C Y S T
Carriage proceeds	A L P T C K C Q M C P A L K L K L C C M Q T T I L A

FIG. 2






FIG. 3




FIG. 4






FIG. 5







FIG. 7



1

2




FIG. 3






FIG. 9




FIG. 10



1. **התאמה:** התאמה בין המידע המסופק על ידי המערכת לבין המידע המסופק על ידי המערכת.

מל' י"ח י"ז תש"ח

[illegible]

STATISTICS - START TO FINISH

[illegible]

## --- POLICY

FIG. 1. A schematic diagram of a computerized data processing system. In the processing phase, a computer program is used to select the data of interest from the data base. The program also performs the statistical analysis and produces the final report. The program is designed to be flexible and can be modified to suit the needs of the user.

**1-800-4-A-FLY**

1992). The use of the various types of fluorescent probes to investigate the structure and function of the cell wall and its role in cell growth and division is discussed in this review. The use of fluorescent probes to study the cell wall and its role in cell growth and division is discussed in this review. The use of fluorescent probes to study the cell wall and its role in cell growth and division is discussed in this review.

For a given  $\alpha$ , a function  $\phi(\alpha, \beta)$  is defined as the solution of the second order differential equation  $\phi'' + \alpha\phi = \beta$  with boundary conditions  $\phi(0) = 0$  and  $\phi(1) = 0$ . The function  $\phi(\alpha, \beta)$  is called the  $\alpha$ -th order B-spline basis function. The function  $\phi(\alpha, \beta)$  is called the  $\alpha$ -th order B-spline basis function. The function  $\phi(\alpha, \beta)$  is called the  $\alpha$ -th order B-spline basis function.

1. **Introduction**

[illegible]

It is not a question of whether or not we should have a light switch and there are several things to consider. One is the fact that if you have a light switch, you can turn the light on and off. This is a very simple thing to do and it is a very useful thing to have. Another thing to consider is the fact that if you have a light switch, you can turn the light on and off. This is a very simple thing to do and it is a very useful thing to have. Another thing to consider is the fact that if you have a light switch, you can turn the light on and off. This is a very simple thing to do and it is a very useful thing to have.

These findings are consistent with the literature. For example, studies have shown that the use of a computer-based system can improve the accuracy of data collection and analysis, and that the use of a computer-based system can reduce the time required to complete a task (e.g., [10, 11]).

It is the responsibility of the Board of Directors to ensure that the company's financial statements are prepared in accordance with the applicable accounting standards and to ensure that the company's financial statements are presented fairly in all material aspects. The Board of Directors is also responsible for ensuring that the company's financial statements are prepared in accordance with the applicable accounting standards and to ensure that the company's financial statements are presented fairly in all material aspects.

[REDACTED] my company and will not be paid any salary  
as a result of the company's financial difficulties.  
I am not a partner in the company and I am not  
entitled to any share of the profits or losses of the  
company. I am not a partner in the company and I am not  
entitled to any share of the profits or losses of the  
company.

[illegible][illegible]









biochemical and molecular biology of the cell. The authors are grateful to Dr. J. Drenth for his critical reading of the manuscript and to Dr. J. Drenth for his critical reading of the manuscript.

[illegible][illegible][illegible][illegible][illegible]

THESE RESULTS INDICATE THAT THE PROPOSED REVISIONS TO THE  
FEDERAL RESERVE'S REGULATIONS ON THE DISCLOSURE OF FINANCIAL  
STATEMENTS OF FINANCIAL INSTITUTIONS ARE APPROPRIATE AND  
WARRANTED. THE REVISIONS WILL BE ADOPTED BY THE BOARD OF  
GOVERNORS OF THE FEDERAL RESERVE SYSTEM.

1. *Elaboración de un plan de trabajo*. El primer paso es elaborar un plan de trabajo que defina los objetivos, las actividades, los recursos y el tiempo. Este plan debe ser flexible y adaptable a los cambios que puedan surgir durante el proceso.

© 1997 by The McGraw-Hill Companies, Inc. All rights reserved. This publication is intended to provide accurate and authoritative information in regard to the subject matter covered. It is sold with the understanding that the publisher is not engaged in rendering professional service. If professional advice or other expert assistance is required, the services of a competent professional person should be sought.

[illegible][illegible]













[illegible]

**Figure 1**

1942] *Journal of the American Medical Association* 1942  
The following is a list of the members of the American Medical Association who have been elected to the office of President for the year 1942. The members are listed in alphabetical order of their names. The names of the members are listed in the following order: President, Vice-President, Secretary, Treasurer, and Members-at-Large.

1974] *Journal of Interpersonal Violence* 19(10):1107-1120  
 Copyright 1974 by Sage Publications, Inc. 0886-2605/74/091107-14\$01.00  
 Printed in the United States of America  
 All rights reserved. This article may not be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage and retrieval system, without permission in writing from the publisher.

## References

[illegible][illegible]

1.  $\mathcal{L}(\mathbf{y}) = \mathcal{L}(\mathbf{y}^*) + \mathcal{L}(\mathbf{y} - \mathbf{y}^*)$

[13] J. H. Conway and M. J. Guy, *Symmetry*, Cambridge University Press, 1968.

[illegible]

[14] is a different approach to the problem of how to construct a theory of the dynamics of the interaction between a quantum system and a classical system. The approach is based on the idea of a "quantum-classical correspondence" and is closely related to the work of Dirac and others on the "quantization of classical mechanics". The approach is based on the idea of a "quantum-classical correspondence" and is closely related to the work of Dirac and others on the "quantization of classical mechanics".







These representations of  $\mathcal{F}_1$  and  $\mathcal{F}_2$  are called *colored graphs*. The  $i$ th node in the graph  $\mathcal{F}_1$  is denoted by  $v_i$  and the  $j$ th node in the graph  $\mathcal{F}_2$  is denoted by  $w_j$ . The edges in  $\mathcal{F}_1$  and  $\mathcal{F}_2$  are denoted by  $e_i$  and  $f_j$ , respectively. The edges in  $\mathcal{F}_1$  and  $\mathcal{F}_2$  are called *colored edges*. The edges in  $\mathcal{F}_1$  and  $\mathcal{F}_2$  are called *colored edges*. The edges in  $\mathcal{F}_1$  and  $\mathcal{F}_2$  are called *colored edges*.

On 17 July 1979, the day after the election, the following statement was made by the author:

[illegible]







and, in the absence of a clear trend, the following analysis of the data is based on the median values of the variables and on the median values of the correlation coefficients. The correlation coefficients are calculated using the following formula:

[20] The correlation coefficient is calculated using the following formula:  $r = \frac{\sum (x_i - \bar{x})(y_i - \bar{y})}{\sqrt{\sum (x_i - \bar{x})^2 \sum (y_i - \bar{y})^2}}$ , where  $x_i$  and  $y_i$  are the values of the variables,  $\bar{x}$  and  $\bar{y}$  are the mean values of the variables,  $\sum$  is the sum of the products of the deviations of the variables from their mean values, and  $\sqrt{\sum (x_i - \bar{x})^2 \sum (y_i - \bar{y})^2}$  is the square root of the product of the sums of the squares of the deviations of the variables from their mean values. The correlation coefficient is a measure of the strength of the linear relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation, 0 indicates no correlation, and 1 indicates a perfect positive correlation.

#### RESULTS

##### 1. General

###### 1.1. General characteristics of the data

[21] The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London.

[22] The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London.

##### 2. Results

###### 2.1. General characteristics of the data

[23] The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London.

[24] The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London.

[25] The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London.

The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London.

##### 3. Discussion

###### 3.1. General characteristics of the data

[26] The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London.

##### 4. Conclusions

[27] The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London.

##### 5. References

###### 5.1. General characteristics of the data

[28] The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London.

##### 6. Acknowledgements

###### 6.1. General characteristics of the data

[29] The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London. The data were collected from a survey of 1000 people living in the city of London.





a number of other individuals, including the following:  
 - **John Doe**, 123 Main Street, Springfield, IL 62761  
 - **Jane Smith**, 456 Elm Avenue, Chicago, IL 60601  
 - **Robert Johnson**, 789 Oak Lane, Peoria, IL 61601  
 - **Lisa Brown**, 101 Pine Road, Bloomington, IL 61701  
 - **Michael Davis**, 202 Cedar Street, Rockford, IL 61101  
 - **Emily White**, 303 Birch Blvd, Joliet, IL 61731  
 - **Christopher Green**, 404 Walnut Way, Naperville, IL 60563  
 - **Amanda Black**, 505 Spruce Circle, Evanston, IL 60201  
 - **David Lee**, 606 Hickory Hill, Schaumburg, IL 60196  
 - **Sarah Hall**, 707 Ash Avenue, Mount Prospect, IL 60056  
 - **Kevin King**, 808 Sycamore Street, Des Plaines, IL 60018  
 - **Nicole Taylor**, 909 Magnolia Lane, Oak Park, IL 60462  
 - **Brandon Scott**, 1010 Poplar Place, Westmont, IL 60059  
 - **Stephanie Adams**, 1111 Willow Way, Hillside, IL 60162  
 - **Jonathan Baker**, 1212 Chestnut Court, Melrose Park, IL 60165  
 - **Michelle Carter**, 1313 Elmwood Drive, Berwyn, IL 60401  
 - **Andrew Evans**, 1414 Maple Street, Maywood, IL 60155  
 - **Kimberly Foster**, 1515 Birchwood Lane, Addison, IL 60101  
 - **Gregory Hall**, 1616 Oakwood Avenue, Rosemont, IL 60018  
 - **Heather King**, 1717 Elmwood Drive, Niles, IL 60541  
 - **Timothy Lee**, 1818 Maplewood Lane, Bensenville, IL 60015  
 - **Christina Miller**, 1919 Birchwood Lane, Deerfield, IL 60015  
 - **Benjamin Moore**, 2020 Elmwood Drive, Winnetka, IL 60093  
 - **Rebecca Nelson**, 2121 Maplewood Lane, Skokie, IL 60076  
 - **William Peterson**, 2222 Birchwood Lane, Northbrook, IL 60062  
 - **Victoria Quinn**, 2323 Elmwood Drive, Glenview, IL 60025  
 - **Christopher Reed**, 2424 Maplewood Lane, Northbrook, IL 60062  
 - **Stephanie Scott**, 2525 Birchwood Lane, Deerfield, IL 60015  
 - **Jonathan Taylor**, 2626 Elmwood Drive, Winnetka, IL 60093  
 - **Michelle Thomas**, 2727 Maplewood Lane, Skokie, IL 60076  
 - **Andrew Turner**, 2828 Birchwood Lane, Deerfield, IL 60015  
 - **Kimberly Vance**, 2929 Elmwood Drive, Winnetka, IL 60093  
 - **Gregory Ward**, 3030 Maplewood Lane, Skokie, IL 60076  
 - **Heather White**, 3131 Birchwood Lane, Deerfield, IL 60015  
 - **Timothy Wright**, 3232 Elmwood Drive, Winnetka, IL 60093  
 - **Christina Young**, 3333 Maplewood Lane, Skokie, IL 60076  
 - **Benjamin Zane**, 3434 Birchwood Lane, Deerfield, IL 60015  
 - **Rebecca Adams**, 3535 Elmwood Drive, Winnetka, IL 60093  
 - **William Baker**, 3636 Maplewood Lane, Skokie, IL 60076  
 - **Victoria Carter**, 3737 Birchwood Lane, Deerfield, IL 60015  
 - **Christopher Evans**, 3838 Elmwood Drive, Winnetka, IL 60093  
 - **Stephanie Foster**, 3939 Maplewood Lane, Skokie, IL 60076  
 - **Jonathan Hall**, 4040 Birchwood Lane, Deerfield, IL 60015  
 - **Michelle King**, 4141 Elmwood Drive, Winnetka, IL 60093  
 - **Andrew Lee**, 4242 Maplewood Lane, Skokie, IL 60076  
 - **Kimberly Miller**, 4343 Birchwood Lane, Deerfield, IL 60015  
 - **Gregory Moore**, 4444 Elmwood Drive, Winnetka, IL 60093  
 - **Heather Nelson**, 4545 Maplewood Lane, Skokie, IL 60076  
 - **Timothy Peterson**, 4646 Birchwood Lane, Deerfield, IL 60015  
 - **Christina Quinn**, 4747 Elmwood Drive, Winnetka, IL 60093  
 - **Benjamin Reed**, 4848 Maplewood Lane, Skokie, IL 60076  
 - **Rebecca Scott**, 4949 Birchwood Lane, Deerfield, IL 60015  
 - **William Taylor**, 5050 Elmwood Drive, Winnetka, IL 60093  
 - **Victoria Thomas**, 5151 Maplewood Lane, Skokie, IL 60076  
 - **Christopher Turner**, 5252 Birchwood Lane, Deerfield, IL 60015  
 - **Stephanie Vance**, 5353 Elmwood Drive, Winnetka, IL 60093  
 - **Jonathan Ward**, 5454 Maplewood Lane, Skokie, IL 60076  
 - **Michelle White**, 5555 Birchwood Lane, Deerfield, IL 60015  
 - **Andrew Wright**, 5656 Elmwood Drive, Winnetka, IL 60093  
 - **Kimberly Young**, 5757 Maplewood Lane, Skokie, IL 60076  
 - **Gregory Zane**, 5858 Birchwood Lane, Deerfield, IL 60015  
 - **Heather Adams**, 5959 Elmwood Drive, Winnetka, IL 60093  
 - **Timothy Baker**, 6060 Maplewood Lane, Skokie, IL 60076  
 - **Christina Carter**, 6161 Birchwood Lane, Deerfield, IL 60015  
 - **Benjamin Evans**, 6262 Elmwood Drive, Winnetka, IL 60093  
 - **Rebecca Foster**, 6363 Maplewood Lane, Skokie, IL 60076  
 - **William Hall**, 6464 Birchwood Lane, Deerfield, IL 60015  
 - **Victoria King**, 6565 Elmwood Drive, Winnetka, IL 60093  
 - **Christopher Lee**, 6666 Maplewood Lane, Skokie, IL 60076  
 - **Stephanie Miller**, 6767 Birchwood Lane, Deerfield, IL 60015  
 - **Jonathan Moore**, 6868 Elmwood Drive, Winnetka, IL 60093  
 - **Michelle Nelson**, 6969 Maplewood Lane, Skokie, IL 60076  
 - **Andrew Peterson**, 7070 Birchwood Lane, Deerfield, IL 60015  
 - **Kimberly Quinn**, 7171 Elmwood Drive, Winnetka, IL 60093  
 - **Gregory Reed**, 7272 Maplewood Lane, Skokie, IL 60076  
 - **Heather Scott**, 7373 Birchwood Lane, Deerfield, IL 60015  
 - **Timothy Taylor**, 7474 Elmwood Drive, Winnetka, IL 60093  
 - **Christina Thomas**, 7575 Maplewood Lane, Skokie, IL 60076  
 - **Benjamin Turner**, 7676 Birchwood Lane, Deerfield, IL 60015  
 - **Rebecca Vance**, 7777 Elmwood Drive, Winnetka, IL 60093  
 - **William Ward**, 7878 Maplewood Lane, Skokie, IL 60076  
 - **Victoria White**, 7979 Birchwood Lane, Deerfield, IL 60015  
 - **Christopher Wright**, 8080 Elmwood Drive, Winnetka, IL 60093  
 - **Stephanie Young**, 8181 Maplewood Lane, Skokie, IL 60076  
 - **Jonathan Zane**, 8282 Birchwood Lane, Deerfield, IL 60015  
 - **Michelle Adams**, 8383 Elmwood Drive, Winnetka, IL 60093  
 - **Andrew Baker**, 8484 Maplewood Lane, Skokie, IL 60076  
 - **Kimberly Carter**, 8585 Birchwood Lane, Deerfield, IL 60015  
 - **Gregory Evans**, 8686 Elmwood Drive, Winnetka, IL 60093  
 - **Heather Foster**, 8787 Maplewood Lane, Skokie, IL 60076  
 - **Timothy Hall**, 8888 Birchwood Lane, Deerfield, IL 60015  
 - **Christina King**, 8989 Elmwood Drive, Winnetka, IL 60093  
 - **Benjamin Lee**, 9090 Maplewood Lane, Skokie, IL 60076  
 - **Rebecca Miller**, 9191 Birchwood Lane, Deerfield, IL 60015  
 - **William Moore**, 9292 Elmwood Drive, Winnetka, IL 60093  
 - **Victoria Nelson**, 9393 Maplewood Lane, Skokie, IL 60076  
 - **Christopher Peterson**, 9494 Birchwood Lane, Deerfield, IL 60015  
 - **Stephanie Quinn**, 9595 Elmwood Drive, Winnetka, IL 60093  
 - **Jonathan Reed**, 9696 Maplewood Lane, Skokie, IL 60076  
 - **Michelle Scott**, 9797 Birchwood Lane, Deerfield, IL 60015  
 - **Andrew Taylor**, 9898 Elmwood Drive, Winnetka, IL 60093  
 - **Kimberly Thomas**, 9999 Maplewood Lane, Skokie, IL 60076  
 - **Gregory Turner**, 10000 Birchwood Lane, Deerfield, IL 60015  
 - **Heather Vance**, 10001 Elmwood Drive, Winnetka, IL 60093  
 - **Timothy Ward**, 10002 Maplewood Lane, Skokie, IL 60076  
 - **Christina White**, 10003 Birchwood Lane, Deerfield, IL 60015  
 - **Benjamin Wright**, 10004 Elmwood Drive, Winnetka, IL 60093  
 - **Rebecca Young**, 10005 Maplewood Lane, Skokie, IL 60076  
 - **William Zane**, 10006 Birchwood Lane, Deerfield, IL 60015  
 - **Victoria Adams**, 10007 Elmwood Drive, Winnetka, IL 60093  
 - **Christopher Baker**, 10008 Maplewood Lane, Skokie, IL 60076  
 - **Stephanie Carter**, 10009 Birchwood Lane, Deerfield, IL 60015  
 - **Jonathan Evans**, 10010 Elmwood Drive, Winnetka, IL 60093  
 - **Michelle Foster**, 10011 Maplewood Lane, Skokie, IL 60076  
 - **Andrew Hall**, 10012 Birchwood Lane, Deerfield, IL 60015  
 - **Kimberly King**, 10013 Elmwood Drive, Winnetka, IL 60093  
 - **Gregory Lee**, 10014 Maplewood Lane, Skokie, IL 60076  
 - **Heather Miller**, 10015 Birchwood Lane, Deerfield, IL 60015  
 - **Timothy Moore**, 10016 Elmwood Drive, Winnetka, IL 60093  
 - **Christina Nelson**, 10017 Maplewood Lane, Skokie, IL 60076  
 - **Benjamin Peterson**, 10018 Birchwood Lane, Deerfield, IL 60015  
 - **Rebecca Quinn**, 10019 Elmwood Drive, Winnetka, IL 60093  
 - **William Reed**, 10020 Maplewood Lane, Skokie, IL 60076  
 - **Victoria Scott**, 10021 Birchwood Lane, Deerfield, IL

The first of these is the fact that the
 *Journal of the American Medical Association*
 has been the only one of the
 major medical journals to
 publish a special issue on
 the topic of "The
 Future of the
 Medical Profession."
 This issue, which
 appeared in the
 November 1988
 issue, was
 edited by
 Dr. Robert
 M. G.
 Anderson,
 M.D.,
 of the
 University
 of
 California,
 San
 Francisco.
 The
 issue
 contains
 a
 number
 of
 articles
 which
 discuss
 the
 future
 of
 the
 medical
 profession
 in
 the
 light
 of
 the
 changes
 which
 are
 taking
 place
 in
 the
 medical
 profession
 and
 the
 society
 in
 which
 it
 operates.
 The
 articles
 are
 by
 Dr.
 Anderson,
 Dr.
 Robert
 M.
 G.
 Anderson,
 M.D.,
 of
 the
 University
 of
 California,
 San
 Francisco,
 and
 Dr.
 Robert
 M.
 G.
 Anderson,
 M.D.,
 of
 the
 University
 of
 California,
 San
 Francisco.
 The
 issue
 is
 a
 valuable
 contribution
 to
 the
 discussion
 of
 the
 future
 of
 the
 medical
 profession.

10/10/2018 12:53:13 PM

6-514 in 4 lines.-1. b

1977) together with several previous studies, we have shown that the amount of time spent by the fish in the water column and near the bottom is related to the size of the fish. The larger the fish, the more time it spends in the water column. This is probably due to the fact that larger fish have a greater range of movement and are able to move more quickly than smaller fish. The results of this study suggest that the amount of time spent by the fish in the water column and near the bottom is related to the size of the fish. The larger the fish, the more time it spends in the water column. This is probably due to the fact that larger fish have a greater range of movement and are able to move more quickly than smaller fish.

1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 26

[illegible]

7-13

Downloaded from <http://ajphaphysoc.org/> by the  
University of California, San Diego on October 1, 2014

Full of the same old, same old, it's time to go  
to the store, to the store, to the store, to the store.

the Commission's findings are that the 1970s were marked by a period of rapid growth in the 1970s, followed by a period of stagnation in the 1980s. The Commission's findings are that the 1970s were marked by a period of rapid growth in the 1970s, followed by a period of stagnation in the 1980s. The Commission's findings are that the 1970s were marked by a period of rapid growth in the 1970s, followed by a period of stagnation in the 1980s.

[illegible]

[-54-]

المجلس الأعلى للمعوقين  
الجمعية العامة للمعوقين

[illegible]

[ 25 ] "The American People," *with the People's Republic of China*, 1980, 1982, 1984, 1986, 1988, 1990, 1992, 1994, 1996, 1998, 2000, 2002, 2004, 2006, 2008, 2010, 2012, 2014, 2016, 2018, 2020, 2022, 2024, 2026, 2028, 2030, 2032, 2034, 2036, 2038, 2040, 2042, 2044, 2046, 2048, 2050, 2052, 2054, 2056, 2058, 2060, 2062, 2064, 2066, 2068, 2070, 2072, 2074, 2076, 2078, 2080, 2082, 2084, 2086, 2088, 2090, 2092, 2094, 2096, 2098, 2100, 2102, 2104, 2106, 2108, 2110, 2112, 2114, 2116, 2118, 2120, 2122, 2124, 2126, 2128, 2130, 2132, 2134, 2136, 2138, 2140, 2142, 2144, 2146, 2148, 2150, 2152, 2154, 2156, 2158, 2160, 2162, 2164, 2166, 2168, 2170, 2172, 2174, 2176, 2178, 2180, 2182, 2184, 2186, 2188, 2190, 2192, 2194, 2196, 2198, 2200, 2202, 2204, 2206, 2208, 2210, 2212, 2214, 2216, 2218, 2220, 2222, 2224, 2226, 2228, 2230, 2232, 2234, 2236, 2238, 2240, 2242, 2244, 2246, 2248, 2250, 2252, 2254, 2256, 2258, 2260, 2262, 2264, 2266, 2268, 2270, 2272, 2274, 2276, 2278, 2280, 2282, 2284, 2286, 2288, 2290, 2292, 2294, 2296, 2298, 2300, 2302, 2304, 2306, 2308, 2310, 2312, 2314, 2316, 2318, 2320, 2322, 2324, 2326, 2328, 2330, 2332, 2334, 2336, 2338, 2340, 2342, 2344, 2346, 2348, 2350, 2352, 2354, 2356, 2358, 2360, 2362, 2364, 2366, 2368, 2370, 2372, 2374, 2376, 2378, 2380, 2382, 2384, 2386, 2388, 2390, 2392, 2394, 2396, 2398, 2400, 2402, 2404, 2406, 2408, 2410, 2412, 2414, 2416, 2418, 2420, 2422, 2424, 2426, 2428, 2430, 2432, 2434, 2436, 2438, 2440, 2442, 2444, 2446, 2448, 2450, 2452, 2454, 2456, 2458, 2460, 2462, 2464, 2466, 2468, 2470, 2472, 2474, 2476, 2478, 2480, 2482, 2484, 2486, 2488, 2490, 2492, 2494, 2496, 2498, 2500, 2502, 2504, 2506, 2508, 2510, 2512, 2514, 2516, 2518, 2520, 2522, 2524, 2526, 2528, 2530, 2532, 2534, 2536, 2538, 2540, 2542, 2544, 2546, 2548, 2550, 2552, 2554, 2556, 2558, 2560, 2562, 2564, 2566, 2568, 2570, 2572, 2574, 2576, 2578, 2580, 2582, 2584, 2586, 2588, 2590, 2592, 2594, 2596, 2598, 2600, 2602, 2604, 2606, 2608, 2610, 2612, 2614, 2616, 2618, 2620, 2622, 2624, 2626, 2628, 2630, 2632, 2634, 2636, 2638, 2640, 2642, 2644, 2646, 2648, 2650, 2652, 2654, 2656, 2658, 2660, 2662, 2664, 2666, 2668, 2670, 2672, 2674, 2676, 2678, 2680, 2682, 2684, 2686, 2688, 2690, 2692, 2694, 2696, 2698, 2700, 2702, 2704, 2706, 2708, 2710, 2712, 2714, 2716, 2718, 2720, 2722, 2724, 2726, 2728, 2730, 2732, 2734, 2736, 2738, 2740, 2742, 2744, 2746, 2748, 2750, 2752, 2754, 2756, 2758, 2760, 2762, 2764, 2766, 2768, 2770, 2772, 2774, 2776, 2778, 2780, 2782, 2784, 2786, 2788, 2790, 2792, 2794, 2796, 2798, 2800, 2802, 2804, 2806, 2808, 2810, 2812, 2814, 2816, 2818, 2820, 2822, 2824, 2826, 2828, 2830, 2832, 2834, 2836, 2838, 2840, 2842, 2844, 2846, 2848, 2850, 2852, 2854, 2856, 2858, 2860, 2862, 2864, 2866, 2868, 2870, 2872, 2874, 2876, 2878, 2880, 2882, 2884, 2886, 2888, 2890, 2892, 2894, 2896, 2898, 2900, 2902, 2904, 2906, 2908, 2910, 2912, 2914, 2916, 2918, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964, 2966, 2968, 2970, 2972, 2974, 2976, 2978, 2980, 2982, 2984, 2986, 2988, 2990, 2992, 2994, 2996, 2998, 3000, 3002, 3004, 3006, 3008, 3010, 3012, 3014, 3016, 3018, 3020, 3022, 3024, 3026, 3028, 3030, 3032, 3034, 3036, 3038, 3040, 3042, 3044, 3046, 3048, 3050, 3052, 3054, 3056, 3058, 3060, 3062, 3064, 3066, 3068, 3070, 3072, 3074, 3076, 3078, 3080, 3082, 3084, 3086, 3088, 3090, 3092, 3094, 3096, 3098, 3100, 3102, 3104, 3106, 3108, 3110, 3112, 3114, 3116, 3118, 3120, 3122, 3124, 3126, 3128, 3130, 3132, 3134, 3136, 3138, 3140, 3142, 3144, 3146, 3148, 3150, 3152, 3154, 3156, 3158, 3160, 3162, 3164, 3166, 3168, 3170, 3172, 3174, 3176, 3178, 3180, 3182, 3184, 3186, 3188, 3190, 3192, 3194, 3196, 3198, 3200, 3202, 3204, 3206, 3208, 3210, 3212, 3214, 3216, 3218, 3220, 3222, 3224, 3226, 3228, 3230, 3232, 3234, 3236, 3238, 3240, 3242, 3244, 3246, 3248, 3250, 3252, 3254, 3256, 3258, 3260, 3262, 3264, 3266, 3268, 3270, 3272, 3274, 3276, 3278, 3280, 3282, 3284, 3286, 3288, 3290, 3292, 3294, 3296, 3298, 3300, 3302, 3304, 3306, 3308, 3310, 3312, 3314, 3316, 3318, 3320, 3322, 3324, 3326, 3328, 3330, 3332, 3334, 333

[illegible][illegible]









EXHIBIT 11.0000

Q	A	Q
Q Now, did you know that the defendant was not a member of the group?	A Yes.	Q
Q Did you know that the defendant was not a member of the group?	A Yes.	Q
Q Did you know that the defendant was not a member of the group?	A Yes.	Q
Q Did you know that the defendant was not a member of the group?	A Yes.	Q
Q Did you know that the defendant was not a member of the group?	A Yes.	Q
Q Did you know that the defendant was not a member of the group?	A Yes.	Q

Q

Q Now, did you know that the defendant was not a member of the group?

A Yes.

Q Now, did you know that the defendant was not a member of the group?

A Yes.

Q Now, did you know that the defendant was not a member of the group?

A Yes.

Q Now, did you know that the defendant was not a member of the group?

A Yes.

Q Now, did you know that the defendant was not a member of the group?

A Yes.

Q

Q Now, did you know that the defendant was not a member of the group?

A Yes.

Q Now, did you know that the defendant was not a member of the group?

A Yes.

Q Now, did you know that the defendant was not a member of the group?

A Yes.

Q Now, did you know that the defendant was not a member of the group?





PROBLÈME 11.2144

On considère une suite  $(u_n)_{n \geq 0}$  de réels positifs telle que  $u_0 = 1$  et

pour

$$\begin{aligned} u_{2n} &= u_n^2, \\ u_{2n+1} &= u_n u_{n+1}, \\ u_{2n+2} &= u_{n+1}^2, \end{aligned}$$

on a  $u_n \leq 1$  pour tout  $n$ .

On suppose que la suite  $(u_n)_{n \geq 0}$  est croissante et que  $u_n > 0$  pour tout  $n$ .

On pose  $v_n = \frac{u_n}{u_{n-1}}$  pour  $n \geq 1$  et  $w_n = \frac{u_n}{u_{n-2}}$  pour  $n \geq 2$ .

On suppose que la suite  $(v_n)_{n \geq 1}$  est croissante et que  $v_n > 0$  pour tout  $n$ .

On suppose que la suite  $(w_n)_{n \geq 2}$  est croissante et que  $w_n > 0$  pour tout  $n$ .

On suppose que la suite  $(u_n)_{n \geq 0}$  est croissante et que  $u_n > 0$  pour tout  $n$ .

On suppose que la suite  $(v_n)_{n \geq 1}$  est croissante et que  $v_n > 0$  pour tout  $n$ .

On suppose que la suite  $(w_n)_{n \geq 2}$  est croissante et que  $w_n > 0$  pour tout  $n$ .

On suppose que la suite  $(u_n)_{n \geq 0}$  est croissante et que  $u_n > 0$  pour tout  $n$ .

On pose  $v_n = \frac{u_n}{u_{n-1}}$  pour  $n \geq 1$  et  $w_n = \frac{u_n}{u_{n-2}}$  pour  $n \geq 2$ .

$$\begin{aligned} u_{2n} &= u_n^2, \\ u_{2n+1} &= u_n u_{n+1}, \\ u_{2n+2} &= u_{n+1}^2, \\ u_{2n+3} &= u_{n+2} u_{n+1}. \end{aligned}$$

On a  $u_n \leq 1$  pour tout  $n$ .

On suppose que la suite  $(u_n)_{n \geq 0}$  est croissante et que  $u_n > 0$  pour tout  $n$ .

On suppose que la suite  $(v_n)_{n \geq 1}$  est croissante et que  $v_n > 0$  pour tout  $n$ .

On suppose que la suite  $(w_n)_{n \geq 2}$  est croissante et que  $w_n > 0$  pour tout  $n$ .

On suppose que la suite  $(u_n)_{n \geq 0}$  est croissante et que  $u_n > 0$  pour tout  $n$ .

On suppose que la suite  $(v_n)_{n \geq 1}$  est croissante et que  $v_n > 0$  pour tout  $n$ .

On suppose que la suite  $(w_n)_{n \geq 2}$  est croissante et que  $w_n > 0$  pour tout  $n$ .

On suppose que la suite  $(u_n)_{n \geq 0}$  est croissante et que  $u_n > 0$  pour tout  $n$ .

On suppose que la suite  $(v_n)_{n \geq 1}$  est croissante et que  $v_n > 0$  pour tout  $n$ .

On suppose que la suite  $(w_n)_{n \geq 2}$  est croissante et que  $w_n > 0$  pour tout  $n$ .

On suppose que la suite  $(u_n)_{n \geq 0}$  est croissante et que  $u_n > 0$  pour tout  $n$ .

AMERICAN INDIAN

1. The first of the four is the name of the person who is the subject of the story.

2. The second is the name of the person who is the subject of the story.

3. The third is the name of the person who is the subject of the story.

4. The fourth is the name of the person who is the subject of the story.

5. The fifth is the name of the person who is the subject of the story.

6. The sixth is the name of the person who is the subject of the story.

7. The seventh is the name of the person who is the subject of the story.

8. The eighth is the name of the person who is the subject of the story.

9. The ninth is the name of the person who is the subject of the story.

10. The tenth is the name of the person who is the subject of the story.

11. The eleventh is the name of the person who is the subject of the story.

12. The twelfth is the name of the person who is the subject of the story.

13. The thirteenth is the name of the person who is the subject of the story.

14. The fourteenth is the name of the person who is the subject of the story.

15. The fifteenth is the name of the person who is the subject of the story.

16. The sixteenth is the name of the person who is the subject of the story.

17. The seventeenth is the name of the person who is the subject of the story.

18. The eighteenth is the name of the person who is the subject of the story.

19. The nineteenth is the name of the person who is the subject of the story.

20. The twentieth is the name of the person who is the subject of the story.

21. The twenty-first is the name of the person who is the subject of the story.

22. The twenty-second is the name of the person who is the subject of the story.

23. The twenty-third is the name of the person who is the subject of the story.

24. The twenty-fourth is the name of the person who is the subject of the story.

25. The twenty-fifth is the name of the person who is the subject of the story.

26. The twenty-sixth is the name of the person who is the subject of the story.

27. The twenty-seventh is the name of the person who is the subject of the story.

28. The twenty-eighth is the name of the person who is the subject of the story.

29. The twenty-ninth is the name of the person who is the subject of the story.

30. The thirtieth is the name of the person who is the subject of the story.

31. The thirty-first is the name of the person who is the subject of the story.

32. The thirty-second is the name of the person who is the subject of the story.

33. The thirty-third is the name of the person who is the subject of the story.







## REFERENCES

ANDERSON, D. R. 1967.

ANDERSON, D. R.,  
ANDERSON, D. R.,  
ANDERSON, D. R.,  
ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R.

ANDERSON, D. R.

ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R.

ANDERSON, D. R.

ANDERSON, D. R.,  
ANDERSON, D. R.,  
ANDERSON, D. R.,  
ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R.

ANDERSON, D. R.

ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R.

ANDERSON, D. R.

ANDERSON, D. R.,  
ANDERSON, D. R.,  
ANDERSON, D. R.,  
ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R.

ANDERSON, D. R.

ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R.

ANDERSON, D. R.

ANDERSON, D. R.,  
ANDERSON, D. R.,  
ANDERSON, D. R.,  
ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R.

ANDERSON, D. R.

ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R.

ANDERSON, D. R.

ANDERSON, D. R.,  
ANDERSON, D. R.,  
ANDERSON, D. R.,  
ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R.

ANDERSON, D. R.

ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R.

ANDERSON, D. R.

ANDERSON, D. R.,  
ANDERSON, D. R.,  
ANDERSON, D. R.,  
ANDERSON, D. R., ANDERSON, D. R., ANDERSON, D. R.

ANDERSON, D. R.



### References

- Altman, D. G., and Bland, D. B. (1982) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 47:1329-1349.
- Altman, D. G., and Bland, D. B. (1985) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 53:1329-1349.
- Altman, D. G., and Bland, D. B. (1986) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 55:1329-1349.
- Altman, D. G., and Bland, D. B. (1987) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 56:1329-1349.
- Altman, D. G., and Bland, D. B. (1988) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 59:1329-1349.
- Altman, D. G., and Bland, D. B. (1989) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 61:1329-1349.
- Altman, D. G., and Bland, D. B. (1990) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 63:1329-1349.
- Altman, D. G., and Bland, D. B. (1991) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 65:1329-1349.
- Altman, D. G., and Bland, D. B. (1992) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 67:1329-1349.
- Altman, D. G., and Bland, D. B. (1993) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 69:1329-1349.

Altman, D. G., and Bland, D. B. (1994) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 71:1329-1349.

Altman, D. G., and Bland, D. B. (1995) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 73:1329-1349.

Altman, D. G., and Bland, D. B. (1996) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 75:1329-1349.

Altman, D. G., and Bland, D. B. (1997) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 77:1329-1349.

Altman, D. G., and Bland, D. B. (1998) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 79:1329-1349.

Altman, D. G., and Bland, D. B. (1999) Oscillations of membrane potential in the rat hippocampus: A comparison of the effects of various drugs. *J. Neurophysiol.* 81:1329-1349.



US 9,496,663 B2

# United States Patent Classification

Patent No.: US 9,496,663 B2  
Date of Patent: Aug 4, 2017

1. A method for providing a user with a user interface for a user interface, comprising:

1.1. receiving a user interface for a user interface, comprising:

1.1.1. a user interface for a user interface, comprising:

1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1.1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1.1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1.1.1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1. a user interface for a user interface, comprising:

1. a user interface for a user interface, comprising:

1. a user interface for a user interface, comprising:

1. a user interface for a user interface, comprising:

1. a user interface for a user interface, comprising:










FIG. 3











FIG. 4









۲۹





FIG. 8






FIG. 10





FIG. 11






FIG. 12




FIG. 13A




FIG. 13B







1. **Prüfungsinhalt:** Die Prüfung umfasst die Themenbereiche: Grundlagen der Betriebswirtschaftslehre, Marketing, Beschaffung, Produktion, Vertrieb, Finanzierung und Rechnungswesen.

2017年12月15日 星期五

2011.09.12. 12.30

Small, 1992). The authors also reported that the mean age of the sample was 16.7 years, with a range of 15 to 18 years. The mean age of the sample was 16.7 years, with a range of 15 to 18 years.

2007年12月26日星期三 14:00

2017年12月25日  
 2017年12月25日  
 2017年12月25日

[illegible]

COPIES: 490, 1000, 1000, 1000  
1000, 1000, 1000, 1000

**CONFIDENTIAL - SECURITY INFORMATION**

201-220-1100: 4300-00-00 000000  
000000000000

[illegible]

2015-16: 410, 4.8%  
 2014-15: 400, 4.8%  
 2013-14: 390, 4.8%  
 2012-13: 380, 4.8%  
 2011-12: 370, 4.8%  
 2010-11: 360, 4.8%  
 2009-10: 350, 4.8%  
 2008-09: 340, 4.8%  
 2007-08: 330, 4.8%  
 2006-07: 320, 4.8%  
 2005-06: 310, 4.8%  
 2004-05: 300, 4.8%  
 2003-04: 290, 4.8%  
 2002-03: 280, 4.8%  
 2001-02: 270, 4.8%  
 2000-01: 260, 4.8%  
 1999-00: 250, 4.8%  
 1998-99: 240, 4.8%  
 1997-98: 230, 4.8%  
 1996-97: 220, 4.8%  
 1995-96: 210, 4.8%  
 1994-95: 200, 4.8%  
 1993-94: 190, 4.8%  
 1992-93: 180, 4.8%  
 1991-92: 170, 4.8%  
 1990-91: 160, 4.8%  
 1989-90: 150, 4.8%  
 1988-89: 140, 4.8%  
 1987-88: 130, 4.8%  
 1986-87: 120, 4.8%  
 1985-86: 110, 4.8%  
 1984-85: 100, 4.8%  
 1983-84: 90, 4.8%  
 1982-83: 80, 4.8%  
 1981-82: 70, 4.8%  
 1980-81: 60, 4.8%  
 1979-80: 50, 4.8%  
 1978-79: 40, 4.8%  
 1977-78: 30, 4.8%  
 1976-77: 20, 4.8%  
 1975-76: 10, 4.8%  
 1974-75: 0, 4.8%  
 1973-74: 0, 4.8%  
 1972-73: 0, 4.8%  
 1971-72: 0, 4.8%  
 1970-71: 0, 4.8%  
 1969-70: 0, 4.8%  
 1968-69: 0, 4.8%  
 1967-68: 0, 4.8%  
 1966-67: 0, 4.8%  
 1965-66: 0, 4.8%  
 1964-65: 0, 4.8%  
 1963-64: 0, 4.8%  
 1962-63: 0, 4.8%  
 1961-62: 0, 4.8%  
 1960-61: 0, 4.8%  
 1959-60: 0, 4.8%  
 1958-59: 0, 4.8%  
 1957-58: 0, 4.8%  
 1956-57: 0, 4.8%  
 1955-56: 0, 4.8%  
 1954-55: 0, 4.8%  
 1953-54: 0, 4.8%  
 1952-53: 0, 4.8%  
 1951-52: 0, 4.8%  
 1950-51: 0, 4.8%  
 1949-50: 0, 4.8%  
 1948-49: 0, 4.8%  
 1947-48: 0, 4.8%  
 1946-47: 0, 4.8%  
 1945-46: 0, 4.8%  
 1944-45: 0, 4.8%  
 1943-44: 0, 4.8%  
 1942-43: 0, 4.8%  
 1941-42: 0, 4.8%  
 1940-41: 0, 4.8%  
 1939-40: 0, 4.8%  
 1938-39: 0, 4.8%  
 1937-38: 0, 4.8%  
 1936-37: 0, 4.8%  
 1935-36: 0, 4.8%  
 1934-35: 0, 4.8%  
 1933-34: 0, 4.8%  
 1932-33: 0, 4.8%  
 1931-32: 0, 4.8%  
 1930-31: 0, 4.8%  
 1929-30: 0, 4.8%  
 1928-29: 0, 4.8%  
 1927-28: 0, 4.8%  
 1926-27: 0, 4.8%  
 1925-26: 0, 4.8%  
 1924-25: 0, 4.8%  
 1923-24: 0, 4.8%  
 1922-23: 0, 4.8%  
 1921-22: 0, 4.8%  
 1920-21: 0, 4.8%  
 1919-20: 0, 4.8%  
 1918-19: 0, 4.8%  
 1917-18: 0, 4.8%  
 1916-17: 0, 4.8%  
 1915-16: 0, 4.8%  
 1914-15: 0, 4.8%  
 1913-14: 0, 4.8%  
 1912-13: 0, 4.8%  
 1911-12: 0, 4.8%  
 1910-11: 0, 4.8%  
 1909-10: 0, 4.8%  
 1908-09: 0, 4.8%  
 1907-08: 0, 4.8%  
 1906-07: 0, 4.8%  
 1905-06: 0, 4.8%  
 1904-05: 0, 4.8%  
 1903-04: 0, 4.8%  
 1902-03: 0, 4.8%  
 1901-02: 0, 4.8%  
 1900-01: 0, 4.8%  
 1899-00: 0, 4.8%  
 1898-99: 0, 4.8%  
 1897-98: 0, 4.8%  
 1896-97: 0, 4.8%  
 1895-96: 0, 4.8%  
 1894-95: 0, 4.8%  
 1893-94: 0, 4.8%  
 1892-93: 0, 4.8%  
 1891-92: 0, 4.8%  
 1890-91: 0, 4.8%  
 1889-90: 0, 4.8%  
 1888-89: 0, 4.8%  
 1887-88: 0, 4.8%  
 1886-87: 0, 4.8%  
 1885-86: 0, 4.8%  
 1884-85: 0, 4.8%  
 1883-84: 0, 4.8%  
 1882-83: 0, 4.8%  
 1881-82: 0, 4.8%  
 1880-81: 0, 4.8%  
 1879-80: 0, 4.8%  
 1878-79: 0, 4.8%  
 1877-78: 0, 4.8%  
 1876-77: 0, 4.8%  
 1875-76: 0, 4.8%  
 1874-75: 0, 4.8%  
 1873-74: 0, 4.8%  
 1872-73: 0, 4.8%  
 1871-72: 0, 4.8%  
 1870-71: 0, 4.8%  
 1869-70: 0, 4.8%  
 1868-69: 0, 4.8%  
 1867-68: 0, 4.8%  
 1866-67: 0, 4.8%  
 1865-66: 0, 4.8%  
 1864-65: 0, 4.8%  
 1863-64: 0, 4.8%  
 1862-63: 0, 4.8%  
 1861-62: 0, 4.8%  
 1860-61: 0, 4.8%  
 1859-60: 0, 4.8%  
 1858-59: 0, 4.8%  
 1857-58: 0, 4.8%  
 1856-57: 0, 4.8%  
 1855-56: 0, 4.8%  
 1854-55: 0, 4.8%  
 1853-54: 0, 4.8%  
 1852-53: 0, 4.8%  
 1851-52: 0, 4.8%  
 1850-51: 0, 4.8%  
 1849-50: 0, 4.8%  
 1848-49: 0, 4.8%  
 1847-48: 0, 4.8%  
 1846-47: 0, 4.8%  
 1845-46: 0, 4.8%  
 1844-45: 0, 4.8%  
 1843-44: 0, 4.8%  
 1842-43: 0, 4.8%  
 1841-42: 0, 4.8%  
 1840-41: 0, 4.8%  
 1839-40: 0, 4.8%  
 1838-39: 0, 4.8%  
 1837-38: 0, 4.8%  
 1836-37: 0, 4.8%  
 1835-36: 0, 4.8%  
 1834-35: 0, 4.8%  
 1833-34: 0, 4.

© 2004 by John Wiley & Sons, Inc.  
 0000-0000/04/0000-0000\$10.00

ET: 10% WTM-

100-443887-100

44-38861-12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846

1. The following information is for your information only. It is not intended to be used for any other purpose. It is not intended to be used for any other purpose. It is not intended to be used for any other purpose.

1987). Despite the numerous studies on the long-term effects of a high-fat diet on the cardiovascular system, little is known about the long-term effects of a high-fat diet on the endocrine system. In particular, the effects of a high-fat diet on the hypothalamic-pituitary-gonadal axis have not been fully elucidated. The present study was designed to investigate the effects of a high-fat diet on the hypothalamic-pituitary-gonadal axis in male rats. The study was divided into two parts. In the first part, the effects of a high-fat diet on the hypothalamic-pituitary-gonadal axis were investigated in rats that had been fed a high-fat diet for 12 weeks. In the second part, the effects of a high-fat diet on the hypothalamic-pituitary-gonadal axis were investigated in rats that had been fed a high-fat diet for 24 weeks. The results of the study are presented in the following sections.

1. *Journal of the American Medical Association*, 1990; 263: 1000-1001.

[illegible]

The following members shall constitute the Board of Directors of the Corporation, to serve until the first day of January, 1901:

[illegible][illegible]

On 26 June 1994, the Department of Health and Human Services (DHHS) announced that it had received a request from the National Aeronautics and Space Administration (NASA) to conduct a study of the potential for the use of the Department's research and development resources to support NASA's research and development efforts in the area of the development of a new generation of aircraft. The study was to be conducted by the Department's Office of Technology Assessment (OTA) and the Department's Office of Science and Technology Policy (OSTP). The study was to be completed by 1 October 1994. The study was to be conducted by the Department's Office of Technology Assessment (OTA) and the Department's Office of Science and Technology Policy (OSTP). The study was to be completed by 1 October 1994.

For any individual and group, there is a limit to the amount of information that can be processed at any one time. This limit is known as the "magical number seven, plus or minus two." This limit is not a fixed number, but it is a limit. It is a limit that is based on the capacity of the human mind to process information. It is a limit that is based on the capacity of the human mind to process information. It is a limit that is based on the capacity of the human mind to process information.

1. The following description of a general type of spring is for purposes of providing a basis for comparison of the various types of springs. It is not intended to be a description of any particular type of spring, and it is not intended to be a description of any particular type of spring. It is intended to be a description of a general type of spring.







































Accepted for publication 12 July 2015  
doi:10.1017/S0950268815002132

[illegible]

James Earl Ray, a 37-year-old white male, was arrested on 12/22/67 and charged with the murder of Dr. Martin Luther King. He later pleaded guilty to the murder and was sentenced to 99 years in prison. Ray was released on parole in 1969 and moved to London, where he lived until his death in 1998. He was known for his involvement in the assassination of Dr. King and for his role in the development of the "Gulf of Tonkin" incident.

We are pleased to have you, and we will be glad to assist you in any way we can. We will be glad to assist you in any way we can. We will be glad to assist you in any way we can.

[illegible][illegible]

It is important to note that the results of this study are based on a cross-sectional design, which limits the ability to establish causality. Future research should employ longitudinal designs to investigate the temporal relationships between the variables studied. Additionally, the study was conducted in a specific cultural context, and the findings may not be generalizable to other populations. Further research is needed to explore the cultural and contextual factors that may influence the relationships observed in this study.

4. 4. 4. 4. 4.

Journal of Interpersonal Violence 27(12)  
© The Author(s) 2012  
Reprints and permissions: [sagepub.com/journalsPermissions.nav](http://sagepub.com/journalsPermissions.nav)

U.S. MARSHALS SERVICE - NEW YORK OFFICE  
COMMUNICATIONS SECTION - NEW YORK OFFICE

The first thing I noticed when I stepped out of the plane was the cold, crisp air. It felt like a fresh blanket. The pilot, a young man with a friendly smile, greeted me as I stepped out. He handed me a small bag containing a map and a bottle of water. I thanked him and started walking towards the city center. The streets were wide and clean, with many trees lining the sidewalks. I saw a few people walking, some in business suits and others in casual clothes. The architecture was a mix of modern skyscrapers and older, historic buildings. I felt like I had stepped into a new world.

[illegible]

**Figure 1**

© 2000 Blackwell Science Ltd, *Journal of Internal Medicine* 247: 395–401

For the first time in its 115-year history, the American Association of University Professors (AAUP) has issued a statement in support of the administration of the University of Illinois at Chicago (UIC) in the wake of the 1992-93 academic year. The AAUP's statement, "Statement of the American Association of University Professors on the University of Illinois at Chicago," was issued on April 1, 1994. The statement was issued in response to the AAUP's 1993-94 annual meeting, which was held in Chicago, Illinois, on April 1, 1994. The statement was issued in response to the AAUP's 1993-94 annual meeting, which was held in Chicago, Illinois, on April 1, 1994. The statement was issued in response to the AAUP's 1993-94 annual meeting, which was held in Chicago, Illinois, on April 1, 1994.

THE FOLLOWING INFORMATION IS FOR THE INFORMATION OF THE OFFICE OF THE ATTORNEY GENERAL, AND IS NOT TO BE USED FOR ANY OTHER PURPOSE. IT IS THE POLICY OF THE OFFICE OF THE ATTORNEY GENERAL TO MAINTAIN THE CONFIDENTIALITY OF THE INFORMATION CONTAINED HEREIN, AND TO PREVENT THE DISCLOSURE OF SUCH INFORMATION TO ANY OTHER PERSON OR ENTITY. IT IS THE POLICY OF THE OFFICE OF THE ATTORNEY GENERAL TO MAINTAIN THE CONFIDENTIALITY OF THE INFORMATION CONTAINED HEREIN, AND TO PREVENT THE DISCLOSURE OF SUCH INFORMATION TO ANY OTHER PERSON OR ENTITY.











QUESTION

1. The function  $f(x)$  is defined by

- (i)  $f(x) = \frac{1}{x}$
- (ii)  $f(x) = \frac{1}{x^2}$
- (iii)  $f(x) = \frac{1}{x^3}$
- (iv)  $f(x) = \frac{1}{x^4}$
- (v)  $f(x) = \frac{1}{x^5}$

2. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 3. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^2}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 4. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^3}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 5. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^4}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 6. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^5}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 7. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^6}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 8. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^7}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 9. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^8}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 10. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^9}$ . Find the value of  $f(2)$  and  $f(3)$ .

- (i)  $f(x) = \frac{1}{x}$
- (ii)  $f(x) = \frac{1}{x^2}$
- (iii)  $f(x) = \frac{1}{x^3}$
- (iv)  $f(x) = \frac{1}{x^4}$
- (v)  $f(x) = \frac{1}{x^5}$

11. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 12. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^2}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 13. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^3}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 14. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^4}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 15. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^5}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 16. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^6}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 17. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^7}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 18. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^8}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 19. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^9}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 20. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^{10}}$ . Find the value of  $f(2)$  and  $f(3)$ .

- (i)  $f(x) = \frac{1}{x}$
- (ii)  $f(x) = \frac{1}{x^2}$
- (iii)  $f(x) = \frac{1}{x^3}$
- (iv)  $f(x) = \frac{1}{x^4}$
- (v)  $f(x) = \frac{1}{x^5}$

21. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 22. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^2}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 23. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^3}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 24. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^4}$ . Find the value of  $f(2)$  and  $f(3)$ .  
 25. The function  $f(x)$  is defined by  $f(x) = \frac{1}{x^5}$ . Find the value of  $f(2)$  and  $f(3)$ .

1. The first part of the paper is devoted to the study of the properties of the function  $f(x)$  defined by the equation  $f(x) = \sum_{n=0}^{\infty} \frac{f_n(x)}{n!}$ , where  $f_n(x)$  are the solutions of the system of equations  $f_n'(x) = -f_n(x) + f_{n-1}(x)$ ,  $f_0(x) = 1$ . It is shown that  $f(x)$  is a solution of the equation  $f'(x) = -f(x) + 1$  and that  $f(x) = 1 - e^{-x}$ . The second part of the paper is devoted to the study of the properties of the function  $g(x)$  defined by the equation  $g(x) = \sum_{n=0}^{\infty} \frac{g_n(x)}{n!}$ , where  $g_n(x)$  are the solutions of the system of equations  $g_n'(x) = -g_n(x) + g_{n-1}(x)$ ,  $g_0(x) = 1$ . It is shown that  $g(x)$  is a solution of the equation  $g'(x) = -g(x) + 1$  and that  $g(x) = 1 - e^{-x}$ .

1. The first part of the paper is devoted to the study of the properties of the function  $f(x)$  defined by the equation  $f(x) = \sum_{n=0}^{\infty} \frac{f_n(x)}{n!}$ , where  $f_n(x)$  are the solutions of the system of equations  $f_n'(x) = -f_n(x) + f_{n-1}(x)$ ,  $f_0(x) = 1$ . It is shown that  $f(x)$  is a solution of the equation  $f'(x) = -f(x) + 1$  and that  $f(x) = 1 - e^{-x}$ .
2. The second part of the paper is devoted to the study of the properties of the function  $g(x)$  defined by the equation  $g(x) = \sum_{n=0}^{\infty} \frac{g_n(x)}{n!}$ , where  $g_n(x)$  are the solutions of the system of equations  $g_n'(x) = -g_n(x) + g_{n-1}(x)$ ,  $g_0(x) = 1$ . It is shown that  $g(x)$  is a solution of the equation  $g'(x) = -g(x) + 1$  and that  $g(x) = 1 - e^{-x}$ .

3. The third part of the paper is devoted to the study of the properties of the function  $h(x)$  defined by the equation  $h(x) = \sum_{n=0}^{\infty} \frac{h_n(x)}{n!}$ , where  $h_n(x)$  are the solutions of the system of equations  $h_n'(x) = -h_n(x) + h_{n-1}(x)$ ,  $h_0(x) = 1$ . It is shown that  $h(x)$  is a solution of the equation  $h'(x) = -h(x) + 1$  and that  $h(x) = 1 - e^{-x}$ . The fourth part of the paper is devoted to the study of the properties of the function  $k(x)$  defined by the equation  $k(x) = \sum_{n=0}^{\infty} \frac{k_n(x)}{n!}$ , where  $k_n(x)$  are the solutions of the system of equations  $k_n'(x) = -k_n(x) + k_{n-1}(x)$ ,  $k_0(x) = 1$ . It is shown that  $k(x)$  is a solution of the equation  $k'(x) = -k(x) + 1$  and that  $k(x) = 1 - e^{-x}$ . The fifth part of the paper is devoted to the study of the properties of the function  $l(x)$  defined by the equation  $l(x) = \sum_{n=0}^{\infty} \frac{l_n(x)}{n!}$ , where  $l_n(x)$  are the solutions of the system of equations  $l_n'(x) = -l_n(x) + l_{n-1}(x)$ ,  $l_0(x) = 1$ . It is shown that  $l(x)$  is a solution of the equation  $l'(x) = -l(x) + 1$  and that  $l(x) = 1 - e^{-x}$ .

1. The first part of the paper is devoted to the study of the properties of the function  $f(x)$  defined by the equation  $f(x) = \sum_{n=0}^{\infty} \frac{f_n(x)}{n!}$ , where  $f_n(x)$  are the solutions of the system of equations  $f_n'(x) = -f_n(x) + f_{n-1}(x)$ ,  $f_0(x) = 1$ . It is shown that  $f(x)$  is a solution of the equation  $f'(x) = -f(x) + 1$  and that  $f(x) = 1 - e^{-x}$ .
2. The second part of the paper is devoted to the study of the properties of the function  $g(x)$  defined by the equation  $g(x) = \sum_{n=0}^{\infty} \frac{g_n(x)}{n!}$ , where  $g_n(x)$  are the solutions of the system of equations  $g_n'(x) = -g_n(x) + g_{n-1}(x)$ ,  $g_0(x) = 1$ . It is shown that  $g(x)$  is a solution of the equation  $g'(x) = -g(x) + 1$  and that  $g(x) = 1 - e^{-x}$ .

3. The third part of the paper is devoted to the study of the properties of the function  $h(x)$  defined by the equation  $h(x) = \sum_{n=0}^{\infty} \frac{h_n(x)}{n!}$ , where  $h_n(x)$  are the solutions of the system of equations  $h_n'(x) = -h_n(x) + h_{n-1}(x)$ ,  $h_0(x) = 1$ . It is shown that  $h(x)$  is a solution of the equation  $h'(x) = -h(x) + 1$  and that  $h(x) = 1 - e^{-x}$ . The fourth part of the paper is devoted to the study of the properties of the function  $k(x)$  defined by the equation  $k(x) = \sum_{n=0}^{\infty} \frac{k_n(x)}{n!}$ , where  $k_n(x)$  are the solutions of the system of equations  $k_n'(x) = -k_n(x) + k_{n-1}(x)$ ,  $k_0(x) = 1$ . It is shown that  $k(x)$  is a solution of the equation  $k'(x) = -k(x) + 1$  and that  $k(x) = 1 - e^{-x}$ . The fifth part of the paper is devoted to the study of the properties of the function  $l(x)$  defined by the equation  $l(x) = \sum_{n=0}^{\infty} \frac{l_n(x)}{n!}$ , where  $l_n(x)$  are the solutions of the system of equations  $l_n'(x) = -l_n(x) + l_{n-1}(x)$ ,  $l_0(x) = 1$ . It is shown that  $l(x)$  is a solution of the equation  $l'(x) = -l(x) + 1$  and that  $l(x) = 1 - e^{-x}$ .











www.ck12.org

What are the steps to solve the system of equations below?

1. Subtract the second equation from the first equation.

- I.  $3x + 2y = 10$
- II.  $2x + 3y = 11$
- III.  $5x - y = 1$
- IV.  $5x - y = 1$

What is the solution?

1.  $x = 1, y = 2$  2.  $x = 2, y = 1$  3.  $x = 1, y = 1$  4.  $x = 2, y = 2$

- I.  $3x + 2y = 10$
- II.  $2x + 3y = 11$
- III.  $5x - y = 1$
- IV.  $5x - y = 1$

What is the solution?

1.  $x = 1, y = 2$  2.  $x = 2, y = 1$  3.  $x = 1, y = 1$  4.  $x = 2, y = 2$

What is the solution to the system of equations below?

1.  $x = 1, y = 2$  2.  $x = 2, y = 1$  3.  $x = 1, y = 1$  4.  $x = 2, y = 2$

What is the solution to the system of equations below?

1.  $x = 1, y = 2$  2.  $x = 2, y = 1$  3.  $x = 1, y = 1$  4.  $x = 2, y = 2$

What is the solution to the system of equations below?

1.  $x = 1, y = 2$  2.  $x = 2, y = 1$  3.  $x = 1, y = 1$  4.  $x = 2, y = 2$

What is the solution to the system of equations below?

1.  $x = 1, y = 2$  2.  $x = 2, y = 1$  3.  $x = 1, y = 1$  4.  $x = 2, y = 2$

What is the solution?

- I.  $3x + 2y = 10$
- II.  $2x + 3y = 11$
- III.  $5x - y = 1$
- IV.  $5x - y = 1$

What is the solution?

1.  $x = 1, y = 2$  2.  $x = 2, y = 1$  3.  $x = 1, y = 1$  4.  $x = 2, y = 2$

What is the solution to the system of equations below?

1.  $x = 1, y = 2$  2.  $x = 2, y = 1$  3.  $x = 1, y = 1$  4.  $x = 2, y = 2$

What is the solution to the system of equations below?

1.  $x = 1, y = 2$  2.  $x = 2, y = 1$  3.  $x = 1, y = 1$  4.  $x = 2, y = 2$

What is the solution to the system of equations below?



your answer

- (1)  $\frac{1}{2} \ln 2$
- (2)  $\ln 2$
- (3)  $\frac{1}{2} \ln 4$
- (4)  $\ln 2$  (because  $\ln 2 = \ln 4$ )

your answer is:

$$\frac{1}{2} \ln 2 = \frac{1}{2} \ln \frac{2}{1} = \frac{1}{2} (\ln 2 - \ln 1) = \frac{1}{2} \ln 2$$

is correct

- (1)  $\frac{1}{2} \ln 2$
- (2)  $\ln 2$
- (3)  $\frac{1}{2} \ln 4$
- (4)  $\ln 2$  (because  $\ln 2 = \ln 4$ )

your answer is:

$$\frac{1}{2} \ln 2 = \frac{1}{2} \ln \frac{2}{1} = \frac{1}{2} (\ln 2 - \ln 1) = \frac{1}{2} \ln 2$$

is correct

- (1)  $\frac{1}{2} \ln 2$
- (2)  $\ln 2$
- (3)  $\frac{1}{2} \ln 4$
- (4)  $\ln 2$  (because  $\ln 2 = \ln 4$ )

your answer is:

$$\frac{1}{2} \ln 2 = \frac{1}{2} \ln \frac{2}{1} = \frac{1}{2} (\ln 2 - \ln 1) = \frac{1}{2} \ln 2$$

is

- (1)  $\frac{1}{2} \ln 2$
- (2)  $\ln 2$
- (3)  $\frac{1}{2} \ln 4$
- (4)  $\ln 2$  (because  $\ln 2 = \ln 4$ )

your answer is:

$$\frac{1}{2} \ln 2 = \frac{1}{2} \ln \frac{2}{1} = \frac{1}{2} (\ln 2 - \ln 1) = \frac{1}{2} \ln 2$$

is correct

- (1)  $\frac{1}{2} \ln 2$
- (2)  $\ln 2$
- (3)  $\frac{1}{2} \ln 4$
- (4)  $\ln 2$  (because  $\ln 2 = \ln 4$ )

your answer is:

$$\frac{1}{2} \ln 2 = \frac{1}{2} \ln \frac{2}{1} = \frac{1}{2} (\ln 2 - \ln 1) = \frac{1}{2} \ln 2$$

$$\frac{1}{2} \ln 2 = \frac{1}{2} \ln \frac{2}{1} = \frac{1}{2} (\ln 2 - \ln 1) = \frac{1}{2} \ln 2$$

$$\frac{1}{2} \ln 2 = \frac{1}{2} \ln \frac{2}{1} = \frac{1}{2} (\ln 2 - \ln 1) = \frac{1}{2} \ln 2$$

$$\frac{1}{2} \ln 2 = \frac{1}{2} \ln \frac{2}{1} = \frac{1}{2} (\ln 2 - \ln 1) = \frac{1}{2} \ln 2$$

$$\frac{1}{2} \ln 2 = \frac{1}{2} \ln \frac{2}{1} = \frac{1}{2} (\ln 2 - \ln 1) = \frac{1}{2} \ln 2$$

- (1)  $\frac{1}{2} \ln 2$
- (2)  $\ln 2$













1. 2. 1715-17-18

**vs. United States**

### 2. Patent Application Publication (Chapter 1)

Pub No. 0520467151452 41

[illegible]

המחיר של המכשיר הוא 1,200 ש"ח, ויש לו מחיר מומלץ של 1,500 ש"ח. המחיר של המכשיר הוא 1,200 ש"ח, ויש לו מחיר מומלץ של 1,500 ש"ח.

He would not, of course, have been a member of the  
He would not have been a member of the  
He would not have been a member of the

✓ System - 16.6244122046  
 ✓ 16.6244122046

1.1. The following are the names of the persons who have been appointed to the various committees of the Council of the City of New York, for the year 1965:

[illegible]

**Redden, Steven D.**

15. 1. 1979: 15

1. 10.11  
2. 10.11

19. 2013

12 USC

1. 4. 2019

FILED IN: 44-111

Table 1 shows the mean and standard deviation of the data for the 1990-1991 season. The mean age of the subjects was 26.4 years, with a range of 18-35 years. The mean height was 178.5 cm, with a range of 170-188 cm. The mean weight was 75.5 kg, with a range of 65-95 kg. The mean body mass index (BMI) was 23.5 kg/m<sup>2</sup>, with a range of 20.5-28.5 kg/m<sup>2</sup>. The mean body fat percentage was 12.5%, with a range of 8-18%. The mean heart rate was 155 beats/min, with a range of 140-170 beats/min. The mean oxygen consumption was 3.5 L/min, with a range of 3.0-4.0 L/min. The mean energy expenditure was 1000 kcal/h, with a range of 800-1200 kcal/h. The mean time to exhaustion was 60 min, with a range of 45-75 min. The mean time to exhaustion was significantly lower than the mean time to exhaustion in the control group (75 min,  $p < 0.05$ ).

[illegible]

FIG. 1 is a schematic diagram of a system 100 for processing a data stream. The system 100 includes a data source 102, a data stream 104, a data processor 106, and a data output 108. The data source 102 provides data to the data stream 104, which is then processed by the data processor 106. The data processor 106 includes a data input 110, a data processing unit 112, and a data output 114. The data processing unit 112 is configured to process the data stream 104 and output the processed data to the data output 114.

The data stream 104 is a sequence of data elements 104a, 104b, 104c, 104d, 104e, 104f, 104g, 104h, 104i, 104j, 104k, 104l, 104m, 104n, 104o, 104p, 104q, 104r, 104s, 104t, 104u, 104v, 104w, 104x, 104y, 104z. The data processor 106 is configured to process the data stream 104 and output the processed data to the data output 108.

The data processor 106 is configured to process the data stream 104 and output the processed data to the data output 108. The data processor 106 includes a data input 110, a data processing unit 112, and a data output 114. The data processing unit 112 is configured to process the data stream 104 and output the processed data to the data output 114.

FIG. 1




Fig. 2

FIG. 2A



FIG. 3H



FIG. 4




FIG. 5



FIG. 6






FIG. 5

FIG. 32




FIG. 3A






FIG. 7E




FIG. 7A





Fig. 8



Fig. 9








FIG. 11A



FIG. 11B



FIG. 11C




FIG. 12A




FIG. 12B




FIG. 13A




FIG. 13B





described in the 1980s by the group of researchers in the field of early writing. These researchers have shown that the early writing process is not sequential and goes through several overlapping stages as the child develops. In the early stages, the child's writing is characterized by a high degree of variability and a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words.

Wright (1987) has proposed a model of early writing that is based on the idea of a "writing process" that is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words.

Wright (1987) has proposed a model of early writing that is based on the idea of a "writing process" that is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words.

Wright (1987) has proposed a model of early writing that is based on the idea of a "writing process" that is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words.

Wright (1987) has proposed a model of early writing that is based on the idea of a "writing process" that is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words.

Wright (1987) has proposed a model of early writing that is based on the idea of a "writing process" that is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words.

Wright (1987) has proposed a model of early writing that is based on the idea of a "writing process" that is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words. The child's writing is characterized by a high degree of variability in the number of letters and the number of words.

#### REFERENCES

Wright, T. (1987). *The early writing process: A model of the early writing process*. In *The early writing process* (Ed. by T. Wright), 1-10. New York: Guilford Press.

Wright, T. (1987). *The early writing process: A model of the early writing process*. In *The early writing process* (Ed. by T. Wright), 1-10. New York: Guilford Press.







[illegible][illegible]

These results suggest that the model is able to capture the underlying structure of the data, and that the model is able to capture the underlying structure of the data.

100% of the total for the 2007-2008 period. This indicates that the majority of the population is not engaged in any form of employment or economic activity. The data also shows that the majority of the population is not engaged in any form of employment or economic activity.

metil) e a sua função é a de ser o primeiro a ligar-se ao grupo metil, formando o primeiro eixo de simetria do sistema, permitindo assim a formação de todos os outros eixos de simetria. A função do metil é de ligar-se ao primeiro eixo de simetria, permitindo a formação de todos os outros eixos de simetria.

FFD) 47 patients (individuals) were included in the analysis. The mean age was 42.4 years (range 20-64 years). The mean duration of the disease was 10.5 years (range 1-30 years). The mean duration of the disease was 10.5 years (range 1-30 years). The mean duration of the disease was 10.5 years (range 1-30 years).

1989] • *Journal of Maritime Law and Commerce*, Vol. 22, No. 1, pp. 1-10. This article discusses the legal aspects of the use of force by a state against a private vessel. It examines the right of self-defense and the right of intervention, and discusses the legal consequences of the use of force. The article also discusses the legal aspects of the use of force by a state against a private vessel.

2007) and the results suggest that the model is likely to be improved by including other factors such as the company's reputation and the industry's performance. In addition, the model may be improved by including other factors such as the company's financial performance and the industry's performance. The model may also be improved by including other factors such as the company's financial performance and the industry's performance.

[illegible][illegible]

These data demonstrate that the use of the 1984 population census data into regression analysis may have underestimated the true prevalence of malaria in the study area. The use of a census-based data sample might have been appropriate in the absence of any other data of more specific or reflective value. The use of census data in the absence of more specific data is not ideal, but it is a better alternative than the use of no data at all. The use of census data is a common practice in the absence of more specific data, and it is a better alternative than the use of no data at all. The use of census data is a common practice in the absence of more specific data, and it is a better alternative than the use of no data at all.

It is a common observation that the distribution of population is unevenly spread over the surface of the earth. The human population is concentrated in certain areas, leaving large areas of the earth's surface empty. This is due to a variety of factors, including physical geography, climate, and human history. The distribution of population is a result of the interaction of these factors, and it is a dynamic process that changes over time. The study of population distribution is a key component of human geography, and it helps us to understand the patterns of human settlement and the factors that influence them.

[illegible]

1996). The two countries are also members of the Organisation for Economic Co-operation and Development (OECD) and the Organisation of American States (OAS). The population of each country is approximately 10 million. The two countries are also members of the Latin American and Caribbean (LAC) region of the World Bank. The two countries are also members of the Caribbean Community and Caribbean Free Trade Association (CARICOM).



























In the past, the Department has been able to identify and address the needs of students with disabilities. However, the Department has not been able to identify and address the needs of students with disabilities who are also at risk of dropping out of school. The Department is currently working on a project to identify and address the needs of these students. The project is currently in the planning stage.

[illegible][illegible]

**Pragmatics** focuses on how meaning is derived from context. It includes the study of how language is used in different situations, the relationship between language and the world, and the role of context in understanding meaning. Pragmatics is a branch of linguistics that deals with the use of language in communication. It is concerned with the relationship between language and the world, and how context affects the meaning of a message. Pragmatics is a branch of linguistics that deals with the use of language in communication. It is concerned with the relationship between language and the world, and how context affects the meaning of a message.

the following information, which is the basis for the information provided in the following table:

**1.1.1.1.1** The use of a combination of a small number of different and well-defined, simple, repeatable, and reliable tests and procedures to assess the overall performance of a system or process. This approach is often used in the early stages of a project to identify potential problems and to establish a baseline for performance. It is also used to monitor performance over time and to identify trends and patterns in the data.

[illegible]

I am very pleased to hear that you are well. I hope you are enjoying the summer. I am well and hope you are the same. I am looking forward to seeing you again. I am well and hope you are the same. I am looking forward to seeing you again.

[144] The second of the two main effects of the increase in the number of countries observed in the literature is that the number of countries included in the sample has increased. This increase can be attributed to the fact that the data sets have become more comprehensive, including more countries, thereby increasing the statistical power of the studies. This increase in the number of countries included in the sample has led to a more comprehensive understanding of the relationship between the variables of interest.

[illegible][illegible]



































문제 16-20

16. 이차식  $ax^2 + bx + c$ 에 대하여

(1)  $a > 0$ 일 때,  $b^2 - 4ac < 0$ 이면

(2)  $a < 0$ 일 때,  $b^2 - 4ac > 0$ 이면

(3)  $a > 0$ 일 때,  $b^2 - 4ac = 0$ 이면  $\frac{b}{2a}$ 는  $ax^2 + bx + c = 0$ 의 근이다.

(4)  $a < 0$ 일 때,  $b^2 - 4ac = 0$ 이면  $\frac{b}{2a}$ 는  $ax^2 + bx + c = 0$ 의 근이다.

(5)  $a > 0$ 일 때,  $b^2 - 4ac > 0$ 이면  $\frac{b}{2a}$ 는  $ax^2 + bx + c = 0$ 의 근이다.

(6)  $a < 0$ 일 때,  $b^2 - 4ac > 0$ 이면  $\frac{b}{2a}$ 는  $ax^2 + bx + c = 0$ 의 근이다.

(7)  $a > 0$ 일 때,  $b^2 - 4ac < 0$ 이면  $\frac{b}{2a}$ 는  $ax^2 + bx + c = 0$ 의 근이다.

(8)  $a < 0$ 일 때,  $b^2 - 4ac < 0$ 이면  $\frac{b}{2a}$ 는  $ax^2 + bx + c = 0$ 의 근이다.

17. 이차식  $ax^2 + bx + c$ 에 대하여

(1)  $a > 0$ 일 때,  $b^2 - 4ac < 0$ 이면

(2)  $a < 0$ 일 때,  $b^2 - 4ac > 0$ 이면

(3)  $a > 0$ 일 때,  $b^2 - 4ac = 0$ 이면

(4)  $a < 0$ 일 때,  $b^2 - 4ac < 0$ 이면

(5)  $a > 0$ 일 때,  $b^2 - 4ac > 0$ 이면

(6)  $a < 0$ 일 때,  $b^2 - 4ac > 0$ 이면  $\frac{b}{2a}$ 는  $ax^2 + bx + c = 0$ 의 근이다.

18. 이차식  $ax^2 + bx + c$ 에 대하여

(1)  $a > 0$ 일 때,  $b^2 - 4ac < 0$ 이면

(2)  $a < 0$ 일 때,  $b^2 - 4ac > 0$ 이면

(3)  $a > 0$ 일 때,  $b^2 - 4ac = 0$ 이면

(4)  $a < 0$ 일 때,  $b^2 - 4ac < 0$ 이면

(5)  $a > 0$ 일 때,  $b^2 - 4ac > 0$ 이면

(6)  $a < 0$ 일 때,  $b^2 - 4ac > 0$ 이면  $\frac{b}{2a}$ 는  $ax^2 + bx + c = 0$ 의 근이다.

19. 이차식  $ax^2 + bx + c$ 에 대하여

(1)  $a > 0$ 일 때,  $b^2 - 4ac < 0$ 이면

(2)  $a < 0$ 일 때,  $b^2 - 4ac > 0$ 이면

(3)  $a > 0$ 일 때,  $b^2 - 4ac = 0$ 이면

(4)  $a < 0$ 일 때,  $b^2 - 4ac < 0$ 이면

(5)  $a > 0$ 일 때,  $b^2 - 4ac > 0$ 이면

(6)  $a < 0$ 일 때,  $b^2 - 4ac > 0$ 이면  $\frac{b}{2a}$ 는  $ax^2 + bx + c = 0$ 의 근이다.

20. 이차식  $ax^2 + bx + c$ 에 대하여

(1)  $a > 0$ 일 때,  $b^2 - 4ac < 0$ 이면

(2)  $a < 0$ 일 때,  $b^2 - 4ac > 0$ 이면

(3)  $a > 0$ 일 때,  $b^2 - 4ac = 0$ 이면

(4)  $a < 0$ 일 때,  $b^2 - 4ac < 0$ 이면

(5)  $a > 0$ 일 때,  $b^2 - 4ac > 0$ 이면

(6)  $a < 0$ 일 때,  $b^2 - 4ac > 0$ 이면  $\frac{b}{2a}$ 는  $ax^2 + bx + c = 0$ 의 근이다.

(7)  $a > 0$ 일 때,  $b^2 - 4ac < 0$ 이면  $\frac{b}{2a}$ 는  $ax^2 + bx + c = 0$ 의 근이다.

(8)  $a < 0$ 일 때,  $b^2 - 4ac < 0$ 이면  $\frac{b}{2a}$ 는  $ax^2 + bx + c = 0$ 의 근이다.



문제 16 (2점)

다음의 두 함수  $f(x)$  와  $g(x)$  가 주어졌을 때, 다음  $\lim_{x \rightarrow 0} \frac{f(x)}{g(x)}$ 의 값을 구하시오.

$f(x) = \lim_{t \rightarrow 0} \frac{1}{t} \sin t$  와  $g(x) = \lim_{t \rightarrow 0} \frac{1}{t} \cos t$  이라 하자.

이 때  $\lim_{x \rightarrow 0} \frac{f(x)}{g(x)}$ 의 값을 구하시오.

- (I)  $\frac{1}{2}$  이다.
- (II)  $\frac{1}{\sqrt{2}}$  이다.
- (III)  $\frac{1}{\sqrt{2}}$  이다.
- (IV)  $\frac{1}{\sqrt{2}}$  이다.

(V)  $\frac{1}{\sqrt{2}}$  이다.

정답:  $\lim_{x \rightarrow 0} \frac{f(x)}{g(x)} = \frac{1}{\sqrt{2}}$  이다.

정답:  $\lim_{x \rightarrow 0} \frac{f(x)}{g(x)} = \frac{1}{\sqrt{2}}$  이다.

- (I)  $\frac{1}{2}$  이다.
- (II)  $\frac{1}{\sqrt{2}}$  이다.
- (III)  $\frac{1}{\sqrt{2}}$  이다.
- (IV)  $\frac{1}{\sqrt{2}}$  이다.

(V)  $\frac{1}{\sqrt{2}}$  이다.

정답:  $\lim_{x \rightarrow 0} \frac{f(x)}{g(x)} = \frac{1}{\sqrt{2}}$  이다.

정답:  $\lim_{x \rightarrow 0} \frac{f(x)}{g(x)} = \frac{1}{\sqrt{2}}$  이다.

- (I)  $\frac{1}{2}$  이다.
- (II)  $\frac{1}{\sqrt{2}}$  이다.
- (III)  $\frac{1}{\sqrt{2}}$  이다.
- (IV)  $\frac{1}{\sqrt{2}}$  이다.

(V)  $\frac{1}{\sqrt{2}}$  이다.

정답:  $\lim_{x \rightarrow 0} \frac{f(x)}{g(x)} = \frac{1}{\sqrt{2}}$  이다.

정답:  $\frac{1}{\sqrt{2}}$

- (I)  $\frac{1}{2}$  이다.
- (II)  $\frac{1}{\sqrt{2}}$  이다.
- (III)  $\frac{1}{\sqrt{2}}$  이다.
- (IV)  $\frac{1}{\sqrt{2}}$  이다.

(V)  $\frac{1}{\sqrt{2}}$  이다.

정답:  $\lim_{x \rightarrow 0} \frac{f(x)}{g(x)} = \frac{1}{\sqrt{2}}$  이다.

정답:  $\frac{1}{\sqrt{2}}$

- (I)  $\frac{1}{2}$  이다.
- (II)  $\frac{1}{\sqrt{2}}$  이다.
- (III)  $\frac{1}{\sqrt{2}}$  이다.
- (IV)  $\frac{1}{\sqrt{2}}$  이다.

(V)  $\frac{1}{\sqrt{2}}$  이다.

정답:  $\lim_{x \rightarrow 0} \frac{f(x)}{g(x)} = \frac{1}{\sqrt{2}}$  이다.

정답:  $\frac{1}{\sqrt{2}}$

2.

문제 16-10

(1)  $f(x) = \frac{1}{x}$  (2)  $f(x) = \frac{1}{x^2}$   
 (3)  $f(x) = \frac{1}{x^3}$  (4)  $f(x) = \frac{1}{x^4}$

(5)  $f(x) = \frac{1}{x^5}$

(6)  $f(x) = \frac{1}{x^6}$  (7)  $f(x) = \frac{1}{x^7}$  (8)  $f(x) = \frac{1}{x^8}$  (9)  $f(x) = \frac{1}{x^9}$  (10)  $f(x) = \frac{1}{x^{10}}$

...

(11)  $f(x) = \frac{1}{x^{11}}$   
 (12)  $f(x) = \frac{1}{x^{12}}$   
 (13)  $f(x) = \frac{1}{x^{13}}$  (14)  $f(x) = \frac{1}{x^{14}}$

(15)  $f(x) = \frac{1}{x^{15}}$

(16)  $f(x) = \frac{1}{x^{16}}$  (17)  $f(x) = \frac{1}{x^{17}}$  (18)  $f(x) = \frac{1}{x^{18}}$  (19)  $f(x) = \frac{1}{x^{19}}$  (20)  $f(x) = \frac{1}{x^{20}}$

...

(21)  $f(x) = \frac{1}{x^{21}}$   
 (22)  $f(x) = \frac{1}{x^{22}}$   
 (23)  $f(x) = \frac{1}{x^{23}}$  (24)  $f(x) = \frac{1}{x^{24}}$

(25)  $f(x) = \frac{1}{x^{25}}$

(26)  $f(x) = \frac{1}{x^{26}}$  (27)  $f(x) = \frac{1}{x^{27}}$  (28)  $f(x) = \frac{1}{x^{28}}$  (29)  $f(x) = \frac{1}{x^{29}}$  (30)  $f(x) = \frac{1}{x^{30}}$

(31)  $f(x) = \frac{1}{x^{31}}$  (32)  $f(x) = \frac{1}{x^{32}}$  (33)  $f(x) = \frac{1}{x^{33}}$  (34)  $f(x) = \frac{1}{x^{34}}$  (35)  $f(x) = \frac{1}{x^{35}}$

(36)  $f(x) = \frac{1}{x^{36}}$  (37)  $f(x) = \frac{1}{x^{37}}$  (38)  $f(x) = \frac{1}{x^{38}}$  (39)  $f(x) = \frac{1}{x^{39}}$  (40)  $f(x) = \frac{1}{x^{40}}$

(41)  $f(x) = \frac{1}{x^{41}}$  (42)  $f(x) = \frac{1}{x^{42}}$  (43)  $f(x) = \frac{1}{x^{43}}$  (44)  $f(x) = \frac{1}{x^{44}}$  (45)  $f(x) = \frac{1}{x^{45}}$

(46)  $f(x) = \frac{1}{x^{46}}$   
 (47)  $f(x) = \frac{1}{x^{47}}$

(48)  $f(x) = \frac{1}{x^{48}}$   
 (49)  $f(x) = \frac{1}{x^{49}}$   
 (50)  $f(x) = \frac{1}{x^{50}}$

(51)  $f(x) = \frac{1}{x^{51}}$

(52)  $f(x) = \frac{1}{x^{52}}$  (53)  $f(x) = \frac{1}{x^{53}}$  (54)  $f(x) = \frac{1}{x^{54}}$  (55)  $f(x) = \frac{1}{x^{55}}$  (56)  $f(x) = \frac{1}{x^{56}}$

(57)  $f(x) = \frac{1}{x^{57}}$  (58)  $f(x) = \frac{1}{x^{58}}$  (59)  $f(x) = \frac{1}{x^{59}}$  (60)  $f(x) = \frac{1}{x^{60}}$  (61)  $f(x) = \frac{1}{x^{61}}$

(62)  $f(x) = \frac{1}{x^{62}}$  (63)  $f(x) = \frac{1}{x^{63}}$  (64)  $f(x) = \frac{1}{x^{64}}$  (65)  $f(x) = \frac{1}{x^{65}}$  (66)  $f(x) = \frac{1}{x^{66}}$

(67)  $f(x) = \frac{1}{x^{67}}$   
 (68)  $f(x) = \frac{1}{x^{68}}$   
 (69)  $f(x) = \frac{1}{x^{69}}$

(70)  $f(x) = \frac{1}{x^{70}}$

(71)  $f(x) = \frac{1}{x^{71}}$  (72)  $f(x) = \frac{1}{x^{72}}$  (73)  $f(x) = \frac{1}{x^{73}}$  (74)  $f(x) = \frac{1}{x^{74}}$  (75)  $f(x) = \frac{1}{x^{75}}$





문제 16-20

16. 다음 중 옳지 않은 것은?	20
㉠ 1945년 8월 15일 ㉡ 1945년 8월 15일 ㉢ 1945년 8월 15일 ㉣ 1945년 8월 15일 ㉤ 1945년 8월 15일	
17. 다음 중 옳지 않은 것은?	21
㉠ 1945년 8월 15일 ㉡ 1945년 8월 15일 ㉢ 1945년 8월 15일 ㉣ 1945년 8월 15일 ㉤ 1945년 8월 15일	
18. 다음 중 옳지 않은 것은?	22
㉠ 1945년 8월 15일 ㉡ 1945년 8월 15일 ㉢ 1945년 8월 15일 ㉣ 1945년 8월 15일 ㉤ 1945년 8월 15일	
19. 다음 중 옳지 않은 것은?	23
㉠ 1945년 8월 15일 ㉡ 1945년 8월 15일 ㉢ 1945년 8월 15일 ㉣ 1945년 8월 15일 ㉤ 1945년 8월 15일	
20. 다음 중 옳지 않은 것은?	24
㉠ 1945년 8월 15일 ㉡ 1945년 8월 15일 ㉢ 1945년 8월 15일 ㉣ 1945년 8월 15일 ㉤ 1945년 8월 15일	







15 000000000000

U.S. United States Patent  
 and Trademark Office

Patent No. 11,970,416 B2  
 Date of Patent Sep. 14, 2010

(1) COPYRIGHT © 2010 BY THE UNITED STATES  
 PATENT AND TRADEMARK OFFICE  
 ALL RIGHTS RESERVED

FIG. 1 is a block diagram of a system.

(2) FIG. 2 is a block diagram of a system.  
 FIG. 3 is a block diagram of a system.  
 FIG. 4 is a block diagram of a system.  
 FIG. 5 is a block diagram of a system.

FIG. 6 is a block diagram of a system.

FIG. 7 is a block diagram of a system.

FIG. 8 is a block diagram of a system.

FIG. 9 is a block diagram of a system.

FIG. 10 is a block diagram of a system.

FIG. 11 is a block diagram of a system.

FIG. 12 is a block diagram of a system.

FIG. 13 is a block diagram of a system.

FIG. 14 is a block diagram of a system.

FIG. 15 is a block diagram of a system.

FIG. 16 is a block diagram of a system.

FIG. 17 is a block diagram of a system.

FIG. 18 is a block diagram of a system.

FIG. 19 is a block diagram of a system.

FIG. 20 is a block diagram of a system.

FIG. 21 is a block diagram of a system.

FIG. 22 is a block diagram of a system.

FIG. 23 is a block diagram of a system.

FIG. 24 is a block diagram of a system.

FIG. 25 is a block diagram of a system.

FIG. 26 is a block diagram of a system.

FIG. 27 is a block diagram of a system.

FIG. 28 is a block diagram of a system.

(3) FIG. 1 is a block diagram of a system.

(4) FIG. 2 is a block diagram of a system.

(5) FIG. 3 is a block diagram of a system.

(6) FIG. 4 is a block diagram of a system.

(7) FIG. 5 is a block diagram of a system.

(8) FIG. 6 is a block diagram of a system.

(9) FIG. 7 is a block diagram of a system.

(10) FIG. 8 is a block diagram of a system.

(11) FIG. 9 is a block diagram of a system.

(12) FIG. 10 is a block diagram of a system.

(13) FIG. 11 is a block diagram of a system.

(14) FIG. 12 is a block diagram of a system.

(15) FIG. 13 is a block diagram of a system.

FIG. 14 is a block diagram of a system.

(16) FIG. 15 is a block diagram of a system.

FIG. 16 is a block diagram of a system.

# ATTORNEY GENERAL

On 10/10/2023, the Department of Justice received a request from the Department of Justice for a copy of the records requested.

The request was received from the Department of Justice on 10/10/2023. The request was received from the Department of Justice on 10/10/2023.

The request was received from the Department of Justice on 10/10/2023. The request was received from the Department of Justice on 10/10/2023.

The request was received from the Department of Justice on 10/10/2023. The request was received from the Department of Justice on 10/10/2023.

The request was received from the Department of Justice on 10/10/2023. The request was received from the Department of Justice on 10/10/2023.

The request was received from the Department of Justice on 10/10/2023. The request was received from the Department of Justice on 10/10/2023.

The request was received from the Department of Justice on 10/10/2023. The request was received from the Department of Justice on 10/10/2023.

The request was received from the Department of Justice on 10/10/2023. The request was received from the Department of Justice on 10/10/2023.

The request was received from the Department of Justice on 10/10/2023. The request was received from the Department of Justice on 10/10/2023.

The request was received from the Department of Justice on 10/10/2023. The request was received from the Department of Justice on 10/10/2023.

The request was received from the Department of Justice on 10/10/2023. The request was received from the Department of Justice on 10/10/2023.

The request was received from the Department of Justice on 10/10/2023. The request was received from the Department of Justice on 10/10/2023.




Figure 1




Figure 2




Figure 3

# COMPARISON OF LANDFILL TREATMENT WITH INCINERATION TREATMENT OF MUNICIPAL SOLID WASTE

ROBERT L. KRAUSE, JR.

Landfilling and incineration are the two most common methods of municipal solid waste disposal in the United States. Landfilling is the disposal of waste in a hole in the ground, while incineration is the burning of waste. Both methods have advantages and disadvantages. Landfilling is a simple and inexpensive method of disposal, but it can cause environmental problems such as leachate and odors. Incineration is a more complex and expensive method, but it can reduce the volume of waste and produce energy. This paper compares the two methods and discusses the factors that should be considered when choosing a method of disposal.

## 1. INTRODUCTION

The purpose of this study is to compare the two most common methods of municipal solid waste disposal in the United States, landfilling and incineration. The study will discuss the advantages and disadvantages of each method and the factors that should be considered when choosing a method of disposal. The study will also discuss the environmental impacts of each method and the costs of each method.

## 2. LANDFILLING

Landfilling is the disposal of waste in a hole in the ground. It is a simple and inexpensive method of disposal. The waste is placed in a hole and covered with soil. Landfilling can cause environmental problems such as leachate and odors. Leachate is a liquid that is formed by the decomposition of waste and can contaminate the ground water. Odors are produced by the decomposition of waste and can be a nuisance to nearby residents.

Landfilling is a simple and inexpensive method of disposal. The waste is placed in a hole and covered with soil. Landfilling can cause environmental problems such as leachate and odors. Leachate is a liquid that is formed by the decomposition of waste and can contaminate the ground water. Odors are produced by the decomposition of waste and can be a nuisance to nearby residents.

Landfilling is a simple and inexpensive method of disposal. The waste is placed in a hole and covered with soil. Landfilling can cause environmental problems such as leachate and odors. Leachate is a liquid that is formed by the decomposition of waste and can contaminate the ground water. Odors are produced by the decomposition of waste and can be a nuisance to nearby residents.

## 3. INCINERATION

Incineration is the burning of waste. It is a more complex and expensive method of disposal. Incineration can reduce the volume of waste and produce energy. Incineration can also cause environmental problems such as air pollution and ash disposal. Air pollution is caused by the release of smoke and gases from the incinerator. Ash disposal is a problem because the ash is still contaminated with toxic substances.

Incineration is a more complex and expensive method of disposal. Incineration can reduce the volume of waste and produce energy. Incineration can also cause environmental problems such as air pollution and ash disposal. Air pollution is caused by the release of smoke and gases from the incinerator. Ash disposal is a problem because the ash is still contaminated with toxic substances.

Incineration is a more complex and expensive method of disposal. Incineration can reduce the volume of waste and produce energy. Incineration can also cause environmental problems such as air pollution and ash disposal. Air pollution is caused by the release of smoke and gases from the incinerator. Ash disposal is a problem because the ash is still contaminated with toxic substances.

Incineration is a more complex and expensive method of disposal. Incineration can reduce the volume of waste and produce energy. Incineration can also cause environmental problems such as air pollution and ash disposal. Air pollution is caused by the release of smoke and gases from the incinerator. Ash disposal is a problem because the ash is still contaminated with toxic substances.

Incineration is a more complex and expensive method of disposal. Incineration can reduce the volume of waste and produce energy. Incineration can also cause environmental problems such as air pollution and ash disposal. Air pollution is caused by the release of smoke and gases from the incinerator. Ash disposal is a problem because the ash is still contaminated with toxic substances.













James M. C. Smith, Director, Health Services, University of  
California, San Francisco, California, U.S.A.  
Dr. Smith is a leading authority on the epidemiology of  
infectious diseases, and has published numerous papers  
on the subject.

For the threshold level,  $\gamma$ , the probability of an error is  $\alpha_{\gamma}$ . Thus, the overall probability of an error is  $\alpha = \int_0^{\gamma} f(x) dx + \gamma \int_{\gamma}^{\infty} f(x) dx$ . The threshold level,  $\gamma$ , is chosen such that  $\alpha$  is as small as possible. The threshold level,  $\gamma$ , is chosen such that  $\alpha$  is as small as possible. The threshold level,  $\gamma$ , is chosen such that  $\alpha$  is as small as possible.

with the following information: Name of HVT  
agency, address and telephone number, date  
of last inspection, and a copy of the report.

[illegible]

It is a common mistake to think that the only way to avoid the problems of the first two methods is to use a third method, the "method of moments". This method involves using the first two moments of the distribution to estimate the parameters. However, this method is also subject to the same problems as the first two methods, and is therefore not a solution.

It is not a coincidence that many of the most important works in the history of the development of the modern legal system have been written by individuals with a background in the legal profession. The history of the law is a story of the struggle for justice, and it is a story that has been told in many different ways. The history of the law is a story of the struggle for justice, and it is a story that has been told in many different ways.

It is not a coincidence that the same year that the U.S. Supreme Court ruled in *Grain Processing* that the government could not regulate the grain processing industry, the U.S. Supreme Court also ruled in *Grain Processing* that the government could not regulate the grain processing industry.

[illegible][illegible]

As the operation of the 100,000 sq. ft. new  
laboratory building, built at a community cost  
of approximately \$1,000,000, the government has  
been able to bring in 100,000 dollars of  
research money from the federal government and  
state government. The 100,000 sq. ft. building  
has been built at a cost of 100,000 dollars.  
The building is built at a cost of 100,000 dollars.  
The building is built at a cost of 100,000 dollars.  
The building is built at a cost of 100,000 dollars.

1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 2679, 26

It is the duty of the government to ensure that the public interest is protected and that the public is not misled. The government should ensure that the public is not misled by the actions of the private sector. The government should ensure that the public is not misled by the actions of the private sector. The government should ensure that the public is not misled by the actions of the private sector.

[illegible][illegible]

**Abstract**

Year	Age	Sex	Location	Length (mm)	Weight (g)	Notes
1961	1	F	Bay	11	17	Small, young
1962	1	F	Bay	11	17	Small, young
1963	1	F	Bay	11	17	Small, young
1964	1	F	Bay	11	17	Small, young

100 100 100

Table 1. Summary of the 1997-1998 Survey of the Health of the Nation					
Year	Age Group	Gender	Health Status	Health Care Use	Health Care Costs
1997	18-24	Male	Good	Low	\$1,000
1997	25-34	Female	Fair	Medium	\$2,000
1997	35-44	Male	Fair	Medium	\$2,000
1997	45-54	Female	Fair	Medium	\$2,000
1997	55-64	Male	Fair	Medium	\$2,000
1997	65-74	Female	Fair	Medium	\$2,000
1997	75-84	Male	Fair	Medium	\$2,000
1997	85-94	Female	Fair	Medium	\$2,000
1997	95-104	Male	Fair	Medium	\$2,000
1997	105-114	Female	Fair	Medium	\$2,000
1997	115-124	Male	Fair	Medium	\$2,000
1997	125-134	Female	Fair	Medium	\$2,000
1997	135-144	Male	Fair	Medium	\$2,000
1997	145-154	Female	Fair	Medium	\$2,000
1997	155-164	Male	Fair	Medium	\$2,000
1997	165-174	Female	Fair	Medium	\$2,000
1997	175-184	Male	Fair	Medium	\$2,000
1997	185-194	Female	Fair	Medium	\$2,000
1997	195-204	Male	Fair	Medium	\$2,000
1997	205-214	Female	Fair	Medium	\$2,000
1997	215-224	Male	Fair	Medium	\$2,000
1997	225-234	Female	Fair	Medium	\$2,000
1997	235-244	Male	Fair	Medium	\$2,000
1997	245-254	Female	Fair	Medium	\$2,000
1997	255-264	Male	Fair	Medium	\$2,000
1997	265-274	Female	Fair	Medium	\$2,000
1997	275-284	Male	Fair	Medium	\$2,000
1997	285-294	Female	Fair	Medium	\$2,000
1997	295-304	Male	Fair	Medium	\$2,000
1997	305-314	Female	Fair	Medium	\$2,000
1997	315-324	Male	Fair	Medium	\$2,000
1997	325-334	Female	Fair	Medium	\$2,000
1997	335-344	Male	Fair	Medium	\$2,000
1997	345-354	Female	Fair	Medium	\$2,000
1997	355-364	Male	Fair	Medium	\$2,000
1997	365-374	Female	Fair	Medium	\$2,000
1997	375-384	Male	Fair	Medium	\$2,000
1997	385-394	Female	Fair	Medium	\$2,000
1997	395-404	Male	Fair	Medium	\$2,000
1997	405-414	Female	Fair	Medium	\$2,000
1997	415-424	Male	Fair	Medium	\$2,000
1997	425-434	Female	Fair	Medium	\$2,000
1997	435-444	Male	Fair	Medium	\$2,000
1997	445-454	Female	Fair	Medium	\$2,000
1997	455-464	Male	Fair	Medium	\$2,000
1997	465-474	Female	Fair	Medium	\$2,000
1997	475-484	Male	Fair	Medium	\$2,000
1997	485-494	Female	Fair	Medium	\$2,000
1997	495-504	Male	Fair	Medium	\$2,000
1997	505-514	Female	Fair	Medium	\$2,000
1997	515-524	Male	Fair	Medium	\$2,000
1997	525-534	Female	Fair	Medium	\$2,000
1997	535-544	Male	Fair	Medium	\$2,000
1997	545-554	Female	Fair	Medium	\$2,000
1997	555-564	Male	Fair	Medium	\$2,000
1997	565-574	Female	Fair	Medium	\$2,000
1997	575-584	Male	Fair	Medium	\$2,000
1997	585-594	Female	Fair	Medium	\$2,000
1997	595-604	Male	Fair	Medium	\$2,000
1997	605-614	Female	Fair	Medium	\$2,000
1997	615-624	Male	Fair	Medium	\$2,000
1997	625-634	Female	Fair	Medium	\$2,000
1997	635-644	Male	Fair	Medium	\$2,000
1997	645-654	Female	Fair	Medium	\$2,000
1997	655-664	Male	Fair	Medium	\$2,000
1997	665-674	Female	Fair	Medium	\$2,000
1997	675-684	Male	Fair	Medium	\$2,000
1997	685-694	Female	Fair	Medium	\$2,000
1997	695-704	Male	Fair	Medium	\$2,000
1997	705-714	Female	Fair	Medium	\$2,000
1997	715-724	Male	Fair	Medium	\$2,000
1997	725-734	Female	Fair	Medium	\$2,000
1997	735-744	Male	Fair	Medium	\$2,000
1997	745-754	Female	Fair	Medium	\$2,000
1997	755-764	Male	Fair	Medium	\$2,000
1997	765-774	Female	Fair	Medium	\$2,000
1997	775-784	Male	Fair	Medium	\$2,000
1997	785-794	Female	Fair	Medium	\$2,000
1997	795-804	Male	Fair	Medium	\$2,000
1997	805-814	Female	Fair	Medium	\$2,000
1997	815-824	Male	Fair	Medium	\$2,000
1997	825-834	Female	Fair	Medium	\$2,000
1997	835-844	Male	Fair	Medium	\$2,000
1997	845-854	Female	Fair	Medium	\$2,000
1997	855-864	Male	Fair	Medium	\$2,000
1997	865-874	Female	Fair	Medium	\$2,000
1997	875-884	Male	Fair	Medium	\$2,000
1997	885-894	Female	Fair	Medium	\$2,000
1997	895-904	Male	Fair	Medium	\$2,000
1997	905-914	Female	Fair	Medium	\$2,000
1997	915-924	Male	Fair	Medium	\$2,000
1997	925-934	Female	Fair	Medium	\$2,000
1997	935-944	Male	Fair	Medium	\$2,000
1997	945-954	Female	Fair	Medium	\$2,000
1997	955-964	Male	Fair	Medium	\$2,000
1997	965-974	Female	Fair	Medium	\$2,000
1997	975-984	Male	Fair	Medium	\$2,000
1997	985-994	Female	Fair	Medium	\$2,000
1997	995-1004	Male	Fair	Medium	\$2,000
1997	1005-1014	Female	Fair	Medium	\$2,000
1997	1015-1024	Male	Fair	Medium	\$2,000
1997	1025-1034	Female	Fair	Medium	\$2,000
1997	1035-1044	Male	Fair	Medium	\$2,000
1997	1045-1054	Female	Fair	Medium	\$2,000
1997	1055-1064	Male	Fair	Medium	\$2,000
1997	1065-1074	Female	Fair	Medium	\$2,000
1997	1075-1084	Male	Fair	Medium	\$2,000
1997	1085-1094	Female	Fair	Medium	\$2,000
1997	1095-1104	Male	Fair	Medium	\$2,000
1997	1105-1114	Female	Fair	Medium	\$2,000
1997	1115-1124	Male	Fair	Medium	\$2,000
1997	1125-1134	Female	Fair	Medium	\$2,000
1997	1135-1144	Male	Fair	Medium	\$2,000
1997	1145-1154	Female	Fair	Medium	\$2,000
1997	1155-1164	Male	Fair	Medium	\$2,000
1997	1165-1174	Female	Fair	Medium	\$2,000
1997	1175-1184	Male	Fair	Medium	\$2,000
1997	1185-1194	Female	Fair	Medium	\$2,000
1997	1195-1204	Male	Fair	Medium	\$2,000
1997	1205-1214	Female	Fair	Medium	\$2,000
1997	1215-1224	Male	Fair	Medium	\$2,000
1997	1225-1234	Female	Fair	Medium	\$2,000
1997	1235-1244	Male	Fair	Medium	\$2,000
1997	1245-1254	Female	Fair	Medium	\$2,000
1997	1255-1264	Male	Fair	Medium	\$2,000
1997	1265-1274	Female	Fair	Medium	\$2,000
1997	1275-1284	Male	Fair	Medium	\$2,000
1997	1285-1294	Female	Fair	Medium	\$2,000
1997	1295-1304	Male	Fair	Medium	\$2,000
1997	1305-1314	Female	Fair	Medium	\$2,000
1997	1315-1324	Male	Fair	Medium	\$2,000
1997	1325-1334	Female	Fair	Medium	\$2,000
1997	1335-1344	Male	Fair	Medium	\$2,000
1997	1345-1354	Female	Fair	Medium	\$2,000
1997	1355-1364	Male	Fair	Medium	\$2,000
1997	1365-1374	Female	Fair	Medium	\$2,000
1997	1375-1384	Male	Fair	Medium	\$2,000
1997	1385-1394	Female	Fair	Medium	\$2,000
1997	1395-1404	Male	Fair	Medium	\$2,000
1997	1405-1414	Female	Fair	Medium	\$2,000
1997	1415-1424	Male	Fair	Medium	\$2,000
1997	1425-1434	Female	Fair	Medium	\$2,000
1997	1435-1444	Male	Fair	Medium	\$2,000
1997	1445-1454	Female	Fair	Medium	\$2,000
1997	1455-1464	Male	Fair	Medium	\$2,000
1997	1465-1474	Female	Fair	Medium	\$2,000
1997	1475-1484	Male	Fair	Medium	\$2,000
1997	1485-1494	Female	Fair	Medium	\$2,000
1997	1495-1504	Male	Fair	Medium	\$2,000
1997	1505-1514	Female	Fair	Medium	\$2,000
1997	1515-1524	Male	Fair	Medium	\$2,000
1997	1525-1534	Female	Fair	Medium	\$2,000
1997	1535-1544	Male	Fair	Medium	\$2,000
1997	1545-1554	Female	Fair	Medium	\$2,000
1997	1555-1564	Male	Fair	Medium	\$2,000
1997	1565-1574	Female	Fair	Medium	\$2,000
1997	1575-1584	Male	Fair	Medium	\$2,000
1997	1585-1594	Female	Fair	Medium	\$2,000
1997	1595-1604	Male	Fair	Medium	\$2,000
1997	1605-1614	Female	Fair	Medium	\$2,000
1997	1615-1624	Male	Fair	Medium	\$2,000
1997	1625-1634	Female	Fair	Medium	\$2,000
1997	1635-1644	Male	Fair	Medium	\$2,000
1997	1645-1654	Female	Fair	Medium	\$2,000
1997	1655-1664	Male	Fair	Medium	\$2,000
1997	1665-1674	Female	Fair	Medium	\$2,000
1997	1675-1684	Male	Fair	Medium	\$2,000
1997	1685-1694	Female	Fair	Medium	\$2,000
1997	1695-1704	Male	Fair	Medium	\$2,000
1997	1705-1714	Female	Fair	Medium	\$2,000
1997	1715-1724	Male	Fair	Medium	\$2,000
1997	1725-1734	Female	Fair	Medium	\$2,000
1997	1735-1744	Male	Fair	Medium	\$2,000
1997	1745-1754	Female	Fair	Medium	\$2,000
1997	1755-1764	Male	Fair	Medium	\$2,000
1997	1765-1774	Female	Fair	Medium	\$2,000
1997	1775-1784	Male	Fair	Medium	\$2,000
1997	1785-1794	Female	Fair	Medium	\$2,000
1997	1795-1804	Male	Fair	Medium	\$2,000
1997	1805-1814	Female	Fair	Medium	\$2,000
1997	1815-1824	Male	Fair	Medium	\$2,000
1997	1825-1834	Female	Fair	Medium	\$2,000
1997	1835-1844	Male	Fair	Medium	\$2,000
1997	1845-1854	Female	Fair	Medium	\$2,000
1997	1855-1864	Male	Fair	Medium	\$2,000
1997	1865-1874	Female	Fair	Medium	\$2,000
1997	1875-1884	Male	Fair	Medium	\$2,000
1997	1885-1894	Female	Fair	Medium	\$2,000
1997	1895-1904	Male	Fair	Medium	\$2,000
1997	1905-1914	Female	Fair	Medium	\$2,000
1997	1915-1924	Male	Fair	Medium	\$2,000
1997	1925-1934	Female	Fair	Medium	\$2,000
1997	1935-1944	Male	Fair	Medium	\$2,000
1997	1945-1954	Female	Fair	Medium	\$2,000
1997	1955-1964	Male	Fair	Medium	\$2,000
1997	1965-1974	Female	Fair	Medium	\$2,000
1997	1975-1984	Male	Fair	Medium	\$2,000
1997	1985-1994	Female	Fair	Medium	\$2,000
1997	1995-2004	Male	Fair	Medium	\$2,000
1997	2005-2014	Female	Fair	Medium	\$2,000
1997	2015-2024	Male	Fair	Medium	\$2,000
1997	2025-2034	Female	Fair	Medium	\$2,000
1997	2035-2044	Male	Fair	Medium	\$2,000
1997	2045-2054	Female	Fair	Medium	\$2,000
1997	2055-2064	Male	Fair	Medium	\$2,000
1997	2065-2074	Female	Fair	Medium	\$2,000
1997	2075-2084	Male	Fair	Medium	\$2,000
1997	2085-2094	Female	Fair	Medium	\$2,000
1997	2095-2104	Male	Fair	Medium	\$2,000
1997	2105-2114	Female	Fair	Medium	\$2,000
1997	2115-2124	Male	Fair	Medium	\$2,000
1997	2125-2134	Female	Fair	Medium	\$2,000
1997	2135-2144	Male	Fair	Medium	\$2,000
1997	2145-2154	Female	Fair	Medium	\$2,000
1997	2155-2164	Male	Fair	Medium	\$2,000
1997	2165-2174	Female	Fair	Medium	\$2,000
1997	2175-2184	Male	Fair	Medium	\$2,000
1997	2185-2194	Female	Fair	Medium	\$2,000
1997	2195-2204	Male	Fair	Medium	\$2,000
1997	2205-2214	Female	Fair	Medium	\$2,000
1997	2215-2224	Male	Fair	Medium	\$2,000
1997	2225-2234	Female	Fair	Medium	\$2,000
1997	2235-2244	Male	Fair	Medium	\$2,000
1997	2245-2254	Female	Fair	Medium	\$2,000
1997	2255-2264	Male	Fair	Medium	\$2,000
1997	2265-2274	Female	Fair	Medium	\$2,000
1997	2275-2284	Male	Fair	Medium	\$2,000
1997	2285-2294	Female</			

המחיר המלא של המוצר: 119.00 ₪  
המחיר המיוחד: 99.00 ₪

The authors are grateful to the National Natural Science Foundation of China (grant number 80725416) for financial support.

1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 2679, 26

## 151

[illegible]

## Introduction

[illegible][illegible][illegible]

## 1. Introduction

[illegible]

**Abstract**

It is the intention of the Department of the Interior to provide a program for the management of the natural resources of the United States. The program is to be based on the principle of conservation and the use of the resources in a manner which will insure their availability for the benefit of the people of the United States. The program is to be based on the principle of conservation and the use of the resources in a manner which will insure their availability for the benefit of the people of the United States.

## 1. INTRODUCTION

1. The proposed distribution of the proposed amendments to the Code of Ethics for the members of the Board of Directors of the Corporation is hereby approved.























49-11-1

• Prüfung : 1. 1. 2019

- ```

1  5.
2  500.
3  700.
4  198. 198. 198. 198.

```

1. **Introduction**

11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840. 841. 842. 843. 844. 845. 846. 847

2011年12月25日 星期一

[illegible]

U. S. 113 11413 • T. 573 2 1144 11 13 11

מחבר: ד"ר יצחק שניידר

11 7

- [illegible]

11

**THE UNIVERSITY OF CHICAGO**

1. *Journal of the American Medical Association*, 2000; 283: 2689-2695.

**התאחדות המורים והמורות**

[illegible]

... and the ... ..

... ..

... ..

- 100 100.00  
 100 100.00  
 100 100.00

• 111 •

[illegible][illegible]

7. In the case of a \_\_\_\_\_ \_\_\_\_\_

[illegible][illegible]

























UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. 7,785,922  
PUBLICATION NO. 2013/0279878  
FILE NO. 13/546,711  
PCT NO. 62/200,000

Page 1 of 1

This certificate is given in accordance with 35 U.S.C. 416 and 37 C.F.R. 1.312 in order to correct the following:

1. In the title page, insert the following:

“In a separate view, a perspective view of the second working example of the subject matter is shown (a).”

2. In the description, insert the following paragraph between paragraphs 0001 and 0002:—

Signed and sealed this

Ninth Day of November, 2016



David J. Kappas, Commissioner



US 8,621,816 B2

# United States Patent Chakrabarty et al.

Patent No. US 8,621,816 B2  
Date of Patent Jan 7, 2014

1. A method for processing a signal, comprising:  
receiving a signal; and  
outputting a signal.

2. The method of claim 1, wherein the signal is a digital signal, and the outputting is performed by a digital-to-analog converter.

3. The method of claim 1, wherein the signal is an analog signal, and the outputting is performed by an analog-to-digital converter.

4. The method of claim 1, wherein the signal is a digital signal, and the outputting is performed by a digital-to-analog converter.

5. The method of claim 1, wherein the signal is an analog signal, and the outputting is performed by an analog-to-digital converter.

6. The method of claim 1, wherein the signal is a digital signal, and the outputting is performed by a digital-to-analog converter.

7. The method of claim 1, wherein the signal is an analog signal, and the outputting is performed by an analog-to-digital converter.

8. The method of claim 1, wherein the signal is a digital signal, and the outputting is performed by a digital-to-analog converter.

9. The method of claim 1, wherein the signal is an analog signal, and the outputting is performed by an analog-to-digital converter.

10. The method of claim 1, wherein the signal is a digital signal, and the outputting is performed by a digital-to-analog converter.

11. The method of claim 1, wherein the signal is an analog signal, and the outputting is performed by an analog-to-digital converter.

12. The method of claim 1, wherein the signal is a digital signal, and the outputting is performed by a digital-to-analog converter.

13. The method of claim 1, wherein the signal is an analog signal, and the outputting is performed by an analog-to-digital converter.

14. The method of claim 1, wherein the signal is a digital signal, and the outputting is performed by a digital-to-analog converter.

15. The method of claim 1, wherein the signal is an analog signal, and the outputting is performed by an analog-to-digital converter.

16. The method of claim 1, wherein the signal is a digital signal, and the outputting is performed by a digital-to-analog converter.

17. The method of claim 1, wherein the signal is an analog signal, and the outputting is performed by an analog-to-digital converter.

18. The method of claim 1, wherein the signal is a digital signal, and the outputting is performed by a digital-to-analog converter.

19. The method of claim 1, wherein the signal is an analog signal, and the outputting is performed by an analog-to-digital converter.

20. The method of claim 1, wherein the signal is a digital signal, and the outputting is performed by a digital-to-analog converter.

21. The method of claim 1, wherein the signal is an analog signal, and the outputting is performed by an analog-to-digital converter.

22. The method of claim 1, wherein the signal is a digital signal, and the outputting is performed by a digital-to-analog converter.

23. The method of claim 1, wherein the signal is an analog signal, and the outputting is performed by an analog-to-digital converter.

24. The method of claim 1, wherein the signal is a digital signal, and the outputting is performed by a digital-to-analog converter.

25. The method of claim 1, wherein the signal is an analog signal, and the outputting is performed by an analog-to-digital converter.

26. The method of claim 1, wherein the signal is a digital signal, and the outputting is performed by a digital-to-analog converter.

27. The method of claim 1, wherein the signal is an analog signal, and the outputting is performed by an analog-to-digital converter.

28. The method of claim 1, wherein the signal is a digital signal, and the outputting is performed by a digital-to-analog converter.




FIG. 1A



FIG. 1B



FIG. 1C




FIG. 2




FIG. 3

STUDIES ON THE EFFECTS OF  
FERTILIZERS ON THE GROWTH OF  
SUGAR BEET

By J. H. H. H. H. H.

The present paper is a preliminary report on the results of a series of experiments conducted in 1949 and 1950 on the effects of various fertilizers on the growth of sugar beet. The experiments were conducted in the experimental station of the Agricultural Research Institute, Wageningen, The Netherlands. The results of the experiments are given in the following tables. The first table shows the results of the experiments conducted in 1949, and the second table shows the results of the experiments conducted in 1950. The results of the experiments are given in the following tables. The first table shows the results of the experiments conducted in 1949, and the second table shows the results of the experiments conducted in 1950.

TABLE 1. Results of the experiments conducted in 1949.

The results of the experiments conducted in 1949 are given in the following table. The table shows the results of the experiments conducted in 1949, and the results of the experiments conducted in 1950. The results of the experiments are given in the following table. The table shows the results of the experiments conducted in 1949, and the results of the experiments conducted in 1950.

TABLE 2. Results of the experiments conducted in 1950.

The results of the experiments conducted in 1950 are given in the following table. The table shows the results of the experiments conducted in 1950, and the results of the experiments conducted in 1949. The results of the experiments are given in the following table. The table shows the results of the experiments conducted in 1950, and the results of the experiments conducted in 1949.

TABLE 3. Results of the experiments conducted in 1951.

The results of the experiments conducted in 1951 are given in the following table. The table shows the results of the experiments conducted in 1951, and the results of the experiments conducted in 1950. The results of the experiments are given in the following table. The table shows the results of the experiments conducted in 1951, and the results of the experiments conducted in 1950.

The results of the experiments conducted in 1951 are given in the following table. The table shows the results of the experiments conducted in 1951, and the results of the experiments conducted in 1950. The results of the experiments are given in the following table. The table shows the results of the experiments conducted in 1951, and the results of the experiments conducted in 1950.

The results of the experiments conducted in 1951 are given in the following table. The table shows the results of the experiments conducted in 1951, and the results of the experiments conducted in 1950. The results of the experiments are given in the following table. The table shows the results of the experiments conducted in 1951, and the results of the experiments conducted in 1950.

The results of the experiments conducted in 1951 are given in the following table. The table shows the results of the experiments conducted in 1951, and the results of the experiments conducted in 1950. The results of the experiments are given in the following table. The table shows the results of the experiments conducted in 1951, and the results of the experiments conducted in 1950.

The results of the experiments conducted in 1951 are given in the following table. The table shows the results of the experiments conducted in 1951, and the results of the experiments conducted in 1950. The results of the experiments are given in the following table. The table shows the results of the experiments conducted in 1951, and the results of the experiments conducted in 1950.

The results of the experiments conducted in 1951 are given in the following table. The table shows the results of the experiments conducted in 1951, and the results of the experiments conducted in 1950. The results of the experiments are given in the following table. The table shows the results of the experiments conducted in 1951, and the results of the experiments conducted in 1950.

The results of the experiments conducted in 1951 are given in the following table. The table shows the results of the experiments conducted in 1951, and the results of the experiments conducted in 1950. The results of the experiments are given in the following table. The table shows the results of the experiments conducted in 1951, and the results of the experiments conducted in 1950.

REFERENCES

The present paper is based on the experiments conducted in 1949, 1950, and 1951. The results of the experiments are given in the following tables.





















1. **Identify the subject and predicate.** The subject is "The  
 2. **Identify the main verb.** The main verb is "is".  
 3. **Identify the object.** The object is "the best of all".  
 4. **Identify the modifier.** The modifier is "The".  
 5. **Identify the complement.** The complement is "the best of all".  
 6. **Identify the adverb.** There are no adverbs in this sentence.  
 7. **Identify the adjective.** There are no adjectives in this sentence.  
 8. **Identify the preposition.** There are no prepositions in this sentence.  
 9. **Identify the conjunction.** There are no conjunctions in this sentence.  
 10. **Identify the interjection.** There are no interjections in this sentence.

The Commission has been asked to consider the possibility of a further increase in the number of members of the Commission. The Commission has been asked to consider the possibility of a further increase in the number of members of the Commission. The Commission has been asked to consider the possibility of a further increase in the number of members of the Commission.

[illegible]

The first three have also been mentioned previously in connection with the development of the HSE. In this case, the authors are not claiming any priority. The idea of having a field school in the summer has been discussed by the German and French governments since the 1920s. The introduction of such an exchange program was highly demanded by the war-torn countries. For the first time, the German and French governments decided to implement such a program. However, it was not until the post-war period that the program was really established as a bilateral exchange program. However, the authors of this article would like to emphasize that the idea of the field school was not only the result of a long-term process, but also the result of the need to solve the problems arising out of the damage to the environment during the last decades of the 20th century.

It is important to note that the above-mentioned policy is implemented in a highly decentralized manner, with the local government being the main actor in the implementation process. The local government is responsible for the implementation of the policy, and it is also responsible for the monitoring and evaluation of the policy. The local government is also responsible for the implementation of the policy, and it is also responsible for the monitoring and evaluation of the policy.

It is common to use the term "disruptive" to describe any technology that disrupts an established business model. The term is often used to describe technologies that are disruptive to the business model of a company. For example, the term "disruptive" is often used to describe technologies that are disruptive to the business model of a company. The term "disruptive" is often used to describe technologies that are disruptive to the business model of a company.

The present findings indicate that the development of a single, more specific, and general measure of self-esteem would be a useful addition to the present study. Such a measure would be useful to the extent that it could be used to assess the effects of the intervention on self-esteem, and to the extent that it could be used to assess the effects of the intervention on self-esteem.

[illegible][illegible][illegible]

It is important to understand that the purpose of the study is not to determine the exact number of people who are involved in the illegal gambling industry, but rather to provide a general estimate of the size of the problem. The study is based on a sample of people who are involved in the illegal gambling industry, and the results are based on the responses of that sample. The study is not a survey of the general population, and the results are not representative of the general population. The study is a study of the illegal gambling industry, and the results are based on the responses of people who are involved in the illegal gambling industry.

[illegible][illegible]

the 1980s, the number of people in the United States who have been diagnosed with cancer has increased by 50 percent. The number of people who have been diagnosed with cancer has increased by 50 percent. The number of people who have been diagnosed with cancer has increased by 50 percent.

There are many reasons why the number of people who have been diagnosed with cancer has increased. One reason is that the number of people who have been diagnosed with cancer has increased. Another reason is that the number of people who have been diagnosed with cancer has increased.

It is important to note that the number of people who have been diagnosed with cancer has increased. This is because the number of people who have been diagnosed with cancer has increased. The number of people who have been diagnosed with cancer has increased.

There are many reasons why the number of people who have been diagnosed with cancer has increased. One reason is that the number of people who have been diagnosed with cancer has increased. Another reason is that the number of people who have been diagnosed with cancer has increased.

There are many reasons why the number of people who have been diagnosed with cancer has increased. One reason is that the number of people who have been diagnosed with cancer has increased. Another reason is that the number of people who have been diagnosed with cancer has increased.

There are many reasons why the number of people who have been diagnosed with cancer has increased. One reason is that the number of people who have been diagnosed with cancer has increased. Another reason is that the number of people who have been diagnosed with cancer has increased.

There are many reasons why the number of people who have been diagnosed with cancer has increased. One reason is that the number of people who have been diagnosed with cancer has increased. Another reason is that the number of people who have been diagnosed with cancer has increased.

There are many reasons why the number of people who have been diagnosed with cancer has increased. One reason is that the number of people who have been diagnosed with cancer has increased. Another reason is that the number of people who have been diagnosed with cancer has increased.

There are many reasons why the number of people who have been diagnosed with cancer has increased. One reason is that the number of people who have been diagnosed with cancer has increased. Another reason is that the number of people who have been diagnosed with cancer has increased.

There are many reasons why the number of people who have been diagnosed with cancer has increased. One reason is that the number of people who have been diagnosed with cancer has increased. Another reason is that the number of people who have been diagnosed with cancer has increased.

There are many reasons why the number of people who have been diagnosed with cancer has increased. One reason is that the number of people who have been diagnosed with cancer has increased. Another reason is that the number of people who have been diagnosed with cancer has increased.

There are many reasons why the number of people who have been diagnosed with cancer has increased. One reason is that the number of people who have been diagnosed with cancer has increased. Another reason is that the number of people who have been diagnosed with cancer has increased.

There are many reasons why the number of people who have been diagnosed with cancer has increased. One reason is that the number of people who have been diagnosed with cancer has increased. Another reason is that the number of people who have been diagnosed with cancer has increased.

There are many reasons why the number of people who have been diagnosed with cancer has increased. One reason is that the number of people who have been diagnosed with cancer has increased. Another reason is that the number of people who have been diagnosed with cancer has increased.

TABLE 1

| Cancer Incidence by Site and Sex, 1973-1977 |        |        |        |                  |
|---------------------------------------------|--------|--------|--------|------------------|
| Site                                        | Male   | Female | Total  | Rate per 100,000 |
| Bladder                                     | 10,000 | 5,000  | 15,000 | 15.0             |
| Breast                                      | 5,000  | 10,000 | 15,000 | 15.0             |
| Colon                                       | 10,000 | 10,000 | 20,000 | 20.0             |
| Prostate                                    | 10,000 | 0      | 10,000 | 10.0             |
| Lung                                        | 10,000 | 5,000  | 15,000 | 15.0             |

Source: American Cancer Society, *Cancer Facts and Figures*, 1978.











| DATE       | DESCRIPTION      | AMOUNT |
|------------|------------------|--------|
| 1971-01-01 | Initial deposit  | 100.00 |
| 1971-01-15 | Interest payment | 1.50   |
| 1971-02-01 | Withdrawal       | 50.00  |
| 1971-02-15 | Interest payment | 1.50   |
| 1971-03-01 | Deposit          | 25.00  |
| 1971-03-15 | Interest payment | 1.50   |
| 1971-04-01 | Withdrawal       | 10.00  |
| 1971-04-15 | Interest payment | 1.50   |
| 1971-05-01 | Deposit          | 15.00  |
| 1971-05-15 | Interest payment | 1.50   |
| 1971-06-01 | Withdrawal       | 5.00   |
| 1971-06-15 | Interest payment | 1.50   |
| 1971-07-01 | Deposit          | 10.00  |
| 1971-07-15 | Interest payment | 1.50   |
| 1971-08-01 | Withdrawal       | 5.00   |
| 1971-08-15 | Interest payment | 1.50   |
| 1971-09-01 | Deposit          | 10.00  |
| 1971-09-15 | Interest payment | 1.50   |
| 1971-10-01 | Withdrawal       | 5.00   |
| 1971-10-15 | Interest payment | 1.50   |
| 1971-11-01 | Deposit          | 10.00  |
| 1971-11-15 | Interest payment | 1.50   |
| 1971-12-01 | Withdrawal       | 5.00   |
| 1971-12-15 | Interest payment | 1.50   |
| 1972-01-01 | Final balance    | 100.00 |

1971-01-01 to 1972-01-01

The following table shows the balance of the account at the end of each month. The balance is calculated by adding the interest payment to the previous balance and subtracting the withdrawal. The balance is rounded to the nearest cent.

1971-01-01 to 1972-01-01

1971-01-01 to 1972-01-01

The following table shows the balance of the account at the end of each month. The balance is calculated by adding the interest payment to the previous balance and subtracting the withdrawal. The balance is rounded to the nearest cent.

The following table shows the balance of the account at the end of each month. The balance is calculated by adding the interest payment to the previous balance and subtracting the withdrawal. The balance is rounded to the nearest cent.

The following table shows the balance of the account at the end of each month. The balance is calculated by adding the interest payment to the previous balance and subtracting the withdrawal. The balance is rounded to the nearest cent.

The following table shows the balance of the account at the end of each month. The balance is calculated by adding the interest payment to the previous balance and subtracting the withdrawal. The balance is rounded to the nearest cent.

The following table shows the balance of the account at the end of each month. The balance is calculated by adding the interest payment to the previous balance and subtracting the withdrawal. The balance is rounded to the nearest cent.

The following table shows the balance of the account at the end of each month. The balance is calculated by adding the interest payment to the previous balance and subtracting the withdrawal. The balance is rounded to the nearest cent.

The following table shows the balance of the account at the end of each month. The balance is calculated by adding the interest payment to the previous balance and subtracting the withdrawal. The balance is rounded to the nearest cent.

The following table shows the balance of the account at the end of each month. The balance is calculated by adding the interest payment to the previous balance and subtracting the withdrawal. The balance is rounded to the nearest cent.

The following table shows the balance of the account at the end of each month. The balance is calculated by adding the interest payment to the previous balance and subtracting the withdrawal. The balance is rounded to the nearest cent.







DATE 12/16/12

1010 10/16/12 12:16:12

1011 10/16/12 12:16:12

1012 10/16/12 12:16:12

1013 10/16/12 12:16:12 10/16/12 12:16:12

1014 10/16/12 12:16:12

1015 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1016 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1017 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1018 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1019 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1020 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1021 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1022 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1023 10/16/12 12:16:12

1024 10/16/12 12:16:12

1025 10/16/12 12:16:12

1026 10/16/12 12:16:12 10/16/12 12:16:12

1027 10/16/12 12:16:12

1028 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1029 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1030 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1031 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1032 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1033 10/16/12 12:16:12

1034 10/16/12 12:16:12

1035 10/16/12 12:16:12

1036 10/16/12 12:16:12 10/16/12 12:16:12

1037 10/16/12 12:16:12

1038 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1039 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1040 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12

1041 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12 10/16/12 12:16:12







[illegible][illegible]

| Year | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | 2050 | 2051 | 2052 | 2053 | 2054 | 2055 | 2056 | 2057 | 2058 | 2059 | 2060 | 2061 | 2062 | 2063 | 2064 | 2065 | 2066 | 2067 | 2068 | 2069 | 2070 | 2071 | 2072 | 2073 | 2074 | 2075 | 2076 | 2077 | 2078 | 2079 | 2080 | 2081 | 2082 | 2083 | 2084 | 2085 | 2086 | 2087 | 2088 | 2089 | 2090 | 2091 | 2092 | 2093 | 2094 | 2095 | 2096 | 2097 | 2098 | 2099 | 2100 |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | 2050 | 2051 | 2052 | 2053 | 2054 | 2055 | 2056 | 2057 | 2058 | 2059 | 2060 | 2061 | 2062 | 2063 | 2064 | 2065 | 2066 | 2067 | 2068 | 2069 | 2070 | 2071 | 2072 | 2073 | 2074 | 2075 | 2076 | 2077 | 2078 | 2079 | 2080 | 2081 | 2082 | 2083 | 2084 | 2085 | 2086 | 2087 | 2088 | 2089 | 2090 | 2091 | 2092 | 2093 | 2094 | 2095 | 2096 | 2097 | 2098 | 2099 | 2100 |      |

2017-01-01 to 2017-01-01

DATE: 11/11/11


 UNIVERSITY OF ILLINOIS PRESS

**III. 2. 2. 2. 2. 2.**

[illegible]

11. 7. 2019.

2. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840.

20 1-8. 11. 2. 1 1-1 11. 1-1. 11. 2-7. 1-4  
11 11

[illegible]

$\gamma_1 = \frac{1}{\sqrt{1 - \beta^2}}$ ,  $\gamma_2 = \frac{1}{\sqrt{1 - \beta'^2}}$ ,  $\beta = \frac{v}{c}$ ,  $\beta' = \frac{v'}{c}$

[illegible][illegible]

2018年1月1日

7. 1. 67 11. 6, 7. 8. 67 9. 10. 67 11. 12. 67

[illegible][illegible]

■ ■ ■ ■ ■

11. UNITED STATES

**■** **I** **'** **n** **a** **r**

**-** **i** **m** **p** **e** **t** **s** **-**

[illegible]

**■ ■ ■ ■ ■**

— *Journal of the American Medical Association*, 1967, 201: 1011-1012.

"I am not a Jew," said the man.

• **Prüfung** : 1. April 2014, 14:00 Uhr

המחיר הממוצע של המכשיר הוא 1,200 ש"ח.

[illegible]

"I'm not going to let you go," said the man.





151. 71416-119

151. 71416-119. The first part of the paper is devoted to the study of the properties of the function  $f(x)$  defined by the equation  $f(x) = \sum_{n=0}^{\infty} \frac{f_n(x)}{n!}$ , where  $f_n(x)$  are the solutions of the system of differential equations  $f_n'(x) = f_{n+1}(x)$ ,  $f_0(x) = 1$ . It is shown that the function  $f(x)$  is analytic in the whole plane and that it satisfies the equation  $f(x) = e^{f(x)}$ . The second part of the paper is devoted to the study of the properties of the function  $f(x)$  defined by the equation  $f(x) = \sum_{n=0}^{\infty} \frac{f_n(x)}{n!}$ , where  $f_n(x)$  are the solutions of the system of differential equations  $f_n'(x) = f_{n+1}(x)$ ,  $f_0(x) = 1$ . It is shown that the function  $f(x)$  is analytic in the whole plane and that it satisfies the equation  $f(x) = e^{f(x)}$ .

151. 71416-119. The first part of the paper is devoted to the study of the properties of the function  $f(x)$  defined by the equation  $f(x) = \sum_{n=0}^{\infty} \frac{f_n(x)}{n!}$ , where  $f_n(x)$  are the solutions of the system of differential equations  $f_n'(x) = f_{n+1}(x)$ ,  $f_0(x) = 1$ . It is shown that the function  $f(x)$  is analytic in the whole plane and that it satisfies the equation  $f(x) = e^{f(x)}$ .

151. 71416-119. The first part of the paper is devoted to the study of the properties of the function  $f(x)$  defined by the equation  $f(x) = \sum_{n=0}^{\infty} \frac{f_n(x)}{n!}$ , where  $f_n(x)$  are the solutions of the system of differential equations  $f_n'(x) = f_{n+1}(x)$ ,  $f_0(x) = 1$ . It is shown that the function  $f(x)$  is analytic in the whole plane and that it satisfies the equation  $f(x) = e^{f(x)}$ . The second part of the paper is devoted to the study of the properties of the function  $f(x)$  defined by the equation  $f(x) = \sum_{n=0}^{\infty} \frac{f_n(x)}{n!}$ , where  $f_n(x)$  are the solutions of the system of differential equations  $f_n'(x) = f_{n+1}(x)$ ,  $f_0(x) = 1$ . It is shown that the function  $f(x)$  is analytic in the whole plane and that it satisfies the equation  $f(x) = e^{f(x)}$ .

151. 71416-119. The first part of the paper is devoted to the study of the properties of the function  $f(x)$  defined by the equation  $f(x) = \sum_{n=0}^{\infty} \frac{f_n(x)}{n!}$ , where  $f_n(x)$  are the solutions of the system of differential equations  $f_n'(x) = f_{n+1}(x)$ ,  $f_0(x) = 1$ . It is shown that the function  $f(x)$  is analytic in the whole plane and that it satisfies the equation  $f(x) = e^{f(x)}$ .

151. 71416-119. The first part of the paper is devoted to the study of the properties of the function  $f(x)$  defined by the equation  $f(x) = \sum_{n=0}^{\infty} \frac{f_n(x)}{n!}$ , where  $f_n(x)$  are the solutions of the system of differential equations  $f_n'(x) = f_{n+1}(x)$ ,  $f_0(x) = 1$ . It is shown that the function  $f(x)$  is analytic in the whole plane and that it satisfies the equation  $f(x) = e^{f(x)}$ .

W. I. R. v. v.

[illegible]

1. The following information is provided for the year ended 31/12/2019:

**تاریخ و نام**

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840.

$$\dots \text{value} = \frac{\text{index} \cdot \text{factor} \cdot \text{value}}{n}$$

[illegible]

7A 2B 3C 4D 5E 6F 7G 8H 9I 10J 11K 12L 13M 14N 15O 16P 17Q 18R 19S 20T 21U 22V 23W 24X 25Y 26Z

20. 28 6 9. 3 - 1. 14 6-7. 27-30.

III. **THE** **NEW** **WORLD**

• III 1974. I

■ ■ ■      ■ ■ ■      ■ ■ ■

[illegible]

• **•••** **TTT** • **•**

70.  $\frac{1}{2} \times \frac{1}{2} = \frac{1}{4}$        $\frac{1}{2} \times \frac{1}{4} = \frac{1}{8}$        $\frac{1}{4} \times \frac{1}{4} = \frac{1}{16}$

**B. R. B. S. T. I. L. I. N. E. P. A. M. U. S.**

[illegible]

7. The following information is available for the year ended 31/12/2019:

1. 1. 7. 11. 7. 16 = 1. 6. 21 7-6 1, 22 1, 7-6  
1

[illegible]

• **1. 2. 3. 4. 5.** •

• **Illegitimate** •

■ ■ ■ ■ ■

• I 17. • I.. -17.

..

[illegible]

1971 4-15 13 9 13 1.17 20.17

ה'תשנ"ח י"ב י"ג י"ד י"ה י"ו י"ז י"ח י"ט

[illegible]

**Figure 1.** The effect of the number of trials on the mean accuracy of the responses ( $n = 10$ ) as a function of the number of items ( $n = 8$ ). Error bars represent standard error.

..

**א** וְהָיָה כִּי יֵרָד מִן הַשָּׁמַיִם אֵשׁ וְחֶלֶד וְנֹפֶת וְכָל בְּרִית לְעוֹלָם  
וְהָיָה כִּי יֵרָד מִן הַשָּׁמַיִם אֵשׁ וְחֶלֶד וְנֹפֶת וְכָל בְּרִית לְעוֹלָם





# 151. 71416-11

20

20

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

20

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

20

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

20

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

20

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

20

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

20

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

151. 71416-11

20

151. 71416-11

# 151. 7116-11

Q1

Q2

Answer: 100

- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5

100. 100/20 = 5

100. 100/20 = 5

- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5

100. 100/20 = 5

100. 100/20 = 5

- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5

100. 100/20 = 5

100. 100/20 = 5

- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5

100. 100/20 = 5

100. 100/20 = 5

- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5
- 100. 100/20 = 5

100. 100/20 = 5

100. 100/20 = 5

100. 100/20 = 5

100. 100/20 = 5

100. 100/20 = 5

100. 100/20 = 5

100. 100/20 = 5



12. 13. 14. 15.

U.S. United States Patent  
Department

File Number: 19-8124-055 R2  
 Date of Entry: Feb. 20, 2013

34. RECENTLY, THE U.S. GOVERNMENT HAS  
ANNOUNCED THAT IT WILL  
INCREASE THE

1990. *Journal of Interpersonal Violence* 5:407-417.  
Holtzworth-Munroe, A., M. Stuart, and J. Gelles.  
1994. *Family Violence: The Changing Face of  
Violence in the Home*. New York: Basic Books.  
Tjebkjes, T. T. 1990. *Journal of Interpersonal  
Violence* 5:329-345.

17. What is the purpose of the study?  
The purpose of the study is to determine the effect of the use of a computer program on the learning of the English language.

19. 5. 1961     3400 ft., back-country, near base of  
 P. 11100-14000 ft.     (see also 1961  
 1. 1. 1961, 1961, 1961)

**DATE RECEIVED**

12. 10 10.12.20

**179**                 **Hilary Putnam**

2020年12月15日

### Individuals and the Environment

1977. Considerable sample bias was found (1977) and was due to the fact that the 1976 survey was conducted during an upturn in the 1976-1977 wheat harvest (1976) and the 1977 survey was conducted during a decline in the 1977-1978 wheat harvest (1977). The 1976 survey was conducted during an upturn in the 1976-1977 wheat harvest (1976) and the 1977 survey was conducted during a decline in the 1977-1978 wheat harvest (1977). The 1976 survey was conducted during an upturn in the 1976-1977 wheat harvest (1976) and the 1977 survey was conducted during a decline in the 1977-1978 wheat harvest (1977).

[illegible]

|            |            |
|------------|------------|
| 10. 10. 10 | 10. 10. 10 |
| 10. 10. 10 | 10. 10. 10 |
| 10. 10. 10 | 10. 10. 10 |

[illegible]

12. Walter J. Rife 1901  
1901 1901 1901 1901  
1901 1901 1901 1901

המחיר הנמוך ביותר

23. Answer: D

11-15-77 10:15 AM

[illegible]

1. I have been a member of the [redacted] since [redacted] and have been active in the [redacted] since [redacted].

..... I did not know.

**DATE RECEIVED**

|   |   |   |
|---|---|---|
| ✓ | ✓ | ✓ |
| ✓ | ✓ | ✓ |
| ✓ | ✓ | ✓ |

STRENGTHS AND WEAKNESSES

1. James Earl Ray (1928-1998) was an American  
 2. murderer who was convicted of the assassination  
 3. of Martin Luther King Jr. in 1968. He was  
 4. executed by hanging in 1999.  
 5. He was a member of the Black Panther Party  
 6. and was involved in the civil rights movement.  
 7. He was also a member of the Weathermen  
 8. and was involved in the 1969 New York City  
 9. riot.  
 10. He was also involved in the 1971  
 11. Chicago riot.  
 12. He was also involved in the 1972  
 13. Democratic National Convention.  
 14. He was also involved in the 1973  
 15. Watergate scandal.  
 16. He was also involved in the 1974  
 17. Democratic National Convention.  
 18. He was also involved in the 1975  
 19. Democratic National Convention.  
 20. He was also involved in the 1976  
 21. Democratic National Convention.  
 22. He was also involved in the 1977  
 23. Democratic National Convention.  
 24. He was also involved in the 1978  
 25. Democratic National Convention.  
 26. He was also involved in the 1979  
 27. Democratic National Convention.  
 28. He was also involved in the 1980  
 29. Democratic National Convention.  
 30. He was also involved in the 1981  
 31. Democratic National Convention.  
 32. He was also involved in the 1982  
 33. Democratic National Convention.  
 34. He was also involved in the 1983  
 35. Democratic National Convention.  
 36. He was also involved in the 1984  
 37. Democratic National Convention.  
 38. He was also involved in the 1985  
 39. Democratic National Convention.  
 40. He was also involved in the 1986  
 41. Democratic National Convention.  
 42. He was also involved in the 1987  
 43. Democratic National Convention.  
 44. He was also involved in the 1988  
 45. Democratic National Convention.  
 46. He was also involved in the 1989  
 47. Democratic National Convention.  
 48. He was also involved in the 1990  
 49. Democratic National Convention.  
 50. He was also involved in the 1991  
 51. Democratic National Convention.  
 52. He was also involved in the 1992  
 53. Democratic National Convention.  
 54. He was also involved in the 1993  
 55. Democratic National Convention.  
 56. He was also involved in the 1994  
 57. Democratic National Convention.  
 58. He was also involved in the 1995  
 59. Democratic National Convention.  
 60. He was also involved in the 1996  
 61. Democratic National Convention.  
 62. He was also involved in the 1997  
 63. Democratic National Convention.  
 64. He was also involved in the 1998  
 65. Democratic National Convention.  
 66. He was also involved in the 1999  
 67. Democratic National Convention.  
 68. He was also involved in the 2000  
 69. Democratic National Convention.  
 70. He was also involved in the 2001  
 71. Democratic National Convention.  
 72. He was also involved in the 2002  
 73. Democratic National Convention.  
 74. He was also involved in the 2003  
 75. Democratic National Convention.  
 76. He was also involved in the 2004  
 77. Democratic National Convention.  
 78. He was also involved in the 2005  
 79. Democratic National Convention.  
 80. He was also involved in the 2006  
 81. Democratic National Convention.  
 82. He was also involved in the 2007  
 83. Democratic National Convention.  
 84. He was also involved in the 2008  
 85. Democratic National Convention.  
 86. He was also involved in the 2009  
 87. Democratic National Convention.  
 88. He was also involved in the 2010  
 89. Democratic National Convention.  
 90. He was also involved in the 2011  
 91. Democratic National Convention.  
 92. He was also involved in the 2012  
 93. Democratic National Convention.  
 94. He was also involved in the 2013  
 95. Democratic National Convention.  
 96. He was also involved in the 2014  
 97. Democratic National Convention.  
 98. He was also involved in the 2015  
 99. Democratic National Convention.  
 100. He was also involved in the 2016  
 101. Democratic National Convention.  
 102. He was also involved in the 2017  
 103. Democratic National Convention.  
 104. He was also involved in the 2018  
 105. Democratic National Convention.  
 106. He was also involved in the 2019  
 107. Democratic National Convention.  
 108. He was also involved in the 2020  
 109. Democratic National Convention.  
 110. He was also involved in the 2021  
 111. Democratic National Convention.  
 112. He was also involved in the 2022  
 113. Democratic National Convention.  
 114. He was also involved in the 2023  
 115. Democratic National Convention.  
 116. He was also involved in the 2024  
 117. Democratic National Convention.  
 118. He was also involved in the 2025  
 119. Democratic National Convention.  
 120. He was also involved in the 2026  
 121. Democratic National Convention.  
 122. He was also involved in the 2027  
 123. Democratic National Convention.  
 124. He was also involved in the 2028  
 125. Democratic National Convention.  
 126. He was also involved in the 2029  
 127. Democratic National Convention.  
 128. He was also involved in the 2030  
 129. Democratic National Convention.  
 130. He was also involved in the 2031  
 131. Democratic National Convention.  
 132. He was also involved in the 2032  
 133. Democratic National Convention.  
 134. He was also involved in the 2033  
 135. Democratic National Convention.  
 136. He was also involved in the 2034  
 137. Democratic National Convention.  
 138. He was also involved in the 2035  
 139. Democratic National Convention.  
 140. He was also involved in the 2036  
 141. Democratic National Convention.  
 142. He was also involved in the 2037  
 143. Democratic National Convention.  
 144. He was also involved in the 2038  
 145. Democratic National Convention.  
 146. He was also involved in the 2039  
 147. Democratic National Convention.  
 148. He was also involved in the 2040  
 149. Democratic National Convention.  
 150. He was also involved in the 2041  
 151. Democratic National Convention.  
 152. He was also involved in the 2042  
 153. Democratic National Convention.  
 154. He was also involved in the 2043  
 155. Democratic National Convention.  
 156. He was also involved in the 2044  
 157. Democratic National Convention.  
 158. He was also involved in the 2045  
 159. Democratic National Convention.  
 160. He was also involved in the 2046  
 161. Democratic National Convention.  
 162. He was also involved in the 2047  
 163. Democratic National Convention.  
 164. He was also involved in the 2048  
 165. Democratic National Convention.  
 166. He was also involved in the 2049  
 167. Democratic National Convention.  
 168. He was also involved in the 2050  
 169. Democratic National Convention.  
 170. He was also involved in the 2051  
 171. Democratic National Convention.  
 172. He was also involved in the 2052  
 173. Democratic National Convention.  
 174. He was also involved in the 2053  
 175. Democratic National Convention.  
 176. He was also involved in the 2054  
 177. Democratic National Convention.  
 178. He was also involved in the 2055  
 179. Democratic National Convention.  
 180. He was also involved in the 2056  
 181. Democratic National Convention.  
 182. He was also involved in the 2057  
 183. Democratic National Convention.  
 184. He was also involved in the 2058  
 185. Democratic National Convention.  
 186. He was also involved in

© 2000 Blackwell Science Ltd  
Journal of Internal Medicine 247: 173–179  
Received 15 March 2000; accepted 15 May 2000

12 46 60 1

[illegible]

142 MEJ-PJ-1753b




FIG. 1A




FIG. 1B






FIG. 2A




FIG. 2B

FIG. 3A



FIG. 3B




FIG. 3C





FIG. 3D




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F




FIG. 5




FIG. 6A




FIG. 6B











2. *Justification* – even in 'normal' conditions, it is not possible to determine the exact time when the 'normal' population begins to die.



1. The first of the two main parts of the book is devoted to a study of the history of the English language. It begins with a chapter on the English language in the Middle Ages, and then goes on to discuss the changes in the language during the Renaissance, the 17th century, and the 18th century. The second part of the book is devoted to a study of the English language in the 19th and 20th centuries. It begins with a chapter on the English language in the 19th century, and then goes on to discuss the changes in the language during the 20th century.

1. The first step is to identify the problem.

Table 1 shows the mean number of eggs per female egg mass and the mean number of eggs per egg mass. The mean number of eggs per egg mass was 1.0 (range 1-2) and the mean number of eggs per female egg mass was 1.0 (range 1-2). The mean number of eggs per egg mass was 1.0 (range 1-2) and the mean number of eggs per female egg mass was 1.0 (range 1-2).

[illegible]

There is a need to develop a methodology that allows a more systematic and comprehensive analysis of the various factors that influence the development of the economy. This is particularly true in the case of the developing countries, where the economic situation is often characterized by a high degree of instability and uncertainty. The methodology proposed in this paper aims to address this need by providing a framework for the analysis of the economic situation in these countries. The methodology is based on the following principles: (1) the identification of the key factors that influence the economic situation; (2) the analysis of the interactions between these factors; (3) the development of a model that can be used to predict the economic situation; and (4) the validation of the model using historical data. The methodology is applied to the case of the developing countries in the Americas, where the economic situation is often characterized by a high degree of instability and uncertainty. The results of the analysis show that the methodology is able to identify the key factors that influence the economic situation and to develop a model that can be used to predict the economic situation. The methodology is therefore a valuable tool for the analysis of the economic situation in the developing countries.

Improving the way we do business is another challenge facing the transportation industry. The American Road & Transportation Builders Association (ARTBA) has a number of programs in place to help transportation agencies and the private sector work together to improve the way we do business. ARTBA has a number of programs in place to help transportation agencies and the private sector work together to improve the way we do business.

[illegible][illegible][illegible]

There is a growing need for research on the impact of the experience of a child on the child's experience of the world. This is a topic that has been largely ignored in the past. The purpose of this research is to explore the impact of the experience of a child on the child's experience of the world. The research will be conducted in a series of steps. First, the researcher will identify the key factors that influence the child's experience of the world. Then, the researcher will collect data on these factors. Finally, the researcher will analyze the data to determine the impact of the experience of a child on the child's experience of the world. The results of this research will be used to develop interventions that can help children experience the world in a more positive way.











the development of a new system for the control of the system, and the development of a new system for the control of the system.

The system is a new system for the control of the system, and the development of a new system for the control of the system.

The system is a new system for the control of the system, and the development of a new system for the control of the system.

The system is a new system for the control of the system, and the development of a new system for the control of the system.

The system is a new system for the control of the system, and the development of a new system for the control of the system.

The system is a new system for the control of the system, and the development of a new system for the control of the system.

The system is a new system for the control of the system, and the development of a new system for the control of the system.

The system is a new system for the control of the system, and the development of a new system for the control of the system.

The system is a new system for the control of the system, and the development of a new system for the control of the system.

The system is a new system for the control of the system, and the development of a new system for the control of the system.

The system is a new system for the control of the system, and the development of a new system for the control of the system.

The system is a new system for the control of the system, and the development of a new system for the control of the system.

cannot be determined until the case is referred to the appropriate authorities.

There have also been discussions in the past about the possibility of a new form of the characterisation of the language. This has been the subject of a number of studies, but no final decision has been reached. It is possible that a new form of the characterisation of the language will be developed in the future.

There have also been discussions in the past about the possibility of a new form of the characterisation of the language. This has been the subject of a number of studies, but no final decision has been reached. It is possible that a new form of the characterisation of the language will be developed in the future.

The results of the study are discussed in the following sections.

The results of the study are discussed in the following sections.

The results of the study are discussed in the following sections.

The results of the study are discussed in the following sections.

The results of the study are discussed in the following sections.

The results of the study are discussed in the following sections.

The results of the study are discussed in the following sections.

TABLE 1

The results of the study are discussed in the following sections.

| Year | Year | Year | Year | Year |
|------|------|------|------|------|
| 1970 | 1971 | 1972 | 1973 | 1974 |
| 1975 | 1976 | 1977 | 1978 | 1979 |
| 1980 | 1981 | 1982 | 1983 | 1984 |
| 1985 | 1986 | 1987 | 1988 | 1989 |
| 1990 | 1991 | 1992 | 1993 | 1994 |

The results of the study are discussed in the following sections.

The results of the study are discussed in the following sections.

The results of the study are discussed in the following sections.

The results of the study are discussed in the following sections.





water, which has been found to contain a significant concentration of polychlorinated biphenyls (PCBs). The water is used for drinking and irrigation, and the PCBs are a known carcinogen. The water is also used for fishing, and the PCBs are a known carcinogen.

# TABLE 1

## Summary of Data

| Year | Number of Cases |
|------|-----------------|
| 1980 | 10              |
| 1981 | 15              |
| 1982 | 20              |
| 1983 | 25              |
| 1984 | 30              |
| 1985 | 35              |
| 1986 | 40              |
| 1987 | 45              |
| 1988 | 50              |
| 1989 | 55              |
| 1990 | 60              |

The data show a steady increase in the number of cases from 1980 to 1990. The increase is most pronounced in the years 1988, 1989, and 1990, when the number of cases reached 50, 55, and 60, respectively. This increase is consistent with the trend shown in the graph, which shows a steady increase in the number of cases over the same period.

The data also show that the number of cases is highest in the years 1988, 1989, and 1990, when the number of cases reached 50, 55, and 60, respectively. This increase is consistent with the trend shown in the graph, which shows a steady increase in the number of cases over the same period. The data also show that the number of cases is lowest in the years 1980, 1981, and 1982, when the number of cases was 10, 15, and 20, respectively.

The data also show that the number of cases is highest in the years 1988, 1989, and 1990, when the number of cases reached 50, 55, and 60, respectively. This increase is consistent with the trend shown in the graph, which shows a steady increase in the number of cases over the same period. The data also show that the number of cases is lowest in the years 1980, 1981, and 1982, when the number of cases was 10, 15, and 20, respectively.

# TABLE 2

## Summary of Data

The data show a steady increase in the number of cases from 1980 to 1990.

The data also show that the number of cases is highest in the years 1988, 1989, and 1990, when the number of cases reached 50, 55, and 60, respectively. This increase is consistent with the trend shown in the graph, which shows a steady increase in the number of cases over the same period.

The data show a steady increase in the number of cases from 1980 to 1990. The increase is most pronounced in the years 1988, 1989, and 1990, when the number of cases reached 50, 55, and 60, respectively. This increase is consistent with the trend shown in the graph, which shows a steady increase in the number of cases over the same period.

The data also show that the number of cases is highest in the years 1988, 1989, and 1990, when the number of cases reached 50, 55, and 60, respectively. This increase is consistent with the trend shown in the graph, which shows a steady increase in the number of cases over the same period. The data also show that the number of cases is lowest in the years 1980, 1981, and 1982, when the number of cases was 10, 15, and 20, respectively.

The data also show that the number of cases is highest in the years 1988, 1989, and 1990, when the number of cases reached 50, 55, and 60, respectively. This increase is consistent with the trend shown in the graph, which shows a steady increase in the number of cases over the same period. The data also show that the number of cases is lowest in the years 1980, 1981, and 1982, when the number of cases was 10, 15, and 20, respectively.

# TABLE 3

## Summary of Data

The data show a steady increase in the number of cases from 1980 to 1990. The increase is most pronounced in the years 1988, 1989, and 1990, when the number of cases reached 50, 55, and 60, respectively. This increase is consistent with the trend shown in the graph, which shows a steady increase in the number of cases over the same period. The data also show that the number of cases is lowest in the years 1980, 1981, and 1982, when the number of cases was 10, 15, and 20, respectively.

The data also show that the number of cases is highest in the years 1988, 1989, and 1990, when the number of cases reached 50, 55, and 60, respectively. This increase is consistent with the trend shown in the graph, which shows a steady increase in the number of cases over the same period. The data also show that the number of cases is lowest in the years 1980, 1981, and 1982, when the number of cases was 10, 15, and 20, respectively.

# TABLE 4

## Summary of Data

The data show a steady increase in the number of cases from 1980 to 1990. The increase is most pronounced in the years 1988, 1989, and 1990, when the number of cases reached 50, 55, and 60, respectively. This increase is consistent with the trend shown in the graph, which shows a steady increase in the number of cases over the same period. The data also show that the number of cases is lowest in the years 1980, 1981, and 1982, when the number of cases was 10, 15, and 20, respectively.





W. Irwin

[illegible]

1. The  $\alpha$ -value  
2. The  $\beta$ -value  
3. The  $\gamma$ -value  
4. The  $\delta$ -value

[illegible]

11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840. 841. 842. 843. 844. 845. 846. 847

1.  $\lim_{x \rightarrow 0} \frac{1}{x} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 2.  $\lim_{x \rightarrow 0} \frac{1}{x^2} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 3.  $\lim_{x \rightarrow 0} \frac{1}{x^3} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 4.  $\lim_{x \rightarrow 0} \frac{1}{x^4} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 5.  $\lim_{x \rightarrow 0} \frac{1}{x^5} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 6.  $\lim_{x \rightarrow 0} \frac{1}{x^6} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 7.  $\lim_{x \rightarrow 0} \frac{1}{x^7} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 8.  $\lim_{x \rightarrow 0} \frac{1}{x^8} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 9.  $\lim_{x \rightarrow 0} \frac{1}{x^9} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 10.  $\lim_{x \rightarrow 0} \frac{1}{x^{10}} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)









21. The first two terms of the sequence are 61 and 59. The next two terms are 57 and 55.

22. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

23. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

- (I) 100, 101, 102, 103
- (II) 100, 101, 102, 103
- (III) 100, 101, 102, 103
- (IV) 100, 101, 102, 103

24. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

25. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

26. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

27. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

28. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

29. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

30. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

31. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

32. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

- (I) 100, 101, 102, 103
- (II) 100, 101, 102, 103
- (III) 100, 101, 102, 103
- (IV) 100, 101, 102, 103

33. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

34. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

35. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

36. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

37. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

38. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

39. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

40. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

41. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.

42. The first two terms of the sequence are 100 and 101. The next two terms are 102 and 103.







20

1. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table.

2. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table.

50

1. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table.

2. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table.

1511-1512-113





US 8,124,065 B2

U.S. Patent  
Molnar et al.

Patent No.: US 8,124,065 B2  
Date of Patent: Feb. 28, 2012

68. A METHOD FOR PROVIDING A  
SERVICE TO A USER OF A  
MOBILE DEVICE

69. A method for providing a service to a user of a mobile device, comprising:  
receiving, from a user of a mobile device, a request for a service;  
determining, based on the request, a service to be provided to the user;  
providing the service to the user of the mobile device;

70. The method of claim 69, wherein the service is a service that is provided to the user of the mobile device.

71. The method of claim 69, wherein the service is a service that is provided to the user of the mobile device.

72. The method of claim 69, wherein the service is a service that is provided to the user of the mobile device.

73. The method of claim 69, wherein the service is a service that is provided to the user of the mobile device.

74. The method of claim 69, wherein the service is a service that is provided to the user of the mobile device.

75. The method of claim 69, wherein the service is a service that is provided to the user of the mobile device.

76. The method of claim 69, wherein the service is a service that is provided to the user of the mobile device.

77. A method for providing a service to a user of a mobile device, comprising:  
receiving, from a user of a mobile device, a request for a service;  
determining, based on the request, a service to be provided to the user;  
providing the service to the user of the mobile device;

78. The method of claim 77, wherein the service is a service that is provided to the user of the mobile device.

79. The method of claim 77, wherein the service is a service that is provided to the user of the mobile device.

80. The method of claim 77, wherein the service is a service that is provided to the user of the mobile device.

81. The method of claim 77, wherein the service is a service that is provided to the user of the mobile device.

82. The method of claim 77, wherein the service is a service that is provided to the user of the mobile device.

83. The method of claim 77, wherein the service is a service that is provided to the user of the mobile device.

84. The method of claim 77, wherein the service is a service that is provided to the user of the mobile device.

85. The method of claim 77, wherein the service is a service that is provided to the user of the mobile device.

86. The method of claim 77, wherein the service is a service that is provided to the user of the mobile device.

87. The method of claim 77, wherein the service is a service that is provided to the user of the mobile device.

88. A method for providing a service to a user of a mobile device

|    |    |    |
|----|----|----|
| 88 | 88 | 88 |
| 88 | 88 | 88 |
| 88 | 88 | 88 |
| 88 | 88 | 88 |

89. A method for providing a service to a user of a mobile device

90. A method for providing a service to a user of a mobile device, comprising:  
receiving, from a user of a mobile device, a request for a service;  
determining, based on the request, a service to be provided to the user;  
providing the service to the user of the mobile device;

91. The method of claim 90, wherein the service is a service that is provided to the user of the mobile device.

92. The method of claim 90, wherein the service is a service that is provided to the user of the mobile device.

93. The method of claim 90, wherein the service is a service that is provided to the user of the mobile device.

94. The method of claim 90, wherein the service is a service that is provided to the user of the mobile device.




FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B

FIG. 3A



FIG. 3B




FIG. 3C







FIG. 3D






FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F




FIG. 5






FIG. 6A




FIG. 6B





















the other steps, we can only say that the value of  $\alpha$  is not the same as the value of  $\beta$ . But we can say that the value of  $\alpha$  is not the same as the value of  $\beta$ .

3. There is a significant difference between the number of species which are reported to be common and the number of species which are reported to be uncommon. This difference is significant at the 0.05 level.

U.S. officials have shown interest in the Chinese company. The state-owned firm is seeking to establish a relationship with the program, and is currently working on a contract for the purchase of the aircraft. The company is also working on a contract for the purchase of the aircraft. The company is also working on a contract for the purchase of the aircraft.

[illegible][illegible][illegible]

1. **Identify the main topic of the passage.**  
 2. **Summarize the main idea in your own words.**  
 3. **Identify the author's purpose.**  
 4. **Identify the author's tone.**  
 5. **Identify the author's style.**  
 6. **Identify the author's audience.**  
 7. **Identify the author's point of view.**  
 8. **Identify the author's bias.**  
 9. **Identify the author's bias.**  
 10. **Identify the author's bias.**

[illegible]

As a result, the authors have found that the use of a single, one-dimensional approach to the analysis of the data is not sufficient to capture the complexity of the data. The authors suggest that a more comprehensive approach, one that takes into account the multiple dimensions of the data, is needed to fully understand the complexity of the data.

The first of these is the fact that the majority of the population of the United States is of European descent. This is a result of the fact that the United States was founded by people of European descent, and the majority of the population of the United States today is of European descent. This is a result of the fact that the United States was founded by people of European descent, and the majority of the population of the United States today is of European descent.

[illegible]

**Abstract**—The purpose of this study was to determine if there were differences in the prevalence of musculoskeletal disorders between two groups of nurses working in different units of a tertiary care hospital. The prevalence of musculoskeletal disorders was determined by means of a self-administered questionnaire among 100 nurses working in the intensive care unit (ICU) and 100 nurses working in the medical-surgical unit. The prevalence of musculoskeletal disorders was significantly higher among ICU nurses than among medical-surgical nurses ( $p < .001$ ). The prevalence of musculoskeletal disorders was also significantly higher among nurses who worked longer shifts ( $p < .001$ ) and among nurses who had been employed longer ( $p < .001$ ). The prevalence of musculoskeletal disorders was also significantly higher among nurses who reported more physical demands at work ( $p < .001$ ) and among nurses who reported more psychosocial stressors at work ( $p < .001$ ). The results of this study suggest that the prevalence of musculoskeletal disorders is higher among ICU nurses than among medical-surgical nurses. The results also suggest that the prevalence of musculoskeletal disorders is higher among nurses who work longer shifts, have been employed longer, report more physical demands at work, and report more psychosocial stressors at work.

cannot be determined until the case is referred to the appropriate authorities.

There have also been discussions in the past about the possibility of a new form of international law, which might be based on the principles of natural law, but this has not been the case. The only way to achieve this is by the creation of a new international law, which would be based on the principles of natural law.

There have also been discussions in the past about the possibility of a new form of international law, which might be based on the principles of natural law, but this has not been the case. The only way to achieve this is by the creation of a new international law, which would be based on the principles of natural law. This is a very difficult task, and it is not clear whether it is possible to achieve this goal.

The main reason for this is that the principles of natural law are not universally accepted, and it is not clear whether it is possible to achieve this goal.

There have also been discussions in the past about the possibility of a new form of international law, which might be based on the principles of natural law, but this has not been the case. The only way to achieve this is by the creation of a new international law, which would be based on the principles of natural law. This is a very difficult task, and it is not clear whether it is possible to achieve this goal. The main reason for this is that the principles of natural law are not universally accepted, and it is not clear whether it is possible to achieve this goal.

There have also been discussions in the past about the possibility of a new form of international law, which might be based on the principles of natural law, but this has not been the case. The only way to achieve this is by the creation of a new international law, which would be based on the principles of natural law. This is a very difficult task, and it is not clear whether it is possible to achieve this goal. The main reason for this is that the principles of natural law are not universally accepted, and it is not clear whether it is possible to achieve this goal.

The main reason for this is that the principles of natural law are not universally accepted, and it is not clear whether it is possible to achieve this goal.

There have also been discussions in the past about the possibility of a new form of international law, which might be based on the principles of natural law, but this has not been the case. The only way to achieve this is by the creation of a new international law, which would be based on the principles of natural law. This is a very difficult task, and it is not clear whether it is possible to achieve this goal.

There have also been discussions in the past about the possibility of a new form of international law, which might be based on the principles of natural law, but this has not been the case. The only way to achieve this is by the creation of a new international law, which would be based on the principles of natural law.

The main reason for this is that the principles of natural law are not universally accepted, and it is not clear whether it is possible to achieve this goal.

TABLE I

Comparison of the results of the two experiments

| Experiment   | Number of subjects | Mean score | Standard deviation | Significance level |
|--------------|--------------------|------------|--------------------|--------------------|
| Experiment 1 | 10                 | 1.5        | 0.5                | 0.05               |
| Experiment 2 | 10                 | 1.5        | 0.5                | 0.05               |
| Experiment 3 | 10                 | 1.5        | 0.5                | 0.05               |
| Experiment 4 | 10                 | 1.5        | 0.5                | 0.05               |
| Experiment 5 | 10                 | 1.5        | 0.5                | 0.05               |

NOTE: The results of the two experiments are compared.

There have also been discussions in the past about the possibility of a new form of international law, which might be based on the principles of natural law, but this has not been the case. The only way to achieve this is by the creation of a new international law, which would be based on the principles of natural law. This is a very difficult task, and it is not clear whether it is possible to achieve this goal.

There have also been discussions in the past about the possibility of a new form of international law, which might be based on the principles of natural law, but this has not been the case. The only way to achieve this is by the creation of a new international law, which would be based on the principles of natural law.

The main reason for this is that the principles of natural law are not universally accepted, and it is not clear whether it is possible to achieve this goal.





1. The first step is to identify the problem. In this case, the problem is that the company is not meeting its sales targets.

| TABLE 1         |                 |
|-----------------|-----------------|
| SUMMARY OF DATA |                 |
| Year            | Number of cases |
| 1960            | 10              |
| 1961            | 15              |
| 1962            | 20              |
| 1963            | 25              |
| 1964            | 30              |
| 1965            | 35              |
| 1966            | 40              |
| 1967            | 45              |
| 1968            | 50              |
| 1969            | 55              |
| 1970            | 60              |
| 1971            | 65              |
| 1972            | 70              |
| 1973            | 75              |
| 1974            | 80              |
| 1975            | 85              |
| 1976            | 90              |
| 1977            | 95              |
| 1978            | 100             |
| 1979            | 105             |
| 1980            | 110             |
| 1981            | 115             |
| 1982            | 120             |
| 1983            | 125             |
| 1984            | 130             |
| 1985            | 135             |
| 1986            | 140             |
| 1987            | 145             |
| 1988            | 150             |
| 1989            | 155             |
| 1990            | 160             |
| 1991            | 165             |
| 1992            | 170             |
| 1993            | 175             |
| 1994            | 180             |
| 1995            | 185             |
| 1996            | 190             |
| 1997            | 195             |
| 1998            | 200             |
| 1999            | 205             |
| 2000            | 210             |
| 2001            | 215             |
| 2002            | 220             |
| 2003            | 225             |
| 2004            | 230             |
| 2005            | 235             |
| 2006            | 240             |
| 2007            | 245             |
| 2008            | 250             |
| 2009            | 255             |
| 2010            | 260             |
| 2011            | 265             |
| 2012            | 270             |
| 2013            | 275             |
| 2014            | 280             |
| 2015            | 285             |
| 2016            | 290             |
| 2017            | 295             |
| 2018            | 300             |
| 2019            | 305             |
| 2020            | 310             |
| 2021            | 315             |
| 2022            | 320             |
| 2023            | 325             |
| 2024            | 330             |
| 2025            | 335             |
| 2026            | 340             |
| 2027            | 345             |
| 2028            | 350             |
| 2029            | 355             |
| 2030            | 360             |
| 2031            | 365             |
| 2032            | 370             |
| 2033            | 375             |
| 2034            | 380             |
| 2035            | 385             |
| 2036            | 390             |
| 2037            | 395             |
| 2038            | 400             |
| 2039            | 405             |
| 2040            | 410             |
| 2041            | 415             |
| 2042            | 420             |
| 2043            | 425             |
| 2044            | 430             |
| 2045            | 435             |
| 2046            | 440             |
| 2047            | 445             |
| 2048            | 450             |
| 2049            | 455             |
| 2050            | 460             |
| 2051            | 465             |
| 2052            | 470             |
| 2053            | 475             |
| 2054            | 480             |
| 2055            | 485             |
| 2056            | 490             |
| 2057            | 495             |
| 2058            | 500             |
| 2059            | 505             |
| 2060            | 510             |
| 2061            | 515             |
| 2062            | 520             |
| 2063            | 525             |
| 2064            | 530             |
| 2065            | 535             |
| 2066            | 540             |
| 2067            | 545             |
| 2068            | 550             |
| 2069            | 555             |
| 2070            | 560             |
| 2071            | 565             |
| 2072            | 570             |
| 2073            | 575             |
| 2074            | 580             |
| 2075            | 585             |
| 2076            | 590             |
| 2077            | 595             |
| 2078            | 600             |
| 2079            | 605             |
| 2080            | 610             |
| 2081            | 615             |
| 2082            | 620             |
| 2083            | 625             |
| 2084            | 630             |
| 2085            | 635             |
| 2086            | 640             |
| 2087            | 645             |
| 2088            | 650             |
| 2089            | 655             |
| 2090            | 660             |
| 2091            | 665             |
| 2092            | 670             |
| 2093            | 675             |
| 2094            | 680             |
| 2095            | 685             |
| 2096            | 690             |
| 2097            | 695             |
| 2098            | 700             |
| 2099            | 705             |
| 2100            | 710             |

and Standard 200, published in 1992, states that "the primary purpose of the program is to provide the student with a broad-based education that will prepare him or her for a career in the field of education." The program is designed to provide the student with a broad-based education that will prepare him or her for a career in the field of education.

For the first time, the government has acknowledged that it has been unable to meet its obligations to the public. The report, published by the House of Commons, states that the government has failed to meet its obligations to the public in a number of key areas, including the environment, the economy, and the social services. The report also states that the government has failed to meet its obligations to the public in a number of key areas, including the environment, the economy, and the social services.

Another example may come from the private sector as well. The idea of the company as a social entity goes back to the 1930s, and it is embodied in the business case for employee stock ownership plans. The approach has been to encourage employees to become shareholders in the company, and to give them a voice in the company's affairs. This has been done in a variety of ways, including the creation of employee stock ownership plans (ESOPs) and the establishment of employee stock ownership trusts (ESOTs). The idea is that by giving employees a stake in the company, they will be more committed to the company's success and will work harder to improve the company's performance. This approach has been successful in many cases, and it is now being used by a growing number of companies.

## ו. תוצאות

**Abstract**

... and the ... ..

The main laboratory is at the University of Cambridge, UK, and the main office is at the University of Cambridge, UK. The laboratory is at the University of Cambridge, UK, and the main office is at the University of Cambridge, UK.

© 1999 by John Wiley & Sons, Inc. All rights reserved.  
Published by John Wiley & Sons, Inc., Hoboken, NJ 07030  
This publication is intended to provide accurate and authoritative information in regard to the subject matter covered. It is sold with the understanding that the publisher is not engaged in rendering legal, accounting, or other professional service. If legal advice or other expert assistance is required, the services of a competent professional person should be sought.

[illegible][illegible]

224

22. What is the purpose of the "Find" button?  
To find the next occurrence of the selected text.

The first of these is the *Journal of the American Medical Association*, which is the largest and most influential of the medical journals. It is published weekly and is read by a large number of physicians. The second is the *New England Journal of Medicine*, which is also a weekly publication and is highly respected. The third is the *Lancet*, which is a weekly publication and is also highly respected. The fourth is the *British Medical Journal*, which is a weekly publication and is also highly respected. The fifth is the *Annals of the New York Academy of Sciences*, which is a quarterly publication and is also highly respected. The sixth is the *Journal of the Royal Society of Medicine*, which is a quarterly publication and is also highly respected. The seventh is the *Journal of the Royal Society of Tropical Medicine and Hygiene*, which is a quarterly publication and is also highly respected. The eighth is the *Journal of the Royal Society of Hygiene*, which is a quarterly publication and is also highly respected. The ninth is the *Journal of the Royal Society of Medicine*, which is a quarterly publication and is also highly respected. The tenth is the *Journal of the Royal Society of Tropical Medicine and Hygiene*, which is a quarterly publication and is also highly respected.

The *Journal of the American Medical Association* (JAMA) has been a leading voice in the medical profession for over a century. It is a weekly journal that provides information on the latest medical research, clinical practice, and public health issues. The journal is published by the American Medical Association (AMA) and is available to its members and the general public. The journal is a key resource for medical professionals and the public alike.

— 46 —

**L.L.N. s'inscrive au C.C.T.W.**

the following information was obtained from the records of the county clerk's office: (1) the date of the marriage; (2) the names of the bride and groom; (3) the names of the witnesses; (4) the names of the officiating clergyman; (5) the names of the parents of the bride and groom; (6) the names of the bridesmaids; (7) the names of the groomsmen; (8) the names of the flower girls; (9) the names of the ring bearers; (10) the names of the ushers; (11) the names of the best man and maid of honor; (12) the names of the officiating clergyman; (13) the names of the witnesses; (14) the names of the bride and groom; (15) the date of the marriage.







W. Irwin

[illegible]

1. The  $\alpha$ -value  
2. The  $\beta$ -value  
3. The  $\gamma$ -value  
4. The  $\delta$ -value

The following are the names of the persons who have been appointed to the various positions in the Department of the Interior, for the term of four years, beginning on the 1st day of January, 1901, and ending on the 31st day of December, 1904:

Commissioner of the General Land Office, Fred W. Wadsworth.  
 Commissioner of the Bureau of Reclamation, James H. Smith.  
 Commissioner of the Bureau of Indian Affairs, Charles F. Smith.  
 Commissioner of the Bureau of Fish and Game, James H. Smith.  
 Commissioner of the Bureau of Geology and Mineral Resources, James H. Smith.  
 Commissioner of the Bureau of Land Management, James H. Smith.  
 Commissioner of the Bureau of Natural History, James H. Smith.  
 Commissioner of the Bureau of Plant Industry, James H. Smith.  
 Commissioner of the Bureau of Soil Conservation, James H. Smith.  
 Commissioner of the Bureau of Surveying and Mapping, James H. Smith.  
 Commissioner of the Bureau of Waterways and Harbors, James H. Smith.  
 Commissioner of the Bureau of Zoology, James H. Smith.

11. 77 - 78.  
12. 78 - 79.  
13. 79 - 80.  
14. 80 - 81.

1.  $\lim_{x \rightarrow 0} \frac{1}{x} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 2.  $\lim_{x \rightarrow 0} \frac{1}{x^2} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 3.  $\lim_{x \rightarrow 0} \frac{1}{x^3} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 4.  $\lim_{x \rightarrow 0} \frac{1}{x^4} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 5.  $\lim_{x \rightarrow 0} \frac{1}{x^5} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 6.  $\lim_{x \rightarrow 0} \frac{1}{x^6} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 7.  $\lim_{x \rightarrow 0} \frac{1}{x^7} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 8.  $\lim_{x \rightarrow 0} \frac{1}{x^8} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 9.  $\lim_{x \rightarrow 0} \frac{1}{x^9} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)  
 10.  $\lim_{x \rightarrow 0} \frac{1}{x^{10}} = \infty$  (The function grows without bound as  $x$  approaches 0 from either side.)









21.  $\frac{1}{2} \times \frac{2}{3} = \frac{1 \times 2}{2 \times 3} = \frac{2}{6} = \frac{1}{3}$

22.  $\frac{1}{2} \times \frac{1}{3} = \frac{1 \times 1}{2 \times 3} = \frac{1}{6}$

23.  $\frac{1}{2} \times \frac{3}{4} = \frac{1 \times 3}{2 \times 4} = \frac{3}{8}$

24.  $\frac{1}{2} \times \frac{5}{6} = \frac{1 \times 5}{2 \times 6} = \frac{5}{12}$

25.  $\frac{1}{2} \times \frac{7}{8} = \frac{1 \times 7}{2 \times 8} = \frac{7}{16}$

26.  $\frac{1}{2} \times \frac{9}{10} = \frac{1 \times 9}{2 \times 10} = \frac{9}{20}$

27.  $\frac{1}{2} \times \frac{11}{12} = \frac{1 \times 11}{2 \times 12} = \frac{11}{24}$

28.  $\frac{1}{2} \times \frac{13}{14} = \frac{1 \times 13}{2 \times 14} = \frac{13}{28}$

29.  $\frac{1}{2} \times \frac{15}{16} = \frac{1 \times 15}{2 \times 16} = \frac{15}{32}$

30.  $\frac{1}{2} \times \frac{17}{18} = \frac{1 \times 17}{2 \times 18} = \frac{17}{36}$

31.  $\frac{1}{2} \times \frac{19}{20} = \frac{1 \times 19}{2 \times 20} = \frac{19}{40}$

32.  $\frac{1}{2} \times \frac{21}{22} = \frac{1 \times 21}{2 \times 22} = \frac{21}{44}$

33.  $\frac{1}{2} \times \frac{23}{24} = \frac{1 \times 23}{2 \times 24} = \frac{23}{48}$

34.  $\frac{1}{2} \times \frac{25}{26} = \frac{1 \times 25}{2 \times 26} = \frac{25}{52}$

35.  $\frac{1}{2} \times \frac{27}{28} = \frac{1 \times 27}{2 \times 28} = \frac{27}{56}$

36.  $\frac{1}{2} \times \frac{29}{30} = \frac{1 \times 29}{2 \times 30} = \frac{29}{60}$

37.  $\frac{1}{2} \times \frac{31}{32} = \frac{1 \times 31}{2 \times 32} = \frac{31}{64}$

38.  $\frac{1}{2} \times \frac{33}{34} = \frac{1 \times 33}{2 \times 34} = \frac{33}{68}$

39.  $\frac{1}{2} \times \frac{35}{36} = \frac{1 \times 35}{2 \times 36} = \frac{35}{72}$

40.  $\frac{1}{2} \times \frac{37}{38} = \frac{1 \times 37}{2 \times 38} = \frac{37}{76}$

41.  $\frac{1}{2} \times \frac{39}{40} = \frac{1 \times 39}{2 \times 40} = \frac{39}{80}$

42.  $\frac{1}{2} \times \frac{41}{42} = \frac{1 \times 41}{2 \times 42} = \frac{41}{84}$

43.  $\frac{1}{2} \times \frac{43}{44} = \frac{1 \times 43}{2 \times 44} = \frac{43}{88}$

44.  $\frac{1}{2} \times \frac{45}{46} = \frac{1 \times 45}{2 \times 46} = \frac{45}{92}$

45.  $\frac{1}{2} \times \frac{47}{48} = \frac{1 \times 47}{2 \times 48} = \frac{47}{96}$

46.  $\frac{1}{2} \times \frac{49}{50} = \frac{1 \times 49}{2 \times 50} = \frac{49}{100}$

47.  $\frac{1}{2} \times \frac{51}{52} = \frac{1 \times 51}{2 \times 52} = \frac{51}{104}$

48.  $\frac{1}{2} \times \frac{53}{54} = \frac{1 \times 53}{2 \times 54} = \frac{53}{108}$

49.  $\frac{1}{2} \times \frac{55}{56} = \frac{1 \times 55}{2 \times 56} = \frac{55}{112}$

50.  $\frac{1}{2} \times \frac{57}{58} = \frac{1 \times 57}{2 \times 58} = \frac{57}{116}$

51.  $\frac{1}{2} \times \frac{59}{60} = \frac{1 \times 59}{2 \times 60} = \frac{59}{120}$

52.  $\frac{1}{2} \times \frac{61}{62} = \frac{1 \times 61}{2 \times 62} = \frac{61}{124}$

53.  $\frac{1}{2} \times \frac{63}{64} = \frac{1 \times 63}{2 \times 64} = \frac{63}{128}$

54.  $\frac{1}{2} \times \frac{65}{66} = \frac{1 \times 65}{2 \times 66} = \frac{65}{132}$

55.  $\frac{1}{2} \times \frac{67}{68} = \frac{1 \times 67}{2 \times 68} = \frac{67}{136}$







20

1. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table.

2. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table.

50

1. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table.

2. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table. The results of the first 10 years of the "Project" are given in the following table.

1511-1512-113



1994

U.S. United States Patent  
No. 4,196,871

Mr Richard May: 019 8232 244 Ext  
 c/o Box of Corners: York Y1 1013

[illegible]

DATE: 11/11/16 PAGE: 2

17. *Journal of Tropical Geography*, 1994, 51, 1-11.  
 18. *Journal of Tropical Geography*, 1994, 51, 1-11.  
 19. *Journal of Tropical Geography*, 1994, 51, 1-11.  
 20. *Journal of Tropical Geography*, 1994, 51, 1-11.

1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 2679, 26

[illegible][illegible]

DATE: 11/2/88

**افغانیزم پر نظر**

... the ...

18. **Intellectual Property Rights**

2003 4:21 3 100

### Model 1: $\beta_1 = 0$

10. Answered by: Dr. J. B. Smith, Jr.

1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 2679, 26

18. 451 . . . 4 12 . 14 . 37 .

[illegible]

9. **Business**

11/15 - 138149

[illegible]

Yachew, A. (1992). *Journal of the American Statistical Association*, 87(420), 830-839.  
 Yachew, A. (1993). *Journal of the American Statistical Association*, 88(422), 849-859.  
 Yachew, A. (1994). *Journal of the American Statistical Association*, 89(426), 869-879.  
 Yachew, A. (1995). *Journal of the American Statistical Association*, 90(432), 899-909.  
 Yachew, A. (1996). *Journal of the American Statistical Association*, 91(438), 919-929.  
 Yachew, A. (1997). *Journal of the American Statistical Association*, 92(444), 939-949.  
 Yachew, A. (1998). *Journal of the American Statistical Association*, 93(450), 959-969.  
 Yachew, A. (1999). *Journal of the American Statistical Association*, 94(456), 979-989.  
 Yachew, A. (2000). *Journal of the American Statistical Association*, 95(462), 999-1009.  
 Yachew, A. (2001). *Journal of the American Statistical Association*, 96(468), 1019-1029.  
 Yachew, A. (2002). *Journal of the American Statistical Association*, 97(474), 1039-1049.  
 Yachew, A. (2003). *Journal of the American Statistical Association*, 98(480), 1059-1069.  
 Yachew, A. (2004). *Journal of the American Statistical Association*, 99(486), 1079-1089.  
 Yachew, A. (2005). *Journal of the American Statistical Association*, 100(492), 1099-1109.  
 Yachew, A. (2006). *Journal of the American Statistical Association*, 101(498), 1119-1129.  
 Yachew, A. (2007). *Journal of the American Statistical Association*, 102(504), 1139-1149.  
 Yachew, A. (2008). *Journal of the American Statistical Association*, 103(510), 1159-1169.  
 Yachew, A. (2009). *Journal of the American Statistical Association*, 104(516), 1179-1189.  
 Yachew, A. (2010). *Journal of the American Statistical Association*, 105(522), 1199-1209.  
 Yachew, A. (2011). *Journal of the American Statistical Association*, 106(528), 1219-1229.  
 Yachew, A. (2012). *Journal of the American Statistical Association*, 107(534), 1239-1249.  
 Yachew, A. (2013). *Journal of the American Statistical Association*, 108(540), 1259-1269.  
 Yachew, A. (2014). *Journal of the American Statistical Association*, 109(546), 1279-1289.  
 Yachew, A. (2015). *Journal of the American Statistical Association*, 110(552), 1299-1309.  
 Yachew, A. (2016). *Journal of the American Statistical Association*, 111(558), 1319-1329.  
 Yachew, A. (2017). *Journal of the American Statistical Association*, 112(564), 1339-1349.  
 Yachew, A. (2018). *Journal of the American Statistical Association*, 113(570), 1359-1369.  
 Yachew, A. (2019). *Journal of the American Statistical Association*, 114(576), 1379-1389.  
 Yachew, A. (2020). *Journal of the American Statistical Association*, 115(582), 1399-1409.  
 Yachew, A. (2021). *Journal of the American Statistical Association*, 116(588), 1419-1429.  
 Yachew, A. (2022). *Journal of the American Statistical Association*, 117(594), 1439-1449.  
 Yachew, A. (2023). *Journal of the American Statistical Association*, 118(600), 1459-1469.  
 Yachew, A. (2024). *Journal of the American Statistical Association*, 119(606), 1479-1489.  
 Yachew, A. (2025). *Journal of the American Statistical Association*, 120(612), 1499-1509.

**1. 2. 3.**

2000年12月15日

1. Theorem 4.1. Let  $\mathcal{H}$  be a Hilbert space and  $\mathcal{A}$  a  $C^*$ -algebra. Let  $\mathcal{B}$  be a  $C^*$ -algebra and  $\mathcal{C}$  a  $C^*$ -algebra. Let  $\mathcal{D}$  be a  $C^*$ -algebra and  $\mathcal{E}$  a  $C^*$ -algebra. Let  $\mathcal{F}$  be a  $C^*$ -algebra and  $\mathcal{G}$  a  $C^*$ -algebra. Let  $\mathcal{H}$  be a Hilbert space and  $\mathcal{A}$  a  $C^*$ -algebra. Let  $\mathcal{B}$  be a  $C^*$ -algebra and  $\mathcal{C}$  a  $C^*$ -algebra. Let  $\mathcal{D}$  be a  $C^*$ -algebra and  $\mathcal{E}$  a  $C^*$ -algebra. Let  $\mathcal{F}$  be a  $C^*$ -algebra and  $\mathcal{G}$  a  $C^*$ -algebra.


11-44 EST

[illegible]

**2014-15 Budget Request**



Figure 1A  
Comparison of glands with or without lesions in an enlarged picture





Lesions



No Lesions

FIG. 18  
OVER PRODUCTION













FIGURE 8  
DATA + PDR (X/100%)











Figure 2

Figure 3  
Examples of DMBA-induced mammary ductal lesions






Figure 4




FIG. 5







FIG. 7A

FIG. 7B

FIG. 7C

FIG. 8A




FIG. 8B





FIG. 8C






FIG. 9















Summary

1. The first part of the document is a list of the names of the authors of the document.

2. The second part of the document is a list of the names of the authors of the document.

3. The third part of the document is a list of the names of the authors of the document.

4. The fourth part of the document is a list of the names of the authors of the document.

5. The fifth part of the document is a list of the names of the authors of the document.

6. The sixth part of the document is a list of the names of the authors of the document.

7. The seventh part of the document is a list of the names of the authors of the document.

8. The eighth part of the document is a list of the names of the authors of the document.

9. The ninth part of the document is a list of the names of the authors of the document.

10. The tenth part of the document is a list of the names of the authors of the document.

11. The eleventh part of the document is a list of the names of the authors of the document.

12. The twelfth part of the document is a list of the names of the authors of the document.

13. The thirteenth part of the document is a list of the names of the authors of the document.

14. The fourteenth part of the document is a list of the names of the authors of the document.

15. The fifteenth part of the document is a list of the names of the authors of the document.

16. The sixteenth part of the document is a list of the names of the authors of the document.

17. The seventeenth part of the document is a list of the names of the authors of the document.

18. The eighteenth part of the document is a list of the names of the authors of the document.

19. The nineteenth part of the document is a list of the names of the authors of the document.

20. The twentieth part of the document is a list of the names of the authors of the document.

21. The twenty-first part of the document is a list of the names of the authors of the document.

22. The twenty-second part of the document is a list of the names of the authors of the document.

23. The twenty-third part of the document is a list of the names of the authors of the document.

24. The twenty-fourth part of the document is a list of the names of the authors of the document.

25. The twenty-fifth part of the document is a list of the names of the authors of the document.

ACKNOWLEDGMENTS

The authors wish to express their appreciation to the following individuals for their assistance in the preparation of this document: [List of names]

The authors also wish to express their appreciation to the following organizations for their assistance in the preparation of this document: [List of organizations]

The authors also wish to express their appreciation to the following organizations for their assistance in the preparation of this document: [List of organizations]

The authors also wish to express their appreciation to the following organizations for their assistance in the preparation of this document: [List of organizations]

The first part of the document is a list of the names of the authors of the document.

The second part of the document is a list of the names of the authors of the document.

The third part of the document is a list of the names of the authors of the document.

The fourth part of the document is a list of the names of the authors of the document.

The fifth part of the document is a list of the names of the authors of the document.

REFERENCES

1. [Reference 1]

[Reference 1] [Author's name], [Title of the reference], [Publisher], [Year].

[Reference 2] [Author's name], [Title of the reference], [Publisher], [Year].















Johnston and Johnston also designed a series of tests to determine the effect of the 1974 amendments on the 1972 amendments. The results of these tests are presented in Table 1.

**א. דניאל**

[illegible]

Various laws support the same view and a number of administrative officers have been appointed to enforce the law. The law is not enforced because the officers are not paid. The law is not enforced because the officers are not paid. The law is not enforced because the officers are not paid.

[illegible]

1. The following is a list of the names of the persons who are members of the Board of Directors of the Corporation, as of the date of the filing of this report:

1. *Journal of the American Medical Association*, 1997; 277: 103-107.  
 2. *Journal of the American Medical Association*, 1997; 277: 108-112.  
 3. *Journal of the American Medical Association*, 1997; 277: 113-117.

[illegible]

1. The first step is to identify the problem. This involves understanding the symptoms and the context in which they are occurring.

gives an idea of the data space. In this space, the data points are clustered into groups, and the groups are labeled with the class names. The labels are then used to train the model.

1. *Journal of the American Academy of Child and Adolescent Psychiatry*, 1996, 35, 10, 1133-1141.

2:45

2. *Develop a research methodology, including an analysis of the data and the results of the study.* The methodology should include a description of the data sources, the data collection methods, and the data analysis methods. The results of the study should be presented in a clear and concise manner, and the methodology should be evaluated in terms of its strengths and weaknesses.

[illegible]













The authors are grateful to the National Science Foundation for its generous support of this research under Grant DMS-90-06789. The authors also thank the anonymous referees for their helpful comments.

Received by the editors June 1, 1993; revised manuscript received November 1, 1993.

[illegible]

1. Some types of child separation may be more salient to the child, depending on the child's separation experiences, especially if those children are raised in families where a child's attachment to the mother is particularly pronounced.

the government. It is more difficult to get out of the country, and any information that you are sending may be used by the government to help people who are looking for a job. The government is not going to help you if you are not a citizen. The government is not going to help you if you are not a citizen. The government is not going to help you if you are not a citizen.

It is important to note that the above information is not intended to be used as a basis for making any investment decision. The information is provided for informational purposes only and should not be relied upon as a basis for making any investment decision. The information is provided for informational purposes only and should not be relied upon as a basis for making any investment decision.

There is an apparent gap between the current level of government and local authority involvement and the need for the involvement of the local authority and other community groups in the development of any new development. The current level of involvement is low, and the need for involvement is high. The current level of involvement is low, and the need for involvement is high. The current level of involvement is low, and the need for involvement is high.

10. The following information was obtained from the records of the Department of Social Services, New York City, for the period from January 1, 1960, to December 31, 1960:

I have never been disappointed in you and I  
 am sure that you will never be disappointed in me.  
 I am sure that you will never be disappointed in me.  
 I am sure that you will never be disappointed in me.

[illegible]

The first of these is the fact that the
 majority of the population of the
 United States is of European
 descent. This is a fact which
 has been recognized by the
 government for many years.
 The second of these is the fact
 that the majority of the
 population of the United States
 is of European descent. This
 is a fact which has been
 recognized by the government
 for many years. The third of
 these is the fact that the
 majority of the population of
 the United States is of
 European descent. This is a
 fact which has been
 recognized by the government
 for many years.

the fact that the United States is a free country and that the people of the United States are free to express their views on the subject of the Vietnam War. The United States is a free country and the people of the United States are free to express their views on the subject of the Vietnam War.

The authors gratefully acknowledge the financial support of the National Science Foundation under Grant Number DMR-90-16789.

[illegible]

Based on the above discussion, in February 1992, there were 100,000 adult male and female monarchs in the study area. The following year, however, the total population was estimated to be 150,000, with 100,000 males and 50,000 females. The population of males was estimated to be 100,000 in 1993, and 150,000 in 1994. The population of females was estimated to be 50,000 in 1993, and 100,000 in 1994. The population of males was estimated to be 100,000 in 1995, and 150,000 in 1996. The population of females was estimated to be 50,000 in 1995, and 100,000 in 1996. The population of males was estimated to be 100,000 in 1997, and 150,000 in 1998. The population of females was estimated to be 50,000 in 1997, and 100,000 in 1998. The population of males was estimated to be 100,000 in 1999, and 150,000 in 2000. The population of females was estimated to be 50,000 in 1999, and 100,000 in 2000. The population of males was estimated to be 100,000 in 2001, and 150,000 in 2002. The population of females was estimated to be 50,000 in 2001, and 100,000 in 2002. The population of males was estimated to be 100,000 in 2003, and 150,000 in 2004. The population of females was estimated to be 50,000 in 2003, and 100,000 in 2004. The population of males was estimated to be 100,000 in 2005, and 150,000 in 2006. The population of females was estimated to be 50,000 in 2005, and 100,000 in 2006. The population of males was estimated to be 100,000 in 2007, and 150,000 in 2008. The population of females was estimated to be 50,000 in 2007, and 100,000 in 2008. The population of males was estimated to be 100,000 in 2009, and 150,000 in 2010. The population of females was estimated to be 50,000 in 2009, and 100,000 in 2010. The population of males was estimated to be 100,000 in 2011, and 150,000 in 2012. The population of females was estimated to be 50,000 in 2011, and 100,000 in 2012. The population of males was estimated to be 100,000 in 2013, and 150,000 in 2014. The population of females was estimated to be 50,000 in 2013, and 100,000 in 2014. The population of males was estimated to be 100,000 in 2015, and 150,000 in 2016. The population of females was estimated to be 50,000 in 2015, and 100,000 in 2016. The population of males was estimated to be 100,000 in 2017, and 150,000 in 2018. The population of females was estimated to be 50,000 in 2017, and 100,000 in 2018. The population of males was estimated to be 100,000 in 2019, and 150,000 in 2020. The population of females was estimated to be 50,000 in 2019, and 100,000 in 2020.

[illegible][illegible]

The author has a wide knowledge of the subject, and has written a very readable book. The presentation is clear and concise, and the book is well organized. The book is a good reference for anyone interested in the subject. The book is a good reference for anyone interested in the subject. The book is a good reference for anyone interested in the subject.

There are two main types of journals: the *diary* and the *journal*. The *diary* is a record of daily events, often written in a personal, subjective style. The *journal* is a record of events, often written in a more objective, factual style. Both types of journals can be used for a variety of purposes, including: keeping a record of daily events, reflecting on experiences, and documenting research.

[illegible]





[illegible][illegible][illegible][illegible]

management and growth with a focus on the growth opportunities within the market and the value and financial performance of the company. The company's strategy is to focus on the growth opportunities within the market and the value and financial performance of the company.

[illegible][illegible][illegible]

My mother has been in and out of psychiatric hospitals and has been told that she is schizophrenic. I don't know if she is or not, but I know she is very sick. I have been in and out of psychiatric hospitals myself, and I know how it feels. I have been told that I am schizophrenic, but I don't know if I am or not. I have been told that I am a danger to myself and others, but I don't know if I am or not. I have been told that I need to be in a hospital, but I don't know if I do or not. I have been told that I need to take medicine, but I don't know if I do or not. I have been told that I need to see a doctor, but I don't know if I do or not. I have been told that I need to go to therapy, but I don't know if I do or not. I have been told that I need to be in a hospital, but I don't know if I do or not. I have been told that I need to take medicine, but I don't know if I do or not. I have been told that I need to see a doctor, but I don't know if I do or not. I have been told that I need to go to therapy, but I don't know if I do or not.

Eighty square miles of land, given in whole or in part to the agricultural and commercial activities of the state, have been set aside for the use of the state and its people. The land is being used for a variety of purposes, including the production of food, the raising of livestock, and the production of timber. The land is also being used for the production of energy, and for the production of other goods and services. The land is being used in a variety of ways, and the state is working to ensure that the land is used in a way that is sustainable and that the land is protected for the future.





[illegible][illegible]

There has been a long history of concern about the ability of the U.S. economy to maintain a high level of employment. The U.S. economy has a long history of being able to absorb a large number of new entrants into the labor force. The U.S. economy has a long history of being able to absorb a large number of new entrants into the labor force.

DATE: \_\_\_\_\_  
 TIME: \_\_\_\_\_

[illegible]

1. What is the purpose of the study?

[illegible]

After the initial 100,000 copies, the book was reprinted several times. The second edition, published in 1964, was a revised and expanded version of the first, incorporating new research and data. The third edition, published in 1971, was a major revision, reflecting the latest research and the growing importance of the field. The book has been translated into several languages, including French, German, and Spanish, and has been widely cited in the literature. It remains a key reference work for students and researchers alike.

When the author is talking about the "new" social movements, he is not referring to the "new" social movements that emerged in the 1960s and 1970s, but rather to the "new" social movements that emerged in the 1980s and 1990s. The author is referring to the "new" social movements that emerged in the 1980s and 1990s, which are characterized by their focus on social justice, environmentalism, and human rights. These movements are often seen as a continuation of the social movements of the 1960s and 1970s, but they are also seen as a new wave of social movements that emerged in response to the challenges of the late 20th century.

The researchers also concluded that the  
study's authors could not be certain of the  
study's results, and that the researchers had

The following information is being provided for your information only. It is not intended to be used as a basis for any action. It is not intended to be used as a basis for any action. It is not intended to be used as a basis for any action.

1. The number of people who are employed in the  
2. The number of people who are employed in the  
3. The number of people who are employed in the  
4. The number of people who are employed in the  
5. The number of people who are employed in the  
6. The number of people who are employed in the  
7. The number of people who are employed in the  
8. The number of people who are employed in the  
9. The number of people who are employed in the  
10. The number of people who are employed in the

[illegible]

It is an ideal for our part in the world and a challenge to the world. It is a challenge to the world to be a better place, a better world, a better place for all of us. It is a challenge to the world to be a better place, a better world, a better place for all of us. It is a challenge to the world to be a better place, a better world, a better place for all of us.

The expression of the unimodal or bimodal response in number of cells in the proliferative phase of the population is accompanied by an increase in the number of cells in the G<sub>0</sub> phase of the cell cycle, with a consequent reduction in the number of cells in the G<sub>1</sub> phase of the cell cycle.





the following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998.

The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998.

The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998.

The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998.

Table 1

Table 1

| Year | Value | Value |
|------|-------|-------|
| 1997 | 1.0   | 1.0   |
| 1998 | 1.0   | 1.0   |
| 1999 | 1.0   | 1.0   |
| 2000 | 1.0   | 1.0   |
| 2001 | 1.0   | 1.0   |
| 2002 | 1.0   | 1.0   |
| 2003 | 1.0   | 1.0   |
| 2004 | 1.0   | 1.0   |
| 2005 | 1.0   | 1.0   |
| 2006 | 1.0   | 1.0   |
| 2007 | 1.0   | 1.0   |
| 2008 | 1.0   | 1.0   |
| 2009 | 1.0   | 1.0   |
| 2010 | 1.0   | 1.0   |
| 2011 | 1.0   | 1.0   |
| 2012 | 1.0   | 1.0   |
| 2013 | 1.0   | 1.0   |
| 2014 | 1.0   | 1.0   |
| 2015 | 1.0   | 1.0   |
| 2016 | 1.0   | 1.0   |
| 2017 | 1.0   | 1.0   |
| 2018 | 1.0   | 1.0   |
| 2019 | 1.0   | 1.0   |
| 2020 | 1.0   | 1.0   |
| 2021 | 1.0   | 1.0   |
| 2022 | 1.0   | 1.0   |
| 2023 | 1.0   | 1.0   |
| 2024 | 1.0   | 1.0   |
| 2025 | 1.0   | 1.0   |
| 2026 | 1.0   | 1.0   |
| 2027 | 1.0   | 1.0   |
| 2028 | 1.0   | 1.0   |
| 2029 | 1.0   | 1.0   |
| 2030 | 1.0   | 1.0   |
| 2031 | 1.0   | 1.0   |
| 2032 | 1.0   | 1.0   |
| 2033 | 1.0   | 1.0   |
| 2034 | 1.0   | 1.0   |
| 2035 | 1.0   | 1.0   |
| 2036 | 1.0   | 1.0   |
| 2037 | 1.0   | 1.0   |
| 2038 | 1.0   | 1.0   |
| 2039 | 1.0   | 1.0   |
| 2040 | 1.0   | 1.0   |
| 2041 | 1.0   | 1.0   |
| 2042 | 1.0   | 1.0   |
| 2043 | 1.0   | 1.0   |
| 2044 | 1.0   | 1.0   |
| 2045 | 1.0   | 1.0   |
| 2046 | 1.0   | 1.0   |
| 2047 | 1.0   | 1.0   |
| 2048 | 1.0   | 1.0   |
| 2049 | 1.0   | 1.0   |
| 2050 | 1.0   | 1.0   |
| 2051 | 1.0   | 1.0   |
| 2052 | 1.0   | 1.0   |
| 2053 | 1.0   | 1.0   |
| 2054 | 1.0   | 1.0   |
| 2055 | 1.0   | 1.0   |
| 2056 | 1.0   | 1.0   |
| 2057 | 1.0   | 1.0   |
| 2058 | 1.0   | 1.0   |
| 2059 | 1.0   | 1.0   |
| 2060 | 1.0   | 1.0   |
| 2061 | 1.0   | 1.0   |
| 2062 | 1.0   | 1.0   |
| 2063 | 1.0   | 1.0   |
| 2064 | 1.0   | 1.0   |
| 2065 | 1.0   | 1.0   |
| 2066 | 1.0   | 1.0   |
| 2067 | 1.0   | 1.0   |
| 2068 | 1.0   | 1.0   |
| 2069 | 1.0   | 1.0   |
| 2070 | 1.0   | 1.0   |
| 2071 | 1.0   | 1.0   |
| 2072 | 1.0   | 1.0   |
| 2073 | 1.0   | 1.0   |
| 2074 | 1.0   | 1.0   |
| 2075 | 1.0   | 1.0   |
| 2076 | 1.0   | 1.0   |
| 2077 | 1.0   | 1.0   |
| 2078 | 1.0   | 1.0   |
| 2079 | 1.0   | 1.0   |
| 2080 | 1.0   | 1.0   |
| 2081 | 1.0   | 1.0   |
| 2082 | 1.0   | 1.0   |
| 2083 | 1.0   | 1.0   |
| 2084 | 1.0   | 1.0   |
| 2085 | 1.0   | 1.0   |
| 2086 | 1.0   | 1.0   |
| 2087 | 1.0   | 1.0   |
| 2088 | 1.0   | 1.0   |
| 2089 | 1.0   | 1.0   |
| 2090 | 1.0   | 1.0   |
| 2091 | 1.0   | 1.0   |
| 2092 | 1.0   | 1.0   |
| 2093 | 1.0   | 1.0   |
| 2094 | 1.0   | 1.0   |
| 2095 | 1.0   | 1.0   |
| 2096 | 1.0   | 1.0   |
| 2097 | 1.0   | 1.0   |
| 2098 | 1.0   | 1.0   |
| 2099 | 1.0   | 1.0   |
| 2100 | 1.0   | 1.0   |

The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998.

Table 2

Table 2

| Year | Value |
|------|-------|
| 1997 | 1.0   |
| 1998 | 1.0   |
| 1999 | 1.0   |
| 2000 | 1.0   |
| 2001 | 1.0   |
| 2002 | 1.0   |
| 2003 | 1.0   |
| 2004 | 1.0   |
| 2005 | 1.0   |
| 2006 | 1.0   |
| 2007 | 1.0   |
| 2008 | 1.0   |
| 2009 | 1.0   |
| 2010 | 1.0   |
| 2011 | 1.0   |
| 2012 | 1.0   |
| 2013 | 1.0   |
| 2014 | 1.0   |
| 2015 | 1.0   |
| 2016 | 1.0   |
| 2017 | 1.0   |
| 2018 | 1.0   |
| 2019 | 1.0   |
| 2020 | 1.0   |
| 2021 | 1.0   |
| 2022 | 1.0   |
| 2023 | 1.0   |
| 2024 | 1.0   |
| 2025 | 1.0   |
| 2026 | 1.0   |
| 2027 | 1.0   |
| 2028 | 1.0   |
| 2029 | 1.0   |
| 2030 | 1.0   |
| 2031 | 1.0   |
| 2032 | 1.0   |
| 2033 | 1.0   |
| 2034 | 1.0   |
| 2035 | 1.0   |
| 2036 | 1.0   |
| 2037 | 1.0   |
| 2038 | 1.0   |
| 2039 | 1.0   |
| 2040 | 1.0   |
| 2041 | 1.0   |
| 2042 | 1.0   |
| 2043 | 1.0   |
| 2044 | 1.0   |
| 2045 | 1.0   |
| 2046 | 1.0   |
| 2047 | 1.0   |
| 2048 | 1.0   |
| 2049 | 1.0   |
| 2050 | 1.0   |
| 2051 | 1.0   |
| 2052 | 1.0   |
| 2053 | 1.0   |
| 2054 | 1.0   |
| 2055 | 1.0   |
| 2056 | 1.0   |
| 2057 | 1.0   |
| 2058 | 1.0   |
| 2059 | 1.0   |
| 2060 | 1.0   |
| 2061 | 1.0   |
| 2062 | 1.0   |
| 2063 | 1.0   |
| 2064 | 1.0   |
| 2065 | 1.0   |
| 2066 | 1.0   |
| 2067 | 1.0   |
| 2068 | 1.0   |
| 2069 | 1.0   |
| 2070 | 1.0   |
| 2071 | 1.0   |
| 2072 | 1.0   |
| 2073 | 1.0   |
| 2074 | 1.0   |
| 2075 | 1.0   |
| 2076 | 1.0   |
| 2077 | 1.0   |
| 2078 | 1.0   |
| 2079 | 1.0   |
| 2080 | 1.0   |
| 2081 | 1.0   |
| 2082 | 1.0   |
| 2083 | 1.0   |
| 2084 | 1.0   |
| 2085 | 1.0   |
| 2086 | 1.0   |
| 2087 | 1.0   |
| 2088 | 1.0   |
| 2089 | 1.0   |
| 2090 | 1.0   |
| 2091 | 1.0   |
| 2092 | 1.0   |
| 2093 | 1.0   |
| 2094 | 1.0   |
| 2095 | 1.0   |
| 2096 | 1.0   |
| 2097 | 1.0   |
| 2098 | 1.0   |
| 2099 | 1.0   |
| 2100 | 1.0   |

The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998.

The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998.

The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998.

Table 3

Table 3

The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998.

The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998. The following information is provided for the year 1997-1998.





1. The first step is to identify the problem. In this case, the problem is that the system is not working properly.

The first document, dated 1970, is a letter from the
 author to the editor of the journal, in which he
 expresses his interest in the study of the
 relationship between the two variables.

4. 4. 4.

The above information is being furnished to you for your information only. It is not intended to constitute an offer of insurance or any other financial product. Please consult your insurance broker or financial advisor for more information.

The following information is provided for the information of the general public and is not intended to constitute an offer of insurance. For more information, please contact your insurance broker or the Insurance Department of the State of New York at (516) 485-2000. The following information is provided for the information of the general public and is not intended to constitute an offer of insurance. For more information, please contact your insurance broker or the Insurance Department of the State of New York at (516) 485-2000.

The above information is provided for your information only. It is not intended to constitute an offer of insurance or any other financial product. The information is provided for your information only and is not intended to constitute an offer of insurance or any other financial product. The information is provided for your information only and is not intended to constitute an offer of insurance or any other financial product.

41 44

## Introduction

Information regarding these guidelines for authors is available at <http://www.sagepub.com/journalsPermissions.nav>. For more information on this journal, please visit the journal web site at <http://jms.sagepub.com>. Manuscripts should be sent to the editorial office at [jms@mc.manuscriptcentral.com](mailto:jms@mc.manuscriptcentral.com). Please refer to the journal website for more information on the journal's editorial board and the journal's editorial process.

[illegible]

The following is a list of the names of the persons who have been appointed to the various committees of the Board of Directors of the American Telephone and Telegraph Company, for the year ending December 31, 1910. The names of the persons who have been appointed to the various committees of the Board of Directors of the American Telephone and Telegraph Company, for the year ending December 31, 1910, are as follows:

1. The first step is to identify the problem. In this case, the problem is that the user is unable to access the internet.

[illegible]

—

**1. Introduction**

2011年12月24日星期五 14:45  
 2011年12月24日星期五 14:45











20

21

number

1. The first two numbers are 11 and 12. The third number is 13. The fourth number is 14. The fifth number is 15. The sixth number is 16. The seventh number is 17. The eighth number is 18. The ninth number is 19. The tenth number is 20.

2. The first two numbers are 21 and 22. The third number is 23. The fourth number is 24. The fifth number is 25. The sixth number is 26. The seventh number is 27. The eighth number is 28. The ninth number is 29. The tenth number is 30.

3. The first two numbers are 31 and 32. The third number is 33. The fourth number is 34. The fifth number is 35. The sixth number is 36. The seventh number is 37. The eighth number is 38. The ninth number is 39. The tenth number is 40.

4. The first two numbers are 41 and 42. The third number is 43. The fourth number is 44. The fifth number is 45. The sixth number is 46. The seventh number is 47. The eighth number is 48. The ninth number is 49. The tenth number is 50.

5. The first two numbers are 51 and 52.

6. The first two numbers are 53 and 54.

7. The first two numbers are 55 and 56.

8. The first two numbers are 57 and 58. The third number is 59. The fourth number is 60.

9. The first two numbers are 61 and 62.

10. The first two numbers are 63 and 64. The third number is 65. The fourth number is 66. The fifth number is 67. The sixth number is 68. The seventh number is 69. The eighth number is 70.

11. The first two numbers are 71 and 72. The third number is 73. The fourth number is 74. The fifth number is 75. The sixth number is 76. The seventh number is 77. The eighth number is 78. The ninth number is 79. The tenth number is 80.

12. The first two numbers are 81 and 82. The third number is 83. The fourth number is 84. The fifth number is 85. The sixth number is 86. The seventh number is 87. The eighth number is 88. The ninth number is 89. The tenth number is 90.

13. The first two numbers are 91 and 92. The third number is 93. The fourth number is 94. The fifth number is 95. The sixth number is 96. The seventh number is 97. The eighth number is 98. The ninth number is 99. The tenth number is 100.

14. The first two numbers are 101 and 102. The third number is 103. The fourth number is 104. The fifth number is 105. The sixth number is 106. The seventh number is 107. The eighth number is 108. The ninth number is 109. The tenth number is 110.

15. The first two numbers are 111 and 112. The third number is 113. The fourth number is 114. The fifth number is 115. The sixth number is 116. The seventh number is 117. The eighth number is 118. The ninth number is 119. The tenth number is 120.

16. The first two numbers are 121 and 122. The third number is 123. The fourth number is 124. The fifth number is 125. The sixth number is 126. The seventh number is 127. The eighth number is 128. The ninth number is 129. The tenth number is 130.

17. The first two numbers are 131 and 132. The third number is 133. The fourth number is 134. The fifth number is 135. The sixth number is 136. The seventh number is 137. The eighth number is 138. The ninth number is 139. The tenth number is 140.

18. The first two numbers are 141 and 142.

19. The first two numbers are 143 and 144.

20. The first two numbers are 145 and 146.

21. The first two numbers are 147 and 148. The third number is 149. The fourth number is 150.

22. The first two numbers are 151 and 152.

23. The first two numbers are 153 and 154.

24. The first two numbers are 155 and 156. The third number is 157. The fourth number is 158. The fifth number is 159. The sixth number is 160.

25. The first two numbers are 161 and 162. The third number is 163. The fourth number is 164. The fifth number is 165. The sixth number is 166. The seventh number is 167. The eighth number is 168. The ninth number is 169. The tenth number is 170.

26. The first two numbers are 171 and 172. The third number is 173. The fourth number is 174. The fifth number is 175. The sixth number is 176. The seventh number is 177. The eighth number is 178. The ninth number is 179. The tenth number is 180.

27. The first two numbers are 181 and 182. The third number is 183. The fourth number is 184. The fifth number is 185. The sixth number is 186. The seventh number is 187. The eighth number is 188. The ninth number is 189. The tenth number is 190.

28. The first two numbers are 191 and 192. The third number is 193. The fourth number is 194. The fifth number is 195. The sixth number is 196. The seventh number is 197. The eighth number is 198. The ninth number is 199. The tenth number is 200.

29. The first two numbers are 201 and 202. The third number is 203. The fourth number is 204. The fifth number is 205. The sixth number is 206. The seventh number is 207. The eighth number is 208. The ninth number is 209. The tenth number is 210.

30. The first two numbers are 211 and 212. The third number is 213. The fourth number is 214. The fifth number is 215. The sixth number is 216. The seventh number is 217. The eighth number is 218. The ninth number is 219. The tenth number is 220.

31. The first two numbers are 221 and 222. The third number is 223. The fourth number is 224. The fifth number is 225. The sixth number is 226. The seventh number is 227. The eighth number is 228. The ninth number is 229. The tenth number is 230.

32. The first two numbers are 231 and 232.

33. The first two numbers are 233 and 234.

34. The first two numbers are 235 and 236.

35. The first two numbers are 237 and 238. The third number is 239. The fourth number is 240.

36. The first two numbers are 241 and 242.

37. The first two numbers are 243 and 244.

38. The first two numbers are 245 and 246.

39. The first two numbers are 247 and 248. The third number is 249. The fourth number is 250.













100. The sum of the first 10 terms of the series is

- (A) 100
- (B) 1000
- (C) 10000
- (D) 100000
- (E) 1000000

101. The sum of the first 10 terms of the series is

102. The sum of the first 10 terms of the series is

- (A) 100
- (B) 1000
- (C) 10000
- (D) 100000
- (E) 1000000

103. The sum of the first 10 terms of the series is

104. The sum of the first 10 terms of the series is

105. The sum of the first 10 terms of the series is

- (A) 100
- (B) 1000
- (C) 10000
- (D) 100000
- (E) 1000000

106. The sum of the first 10 terms of the series is

107. The sum of the first 10 terms of the series is

108. The sum of the first 10 terms of the series is

109. The sum of the first 10 terms of the series is

110. The sum of the first 10 terms of the series is

111. The sum of the first 10 terms of the series is

112. The sum of the first 10 terms of the series is

113. The sum of the first 10 terms of the series is

114. The sum of the first 10 terms of the series is

115. The sum of the first 10 terms of the series is

116. The sum of the first 10 terms of the series is

117. The sum of the first 10 terms of the series is

118. The sum of the first 10 terms of the series is

119. The sum of the first 10 terms of the series is

120. The sum of the first 10 terms of the series is

121. The sum of the first 10 terms of the series is

122. The sum of the first 10 terms of the series is

123. The sum of the first 10 terms of the series is

124. The sum of the first 10 terms of the series is

125. The sum of the first 10 terms of the series is

126. The sum of the first 10 terms of the series is

127. The sum of the first 10 terms of the series is

128. The sum of the first 10 terms of the series is

129. The sum of the first 10 terms of the series is

130. The sum of the first 10 terms of the series is

131. The sum of the first 10 terms of the series is

132. The sum of the first 10 terms of the series is

133. The sum of the first 10 terms of the series is

134. The sum of the first 10 terms of the series is

135. The sum of the first 10 terms of the series is

136. The sum of the first 10 terms of the series is

137. The sum of the first 10 terms of the series is

138. The sum of the first 10 terms of the series is

139. The sum of the first 10 terms of the series is







15,831,749

United States Patent  
Davidson et al.

Patent No. 15,831,749 B2  
Date of Patent: Sep. 15, 2015

68. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

69. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

70. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

71. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

72. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

73. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

74. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

75. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

76. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

77. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

78. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

79. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

80. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

81. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

82. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

83. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

84. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE

85. A METHOD FOR PROVIDING A USER WITH A USER INTERFACE FOR A USER INTERFACE






FIG. 1A-1




FIG. 1A-2




FIG. 1A-3



FIG. 1A-4




FIG. 1A-5




FIG. 1A-6




FIG. 1B



FIG. 1C




FIG. 1D




Fig. 2




Fig. 3










FIG. 6A



FIG. 6B




FIG. 6C



# CHANGING MECHANISMS OF THE CAOZONOTIC PRODUCTION OF METHANE

CHANGING MECHANISMS OF THE

CHANGING MECHANISMS OF THE  
CAOZONOTIC PRODUCTION OF  
METHANE

CHANGING MECHANISMS OF THE

CHANGING MECHANISMS OF THE  
CAOZONOTIC PRODUCTION OF  
METHANE

## THE PRODUCTION OF

THE PRODUCTION OF  
CAOZONOTIC PRODUCTION OF  
METHANE

CHANGING MECHANISMS OF THE

CHANGING MECHANISMS OF THE  
CAOZONOTIC PRODUCTION OF  
METHANE

CHANGING MECHANISMS OF THE  
CAOZONOTIC PRODUCTION OF  
METHANE

CHANGING MECHANISMS OF THE  
CAOZONOTIC PRODUCTION OF  
METHANE

CHANGING MECHANISMS OF THE  
CAOZONOTIC PRODUCTION OF  
METHANE

CHANGING MECHANISMS OF THE  
CAOZONOTIC PRODUCTION OF  
METHANE

CHANGING MECHANISMS OF THE

CHANGING MECHANISMS OF THE  
CAOZONOTIC PRODUCTION OF  
METHANE

CHANGING MECHANISMS OF THE  
CAOZONOTIC PRODUCTION OF  
METHANE











**II**

These results show that the use of the new design of the pump with the 100% efficiency, the use of a variable speed drive, and the use of a variable frequency drive, can reduce the energy consumption of the pump system. The use of a variable speed drive and a variable frequency drive can reduce the energy consumption of the pump system by 10% and 15% respectively. The use of a variable speed drive and a variable frequency drive can also reduce the energy consumption of the pump system by 10% and 15% respectively.

• **உயிரின அழிவு:**

-b-

And I am not alone. In the past few years, the number of people who have been diagnosed with the disease has increased by 10 percent, and the number of people who have died has increased by 15 percent.

101-102-103-104-105-106-107-108-109-110-111-112-113-114-115-116-117-118-119-120-121-122-123-124-125-126-127-128-129-130-131-132-133-134-135-136-137-138-139-140-141-142-143-144-145-146-147-148-149-150-151-152-153-154-155-156-157-158-159-160-161-162-163-164-165-166-167-168-169-170-171-172-173-174-175-176-177-178-179-180-181-182-183-184-185-186-187-188-189-190-191-192-193-194-195-196-197-198-199-200-201-202-203-204-205-206-207-208-209-210-211-212-213-214-215-216-217-218-219-220-221-222-223-224-225-226-227-228-229-230-231-232-233-234-235-236-237-238-239-240-241-242-243-244-245-246-247-248-249-250-251-252-253-254-255-256-257-258-259-260-261-262-263-264-265-266-267-268-269-270-271-272-273-274-275-276-277-278-279-280-281-282-283-284-285-286-287-288-289-290-291-292-293-294-295-296-297-298-299-300-301-302-303-304-305-306-307-308-309-310-311-312-313-314-315-316-317-318-319-320-321-322-323-324-325-326-327-328-329-330-331-332-333-334-335-336-337-338-339-340-341-342-343-344-345-346-347-348-349-350-351-352-353-354-355-356-357-358-359-360-361-362-363-364-365-366-367-368-369-370-371-372-373-374-375-376-377-378-379-380-381-382-383-384-385-386-387-388-389-390-391-392-393-394-395-396-397-398-399-400-401-402-403-404-405-406-407-408-409-410-411-412-413-414-415-416-417-418-419-420-421-422-423-424-425-426-427-428-429-430-431-432-433-434-435-436-437-438-439-440-441-442-443-444-445-446-447-448-449-450-451-452-453-454-455-456-457-458-459-460-461-462-463-464-465-466-467-468-469-470-471-472-473-474-475-476-477-478-479-480-481-482-483-484-485-486-487-488-489-490-491-492-493-494-495-496-497-498-499-500-501-502-503-504-505-506-507-508-509-510-511-512-513-514-515-516-517-518-519-520-521-522-523-524-525-526-527-528-529-530-531-532-533-534-535-536-537-538-539-540-541-542-543-544-545-546-547-548-549-550-551-552-553-554-555-556-557-558-559-560-561-562-563-564-565-566-567-568-569-570-571-572-573-574-575-576-577-578-579-580-581-582-583-584-585-586-587-588-589-590-591-592-593-594-595-596-597-598-599-600-601-602-603-604-605-606-607-608-609-610-611-612-613-614-615-616-617-618-619-620-621-622-623-624-625-626-627-628-629-630-631-632-633-634-635-636-637-638-639-640-641-642-643-644-645-646-647-648-649-650-651-652-653-654-655-656-657-658-659-660-661-662-663-664-665-666-667-668-669-670-671-672-673-674-675-676-677-678-679-680-681-682-683-684-685-686-687-688-689-690-691-692-693-694-695-696-697-698-699-700-701-702-703-704-705-706-707-708-709-710-711-712-713-714-715-716-717-718-719-720-721-722-723-724-725-726-727-728-729-730-731-732-733-734-735-736-737-738-739-740-741-742-743-744-745-746-747-748-749-750-751-752-753-754-755-756-757-758-759-760-761-762-763-764-765-766-767-768-769-770-771-772-773-774-775-776-777-778-779-780-781-782-783-784-785-786-787-788-789-790-791-792-793-794-795-796-797-798-799-800-801-802-803-804-805-806-807-808-809-810-811-812-813-814-815-816-817-818-819-820-821-822-823-824-825-826-827-828-829-830-831-832-833-834-835-836-837-838-839-840-841-842-843-844-845-846-847-848-849-850-851-852-853-854-855-856-857-858-859-860-861-862-863-864-865-866-867-868-869-870-871-872-873-874-875-876-877-878-879-880-881-882-883-884-885-886-887-888-889-890-891-892-893-894-895-896-897-898-899-900-901-902-903-904-905-906-907-908-909-910-911-912-913-914-915-916-917-918-919-920-921-922-923-924-925-926-927-928-929-930-931-932-933-934-935-936-937-938-939-940-941-942-943-944-945-946-947-948-949-950-951-952-953-954-955-956-957-958-959-960-961-962-963-964-965-966-967-968-969-970-971-972-973-974-975-976-977-978-979-980-981-982-983-984-985-986-987-988-989-990-991-992-993-994-995-996-997-998-999-1000-1001-1002-1003-1004-1005-1006-1007-1008-1009-1010-1011-1012-1013-1014-1015-1016-1017-1018-1019-1020-1021-1022-1023-1024-1025-1026-1027-1028-1029-1030-1031-1032-1033-1034-1035-1036-1037-1038-1039-1040-1041-1042-1043-1044-1045-1046-1047-1048-1049-1050-1051-1052-1053-1054-1055-1056-1057-1058-1059-1060-1061-1062-1063-1064-1065-1066-1067-1068-1069-1070-1071-1072-1073-1074-1075-1076-1077-1078-1079-1080-1081-1082-1083-1084-1085-1086-1087-1088-1089-1090-1091-1092-1093-1094-1095-1096-1097-1098-109

[illegible]

計 画 書

1. The first step in the process of the investigation is the identification of the problem. This is done by the investigator who is responsible for the investigation. The investigator must identify the problem and the scope of the investigation. This is done by the investigator who is responsible for the investigation. The investigator must identify the problem and the scope of the investigation.

[illegible]

Plasma levels of cholesterol and triglycerides in adult male DOX-treated and control mice were similar and a mean cholesterol level of 600 mg/dl was observed in the untreated control group. The mean cholesterol level in the DOX-treated group was 1100 mg/dl, which was significantly higher than the control group ( $P < 0.05$ ).

**1**

[illegible][illegible]

It is a pleasure to welcome you to the University of Illinois at Chicago. We are excited to have you join our community of scholars and students. We look forward to your contributions to the field of research and to the vibrant intellectual life of the University.

There were several other members of his family, including a cousin, the physician, who was also an officer in the 101st Airborne Division. He was killed in action during the Battle of the Bulge in December 1944. The family was also involved in the war effort in other ways, with several members serving in the military and others working in the war industry.

[illegible]





[illegible][illegible][illegible][illegible]

1. *What is the purpose of the study?*  
 2. *What are the research objectives?*  
 3. *What is the research methodology?*  
 4. *What are the results of the study?*  
 5. *What are the conclusions of the study?*  
 6. *What are the implications of the study?*  
 7. *What are the limitations of the study?*  
 8. *What are the future research directions?*  
 9. *What are the contributions of the study?*  
 10. *What are the key findings of the study?*

It is important to understand that the Commission's findings are not intended to be a final determination of the Commission's findings. The Commission's findings are based on the information provided to it by the parties and the Commission's own investigation. The Commission's findings are not intended to be a final determination of the Commission's findings. The Commission's findings are based on the information provided to it by the parties and the Commission's own investigation. The Commission's findings are not intended to be a final determination of the Commission's findings. The Commission's findings are based on the information provided to it by the parties and the Commission's own investigation.

[illegible][illegible]

As you can see, the old language is very simple and easy to understand. The new language is very complicated and difficult to understand. The old language is very simple and easy to understand. The new language is very complicated and difficult to understand.

As part of the same process, the national government has introduced a new model for organizing agencies, with a new power structure. At the same time, the government has introduced a new model for organizing the state, with a new power structure. The new model for organizing the state is based on the principle of decentralization, which means that the state is organized into a series of smaller, more autonomous units. This new model for organizing the state is based on the principle of decentralization, which means that the state is organized into a series of smaller, more autonomous units. This new model for organizing the state is based on the principle of decentralization, which means that the state is organized into a series of smaller, more autonomous units.

2008年12月11日，407路开通运营，由  
佛山至肇庆，途经高明、鹤山、开平、恩平、  
新会、台山、江门、阳江、茂名、湛江、  
茂名、阳江、江门、台山、新会、恩平、  
开平、鹤山、高明、佛山。407路开通运营  
后，为佛山至肇庆、高明、鹤山、开平、  
恩平、新会、台山、江门、阳江、茂名、  
湛江、茂名、阳江、江门、台山、新会、  
恩平、开平、鹤山、高明、佛山。

































Exercise 10

| 41                                                       | 71                                                       | 74                                                       | 77                                                       |
|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| 41. $\lim_{x \rightarrow 0} \frac{\sin x}{x} = 1$        | 71. $\lim_{x \rightarrow 0} \frac{\cos x}{x} = \infty$   | 74. $\lim_{x \rightarrow 0} \frac{\tan x}{x} = 1$        | 77. $\lim_{x \rightarrow 0} \frac{\sec x}{x} = \infty$   |
| 42. $\lim_{x \rightarrow 0} \frac{\sin x}{x^2} = \infty$ | 72. $\lim_{x \rightarrow 0} \frac{\cos x}{x^2} = \infty$ | 75. $\lim_{x \rightarrow 0} \frac{\tan x}{x^2} = \infty$ | 78. $\lim_{x \rightarrow 0} \frac{\sec x}{x^2} = \infty$ |
| 43. $\lim_{x \rightarrow 0} \frac{\sin x}{x^3} = \infty$ | 73. $\lim_{x \rightarrow 0} \frac{\cos x}{x^3} = \infty$ | 76. $\lim_{x \rightarrow 0} \frac{\tan x}{x^3} = \infty$ | 79. $\lim_{x \rightarrow 0} \frac{\sec x}{x^3} = \infty$ |

44.  $\lim_{x \rightarrow 0} \frac{\sin x}{x} = 1$   
 45.  $\lim_{x \rightarrow 0} \frac{\cos x}{x} = \infty$   
 46.  $\lim_{x \rightarrow 0} \frac{\tan x}{x} = 1$   
 47.  $\lim_{x \rightarrow 0} \frac{\sec x}{x} = \infty$

48.  $\lim_{x \rightarrow 0} \frac{\sin x}{x} = 1$   
 49.  $\lim_{x \rightarrow 0} \frac{\cos x}{x} = \infty$   
 50.  $\lim_{x \rightarrow 0} \frac{\tan x}{x} = 1$   
 51.  $\lim_{x \rightarrow 0} \frac{\sec x}{x} = \infty$   
 52.  $\lim_{x \rightarrow 0} \frac{\sin x}{x^2} = \infty$   
 53.  $\lim_{x \rightarrow 0} \frac{\cos x}{x^2} = \infty$   
 54.  $\lim_{x \rightarrow 0} \frac{\tan x}{x^2} = \infty$   
 55.  $\lim_{x \rightarrow 0} \frac{\sec x}{x^2} = \infty$   
 56.  $\lim_{x \rightarrow 0} \frac{\sin x}{x^3} = \infty$   
 57.  $\lim_{x \rightarrow 0} \frac{\cos x}{x^3} = \infty$   
 58.  $\lim_{x \rightarrow 0} \frac{\tan x}{x^3} = \infty$   
 59.  $\lim_{x \rightarrow 0} \frac{\sec x}{x^3} = \infty$   
 60.  $\lim_{x \rightarrow 0} \frac{\sin x}{x^4} = \infty$   
 61.  $\lim_{x \rightarrow 0} \frac{\cos x}{x^4} = \infty$   
 62.  $\lim_{x \rightarrow 0} \frac{\tan x}{x^4} = \infty$   
 63.  $\lim_{x \rightarrow 0} \frac{\sec x}{x^4} = \infty$

64.  $\lim_{x \rightarrow 0} \frac{\sin x}{x} = 1$   
 65.  $\lim_{x \rightarrow 0} \frac{\cos x}{x} = \infty$   
 66.  $\lim_{x \rightarrow 0} \frac{\tan x}{x} = 1$   
 67.  $\lim_{x \rightarrow 0} \frac{\sec x}{x} = \infty$

68.  $\lim_{x \rightarrow 0} \frac{\sin x}{x} = 1$   
 69.  $\lim_{x \rightarrow 0} \frac{\cos x}{x} = \infty$   
 70.  $\lim_{x \rightarrow 0} \frac{\tan x}{x} = 1$   
 71.  $\lim_{x \rightarrow 0} \frac{\sec x}{x} = \infty$   
 72.  $\lim_{x \rightarrow 0} \frac{\sin x}{x^2} = \infty$   
 73.  $\lim_{x \rightarrow 0} \frac{\cos x}{x^2} = \infty$   
 74.  $\lim_{x \rightarrow 0} \frac{\tan x}{x^2} = \infty$   
 75.  $\lim_{x \rightarrow 0} \frac{\sec x}{x^2} = \infty$   
 76.  $\lim_{x \rightarrow 0} \frac{\sin x}{x^3} = \infty$   
 77.  $\lim_{x \rightarrow 0} \frac{\cos x}{x^3} = \infty$   
 78.  $\lim_{x \rightarrow 0} \frac{\tan x}{x^3} = \infty$   
 79.  $\lim_{x \rightarrow 0} \frac{\sec x}{x^3} = \infty$



1. The first part of the proof is to show that the sequence  $\{x_n\}$  is bounded. We have  $x_1 = 1$  and  $x_{n+1} = \frac{x_n}{2} + \frac{1}{x_n}$ . By the AM-GM inequality, we have  $\frac{x_n}{2} + \frac{1}{x_n} \geq \sqrt{2}$ . Therefore,  $x_{n+1} \geq \sqrt{2}$  for all  $n \geq 1$ . This implies that the sequence  $\{x_n\}$  is bounded below by  $\sqrt{2}$ .  
 2. Next, we show that the sequence  $\{x_n\}$  is bounded above. We have  $x_1 = 1$  and  $x_{n+1} = \frac{x_n}{2} + \frac{1}{x_n}$ . By the AM-GM inequality, we have  $\frac{x_n}{2} + \frac{1}{x_n} \leq \frac{x_n}{2} + \frac{1}{2x_n} + \frac{1}{2x_n} = \frac{x_n}{2} + \frac{1}{x_n}$ . Therefore,  $x_{n+1} \leq \frac{x_n}{2} + \frac{1}{x_n}$  for all  $n \geq 1$ . This implies that the sequence  $\{x_n\}$  is bounded above by  $1$ .  
 3. Since the sequence  $\{x_n\}$  is bounded, it has a convergent subsequence. Let  $x_{n_k}$  be a convergent subsequence. Then  $x_{n_k} \rightarrow L$  for some  $L \in \mathbb{R}$ . By the definition of a limit, we have  $x_{n_k+1} \rightarrow L$  as well. Therefore,  $L = \frac{L}{2} + \frac{1}{L}$ . Solving this equation, we get  $L = \sqrt{2}$ .  
 4. Finally, we show that the entire sequence  $\{x_n\}$  converges to  $\sqrt{2}$ . We have  $x_{n+1} - \sqrt{2} = \frac{x_n}{2} + \frac{1}{x_n} - \sqrt{2} = \frac{x_n - \sqrt{2}}{2} + \frac{1}{x_n} - \frac{1}{\sqrt{2}}$ . By the AM-GM inequality, we have  $\frac{1}{x_n} - \frac{1}{\sqrt{2}} \leq \frac{1}{\sqrt{2}} - \frac{1}{x_n}$ . Therefore,  $x_{n+1} - \sqrt{2} \leq \frac{x_n - \sqrt{2}}{2}$  for all  $n \geq 1$ . This implies that the sequence  $\{x_n\}$  converges to  $\sqrt{2}$ .

1. The first part of the proof is to show that the sequence  $\{x_n\}$  is bounded. We have  $x_1 = 1$  and  $x_{n+1} = \frac{x_n}{2} + \frac{1}{x_n}$ . By the AM-GM inequality, we have  $\frac{x_n}{2} + \frac{1}{x_n} \geq \sqrt{2}$ . Therefore,  $x_{n+1} \geq \sqrt{2}$  for all  $n \geq 1$ . This implies that the sequence  $\{x_n\}$  is bounded below by  $\sqrt{2}$ .

2. Next, we show that the sequence  $\{x_n\}$  is bounded above.

We have  $x_1 = 1$  and  $x_{n+1} = \frac{x_n}{2} + \frac{1}{x_n}$ . By the AM-GM inequality, we have  $\frac{x_n}{2} + \frac{1}{x_n} \leq \frac{x_n}{2} + \frac{1}{2x_n} + \frac{1}{2x_n} = \frac{x_n}{2} + \frac{1}{x_n}$ . Therefore,  $x_{n+1} \leq \frac{x_n}{2} + \frac{1}{x_n}$  for all  $n \geq 1$ . This implies that the sequence  $\{x_n\}$  is bounded above by  $1$ .  
 Since the sequence  $\{x_n\}$  is bounded, it has a convergent subsequence. Let  $x_{n_k}$  be a convergent subsequence. Then  $x_{n_k} \rightarrow L$  for some  $L \in \mathbb{R}$ . By the definition of a limit, we have  $x_{n_k+1} \rightarrow L$  as well. Therefore,  $L = \frac{L}{2} + \frac{1}{L}$ . Solving this equation, we get  $L = \sqrt{2}$ .  
 Finally, we show that the entire sequence  $\{x_n\}$  converges to  $\sqrt{2}$ . We have  $x_{n+1} - \sqrt{2} = \frac{x_n}{2} + \frac{1}{x_n} - \sqrt{2} = \frac{x_n - \sqrt{2}}{2} + \frac{1}{x_n} - \frac{1}{\sqrt{2}}$ . By the AM-GM inequality, we have  $\frac{1}{x_n} - \frac{1}{\sqrt{2}} \leq \frac{1}{\sqrt{2}} - \frac{1}{x_n}$ . Therefore,  $x_{n+1} - \sqrt{2} \leq \frac{x_n - \sqrt{2}}{2}$  for all  $n \geq 1$ . This implies that the sequence  $\{x_n\}$  converges to  $\sqrt{2}$ .

3. Finally, we show that the entire sequence  $\{x_n\}$  converges to  $\sqrt{2}$ .

We have  $x_{n+1} - \sqrt{2} = \frac{x_n}{2} + \frac{1}{x_n} - \sqrt{2} = \frac{x_n - \sqrt{2}}{2} + \frac{1}{x_n} - \frac{1}{\sqrt{2}}$ . By the AM-GM inequality, we have  $\frac{1}{x_n} - \frac{1}{\sqrt{2}} \leq \frac{1}{\sqrt{2}} - \frac{1}{x_n}$ . Therefore,  $x_{n+1} - \sqrt{2} \leq \frac{x_n - \sqrt{2}}{2}$  for all  $n \geq 1$ . This implies that the sequence  $\{x_n\}$  converges to  $\sqrt{2}$ .

4. Finally, we show that the entire sequence  $\{x_n\}$  converges to  $\sqrt{2}$ .

We have  $x_{n+1} - \sqrt{2} = \frac{x_n}{2} + \frac{1}{x_n} - \sqrt{2} = \frac{x_n - \sqrt{2}}{2} + \frac{1}{x_n} - \frac{1}{\sqrt{2}}$ . By the AM-GM inequality, we have  $\frac{1}{x_n} - \frac{1}{\sqrt{2}} \leq \frac{1}{\sqrt{2}} - \frac{1}{x_n}$ . Therefore,  $x_{n+1} - \sqrt{2} \leq \frac{x_n - \sqrt{2}}{2}$  for all  $n \geq 1$ . This implies that the sequence  $\{x_n\}$  converges to  $\sqrt{2}$ .

Let  $f: \mathbb{R} \rightarrow \mathbb{R}$  be a function. Suppose that  $f$  is continuous at  $x_0$ .  
 (i) Show that  $f$  is bounded on some interval  $(x_0 - \delta, x_0 + \delta)$ .  
 (ii) Show that  $f$  is bounded on some interval  $(x_0 - \delta, x_0 + \delta)$ .  
 (iii) Show that  $f$  is bounded on some interval  $(x_0 - \delta, x_0 + \delta)$ .  
 (iv) Show that  $f$  is bounded on some interval  $(x_0 - \delta, x_0 + \delta)$ .  
 (v) Show that  $f$  is bounded on some interval  $(x_0 - \delta, x_0 + \delta)$ .  
 (vi) Show that  $f$  is bounded on some interval  $(x_0 - \delta, x_0 + \delta)$ .  
 (vii) Show that  $f$  is bounded on some interval  $(x_0 - \delta, x_0 + \delta)$ .  
 (viii) Show that  $f$  is bounded on some interval  $(x_0 - \delta, x_0 + \delta)$ .

(i)  $f$  is continuous at  $x_0$ .  
 (ii)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (iii)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .

(iv)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (v)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (vi)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (vii)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (viii)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (ix)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (x)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .

(i)  $f$  is continuous at  $x_0$ .  
 (ii)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (iii)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (iv)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .

(v)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (vi)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (vii)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (viii)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (ix)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (x)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (xi)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (xii)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (xiii)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .  
 (xiv)  $f$  is bounded on  $(x_0 - \delta, x_0 + \delta)$ .







# EXERCISES

20

21

Exercise 1

1.1.1. The first exercise is to find the first derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.1.2. The second exercise is to find the second derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.1.3. The third exercise is to find the third derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.1.4. The fourth exercise is to find the fourth derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.1.5. The fifth exercise is to find the fifth derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.1.6. The sixth exercise is to find the sixth derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.1.7. The seventh exercise is to find the seventh derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.1.8. The eighth exercise is to find the eighth derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.1.9. The ninth exercise is to find the ninth derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.1.10. The tenth exercise is to find the tenth derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.2.1. The first exercise is to find the first derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.2.2. The second exercise is to find the second derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.2.3. The third exercise is to find the third derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.2.4. The fourth exercise is to find the fourth derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.2.5. The fifth exercise is to find the fifth derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.2.6. The sixth exercise is to find the sixth derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.3.1. The first exercise is to find the first derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.3.2. The second exercise is to find the second derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.3.3. The third exercise is to find the third derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.3.4. The fourth exercise is to find the fourth derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.3.5. The fifth exercise is to find the fifth derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.3.6. The sixth exercise is to find the sixth derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.3.7. The seventh exercise is to find the seventh derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.3.8. The eighth exercise is to find the eighth derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.3.9. The ninth exercise is to find the ninth derivative of the function  $f(x) = x^2 + 3x - 5$ .

1.3.10. The tenth exercise is to find the tenth derivative of the function  $f(x) = x^2 + 3x - 5$ .





# INDEX

vi

vi

CONTENTS

## CONTENTS

|                                 |    |
|---------------------------------|----|
| 1. Introduction                 | 1  |
| 2. The Problem                  | 2  |
| 3. The Solution                 | 3  |
| 4. The Conclusion               | 4  |
| 5. The Appendix                 | 5  |
| 6. The Bibliography             | 6  |
| 7. The Index                    | 7  |
| 8. The Glossary                 | 8  |
| 9. The List of Figures          | 9  |
| 10. The List of Tables          | 10 |
| 11. The List of Equations       | 11 |
| 12. The List of Symbols         | 12 |
| 13. The List of Abbreviations   | 13 |
| 14. The List of References      | 14 |
| 15. The List of Acknowledgments | 15 |
| 16. The List of Contributors    | 16 |
| 17. The List of Reviewers       | 17 |
| 18. The List of Editors         | 18 |
| 19. The List of Publishers      | 19 |
| 20. The List of Distributors    | 20 |

1. Introduction  
2. The Problem  
3. The Solution  
4. The Conclusion

## CONTENTS

|                                 |    |
|---------------------------------|----|
| 1. Introduction                 | 1  |
| 2. The Problem                  | 2  |
| 3. The Solution                 | 3  |
| 4. The Conclusion               | 4  |
| 5. The Appendix                 | 5  |
| 6. The Bibliography             | 6  |
| 7. The Index                    | 7  |
| 8. The Glossary                 | 8  |
| 9. The List of Figures          | 9  |
| 10. The List of Tables          | 10 |
| 11. The List of Equations       | 11 |
| 12. The List of Symbols         | 12 |
| 13. The List of Abbreviations   | 13 |
| 14. The List of References      | 14 |
| 15. The List of Acknowledgments | 15 |
| 16. The List of Contributors    | 16 |
| 17. The List of Reviewers       | 17 |
| 18. The List of Editors         | 18 |
| 19. The List of Publishers      | 19 |
| 20. The List of Distributors    | 20 |

1. Introduction  
2. The Problem  
3. The Solution  
4. The Conclusion

## CONTENTS





|                        |     |
|------------------------|-----|
| 1. Introduction        | 1   |
| 2. Preliminary Results | 2   |
| 3. Main Results        | 3   |
| 4. Conclusions         | 4   |
| 5. Appendix            | 5   |
| 6. Bibliography        | 6   |
| 7. Index               | 7   |
| 8. Acknowledgments     | 8   |
| 9. References          | 9   |
| 10. Notes              | 10  |
| 11. Figures            | 11  |
| 12. Tables             | 12  |
| 13. Glossary           | 13  |
| 14. Abbreviations      | 14  |
| 15. Symbols            | 15  |
| 16. Units              | 16  |
| 17. Constants          | 17  |
| 18. Variables          | 18  |
| 19. Parameters         | 19  |
| 20. Functions          | 20  |
| 21. Operators          | 21  |
| 22. Relations          | 22  |
| 23. Equations          | 23  |
| 24. Inequalities       | 24  |
| 25. Identities         | 25  |
| 26. Theorems           | 26  |
| 27. Lemmas             | 27  |
| 28. Propositions       | 28  |
| 29. Corollaries        | 29  |
| 30. Examples           | 30  |
| 31. Counterexamples    | 31  |
| 32. Conjectures        | 32  |
| 33. Open Problems      | 33  |
| 34. Future Work        | 34  |
| 35. Summary            | 35  |
| 36. Conclusion         | 36  |
| 37. Acknowledgments    | 37  |
| 38. References         | 38  |
| 39. Notes              | 39  |
| 40. Figures            | 40  |
| 41. Tables             | 41  |
| 42. Glossary           | 42  |
| 43. Abbreviations      | 43  |
| 44. Symbols            | 44  |
| 45. Units              | 45  |
| 46. Constants          | 46  |
| 47. Variables          | 47  |
| 48. Parameters         | 48  |
| 49. Functions          | 49  |
| 50. Operators          | 50  |
| 51. Relations          | 51  |
| 52. Equations          | 52  |
| 53. Inequalities       | 53  |
| 54. Identities         | 54  |
| 55. Theorems           | 55  |
| 56. Lemmas             | 56  |
| 57. Propositions       | 57  |
| 58. Corollaries        | 58  |
| 59. Examples           | 59  |
| 60. Counterexamples    | 60  |
| 61. Conjectures        | 61  |
| 62. Open Problems      | 62  |
| 63. Future Work        | 63  |
| 64. Summary            | 64  |
| 65. Conclusion         | 65  |
| 66. Acknowledgments    | 66  |
| 67. References         | 67  |
| 68. Notes              | 68  |
| 69. Figures            | 69  |
| 70. Tables             | 70  |
| 71. Glossary           | 71  |
| 72. Abbreviations      | 72  |
| 73. Symbols            | 73  |
| 74. Units              | 74  |
| 75. Constants          | 75  |
| 76. Variables          | 76  |
| 77. Parameters         | 77  |
| 78. Functions          | 78  |
| 79. Operators          | 79  |
| 80. Relations          | 80  |
| 81. Equations          | 81  |
| 82. Inequalities       | 82  |
| 83. Identities         | 83  |
| 84. Theorems           | 84  |
| 85. Lemmas             | 85  |
| 86. Propositions       | 86  |
| 87. Corollaries        | 87  |
| 88. Examples           | 88  |
| 89. Counterexamples    | 89  |
| 90. Conjectures        | 90  |
| 91. Open Problems      | 91  |
| 92. Future Work        | 92  |
| 93. Summary            | 93  |
| 94. Conclusion         | 94  |
| 95. Acknowledgments    | 95  |
| 96. References         | 96  |
| 97. Notes              | 97  |
| 98. Figures            | 98  |
| 99. Tables             | 99  |
| 100. Glossary          | 100 |







|       |     |
|-------|-----|
| ..... | 10  |
| ..... | 11  |
| ..... | 12  |
| ..... | 13  |
| ..... | 14  |
| ..... | 15  |
| ..... | 16  |
| ..... | 17  |
| ..... | 18  |
| ..... | 19  |
| ..... | 20  |
| ..... | 21  |
| ..... | 22  |
| ..... | 23  |
| ..... | 24  |
| ..... | 25  |
| ..... | 26  |
| ..... | 27  |
| ..... | 28  |
| ..... | 29  |
| ..... | 30  |
| ..... | 31  |
| ..... | 32  |
| ..... | 33  |
| ..... | 34  |
| ..... | 35  |
| ..... | 36  |
| ..... | 37  |
| ..... | 38  |
| ..... | 39  |
| ..... | 40  |
| ..... | 41  |
| ..... | 42  |
| ..... | 43  |
| ..... | 44  |
| ..... | 45  |
| ..... | 46  |
| ..... | 47  |
| ..... | 48  |
| ..... | 49  |
| ..... | 50  |
| ..... | 51  |
| ..... | 52  |
| ..... | 53  |
| ..... | 54  |
| ..... | 55  |
| ..... | 56  |
| ..... | 57  |
| ..... | 58  |
| ..... | 59  |
| ..... | 60  |
| ..... | 61  |
| ..... | 62  |
| ..... | 63  |
| ..... | 64  |
| ..... | 65  |
| ..... | 66  |
| ..... | 67  |
| ..... | 68  |
| ..... | 69  |
| ..... | 70  |
| ..... | 71  |
| ..... | 72  |
| ..... | 73  |
| ..... | 74  |
| ..... | 75  |
| ..... | 76  |
| ..... | 77  |
| ..... | 78  |
| ..... | 79  |
| ..... | 80  |
| ..... | 81  |
| ..... | 82  |
| ..... | 83  |
| ..... | 84  |
| ..... | 85  |
| ..... | 86  |
| ..... | 87  |
| ..... | 88  |
| ..... | 89  |
| ..... | 90  |
| ..... | 91  |
| ..... | 92  |
| ..... | 93  |
| ..... | 94  |
| ..... | 95  |
| ..... | 96  |
| ..... | 97  |
| ..... | 98  |
| ..... | 99  |
| ..... | 100 |



100.  $\frac{1}{2} \ln 2 = \ln \sqrt{2}$

101.  $\ln 2 = \ln 2$

102.  $\ln 2 = \ln 2$

103.  $\ln 2 = \ln 2$

104.  $\ln 2 = \ln 2$

105.  $\ln 2 = \ln 2$

106.  $\ln 2 = \ln 2$

107.  $\ln 2 = \ln 2$

108.  $\ln 2 = \ln 2$

109.  $\ln 2 = \ln 2$

110.  $\ln 2 = \ln 2$

111.  $\ln 2 = \ln 2$

112.  $\ln 2 = \ln 2$

113.  $\ln 2 = \ln 2$

114.  $\ln 2 = \ln 2$

115.  $\ln 2 = \ln 2$

116.  $\ln 2 = \ln 2$

117.  $\ln 2 = \ln 2$

118.  $\ln 2 = \ln 2$

119.  $\ln 2 = \ln 2$

120.  $\ln 2 = \ln 2$

121.  $\ln 2 = \ln 2$

122.  $\ln 2 = \ln 2$

123.  $\ln 2 = \ln 2$

124.  $\ln 2 = \ln 2$

125.  $\ln 2 = \ln 2$

126.  $\ln 2 = \ln 2$

127.  $\ln 2 = \ln 2$

128.  $\ln 2 = \ln 2$

129.  $\ln 2 = \ln 2$

130.  $\ln 2 = \ln 2$

131.  $\ln 2 = \ln 2$

132.  $\ln 2 = \ln 2$

133.  $\ln 2 = \ln 2$

134.  $\ln 2 = \ln 2$

14. The dimensions of the variable  $x$  and  $y$  are the same as in the previous experiment. The parameter  $\alpha$  is the same as in the previous experiment. The parameter  $\beta$  is the same as in the previous experiment. The parameter  $\gamma$  is the same as in the previous experiment.

15. The dimensions of the variable  $x$  and  $y$  are the same as in the previous experiment. The parameter  $\alpha$  is the same as in the previous experiment. The parameter  $\beta$  is the same as in the previous experiment. The parameter  $\gamma$  is the same as in the previous experiment.

16. The dimensions of the variable  $x$  and  $y$  are the same as in the previous experiment. The parameter  $\alpha$  is the same as in the previous experiment. The parameter  $\beta$  is the same as in the previous experiment. The parameter  $\gamma$  is the same as in the previous experiment.

17. The dimensions of the variable  $x$  and  $y$  are the same as in the previous experiment. The parameter  $\alpha$  is the same as in the previous experiment. The parameter  $\beta$  is the same as in the previous experiment. The parameter  $\gamma$  is the same as in the previous experiment.

18. The dimensions of the variable  $x$  and  $y$  are the same as in the previous experiment. The parameter  $\alpha$  is the same as in the previous experiment. The parameter  $\beta$  is the same as in the previous experiment. The parameter  $\gamma$  is the same as in the previous experiment.

19. The dimensions of the variable  $x$  and  $y$  are the same as in the previous experiment. The parameter  $\alpha$  is the same as in the previous experiment. The parameter  $\beta$  is the same as in the previous experiment. The parameter  $\gamma$  is the same as in the previous experiment.

20. The dimensions of the variable  $x$  and  $y$  are the same as in the previous experiment. The parameter  $\alpha$  is the same as in the previous experiment. The parameter  $\beta$  is the same as in the previous experiment. The parameter  $\gamma$  is the same as in the previous experiment.



US 7,601,323 B2

**United States Patent**  
**Chakrabarti et al.**

**Patent No.:** US 7,601,323 B2  
**Date of Patent:** April 6, 2010

**(51) International Classification:**  
**(2006.01)** H04L 1/00 (2006.01)

**(52) Class:** H04L 1/00 (2006.01)  
**(53) Class:** H04L 1/00 (2006.01)

**(54) Title:** H04L 1/00 (2006.01)

**(55) Abstract:** H04L 1/00 (2006.01)

**(56) References:** H04L 1/00 (2006.01)

**(57) Claims:** H04L 1/00 (2006.01)

**(58) Other:** H04L 1/00 (2006.01)

**(59) Other:** H04L 1/00 (2006.01)

**(60) Other:** H04L 1/00 (2006.01)

**(61) Other:** H04L 1/00 (2006.01)

**(62) Other:** H04L 1/00 (2006.01)

**(63) Other:** H04L 1/00 (2006.01)

**(64) Other:** H04L 1/00 (2006.01)

**(65) Other:** H04L 1/00 (2006.01)

**(66) Other:** H04L 1/00 (2006.01)

**(67) Other:** H04L 1/00 (2006.01)

**(68) Other:** H04L 1/00 (2006.01)

**(69) Other:** H04L 1/00 (2006.01)

**(70) Other:** H04L 1/00 (2006.01)

**(71) Other:** H04L 1/00 (2006.01)

**(72) Other:** H04L 1/00 (2006.01)

**(73) Other:** H04L 1/00 (2006.01)

**(74) Other:** H04L 1/00 (2006.01)

**(75) Other:** H04L 1/00 (2006.01)

**(76) Other:** H04L 1/00 (2006.01)

**(77) Other:** H04L 1/00 (2006.01)

**(78) Other:** H04L 1/00 (2006.01)

**(79) Other:** H04L 1/00 (2006.01)

**(80) Other:** H04L 1/00 (2006.01)

**(81) Other:** H04L 1/00 (2006.01)

**(82) Other:** H04L 1/00 (2006.01)

**(83) Other:** H04L 1/00 (2006.01)

**(84) Other:** H04L 1/00 (2006.01)

**(85) Other:** H04L 1/00 (2006.01)

**(86) Other:** H04L 1/00 (2006.01)

**(87) Other:** H04L 1/00 (2006.01)

**(88) Other:** H04L 1/00 (2006.01)

**(89) Other:** H04L 1/00 (2006.01)

**(90) Other:** H04L 1/00 (2006.01)

**(91) Other:** H04L 1/00 (2006.01)

**(92) Other:** H04L 1/00 (2006.01)

**(93) Other:** H04L 1/00 (2006.01)

**(94) Other:** H04L 1/00 (2006.01)

**(95) Other:** H04L 1/00 (2006.01)

**(96) Other:** H04L 1/00 (2006.01)



FIG. 1a




FIG. 1b






FIG. 2a




FIG. 2b








FIG. 4a

FIG. 4b

FIG. 4c

FIG. 5a





FIG. 5b



FIG. 5c






FIG. 6




FIG. 7






FIG. 3 PRIOR ART






FIG. 10





5

1. The first of the following items is the first of the following items.

2. The second of the following items is the second of the following items.

3. The third of the following items is the third of the following items.

4. The fourth of the following items is the fourth of the following items.

5. The fifth of the following items is the fifth of the following items.

1. The first of the following items is the first of the following items.

2. The second of the following items is the second of the following items.

3. The third of the following items is the third of the following items.

4. The fourth of the following items is the fourth of the following items.

5. The fifth of the following items is the fifth of the following items.

6. The sixth of the following items is the sixth of the following items.

6

7. The seventh of the following items is the seventh of the following items.

8. The eighth of the following items is the eighth of the following items.

9. The ninth of the following items is the ninth of the following items.

10. The tenth of the following items is the tenth of the following items.

11. The eleventh of the following items is the eleventh of the following items.

12. The twelfth of the following items is the twelfth of the following items.

# THE END OF THE WORLD

13. The thirteenth of the following items is the thirteenth of the following items.











reduces the risk of infection, and the use of a condom and latex sheath is a further safeguard against infection. The use of condoms and latex sheaths is particularly important for those who have multiple sexual partners, and for those who are at risk of infection from the use of a condom or latex sheath. The use of condoms and latex sheaths is also important for those who are at risk of infection from the use of a condom or latex sheath.

1. The first step is to identify the problem. In this case, the problem is that the system is not working properly.

[illegible]

The purpose of this study was to determine the impact of the use of the Internet on the use of the Internet by the general public. The study was conducted in the United States and the results are presented in this paper. The study was conducted in the United States and the results are presented in this paper. The study was conducted in the United States and the results are presented in this paper.

It is not clear how the 1980s' economic growth affected the regional distribution of human resources and, consequently, the regional distribution of the public sector. The regional distribution of the public sector is measured by the ratio of the public sector to the total population. The ratio of the public sector to the total population in 1980 was 0.12. The ratio of the public sector to the total population in 1990 was 0.14. The ratio of the public sector to the total population in 2000 was 0.16. The ratio of the public sector to the total population in 2010 was 0.18. The ratio of the public sector to the total population in 2020 was 0.20. The ratio of the public sector to the total population in 2030 was 0.22. The ratio of the public sector to the total population in 2040 was 0.24. The ratio of the public sector to the total population in 2050 was 0.26. The ratio of the public sector to the total population in 2060 was 0.28. The ratio of the public sector to the total population in 2070 was 0.30. The ratio of the public sector to the total population in 2080 was 0.32. The ratio of the public sector to the total population in 2090 was 0.34. The ratio of the public sector to the total population in 2100 was 0.36.

[illegible][illegible]

biochemical changes associated with the development of atherosclerosis. The authors suggest that the increased levels of triglycerides and low-density lipoprotein (LDL) cholesterol in the plasma of the subjects with the metabolic syndrome are associated with the increased risk of atherosclerosis. The authors also suggest that the increased levels of triglycerides and LDL cholesterol in the plasma of the subjects with the metabolic syndrome are associated with the increased risk of atherosclerosis.

[illegible][illegible][illegible]

THE UNIVERSITY of Pennsylvania has been an early participant in the development of a new and exciting area of research, the study of the social organization of cognition. Research in this broad area is capable of making significant contributions to understanding the basic principles of human perception and behavior, and is particularly relevant to the study of human communication and problem solving. The University of Pennsylvania has a long and distinguished history of research in this area, and is now leading the way in the development of this new field.





[illegible]

On the 17th of April, 1900, the day after the arrival of the first of the new boats, the following letter was received from the Hon. Mr. J. H. Smith, Secretary of the Navy, Washington, D. C.:

[illegible]

There are many other reasons why the use of a single survey instrument may not be the best choice for a particular research project. For example, a single survey instrument may not be able to capture the full range of responses that are possible, or it may not be able to capture the full range of responses that are possible for a particular research project. For example, a single survey instrument may not be able to capture the full range of responses that are possible, or it may not be able to capture the full range of responses that are possible for a particular research project.

[illegible][illegible]

After more studies are conducted, however, the use of these animals in research may be necessary. In the meantime, the use of these animals in research should be limited to the minimum necessary to develop and test new drugs and procedures. The use of these animals in research should be limited to the minimum necessary to develop and test new drugs and procedures.

[illegible]

On September 1, 1944, the United States Department of Education opened a special school for the blind in the city of New York. The school was named after the late President Franklin D. Roosevelt. It was the first school of its kind in the United States. The school was opened to all blind children in the city of New York. The school was named after the late President Franklin D. Roosevelt. It was the first school of its kind in the United States. The school was opened to all blind children in the city of New York.

1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 26







21  
4-11-11

1. The first step is to identify the problem or goal. This involves understanding the current situation and what needs to be achieved.

[illegible]

There is evidence that the majority of the white women who were arrested in 1967-68 were blacklisted by the FBI as a result of their involvement in the civil rights movement. This is supported by the fact that many of these women were active in the Southern Christian Leadership Conference (SCLC) and the Student Nonviolent Coordinating Committee (SNCC). The FBI's blacklisting of these women was a result of their involvement in the civil rights movement, which was seen as a threat to the status quo.

[illegible]

— 121 —

2014年12月15日  
 2014年12月15日

There are a number of reasons why a company may become dependent on a single country or source of supply. First, the company may have a high degree of specialization in a particular product or service, and the country or source of supply may be the only one that can provide the necessary inputs. Second, the company may have a high degree of specialization in a particular technology, and the country or source of supply may be the only one that can provide the necessary inputs. Third, the company may have a high degree of specialization in a particular market, and the country or source of supply may be the only one that can provide the necessary inputs. Fourth, the company may have a high degree of specialization in a particular distribution channel, and the country or source of supply may be the only one that can provide the necessary inputs. Fifth, the company may have a high degree of specialization in a particular customer base, and the country or source of supply may be the only one that can provide the necessary inputs. Sixth, the company may have a high degree of specialization in a particular regulatory environment, and the country or source of supply may be the only one that can provide the necessary inputs. Seventh, the company may have a high degree of specialization in a particular legal system, and the country or source of supply may be the only one that can provide the necessary inputs. Eighth, the company may have a high degree of specialization in a particular cultural environment, and the country or source of supply may be the only one that can provide the necessary inputs. Ninth, the company may have a high degree of specialization in a particular economic environment, and the country or source of supply may be the only one that can provide the necessary inputs. Tenth, the company may have a high degree of specialization in a particular political environment, and the country or source of supply may be the only one that can provide the necessary inputs.

[illegible]

THE UNIVERSITY OF CHICAGO PRESS  
50 EAST LEXINGTON AVENUE  
NEW YORK, N.Y. 10017-2473  
TEL: 212 850 6640 FAX: 212 850 6890  
WWW.CHICAGO.PRESS.COM

[illegible][illegible]

1. The "1971" was a typo for "1970".  
2. The "1971" was a typo for "1970".

1. The first of these is the fact that the majority of the population of the United Kingdom is now over 40 years of age. This is a significant fact because it means that the majority of the population is now in the age group in which the incidence of cancer is highest. This is a fact which is of great importance to the Government and to the public.

1. The following information is provided for the year ended 31/12/2017:

2. The following information is provided for the year ended 31/12/2017:

3. The following information is provided for the year ended 31/12/2017:

4. The following information is provided for the year ended 31/12/2017:

5. The following information is provided for the year ended 31/12/2017:

6. The following information is provided for the year ended 31/12/2017:

7. The following information is provided for the year ended 31/12/2017:

8. The following information is provided for the year ended 31/12/2017:

9. The following information is provided for the year ended 31/12/2017:

10. The following information is provided for the year ended 31/12/2017:

1. The following information was obtained from the records of the FBI, Bureau of Investigation, Washington, D.C., dated 10/10/67:



Model number: 0-768-0000-00  
Date of issue: 01.01.2000  
Version: 1.0

These two last steps are the most important for the success of the project. The first step is to identify the key stakeholders and their interests. The second step is to develop a communication plan that outlines the goals, objectives, and timeline of the project.

1. The first group, numbered 1-20, represents the 20 "Patriarchal" families. The second group, numbered 21-40, represents the 20 "Matriarchal" families. The third group, numbered 41-60, represents the 20 "Bipolar" families. The fourth group, numbered 61-80, represents the 20 "Unipolar" families. The fifth group, numbered 81-100, represents the 20 "Quadrupolar" families. The sixth group, numbered 101-120, represents the 20 "Quintupolar" families. The seventh group, numbered 121-140, represents the 20 "Sextupolar" families. The eighth group, numbered 141-160, represents the 20 "Septupolar" families. The ninth group, numbered 161-180, represents the 20 "Octupolar" families. The tenth group, numbered 181-200, represents the 20 "Nonupolar" families. The eleventh group, numbered 201-220, represents the 20 "Decupolar" families. The twelfth group, numbered 221-240, represents the 20 "Undecupolar" families. The thirteenth group, numbered 241-260, represents the 20 "Dodecupolar" families. The fourteenth group, numbered 261-280, represents the 20 "Tridecupolar" families. The fifteenth group, numbered 281-300, represents the 20 "Tetradecupolar" families. The sixteenth group, numbered 301-320, represents the 20 "Pentadecupolar" families. The seventeenth group, numbered 321-340, represents the 20 "Hexadecupolar" families. The eighteenth group, numbered 341-360, represents the 20 "Heptadecupolar" families. The nineteenth group, numbered 361-380, represents the 20 "Octadecupolar" families. The twentieth group, numbered 381-400, represents the 20 "Enneadecupolar" families. The twenty-first group, numbered 401-420, represents the 20 "Icosapolar" families. The twenty-second group, numbered 421-440, represents the 20 "Unicupolar" families. The twenty-third group, numbered 441-460, represents the 20 "Bicupolar" families. The twenty-fourth group, numbered 461-480, represents the 20 "Tricupolar" families. The twenty-fifth group, numbered 481-500, represents the 20 "Tetracupolar" families. The twenty-sixth group, numbered 501-520, represents the 20 "Pentacupolar" families. The twenty-seventh group, numbered 521-540, represents the 20 "Hexacupolar" families. The twenty-eighth group, numbered 541-560, represents the 20 "Heptacupolar" families. The twenty-ninth group, numbered 561-580, represents the 20 "Octacupolar" families. The thirtieth group, numbered 581-600, represents the 20 "Enneacupolar" families. The thirty-first group, numbered 601-620, represents the 20 "Icosacupolar" families. The thirty-second group, numbered 621-640, represents the 20 "Unicupolar" families. The thirty-third group, numbered 641-660, represents the 20 "Bicupolar" families. The thirty-fourth group, numbered 661-680, represents the 20 "Tricupolar" families. The thirty-fifth group, numbered 681-700, represents the 20 "Tetracupolar" families. The thirty-sixth group, numbered 701-720, represents the 20 "Pentacupolar" families. The thirty-seventh group, numbered 721-740, represents the 20 "Hexacupolar" families. The thirty-eighth group, numbered 741-760, represents the 20 "Heptacupolar" families. The thirty-ninth group, numbered 761-780, represents the 20 "Octacupolar" families. The fortieth group, numbered 781-800, represents the 20 "Enneacupolar" families. The forty-first group, numbered 801-820, represents the 20 "Icosacupolar" families. The forty-second group, numbered 821-840, represents the 20 "Unicupolar" families. The forty-third group, numbered 841-860, represents the 20 "Bicupolar" families. The forty-fourth group, numbered 861-880, represents the 20 "Tricupolar" families. The forty-fifth group, numbered 881-900, represents the 20 "Tetracupolar" families. The forty-sixth group, numbered 901-920, represents the 20 "Pentacupolar" families. The forty-seventh group, numbered 921-940, represents the 20 "Hexacupolar" families. The forty-eighth group, numbered 941-960, represents the 20 "Heptacupolar" families. The forty-ninth group, numbered 961-980, represents the 20 "Octacupolar" families. The fiftieth group, numbered 981-1000, represents the 20 "Enneacupolar" families.

**Page 4**

1997年12月25日，在加拿大  
“多倫多”郵政局內

A detailed literature review was conducted to identify the most relevant and prominent research in the field of the effect of the COVID-19 pandemic on the mental health of the general population. The search was conducted using the following keywords: COVID-19, mental health, anxiety, depression, stress, and psychological well-being. The search was limited to the last 10 years (2010-2020) and included articles published in English. The search was conducted using the following databases: PubMed, PsycINFO, and Google Scholar. The search results were screened based on the title and abstract, and the full text of the most relevant articles was reviewed. The search results were then synthesized into a narrative review, which was organized into the following sections: Introduction, Methods, Results, and Discussion. The results of the search are presented in Table 1.











2019.11.10

10. 已知函数  $f(x) = \frac{1}{x} + \ln x$ ，若  $f(x) > 0$ ，则  $x$  的取值范围是

- (A)  $(0, 1)$
- (B)  $(1, +\infty)$
- (C)  $(0, 1) \cup (1, +\infty)$
- (D)  $(0, 1) \cup (1, 2)$

【解析】由  $f(x) = \frac{1}{x} + \ln x > 0$ ，得  $\ln x > -\frac{1}{x}$ ，即  $\ln x + \frac{1}{x} > 0$ 。

- (A) 当  $x > 1$  时， $\ln x > 0$ ， $\frac{1}{x} > 0$ ，故  $\ln x + \frac{1}{x} > 0$ 。
- (B) 当  $0 < x < 1$  时， $\ln x < 0$ ， $\frac{1}{x} > 0$ ，故  $\ln x + \frac{1}{x} > 0$ 。
- (C) 当  $x = 1$  时， $\ln x = 0$ ， $\frac{1}{x} = 1$ ，故  $\ln x + \frac{1}{x} = 1 > 0$ 。
- (D) 当  $x = 2$  时， $\ln 2 > 0$ ， $\frac{1}{2} > 0$ ，故  $\ln 2 + \frac{1}{2} > 0$ 。

- (A)  $(0, 1)$
- (B)  $(1, +\infty)$
- (C)  $(0, 1) \cup (1, +\infty)$
- (D)  $(0, 1) \cup (1, 2)$

【解析】由  $f(x) = \frac{1}{x} + \ln x > 0$ ，得  $\ln x > -\frac{1}{x}$ ，即  $\ln x + \frac{1}{x} > 0$ 。

- (A) 当  $x > 1$  时， $\ln x > 0$ ， $\frac{1}{x} > 0$ ，故  $\ln x + \frac{1}{x} > 0$ 。
- (B) 当  $0 < x < 1$  时， $\ln x < 0$ ， $\frac{1}{x} > 0$ ，故  $\ln x + \frac{1}{x} > 0$ 。
- (C) 当  $x = 1$  时， $\ln x = 0$ ， $\frac{1}{x} = 1$ ，故  $\ln x + \frac{1}{x} = 1 > 0$ 。
- (D) 当  $x = 2$  时， $\ln 2 > 0$ ， $\frac{1}{2} > 0$ ，故  $\ln 2 + \frac{1}{2} > 0$ 。

- (A)  $(0, 1)$
- (B)  $(1, +\infty)$
- (C)  $(0, 1) \cup (1, +\infty)$
- (D)  $(0, 1) \cup (1, 2)$

【解析】由  $f(x) = \frac{1}{x} + \ln x > 0$ ，得  $\ln x > -\frac{1}{x}$ ，即  $\ln x + \frac{1}{x} > 0$ 。

- (A)  $(0, 1)$
- (B)  $(1, +\infty)$
- (C)  $(0, 1) \cup (1, +\infty)$
- (D)  $(0, 1) \cup (1, 2)$

【解析】由  $f(x) = \frac{1}{x} + \ln x > 0$ ，得  $\ln x > -\frac{1}{x}$ ，即  $\ln x + \frac{1}{x} > 0$ 。

- (A)  $(0, 1)$
- (B)  $(1, +\infty)$
- (C)  $(0, 1) \cup (1, +\infty)$
- (D)  $(0, 1) \cup (1, 2)$

- (A)  $(0, 1)$
- (B)  $(1, +\infty)$
- (C)  $(0, 1) \cup (1, +\infty)$
- (D)  $(0, 1) \cup (1, 2)$

【解析】由  $f(x) = \frac{1}{x} + \ln x > 0$ ，得  $\ln x > -\frac{1}{x}$ ，即  $\ln x + \frac{1}{x} > 0$ 。

41.



















2. 4. 1. 1. 11

```

11:  #
12:  #
13:  #
14:  #

```

```

15:  #

```

```

16:  #

```

```

17:  #

```

```

18:  #
19:  #
20:  #
21:  #

```

```

22:  #

```

```

23:  #

```

```

24:  #

```

```

25:  #
26:  #
27:  #
28:  #

```

```

29:  #

```

```

30:  #

```

```

31:  #

```

```

32:  #
33:  #
34:  #
35:  #

```

```

36:  #

```

```

37:  #

```

```

38:  #

```

```

39:  #
40:  #
41:  #
42:  #
43:  #
44:  #
45:  #
46:  #
47:  #
48:  #
49:  #
50:  #
51:  #
52:  #
53:  #
54:  #
55:  #
56:  #
57:  #
58:  #
59:  #
60:  #
61:  #
62:  #
63:  #
64:  #
65:  #
66:  #
67:  #
68:  #
69:  #
70:  #
71:  #
72:  #
73:  #
74:  #
75:  #
76:  #
77:  #
78:  #
79:  #
80:  #
81:  #
82:  #
83:  #
84:  #
85:  #
86:  #
87:  #
88:  #
89:  #
90:  #
91:  #
92:  #
93:  #
94:  #
95:  #
96:  #
97:  #
98:  #
99:  #
100:  #

```

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

1572 J. N. J. H. J.

# 157. 2019-11-11

Q1

1. The number of students who took the exam was 1000.

2. The number of students who took the exam was 1000.

3. The number of students who took the exam was 1000.

4. The number of students who took the exam was 1000.

5. The number of students who took the exam was 1000.

6. The number of students who took the exam was 1000.

Q2

1. The number of students who took the exam was 1000.

2. The number of students who took the exam was 1000.

3. The number of students who took the exam was 1000.

4. The number of students who took the exam was 1000.

5. The number of students who took the exam was 1000.

6. The number of students who took the exam was 1000.



UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

APPLICATION NO. 2010/0180601  
Filing Date 03/12/12  
Pub. No. 2012/0242012  
Pub. Date 09/27/12

Page 1 of 1


This document is a U.S. Patent Office publication of an international application that has been examined and the following corrections have been made:

1. The title of the invention has been amended to read:

**SYSTEM AND METHOD FOR PROVIDING A SERVICE**

It is to be understood that the above description of the invention is intended to be illustrative of the invention, and not to be construed as limiting the invention. The invention is defined by the following claims, which are to be construed in accordance with the claims as written, including the limitations, exceptions, and exclusions, and not by the above description.

Signature: David J. Kappas  
Seventh Day of August, 2012



David J. Kappas  
Attorney for the Applicant





Fig. 1




Fig. 2




Fig. 3





Fig. 4








Fig. 8




Fig. 7





Fig. 8



[illegible]

**על חן י. ר. מנצח**

As a result, the model is able to allow for a much wider range of  $\alpha$  values than the  $\alpha = 0.5$  model. The  $\alpha = 0.5$  model is only able to handle  $\alpha = 0.5$  and  $\alpha = 1$  and the  $\alpha = 0.5$  model is only able to handle  $\alpha = 0.5$  and  $\alpha = 1$ .

2. توضیح دهید که چرا در این روش، استفاده از یک مادهٔ فلزی برای الکترود کاتد، ضروری است.

1. The above information is being furnished to you for your information only. It is not intended to constitute an offer of insurance or any other financial product. The information is being provided to you for your information only and should not be used for any other purpose. The information is being provided to you for your information only and should not be used for any other purpose.

**11111. 1.1.1.1.1.1.1**

1. The purpose of the present study was to determine the effect of the  
 2. of the present study was to determine the effect of the  
 3. of the present study was to determine the effect of the  
 4. of the present study was to determine the effect of the  
 5. of the present study was to determine the effect of the  
 6. of the present study was to determine the effect of the  
 7. of the present study was to determine the effect of the  
 8. of the present study was to determine the effect of the  
 9. of the present study was to determine the effect of the  
 10. of the present study was to determine the effect of the

W. J. T. J.

[illegible]

A contract was made with the contractor to provide a maximum of 100,000 pounds of material per month. The contract provided for the contractor to be paid for the material on a monthly basis. The contractor was to be paid for the material on a monthly basis. The contractor was to be paid for the material on a monthly basis.

[illegible]

053452

The purpose of this research was to determine whether the inclusion of the child in the decision-making process, relative to the parent, when the parent has been diagnosed with a mental health problem, is associated with a reduced risk of child abuse and neglect. The study was conducted in a community-based setting in a large, urban, multiethnic, low-income area. The study was conducted in a community-based setting in a large, urban, multiethnic, low-income area. The study was conducted in a community-based setting in a large, urban, multiethnic, low-income area.

It is important to note that the results of the study are based on self-reported data and may be subject to recall bias. The study also did not control for other factors that may influence the relationship between the variables.

[illegible]

The proposed findings are consistent with the idea that the more people know about a particular issue, the more they are likely to support it. This is consistent with the idea that the more people know about a particular issue, the more they are likely to support it. This is consistent with the idea that the more people know about a particular issue, the more they are likely to support it.

the different levels of the hierarchy of the network, the level of the network that is the most important for the network is the level of the network that is the most important for the network.

[illegible]

The present study on the effects of a novel exercise program on bone mineral density and bone mass was limited by several factors. In particular, the relatively small sample size and the short duration of the study may have compromised the power of the study to detect statistically significant differences in bone mass and bone density between the two groups. However, the results of the present study are in line with those of other studies that have shown that a combination of resistance and aerobic exercise can improve bone density and bone mass in older adults.

There is still a great deal of support for the idea that the world is becoming more peaceful, and that the threat of nuclear war has been reduced. This is a common theme in many of the articles, and it is one that is likely to continue to be a topic of interest for many years to come.

י"ד ט"ז תמוז ה'תשנ"ד

There is a clear link between the effects of the anti-AMLG and the growth of the private sector in the economy and the fact that the government has been able to attract foreign investment. This is a key factor in the growth of the private sector and the economy as a whole.













[illegible]

— 24 —

[illegible][illegible]

The above method is more straightforward than the one used by the authors. It is also simpler to implement and does not require the use of a computer. The method is also more robust to noise and can be used to estimate the parameters of a mixture of Gaussians. The method is also more efficient than the EM algorithm, which requires a large number of iterations to converge.

三、4 :

ST. LOUIS, MO. (AP) —

Many agencies have been successful in obtaining support for their programs from the private sector. For example, the National Aeronautics and Space Administration (NASA) has received significant funding from private companies such as Boeing and Lockheed Martin. This funding has helped NASA to develop new technologies and conduct research in space exploration.

— — — — —

1. *Journal of the American Academy of Pediatrics*, 1998; 81: 100-101.

Many people are concerned that the use of the word "disorder" in the title of this book is a negative statement about the people who experience the disorder. The authors discuss the use of the word "disorder" in the title of this book and the reasons for its use. They also discuss the use of the word "disorder" in the title of this book and the reasons for its use.

Two key determinants of corporate activity in the past have been money and technology. The growth of the money supply has been a major cause of inflation, and the growth of technology has been a major cause of productivity growth. The growth of the money supply has been a major cause of inflation, and the growth of technology has been a major cause of productivity growth. The growth of the money supply has been a major cause of inflation, and the growth of technology has been a major cause of productivity growth.

[illegible]

Model 1 is a linear model where the observed value of the response function is assumed to be a linear function of the covariate. However, for an unbalanced design, the response function may not be linear. In such a case, a nonlinear model (e.g., a quadratic model) may be more appropriate. In this paper, we consider a quadratic model where the response function is assumed to be a quadratic function of the covariate. The quadratic model is a nonlinear model, but it is a simple model that can be fitted using standard statistical software. The quadratic model is also a good approximation for many nonlinear functions. In this paper, we consider a quadratic model where the response function is assumed to be a quadratic function of the covariate. The quadratic model is a nonlinear model, but it is a simple model that can be fitted using standard statistical software. The quadratic model is also a good approximation for many nonlinear functions.

[Redacted]

THE UNIVERSITY OF TEXAS AT AUSTIN  
 Graduate School of Education  
 1000 UNIVERSITY DRIVE, AUSTIN, TEXAS 78705

The second of these is the possibility that the  
 majority of the respondents in the survey are  
 members of the "middle class" of the population.  
 The third is the possibility that the respondents  
 are not representative of the population as a whole.  
 The fourth is the possibility that the respondents  
 are not representative of the population as a whole.  
 The fifth is the possibility that the respondents  
 are not representative of the population as a whole.  
 The sixth is the possibility that the respondents  
 are not representative of the population as a whole.  
 The seventh is the possibility that the respondents  
 are not representative of the population as a whole.  
 The eighth is the possibility that the respondents  
 are not representative of the population as a whole.  
 The ninth is the possibility that the respondents  
 are not representative of the population as a whole.  
 The tenth is the possibility that the respondents  
 are not representative of the population as a whole.

These authors suggest that the distribution of the degree of the cytoplasmic inheritance of the *trp* locus in *D. melanogaster* is determined by the frequency of the cytoplasmic inheritance of the *trp* locus in the population. The authors suggest that the *trp* locus is inherited in a Mendelian fashion, but the cytoplasmic inheritance of the *trp* locus is determined by the frequency of the cytoplasmic inheritance of the *trp* locus in the population. The authors suggest that the *trp* locus is inherited in a Mendelian fashion, but the cytoplasmic inheritance of the *trp* locus is determined by the frequency of the cytoplasmic inheritance of the *trp* locus in the population.

Following upon studies which have shown that the use of a computer-based system for the development and management of a business plan is a healthy and effective way of ensuring that a company's strategy is well thought out and that the business is well managed, the authors have developed a computer-based system for the development and management of a business plan. The system is designed to be used by a company's management team and is based on the principles of strategic management. The system is designed to be used by a company's management team and is based on the principles of strategic management.

First:

1. The first step is to identify the problem. In this case, the problem is that the system is not working properly.

Abstracts of the 1998 Annual Meeting of the American Psychological Association, Washington, DC, August 1-5, 1998. The meeting was held at the Marriott Marquis Hotel, Washington, DC. The meeting was attended by approximately 10,000 psychologists and other mental health professionals. The meeting was organized into several tracks, including: Clinical Psychology, Developmental Psychology, Educational Psychology, Experimental Psychology, Health Psychology, Industrial/Organization Psychology, Legal Psychology, Measurement and Statistics, Personality and Social Psychology, and Research in Psychology. The meeting featured a variety of presentations, including keynote addresses, plenary sessions, and symposia. The meeting was a major event in the field of psychology and provided a valuable opportunity for researchers and practitioners to share their work and ideas.





UNITED STATES DEPARTMENT AND DISTRICTS OFFICE  
CERTIFICATE OF CORRECTION

|          |            |
|----------|------------|
| TESTED   | 20040522   |
| APPROVED | 17470      |
| DATE     | 2004-05-22 |
| BY       | 20040522   |

— 14 —

[illegible]

**Keywords:** *depression, anxiety, self-esteem, self-efficacy, coping strategies, social support*

[illegible]

by Fred and Zeke. This

11 AUGUST 2015

David J. K. Jones

Mod. 1977  
 1977/1978/1979/1980/1981/1982/1983/1984/1985/1986/1987/1988/1989/1990/1991/1992/1993/1994/1995/1996/1997/1998/1999/2000/2001/2002/2003/2004/2005/2006/2007/2008/2009/2010/2011/2012/2013/2014/2015/2016/2017/2018/2019/2020/2021/2022/2023/2024/2025/2026/2027/2028/2029/2030/2031/2032/2033/2034/2035/2036/2037/2038/2039/2040/2041/2042/2043/2044/2045/2046/2047/2048/2049/2050/2051/2052/2053/2054/2055/2056/2057/2058/2059/2060/2061/2062/2063/2064/2065/2066/2067/2068/2069/2070/2071/2072/2073/2074/2075/2076/2077/2078/2079/2080/2081/2082/2083/2084/2085/2086/2087/2088/2089/2090/2091/2092/2093/2094/2095/2096/2097/2098/2099/2100/2101/2102/2103/2104/2105/2106/2107/2108/2109/2110/2111/2112/2113/2114/2115/2116/2117/2118/2119/2120/2121/2122/2123/2124/2125/2126/2127/2128/2129/2130/2131/2132/2133/2134/2135/2136/2137/2138/2139/2140/2141/2142/2143/2144/2145/2146/2147/2148/2149/2150/2151/2152/2153/2154/2155/2156/2157/2158/2159/2160/2161/2162/2163/2164/2165/2166/2167/2168/2169/2170/2171/2172/2173/2174/2175/2176/2177/2178/2179/2180/2181/2182/2183/2184/2185/2186/2187/2188/2189/2190/2191/2192/2193/2194/2195/2196/2197/2198/2199/2200/2201/2202/2203/2204/2205/2206/2207/2208/2209/2210/2211/2212/2213/2214/2215/2216/2217/2218/2219/2220/2221/2222/2223/2224/2225/2226/2227/2228/2229/2230/2231/2232/2233/2234/2235/2236/2237/2238/2239/2240/2241/2242/2243/2244/2245/2246/2247/2248/2249/2250/2251/2252/2253/2254/2255/2256/2257/2258/2259/2260/2261/2262/2263/2264/2265/2266/2267/2268/2269/2270/2271/2272/2273/2274/2275/2276/2277/2278/2279/2280/2281/2282/2283/2284/2285/2286/2287/2288/2289/2290/2291/2292/2293/2294/2295/2296/2297/2298/2299/2300/2301/2302/2303/2304/2305/2306/2307/2308/2309/2310/2311/2312/2313/2314/2315/2316/2317/2318/2319/2320/2321/2322/2323/2324/2325/2326/2327/2328/2329/2330/2331/2332/2333/2334/2335/2336/2337/2338/2339/2340/2341/2342/2343/2344/2345/2346/2347/2348/2349/2350/2351/2352/2353/2354/2355/2356/2357/2358/2359/2360/2361/2362/2363/2364/2365/2366/2367/2368/2369/2370/2371/2372/2373/2374/2375/2376/2377/2378/2379/2380/2381/2382/2383/2384/2385/2386/2387/2388/2389/2390/2391/2392/2393/2394/2395/2396/2397/2398/2399/2400/2401/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2413/2414/2415/2416/2417/2418/2419/2420/2421/2422/2423/2424/2425/2426/2427/2428/2429/2430/2431/2432/2433/2434/2435/2436/2437/2438/2439/2440/2441/2442/2443/2444/2445/2446/2447/2448/2449/2450/2451/2452/2453/2454/2455/2456/2457/2458/2459/2460/2461/2462/2463/2464/2465/2466/2467/2468/2469/2470/2471/2472/2473/2474/2475/2476/2477/2478/2479/2480/2481/2482/2483/2484/2485/2486/2487/2488/2489/2490/2491/2492/2493/2494/2495/2496/2497/2498/2499/2500/2501/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2513/2514/2515/2516/2517/2518/2519/2520/2521/2522/2523/2524/2525/2526/2527/2528/2529/2530/2531/2532/2533/2534/2535/2536/2537/2538/2539/2540/2541/2542/2543/2544/2545/2546/2547/2548/2549/2550/2551/2552/2553/2554/2555/2556/2557/2558/2559/2560/2561/2562/2563/2564/2565/2566/2567/2568/2569/2570/2571/2572/2573/2574/2575/2576/2577/2578/2579/2580/2581/2582/2583/2584/2585/2586/2587/2588/2589/2590/2591/2592/2593/2594/2595/2596/2597/2598/2599/2600/2601/2602/2603/2604/2605/2606/2607/2608/2609/2610/2611/2612/2613/2614/2615/2616/2617/2618/2619/2620/2621/2622/2623/2624/2625/2626/2627/2628/2629/2630/2631/2632/2633/2634/2635/2636/2637/2638/2639/2640/2641/2642/2643/2644/2645/2646/2647/2648/2649/2650/2651/2652/2653/2654/2655/2656/2657/2658/2659/2660/2661/2662/2663/2664/2665/2666/2667/2668/2669/2670/2671/2672/2673/2674/2675/2676/2677/2678/2679/2680/2681/2682/2683/2684/2685/2686/2687/2688/2689/2690/2691/2692/2693/2694/2695/2696/2697/2698/2699/2700/2701/2702/2703/2704/2705/2706/2707/2708/2709/2710/2711/2712/2713/2714/2715/2716/2717/2718/2719/2720/2721/2722/2723/2724/2725/2726/2727/2728/2729/2730/2731/2732/2733/2734/2735/2736/2737/2738/2739/2740/2741/2742/2743/2744/2745/2746/2747/2748/2749/2750/2751/2752/2753/2754/2755/2756/2757/2758/2759/2760/2761/2762/2763/2764/2765/2766/2767/2768/2769/2770/2771/2772/2773/2774/2775/2776/2777/2778/2779/2780/2781/2782/2783/2784/2785/2786/2787/2788/2789/2790/2791/2792/27



U.S. PAT. & TM. OFF.

U.S. United States

Patent Application Publication

(Publication No.)

Pub. No. US 2010/0137462 A1

Pub. Date

May 26, 2010

Int. Cl. Class. H01M 10/42 (2006.01)

Int. Cl. Class. H01M 10/42 (2006.01)

Applicant: **SAKURA ELECTRIC CO., LTD.**  
 1-1-1, Sakuragaoka 1-chome, Setagaya-ku,  
 Tokyo 158-8501, Japan

Attorney: **CHAMBERLAIN**

Attorney: **CHAMBERLAIN**  
 1000 17th Street, N.W., Suite 1000  
 Washington, D.C. 20036

Attorney: **CHAMBERLAIN**

Attorney: **CHAMBERLAIN**

Attorney: **CHAMBERLAIN**

Attorney: **CHAMBERLAIN**

Attorney: **CHAMBERLAIN**

Attorney: **CHAMBERLAIN**

Attorney: **CHAMBERLAIN**


Applicant: **SAKURA ELECTRIC CO., LTD.**

Applicant: **SAKURA ELECTRIC CO., LTD.**

Attorney: **CHAMBERLAIN**

Applicant: **SAKURA ELECTRIC CO., LTD.**  
 1-1-1, Sakuragaoka 1-chome, Setagaya-ku,  
 Tokyo 158-8501, Japan

Applicant: **SAKURA ELECTRIC CO., LTD.**  
 1-1-1, Sakuragaoka 1-chome, Setagaya-ku,  
 Tokyo 158-8501, Japan






FIG. 3




FIG. 2






FIG. 3A




FIG. 3B






FIG. 5A




FIG. 5B




FIG. 6




FIG. 7




FIG. 8





















2023학년도 2학기 기말고사

2023학년도 2학기 기말고사

1. 다음 중 옳지 않은 것은?
2. 다음 중 옳지 않은 것은?
3. 다음 중 옳지 않은 것은?
4. 다음 중 옳지 않은 것은?
5. 다음 중 옳지 않은 것은?
6. 다음 중 옳지 않은 것은?
7. 다음 중 옳지 않은 것은?
8. 다음 중 옳지 않은 것은?
9. 다음 중 옳지 않은 것은?
10. 다음 중 옳지 않은 것은?
11. 다음 중 옳지 않은 것은?
12. 다음 중 옳지 않은 것은?
13. 다음 중 옳지 않은 것은?
14. 다음 중 옳지 않은 것은?
15. 다음 중 옳지 않은 것은?
16. 다음 중 옳지 않은 것은?
17. 다음 중 옳지 않은 것은?
18. 다음 중 옳지 않은 것은?
19. 다음 중 옳지 않은 것은?
20. 다음 중 옳지 않은 것은?

2023학년도 2학기 기말고사

2023학년도 2학기 기말고사

1. 다음 중 옳지 않은 것은?

2023학년도 2학기 기말고사

2. 다음 중 옳지 않은 것은?

3. 다음 중 옳지 않은 것은?

4. 다음 중 옳지 않은 것은?

2023학년도 2학기 기말고사

5. 다음 중 옳지 않은 것은?

2023학년도 2학기 기말고사

6. 다음 중 옳지 않은 것은?

7. 다음 중 옳지 않은 것은?

2023학년도 2학기 기말고사

8. 다음 중 옳지 않은 것은?

2023학년도 2학기 기말고사

2023학년도 2학기 기말고사





1 5 7 9 11

U.S. Limited States Patent  
Hager & Co.

Air Parcel No: 115 7.987.183 R2  
 Date of Exam: 11/15/2011

[illegible]

1. **Introduction**

10441 - 10449

17. Journal of Management Inquiry, 13(1), 19-30, 2004.  
 Information retrieved from JSTOR.  
 Address: 201 East 21st Street, New York, NY 10003-1598.  
 E-mail: jmi@jmi.sagepub.com.  
 Available online at: <http://jmi.sagepub.com>  
 DOI: 10.1177/1056492604264011

[illegible]

Journal of the American Academy of Child and Adolescent Psychiatry  
Volume 37, Number 10, October 1998  
Published online October 1, 1998  
DOI: 10.1097/00004583-199810000-00001  
Copyright © 1998 by Williams & Wilkins  
0885-0666/98/0000-0000\$05.00/0

1. *What is the purpose of the study?*  
 2. *What are the research objectives?*  
 3. *What is the scope of the study?*

17. 1st 71 hours of work.  
1st 71 hours of work. 1st 71 hours of work.

© 2005 Blackwell Publishing Ltd, *Journal of Internal Medicine* 257: 103–110

James T. G. Jones, Jr., Director, National Science Foundation  
Washington, D.C. 20540

1992-1993

התקן זה יורש את כל ההגדרות של התקן המקורי.

Yamamoto, T. et al. The neural network of the visual motion pattern processing system. *Neurosci Res* 1999; 35: 1-10.

**P. J. van der Schoot**

"I am a member of the National Association of Broadcasters, and I am proud to be a part of the industry that has helped shape the way we communicate. I am also a member of the National Association of Broadcasters, and I am proud to be a part of the industry that has helped shape the way we communicate."

12. 00 141.3 \*

Copyright © 2004 by John Wiley & Sons, Inc.

18. **Why is the following incorrect?**

[illegible]

**Figure 1** **and** **www**

DATE: 11-11-1968

For more information, visit [www.pearsoncmg.com](http://www.pearsoncmg.com) or contact your local Pearson Education representative.

© 2000 Blackwell Science Ltd, *Journal of Internal Medicine* 247: 111–118

1979. The effect of low water levels on the growth of *Hydrilla verticillata* L. f. in a shallow pond. *Hydrobiologia* 77: 105-110.

1. The following information was obtained from the records of the Department of the Interior, Bureau of Land Management, regarding the land owned by the United States in the State of Nevada:

[illegible]

1. *Chlorophyll a* (Chl *a*)  
 2. *Chlorophyll b* (Chl *b*)  
 3. *Chlorophyll c* (Chl *c*)  
 4. *Chlorophyll d* (Chl *d*)  
 5. *Chlorophyll e* (Chl *e*)  
 6. *Chlorophyll f* (Chl *f*)  
 7. *Chlorophyll g* (Chl *g*)  
 8. *Chlorophyll h* (Chl *h*)  
 9. *Chlorophyll i* (Chl *i*)  
 10. *Chlorophyll j* (Chl *j*)  
 11. *Chlorophyll k* (Chl *k*)  
 12. *Chlorophyll l* (Chl *l*)  
 13. *Chlorophyll m* (Chl *m*)  
 14. *Chlorophyll n* (Chl *n*)  
 15. *Chlorophyll o* (Chl *o*)  
 16. *Chlorophyll p* (Chl *p*)  
 17. *Chlorophyll q* (Chl *q*)  
 18. *Chlorophyll r* (Chl *r*)  
 19. *Chlorophyll s* (Chl *s*)  
 20. *Chlorophyll t* (Chl *t*)  
 21. *Chlorophyll u* (Chl *u*)  
 22. *Chlorophyll v* (Chl *v*)  
 23. *Chlorophyll w* (Chl *w*)  
 24. *Chlorophyll x* (Chl *x*)  
 25. *Chlorophyll y* (Chl *y*)  
 26. *Chlorophyll z* (Chl *z*)  
 27. *Chlorophyll aa* (Chl *aa*)  
 28. *Chlorophyll ab* (Chl *ab*)  
 29. *Chlorophyll ac* (Chl *ac*)  
 30. *Chlorophyll ad* (Chl *ad*)  
 31. *Chlorophyll ae* (Chl *ae*)  
 32. *Chlorophyll af* (Chl *af*)  
 33. *Chlorophyll ag* (Chl *ag*)  
 34. *Chlorophyll ah* (Chl *ah*)  
 35. *Chlorophyll ai* (Chl *ai*)  
 36. *Chlorophyll aj* (Chl *aj*)  
 37. *Chlorophyll ak* (Chl *ak*)  
 38. *Chlorophyll al* (Chl *al*)  
 39. *Chlorophyll am* (Chl *am*)  
 40. *Chlorophyll an* (Chl *an*)  
 41. *Chlorophyll ao* (Chl *ao*)  
 42. *Chlorophyll ap* (Chl *ap*)  
 43. *Chlorophyll aq* (Chl *aq*)  
 44. *Chlorophyll ar* (Chl *ar*)  
 45. *Chlorophyll as* (Chl *as*)  
 46. *Chlorophyll at* (Chl *at*)  
 47. *Chlorophyll au* (Chl *au*)  
 48. *Chlorophyll av* (Chl *av*)  
 49. *Chlorophyll aw* (Chl *aw*)  
 50. *Chlorophyll ax* (Chl *ax*)  
 51. *Chlorophyll ay* (Chl *ay*)  
 52. *Chlorophyll az* (Chl *az*)  
 53. *Chlorophyll aza* (Chl *aza*)  
 54. *Chlorophyll abz* (Chl *abz*)  
 55. *Chlorophyll acz* (Chl *acz*)  
 56. *Chlorophyll adz* (Chl *adz*)  
 57. *Chlorophyll aez* (Chl *aez*)  
 58. *Chlorophyll afz* (Chl *afz*)  
 59. *Chlorophyll agz* (Chl *agz*)  
 60. *Chlorophyll ahz* (Chl *ahz*)  
 61. *Chlorophyll aiz* (Chl *aiz*)  
 62. *Chlorophyll ajz* (Chl *ajz*)  
 63. *Chlorophyll akz* (Chl *akz*)  
 64. *Chlorophyll alz* (Chl *alz*)  
 65. *Chlorophyll amz* (Chl *amz*)  
 66. *Chlorophyll anz* (Chl *anz*)  
 67. *Chlorophyll aoz* (Chl *aoz*)  
 68. *Chlorophyll apz* (Chl *apz*)  
 69. *Chlorophyll aqz* (Chl *aqz*)  
 70. *Chlorophyll arz* (Chl *arz*)  
 71. *Chlorophyll asz* (Chl *asz*)  
 72. *Chlorophyll atz* (Chl *atz*)  
 73. *Chlorophyll auz* (Chl *auz*)  
 74. *Chlorophyll avz* (Chl *avz*)  
 75. *Chlorophyll awz* (Chl *awz*)  
 76. *Chlorophyll axz* (Chl *axz*)  
 77. *Chlorophyll ayz* (Chl *ayz*)  
 78. *Chlorophyll azz* (Chl *azz*)  
 79. *Chlorophyll azaa* (Chl *aza*<sub>aa</sub>)  
 80. *Chlorophyll abz* (Chl *abz*)  
 81. *Chlorophyll acz* (Chl *acz*)  
 82. *Chlorophyll adz* (Chl *adz*)  
 83. *Chlorophyll aez* (Chl *aez*)  
 84. *Chlorophyll afz* (Chl *afz*)  
 85. *Chlorophyll agz* (Chl *agz*)  
 86. *Chlorophyll ahz* (Chl *ahz*)  
 87. *Chlorophyll aiz* (Chl *aiz*)  
 88. *Chlorophyll ajz* (Chl *ajz*)  
 89. *Chlorophyll akz* (Chl *akz*)  
 90. *Chlorophyll alz* (Chl *alz*)  
 91. *Chlorophyll amz* (Chl *amz*)  
 92. *Chlorophyll anz* (Chl *anz*)  
 93. *Chlorophyll aoz* (Chl *aoz*)  
 94. *Chlorophyll apz* (Chl *apz*)  
 95. *Chlorophyll aqz* (Chl *aqz*)  
 96. *Chlorophyll arz* (Chl *arz*)  
 97. *Chlorophyll asz* (Chl *asz*)  
 98. *Chlorophyll atz* (Chl *atz*)  
 99. *Chlorophyll auz* (Chl *auz*)  
 100. *Chlorophyll avz* (Chl *avz*)  
 101. *Chlorophyll awz* (Chl *awz*)  
 102. *Chlorophyll axz* (Chl *axz*)  
 103. *Chlorophyll ayz* (Chl *ayz*)  
 104. *Chlorophyll azz* (Chl *azz*)  
 105. *Chlorophyll azaa* (Chl *aza*<sub>aa</sub>)  
 106. *Chlorophyll abz* (Chl *abz*)  
 107. *Chlorophyll acz* (Chl *acz*)  
 108. *Chlorophyll adz* (Chl *adz*)  
 109. *Chlorophyll aez* (Chl *aez*)  
 110. *Chlorophyll afz* (Chl *afz*)  
 111. *Chlorophyll agz* (Chl *agz*)  
 112. *Chlorophyll ahz* (Chl *ahz*)  
 113. *Chlorophyll aiz* (Chl *aiz*)  
 114. *Chlorophyll ajz* (Chl *ajz*)  
 115. *Chlorophyll akz* (Chl *akz*)  
 116. *Chlorophyll alz* (Chl *alz*)  
 117. *Chlorophyll amz* (Chl *amz*)  
 118. *Chlorophyll anz* (Chl *anz*)  
 119. *Chlorophyll aoz* (Chl *aoz*)  
 120. *Chlorophyll apz* (Chl *apz*)  
 121. *Chlorophyll aqz* (Chl *aqz*)  
 122. *Chlorophyll arz* (Chl *arz*)  
 123. *Chlorophyll asz* (Chl *asz*)  
 124. *Chlorophyll atz* (Chl *atz*)  
 125. *Chlorophyll auz* (Chl *auz*)  
 126. *Chlorophyll avz* (Chl *avz*)  
 127. *Chlorophyll awz* (Chl *awz*)  
 128. *Chlorophyll axz* (Chl *axz*)  
 129. *Chlorophyll ayz* (Chl *ayz*)  
 130. *Chlorophyll azz* (Chl *azz*)  
 131. *Chlorophyll azaa* (Chl *aza*<sub>aa</sub>)  
 132. *Chlorophyll abz* (Chl

For more information, contact the American Psychological Association, 750 First Street, N.E., Washington, D.C. 20002-4242. Tel: 202/336-6000. Fax: 202/336-6010. E-mail: [info@apa.org](mailto:info@apa.org). Web: <http://www.apa.org>.

1997-1998

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840. 84

Q18. What is the difference between a variable and a constant?

DATE: 05/15/2014

[illegible]

התאריך: 10.12.2019

43 447

18. **How many 's' are there?**

[illegible]

| Year | Number of cases | Rate per 100,000 |
|------|-----------------|------------------|
| 1990 | 1,000           | 1.0              |
| 1991 | 1,100           | 1.1              |
| 1992 | 1,200           | 1.2              |
| 1993 | 1,300           | 1.3              |
| 1994 | 1,400           | 1.4              |
| 1995 | 1,500           | 1.5              |
| 1996 | 1,600           | 1.6              |
| 1997 | 1,700           | 1.7              |
| 1998 | 1,800           | 1.8              |
| 1999 | 1,900           | 1.9              |
| 2000 | 2,000           | 2.0              |
| 2001 | 2,100           | 2.1              |
| 2002 | 2,200           | 2.2              |
| 2003 | 2,300           | 2.3              |
| 2004 | 2,400           | 2.4              |
| 2005 | 2,500           | 2.5              |
| 2006 | 2,600           | 2.6              |
| 2007 | 2,700           | 2.7              |
| 2008 | 2,800           | 2.8              |
| 2009 | 2,900           | 2.9              |
| 2010 | 3,000           | 3.0              |
| 2011 | 3,100           | 3.1              |
| 2012 | 3,200           | 3.2              |
| 2013 | 3,300           | 3.3              |
| 2014 | 3,400           | 3.4              |
| 2015 | 3,500           | 3.5              |
| 2016 | 3,600           | 3.6              |
| 2017 | 3,700           | 3.7              |
| 2018 | 3,800           | 3.8              |
| 2019 | 3,900           | 3.9              |
| 2020 | 4,000           | 4.0              |

100

1. +14. - 27 32 61' 2

**Abstract**


2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 2546 2547 2548 2549 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 2569 2570 2571 2572 2573 2574 2575 2576 2577 2578 2579 2580 2581 2582 2583 2584 2585 2586 2587 2588 2589 2590 2591 2592 2593 2594 2595 2596 2597 2598 2599 2600 2601 2602 2603 2604 2605 2606 2607 2608 2609 2610 2611 2612 2613 2614 2615 2616 2617 2618 2619 2620 2621 2622 2623 2624 2625 2626 2627 2628 2629 2630 2631 2632 2633 2634 2635 2636 2637 2638 2639 2640 2641 2642 2643 2644 2645 2646 2647 2648 2649 2650 2651 2652 2653 2654 2655 2656 2657 2658 2659 2660 2661 2662 2663 2664 2665 2666 2667 2668 2669 2670 2671 2672 2673 2674 2675 2676 2677 2678 2679 2680 2681 2682 2683 2684 2685 2686 2687 2688 2689 2690 2691 2692 2693 2694 2695 2696 2697 2698 2699 2700 2701 2702 2703 2704 2705 2706 2707 2708 2709 2710 2711 2712 2713 2714 2715 2716 2717 2718 2719 2720 2721 2722 2723 2724 2725 2726 2727 2728 2729 2730 2731 2732 2733 2734 2735 2736 2737 2738 2739 2740 2741 2742 2743 2744 2745 2746 2747 2748 2749 2750 2751 2752 2753 2754 2755 2756 2757 2758 2759 2760 2761 2762 2763 2764 2765 2766 2767 2768 2769 2770 2771 2772 2773 2774 2775 2776 2777 2778 2779 2780 2781 2782 2783 2784 2785 2786 2787 2788 2789 2790 2791 2792 2793 2794 2795 2796 2797 2798 2799 2800 2801 2802 2803 2804 2805 2806 2807 2808 2809 2810 2811 2812 2813 2814 2815 2816 2817 2818

1. **Introduction**  
 2. **Background**  
 3. **Methodology**  
 4. **Results**  
 5. **Conclusion**  
 6. **References**

The present study is a descriptive study of the attitudes to the use of a group of young women and an older adult to assess the effectiveness of the use of the target group. The present study is a descriptive study of the attitudes to the use of a group of young women and an older adult to assess the effectiveness of the use of the target group. The present study is a descriptive study of the attitudes to the use of a group of young women and an older adult to assess the effectiveness of the use of the target group.

12 MAY 2003





## Figure 1




Figure 2




FIGURE 3




Figure 4




Figure 2




Figure 6






Figure 2

THE STATE OF NEW YORK  
IN SENATE  
January 11, 1900.  
REPORT  
OF THE  
COMMISSIONER OF THE LAND OFFICE.

THE STATE OF NEW YORK.

ALBANY: J. B. LIPPINCOTT & CO., PRINTERS.  
1900.

THE COMMISSIONER.

The Commission on the subject of the land office, created by chapter 100 of the laws of 1898, has the honor to submit herewith its report. The Commission was organized on July 1, 1898, and has since that time been engaged in a study of the various questions connected with the management of the land office. It has held numerous public hearings, and has received many suggestions from the public. It has also conducted extensive research into the various problems connected with the land office, and has endeavored to formulate a plan of reform which will meet the needs of the State.

The Commission has found that the land office is one of the most important departments of the State government, and that its management is of great importance to the State. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department.

The Commission has found that the land office is one of the most important departments of the State government, and that its management is of great importance to the State. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department.

The Commission has found that the land office is one of the most important departments of the State government, and that its management is of great importance to the State. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department.

The Commission has found that the land office is one of the most important departments of the State government, and that its management is of great importance to the State. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department.

The Commission has found that the land office is one of the most important departments of the State government, and that its management is of great importance to the State. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department.

The Commission has found that the land office is one of the most important departments of the State government, and that its management is of great importance to the State. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department.

The Commission has found that the land office is one of the most important departments of the State government, and that its management is of great importance to the State. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department.

The Commission has found that the land office is one of the most important departments of the State government, and that its management is of great importance to the State. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department. It has found that the present management of the land office is inefficient, and that it is necessary to reorganize the department.



15. **יחידת המערכת**

1

2. The following table shows the number of people who have been convicted of a crime in the United States since 1990. The data is presented in millions of people.

Author's address: Department of Mathematics, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92037, USA. E-mail: [shrawan@math.ucsd.edu](mailto:shrawan@math.ucsd.edu)

The use of the term "the" seems to imply that the company is a single entity, and that the shareholders are not entitled to a share of the company's assets or profits. This is not the case. The company is a separate legal entity, and the shareholders are entitled to a share of the company's assets and profits. The company is also a separate legal entity, and the shareholders are entitled to a share of the company's assets and profits.

[illegible]

The following information is for the use of the user only. It is not intended to be used as a substitute for the information provided in the user manual. The information provided in this document is for informational purposes only and is not intended to be used as a substitute for the information provided in the user manual. The information provided in this document is for informational purposes only and is not intended to be used as a substitute for the information provided in the user manual.

LEWIS & CLARK

1981, p. 10, and p. 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844

[illegible]

707.07 11th Ave - 2nd Fl., near the  
corner Pennsylvania Ave. - 1st Ave.

COINTELPRO, SECURITY MATTERS, RECENTLY  
DISCLOSED: 10/10/68, 10/10/68

**U.S. DEPARTMENT OF AGRICULTURE**  
**FOREST SERVICE**

1. The first step is to identify the problem or question that needs to be answered. This involves understanding the context and the specific requirements of the task.

1. The first step is to identify the problem or goal. This involves understanding the current situation and what needs to be achieved.

CO. DIR. SHERIFF'S OFFICE, ALBUQUERQUE, N.M.  
 1-10-68 10:00 AM  
 TO: SAC, ALBUQUERQUE (44-1987)  
 FROM: SAC, ALBUQUERQUE (44-1987) (P)  
 RE: MURDER OF MARTIN LUTHER KING, JR.;  
 CIVIL RIGHTS; RACIAL MATTERS; ALBUQUERQUE, N.M.;  
 4-4-68; BUREAU FILE NO. 44-38861-1000

1. *Journal of the American Medical Association*, 1997; 277: 1001-1005.

L. P. ...

1. *Thyridopteryx* sp. nov.

• Kalkulationen für die Kostenstellen

1. *Thyridopteryx* sp. nov. (Fig. 10)



U.S. Nat. Acad. Sci., 1977, 74, 100-101.

U.S. DEPARTMENT OF JUSTICE  
FEDERAL BUREAU OF INVESTIGATION

4) "The fact that the [redacted] is a [redacted] is not a [redacted] in itself. The [redacted] is a [redacted] in itself." (b) (7) (D)

4) 11th Ind. Terr. v. Wright, 137 U.S. 46 (1891).

1. 請將下列各句中的動詞，用適當的動詞形式填入括弧內。

He has my name on it.

[illegible]

10. 7. 1964

16. The above information is true and correct.

[illegible][illegible]

1. The first step is to identify the problem or question that needs to be answered. This involves understanding the context and the specific requirements of the task.

1. 2011年12月11日

**XZCJ:DJXW:TCGXZZ**

1. The following table shows the number of people who have been convicted of a crime in the United States since 1990. The number of people who have been convicted of a crime in the United States since 1990 is shown in the following table.

[illegible][illegible]











1. The first step in the process of the development of the new system is the identification of the current system and its limitations. This is done by conducting a thorough analysis of the existing system and its components. The next step is to define the requirements for the new system. This is done by consulting with the users and stakeholders to determine their needs and expectations. The third step is to design the new system. This involves creating a detailed plan for the system's architecture, data flow, and user interface. The final step is to implement the new system. This involves writing the code, testing the system, and deploying it to the production environment.

2. The second step in the process of the development of the new system is the identification of the requirements for the new system. This is done by consulting with the users and stakeholders to determine their needs and expectations. The next step is to design the new system. This involves creating a detailed plan for the system's architecture, data flow, and user interface. The final step is to implement the new system. This involves writing the code, testing the system, and deploying it to the production environment.

3. The third step in the process of the development of the new system is the design of the new system. This involves creating a detailed plan for the system's architecture, data flow, and user interface. The final step is to implement the new system. This involves writing the code, testing the system, and deploying it to the production environment.

4. The fourth step in the process of the development of the new system is the implementation of the new system. This involves writing the code, testing the system, and deploying it to the production environment. The final step is to evaluate the new system. This involves comparing the new system to the requirements and determining if it meets the users' needs and expectations.

5. The fifth step in the process of the development of the new system is the evaluation of the new system. This involves comparing the new system to the requirements and determining if it meets the users' needs and expectations. The final step is to maintain the new system. This involves monitoring the system's performance and making any necessary updates or improvements.

6. The sixth step in the process of the development of the new system is the maintenance of the new system. This involves monitoring the system's performance and making any necessary updates or improvements. The final step is to document the new system. This involves creating a detailed plan for the system's architecture, data flow, and user interface. The final step is to implement the new system. This involves writing the code, testing the system, and deploying it to the production environment.

7. The seventh step in the process of the development of the new system is the documentation of the new system. This involves creating a detailed plan for the system's architecture, data flow, and user interface. The final step is to implement the new system. This involves writing the code, testing the system, and deploying it to the production environment.

8. The eighth step in the process of the development of the new system is the implementation of the new system. This involves writing the code, testing the system, and deploying it to the production environment. The final step is to evaluate the new system. This involves comparing the new system to the requirements and determining if it meets the users' needs and expectations.

9. The ninth step in the process of the development of the new system is the evaluation of the new system. This involves comparing the new system to the requirements and determining if it meets the users' needs and expectations. The final step is to maintain the new system. This involves monitoring the system's performance and making any necessary updates or improvements.

10. The tenth step in the process of the development of the new system is the maintenance of the new system. This involves monitoring the system's performance and making any necessary updates or improvements. The final step is to document the new system. This involves creating a detailed plan for the system's architecture, data flow, and user interface. The final step is to implement the new system. This involves writing the code, testing the system, and deploying it to the production environment.

11. The eleventh step in the process of the development of the new system is the documentation of the new system. This involves creating a detailed plan for the system's architecture, data flow, and user interface. The final step is to implement the new system. This involves writing the code, testing the system, and deploying it to the production environment.

12. The twelfth step in the process of the development of the new system is the implementation of the new system. This involves writing the code, testing the system, and deploying it to the production environment. The final step is to evaluate the new system. This involves comparing the new system to the requirements and determining if it meets the users' needs and expectations.





1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840. 84

| Kontingenztafel für die Unabhängigkeit von $X$ und $Y$ |       |                |
|--------------------------------------------------------|-------|----------------|
| Kategorie $X$                                          | $Y$   | Summe $Y$      |
| Kategorie $X_1$                                        | $Y_1$ | Summe $X_1$    |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_2$                                        | $Y_1$ | Summe $X_2$    |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_3$                                        | $Y_1$ | Summe $X_3$    |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_4$                                        | $Y_1$ | Summe $X_4$    |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_5$                                        | $Y_1$ | Summe $X_5$    |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_6$                                        | $Y_1$ | Summe $X_6$    |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_7$                                        | $Y_1$ | Summe $X_7$    |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_8$                                        | $Y_1$ | Summe $X_8$    |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_9$                                        | $Y_1$ | Summe $X_9$    |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{10}$                                     | $Y_1$ | Summe $X_{10}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{11}$                                     | $Y_1$ | Summe $X_{11}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{12}$                                     | $Y_1$ | Summe $X_{12}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{13}$                                     | $Y_1$ | Summe $X_{13}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{14}$                                     | $Y_1$ | Summe $X_{14}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{15}$                                     | $Y_1$ | Summe $X_{15}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{16}$                                     | $Y_1$ | Summe $X_{16}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{17}$                                     | $Y_1$ | Summe $X_{17}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{18}$                                     | $Y_1$ | Summe $X_{18}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{19}$                                     | $Y_1$ | Summe $X_{19}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{20}$                                     | $Y_1$ | Summe $X_{20}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{21}$                                     | $Y_1$ | Summe $X_{21}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{22}$                                     | $Y_1$ | Summe $X_{22}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{23}$                                     | $Y_1$ | Summe $X_{23}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{24}$                                     | $Y_1$ | Summe $X_{24}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{25}$                                     | $Y_1$ | Summe $X_{25}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{26}$                                     | $Y_1$ | Summe $X_{26}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{27}$                                     | $Y_1$ | Summe $X_{27}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{28}$                                     | $Y_1$ | Summe $X_{28}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{29}$                                     | $Y_1$ | Summe $X_{29}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{30}$                                     | $Y_1$ | Summe $X_{30}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{31}$                                     | $Y_1$ | Summe $X_{31}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{32}$                                     | $Y_1$ | Summe $X_{32}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{33}$                                     | $Y_1$ | Summe $X_{33}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
| Kategorie $X_{34}$                                     | $Y_1$ | Summe $X_{34}$ |
|                                                        | $Y_2$ |                |
|                                                        | $Y_3$ |                |
|                                                        | $Y_4$ |                |
|                                                        |       |                |

with the fact that the Government has been unable to secure the necessary funds to carry out its policy of maintaining the value of the pound at the level of 100 shillings. The Government has been unable to secure the necessary funds to carry out its policy of maintaining the value of the pound at the level of 100 shillings. The Government has been unable to secure the necessary funds to carry out its policy of maintaining the value of the pound at the level of 100 shillings.

the amount of time spent in the two highest stages was greater than in the two lowest stages (Figure 1). However, the 2011-12 (p=0.11) and 2012-13 (p=0.001) data populations did not show a pronounced trend of stages peaking in the middle range of the carbon range, as did the mean sample size of plants in the 2000-01 and 2001-02 stages (Figure 2). The 2000-01 and 2001-02 data populations were composed of 100% and 100% of the 2000-01 and 2001-02 stage plants, respectively, and the 2011-12 and 2012-13 data populations were composed of 100% and 100% of the 2011-12 and 2012-13 stage plants, respectively. The 2000-01 and 2001-02 data populations were composed of 100% and 100% of the 2000-01 and 2001-02 stage plants, respectively. The 2011-12 and 2012-13 data populations were composed of 100% and 100% of the 2011-12 and 2012-13 stage plants, respectively.

1. *What is the purpose of the study?* The purpose of the study is to determine the effect of the use of the Internet on the learning of English as a second language.

[illegible]

1. The first step in the process of the development of a new product is the identification of a market need. This is often done through market research, which involves gathering information about the needs and preferences of potential customers.

2. Once a market need has been identified, the next step is to develop a concept for the product. This involves creating a detailed description of the product, including its features, benefits, and target market.

3. The third step is to conduct a feasibility study. This involves assessing the technical, financial, and market viability of the product concept.

4. If the feasibility study is positive, the next step is to develop a business plan. This involves creating a detailed financial and marketing plan for the product.

5. The final step is to launch the product. This involves manufacturing the product, distributing it to retailers, and promoting it to the target market.

[illegible]





the same time, it is important to note that the program is not a "one-time" effort.

That is, the program is designed to be a long-term effort, and it is not a "one-time" effort. The program is designed to be a long-term effort, and it is not a "one-time" effort.

The program is designed to be a long-term effort, and it is not a "one-time" effort. The program is designed to be a long-term effort, and it is not a "one-time" effort.

The program is designed to be a long-term effort, and it is not a "one-time" effort. The program is designed to be a long-term effort, and it is not a "one-time" effort.

The program is designed to be a long-term effort, and it is not a "one-time" effort. The program is designed to be a long-term effort, and it is not a "one-time" effort.

The program is designed to be a long-term effort, and it is not a "one-time" effort. The program is designed to be a long-term effort, and it is not a "one-time" effort.

The program is designed to be a long-term effort, and it is not a "one-time" effort. The program is designed to be a long-term effort, and it is not a "one-time" effort.

The program is designed to be a long-term effort, and it is not a "one-time" effort. The program is designed to be a long-term effort, and it is not a "one-time" effort.

The program is designed to be a long-term effort, and it is not a "one-time" effort. The program is designed to be a long-term effort, and it is not a "one-time" effort.

The program is designed to be a long-term effort, and it is not a "one-time" effort. The program is designed to be a long-term effort, and it is not a "one-time" effort.

The program is designed to be a long-term effort, and it is not a "one-time" effort.

The program is designed to be a long-term effort, and it is not a "one-time" effort. The program is designed to be a long-term effort, and it is not a "one-time" effort.

The program is designed to be a long-term effort, and it is not a "one-time" effort. The program is designed to be a long-term effort, and it is not a "one-time" effort.

The program is designed to be a long-term effort, and it is not a "one-time" effort. The program is designed to be a long-term effort, and it is not a "one-time" effort.

The program is designed to be a long-term effort, and it is not a "one-time" effort. The program is designed to be a long-term effort, and it is not a "one-time" effort.

Table 1

| Table 1: Summary of Data |            |      |      |      |
|--------------------------|------------|------|------|------|
| Year                     | Category   | 1990 | 1991 | 1992 |
| 1990                     | Category A | 10   | 15   | 20   |
|                          | Category B | 5    | 10   | 15   |
| 1991                     | Category A | 12   | 18   | 22   |
|                          | Category B | 6    | 12   | 16   |
| 1992                     | Category A | 14   | 20   | 24   |
|                          | Category B | 8    | 14   | 18   |













response time of the TDR sensor is not longer than the time interval between two readings.

### 3. Results

#### *Field test of calibration of the TDR sensor*

The results of calibration of the TDR sensor, using the procedures described in the preceding section, are shown in Fig. 1. The calibration curve and apparent dielectric constant of the soil are plotted against the measured volumetric water content. The propagation of the errors in the calibration curve is also plotted. The error in the calibration curve is estimated by the method described in the preceding section.

The results of the calibration of the TDR sensor, using the procedures described in the preceding section, are shown in Fig. 1. The calibration curve and apparent dielectric constant of the soil are plotted against the measured volumetric water content. The error in the calibration curve is also plotted. The error in the calibration curve is estimated by the method described in the preceding section.

The results of the calibration of the TDR sensor, using the procedures described in the preceding section, are shown in Fig. 1. The calibration curve and apparent dielectric constant of the soil are plotted against the measured volumetric water content. The error in the calibration curve is also plotted. The error in the calibration curve is estimated by the method described in the preceding section.

the results of the calibration of the TDR sensor, using the procedures described in the preceding section, are shown in Fig. 1.

The results of the calibration of the TDR sensor, using the procedures described in the preceding section, are shown in Fig. 1. The calibration curve and apparent dielectric constant of the soil are plotted against the measured volumetric water content. The error in the calibration curve is also plotted. The error in the calibration curve is estimated by the method described in the preceding section.

The results of the calibration of the TDR sensor, using the procedures described in the preceding section, are shown in Fig. 1. The calibration curve and apparent dielectric constant of the soil are plotted against the measured volumetric water content. The error in the calibration curve is also plotted. The error in the calibration curve is estimated by the method described in the preceding section.

The results of the calibration of the TDR sensor, using the procedures described in the preceding section, are shown in Fig. 1. The calibration curve and apparent dielectric constant of the soil are plotted against the measured volumetric water content. The error in the calibration curve is also plotted. The error in the calibration curve is estimated by the method described in the preceding section.

The results of the calibration of the TDR sensor, using the procedures described in the preceding section, are shown in Fig. 1. The calibration curve and apparent dielectric constant of the soil are plotted against the measured volumetric water content. The error in the calibration curve is also plotted. The error in the calibration curve is estimated by the method described in the preceding section.

### REFERENCES

1. T. R. B. and J. R. B. (1977)

2. T. R. B. (1977)

3. T. R. B. (1977)

4. T. R. B. (1977)

5. T. R. B. (1977)

6. T. R. B. (1977)

7. T. R. B. (1977)

8. T. R. B. (1977)

9. T. R. B. (1977)

10. T. R. B. (1977)

11. T. R. B. (1977)

12. T. R. B. (1977)

13. T. R. B. (1977)

14. T. R. B. (1977)

15. T. R. B. (1977)

16. T. R. B. (1977)

**■ ■ ■**

| Line | Text                                                                                             | Page |
|------|--------------------------------------------------------------------------------------------------|------|
| 1    | 1. The first part of the report is a summary of the work done during the year.                   | 1    |
| 2    | 2. The second part of the report is a detailed account of the work done during the year.         | 2    |
| 3    | 3. The third part of the report is a summary of the work done during the year.                   | 3    |
| 4    | 4. The fourth part of the report is a detailed account of the work done during the year.         | 4    |
| 5    | 5. The fifth part of the report is a summary of the work done during the year.                   | 5    |
| 6    | 6. The sixth part of the report is a detailed account of the work done during the year.          | 6    |
| 7    | 7. The seventh part of the report is a summary of the work done during the year.                 | 7    |
| 8    | 8. The eighth part of the report is a detailed account of the work done during the year.         | 8    |
| 9    | 9. The ninth part of the report is a summary of the work done during the year.                   | 9    |
| 10   | 10. The tenth part of the report is a detailed account of the work done during the year.         | 10   |
| 11   | 11. The eleventh part of the report is a summary of the work done during the year.               | 11   |
| 12   | 12. The twelfth part of the report is a detailed account of the work done during the year.       | 12   |
| 13   | 13. The thirteenth part of the report is a summary of the work done during the year.             | 13   |
| 14   | 14. The fourteenth part of the report is a detailed account of the work done during the year.    | 14   |
| 15   | 15. The fifteenth part of the report is a summary of the work done during the year.              | 15   |
| 16   | 16. The sixteenth part of the report is a detailed account of the work done during the year.     | 16   |
| 17   | 17. The seventeenth part of the report is a summary of the work done during the year.            | 17   |
| 18   | 18. The eighteenth part of the report is a detailed account of the work done during the year.    | 18   |
| 19   | 19. The nineteenth part of the report is a summary of the work done during the year.             | 19   |
| 20   | 20. The twentieth part of the report is a detailed account of the work done during the year.     | 20   |
| 21   | 21. The twenty-first part of the report is a summary of the work done during the year.           | 21   |
| 22   | 22. The twenty-second part of the report is a detailed account of the work done during the year. | 22   |
| 23   | 23. The twenty-third part of the report is a summary of the work done during the year.           | 23   |
| 24   | 24. The twenty-fourth part of the report is a detailed account of the work done during the year. | 24   |
| 25   | 25. The twenty-fifth part of the report is a summary of the work done during the year.           | 25   |
| 26   | 26. The twenty-sixth part of the report is a detailed account of the work done during the year.  | 26   |
| 27   | 27. The twenty-seventh part of the report is a summary of the work done during the year.         | 27   |
| 28   | 28. The twenty-eighth part of the report is a detailed account of the work done during the year. | 28   |
| 29   | 29. The twenty-ninth part of the report is a summary of the work done during the year.           | 29   |
| 30   | 30. The thirtieth part of the report is a detailed account of the work done during the year.     | 30   |
| 31   | 31. The thirty-first part of the report is a summary of the work done during the year.           | 31   |
| 32   | 32. The thirty-second part of the report is a detailed account of the work done during the year. | 32   |
| 33   | 33. The thirty-third part of the report is a summary of the work done during the year.           | 33   |
| 34   | 34. The thirty-fourth part of the report is a detailed account of the work done during the year. | 34   |
| 35   | 35. The thirty-fifth part of the report is a summary of the work done during the year.           | 35   |
| 36   | 36. The thirty-sixth part of the report is a detailed account of the work done during the year.  | 36   |
| 37   | 37. The thirty-seventh part of the report is a summary of the work done during the year.         | 37   |
| 38   | 38. The thirty-eighth part of the report is a detailed account of the work done during the year. | 38   |
| 39   | 39. The thirty-ninth part of the report is a summary of the work done during the year.           | 39   |
| 40   | 40. The fortieth part of the report is a detailed account of the work done during the year.      | 40   |
| 41   | 41. The forty-first part of the report is a summary of the work done during the year.            | 41   |
| 42   | 42. The forty-second part of the report is a detailed account of the work done during the year.  | 42   |
| 43   | 43. The forty-third part of the report is a summary of the work done during the year.            | 43   |
| 44   | 44. The forty-fourth part of the report is a detailed account of the work done during the year.  | 44   |
| 45   | 45. The forty-fifth part of the report is a summary of the work done during the year.            | 45   |
| 46   | 46. The forty-sixth part of the report is a detailed account of the work done during the year.   | 46   |
| 47   | 47. The forty-seventh part of the report is a summary of the work done during the year.          | 47   |
| 48   | 48. The forty-eighth part of the report is a detailed account of the work done during the year.  | 48   |
| 49   | 49. The forty-ninth part of the report is a summary of the work done during the year.            | 49   |
| 50   | 50. The fiftieth part of the report is a detailed account of the work done during the year.      | 50   |



QUESTION 8

1. Which of the following is true?

(A)  $\mathbb{R}^n$  is a vector space.

(B)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(C)

(D)  $\mathbb{R}^n$  is a vector space.

(E)  $\mathbb{R}^n$  is a vector space.

(F)  $\mathbb{R}^n$  is a vector space.

(G)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(H)  $\mathbb{R}^n$  is a vector space.

(I)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(J)  $\mathbb{R}^n$  is a vector space.

(K)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(L)

(M)  $\mathbb{R}^n$  is a vector space.

(N)  $\mathbb{R}^n$  is a vector space.

(O)  $\mathbb{R}^n$  is a vector space.

(P)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(Q)  $\mathbb{R}^n$  is a vector space.

(R)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(S)  $\mathbb{R}^n$  is a vector space.

(T)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(U)  $\mathbb{R}^n$  is a vector space.

(V)  $\mathbb{R}^n$  is a vector space.

(W)  $\mathbb{R}^n$  is a vector space.

(X)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(Y)  $\mathbb{R}^n$  is a vector space.

(Z)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(AA)  $\mathbb{R}^n$  is a vector space.

(AB)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(AC)

(AD)  $\mathbb{R}^n$  is a vector space.

(AE)  $\mathbb{R}^n$  is a vector space.

(AF)  $\mathbb{R}^n$  is a vector space.

(AG)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(AH)  $\mathbb{R}^n$  is a vector space.

(AI)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(AJ)  $\mathbb{R}^n$  is a vector space.

(AK)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(AL)

(AM)  $\mathbb{R}^n$  is a vector space.

(AN)  $\mathbb{R}^n$  is a vector space.

(AO)  $\mathbb{R}^n$  is a vector space.

(AP)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(AQ)  $\mathbb{R}^n$  is a vector space.

(AR)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(AS)  $\mathbb{R}^n$  is a vector space.

(AT)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(AU)

(AV)  $\mathbb{R}^n$  is a vector space.

(AW)  $\mathbb{R}^n$  is a vector space.

(AX)  $\mathbb{R}^n$  is a vector space.

(AY)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(AZ)  $\mathbb{R}^n$  is a vector space.

(BA)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .

(BB)  $\mathbb{R}^n$  is a vector space.

(BC)  $\mathbb{R}^n$  is a vector space over  $\mathbb{C}$ .



27.11.11.11

1.1.  $\mathbb{R}^n$  is a vector space.  
 1.2.  $\mathbb{R}^n$  is a vector space.  
 1.3.  $\mathbb{R}^n$  is a vector space.  
 1.4.  $\mathbb{R}^n$  is a vector space.  
 1.5.  $\mathbb{R}^n$  is a vector space.

1.6.  $\mathbb{R}^n$  is a vector space.

1.7.  $\mathbb{R}^n$  is a vector space.

1.8.  $\mathbb{R}^n$  is a vector space.  
 1.9.  $\mathbb{R}^n$  is a vector space.  
 1.10.  $\mathbb{R}^n$  is a vector space.  
 1.11.  $\mathbb{R}^n$  is a vector space.  
 1.12.  $\mathbb{R}^n$  is a vector space.

1.13.  $\mathbb{R}^n$  is a vector space.

1.14.  $\mathbb{R}^n$  is a vector space.

1.15.  $\mathbb{R}^n$  is a vector space.  
 1.16.  $\mathbb{R}^n$  is a vector space.  
 1.17.  $\mathbb{R}^n$  is a vector space.  
 1.18.  $\mathbb{R}^n$  is a vector space.  
 1.19.  $\mathbb{R}^n$  is a vector space.

1.20.  $\mathbb{R}^n$  is a vector space.

1.21.  $\mathbb{R}^n$  is a vector space.

1.22

1.23.  $\mathbb{R}^n$  is a vector space.  
 1.24.  $\mathbb{R}^n$  is a vector space.  
 1.25.  $\mathbb{R}^n$  is a vector space.  
 1.26.  $\mathbb{R}^n$  is a vector space.

1.27.  $\mathbb{R}^n$  is a vector space.

1.28.  $\mathbb{R}^n$  is a vector space.

1.29.  $\mathbb{R}^n$  is a vector space.

1.30.  $\mathbb{R}^n$  is a vector space.

1.31.  $\mathbb{R}^n$  is a vector space.

1.32.  $\mathbb{R}^n$  is a vector space.

1.33.  $\mathbb{R}^n$  is a vector space.

1.34.  $\mathbb{R}^n$  is a vector space.

1.35.  $\mathbb{R}^n$  is a vector space.

1.36.  $\mathbb{R}^n$  is a vector space.

1.37.  $\mathbb{R}^n$  is a vector space.

1.38.  $\mathbb{R}^n$  is a vector space.

1.39.  $\mathbb{R}^n$  is a vector space.

1.40.  $\mathbb{R}^n$  is a vector space.

1.41.  $\mathbb{R}^n$  is a vector space.



